UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM N‑CSR

CERTIFIED SHAREHOLDER REPORT OF REGISTERED MANAGEMENT INVESTMENT COMPANIES

Investment Company Act file number: 811‑21702

Name of Fund: BlackRock Health Sciences Trust (BME)

Fund Address: 100 Bellevue Parkway, Wilmington, DE 19809

Name and address of agent for service: John M. Perlowski, Chief Executive Officer, BlackRock Health Sciences Trust,
50 Hudson Yards, New York, NY 10001

Registrant’s telephone number, including area code: (800) 882‑0052, Option 4

Date of fiscal year end: 12/31/2023

Date of reporting period: 06/30/2023

Item 1 – Report to Stockholders

(a) The Report to Shareholders is attached herewith.

JUNE 30, 2023

2023 Semi-Annual Report

(Unaudited)

BlackRock Energy and Resources Trust (BGR)

BlackRock Enhanced Capital and Income Fund, Inc. (CII)

BlackRock Enhanced Equity Dividend Trust (BDJ)

BlackRock Enhanced Global Dividend Trust (BOE)

BlackRock Enhanced International Dividend Trust (BGY)

BlackRock Health Sciences Term Trust (BMEZ)

BlackRock Health Sciences Trust (BME)

BlackRock Innovation and Growth Term Trust (BIGZ)

BlackRock Resources & Commodities Strategy Trust (BCX)

BlackRock Science and Technology Term Trust (BSTZ)

BlackRock Science and Technology Trust (BST)

BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI)

Not FDIC Insured • May Lose Value • No Bank Guarantee

Supplemental Information  (unaudited)

Section 19(a) Notices

BlackRock Energy and Resources Trust’s (BGR), BlackRock Enhanced Capital and Income Fund, Inc.’s (CII), BlackRock Enhanced Equity Dividend Trust’s (BDJ), BlackRock Enhanced Global Dividend Trust’s (BOE), BlackRock Enhanced International Dividend Trust’s (BGY), BlackRock Health Sciences Term Trust’s (BMEZ), BlackRock Health Sciences Trust’s (BME), BlackRock Innovation and Growth Term Trust’s (BIGZ), BlackRock Resources & Commodities Strategy Trust’s (BCX), BlackRock Science and Technology Term Trust’s (BSTZ), BlackRock Science and Technology Trust’s (BST) and BlackRock Utilities, Infrastructure & Power Opportunities Trust’s (BUI) (collectively, the “Trusts” or individually, a “Trust”) amounts and sources of distributions reported are estimates and are being provided pursuant to regulatory requirements and are not being provided for tax reporting purposes. The actual amounts and sources for tax reporting purposes will depend upon each Trust’s investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. Each Trust will provide a Form 1099-DIV each calendar year that will tell you how to report these distributions for U.S. federal income tax purposes.

June 30, 2023

	Total Cumulative Distributions for the Fiscal Period											% Breakdown of the Total Cumulative Distributions for the Fiscal Period
Trust Name		Net Income		Net Realized Capital Gains Short‑Term		Net Realized Capital Gains Long‑Term		Return of Capital	(a)		Total Per Common Share		Net Income		Net Realized Capital Gains Short‑Term		Net Realized Capital Gains Long‑Term		Return of Capital		Total Per Common Share
BGR	$	0.191790	$	—	$	—	$	0.188010		$	0.379800		50	%	—	%	—	%	50	%	100	%
CII		0.052450		—		0.544550		—			0.597000		9		—		91		—		100
BDJ		0.184630		0.042340		0.110230		—			0.337200		54		13		33		—		100
BOE		0.125210		—		—		0.252790			0.378000		33		—		—		67		100
BGY		0.060430		—		0.055540		0.086830			0.202800		30		—		27		43		100
BMEZ		—		—		—		0.870000			0.870000		—		—		—		100		100
BME		0.069140		—		0.979780		0.229080			1.278000		5		—		77		18		100
BIGZ		—		—		—		0.420000			0.420000		—		—		—		100		100
BCX		0.149910		—		—		0.160890			0.310800		48		—		—		52		100
BSTZ		—		—		0.130650		0.898550			1.029200		—		—		13		87		100
BST		—		—		—		1.500000			1.500000		—		—		—		100		100
BUI		0.239240		0.127710		0.359050		—			0.726000		33		18		49		—		100

^(a)  Each Trust estimates that it has distributed more than its net income and net realized capital gains; therefore, a portion of the distribution may be a return of capital. A return of capital may occur, for example, when some or all of the shareholder’s investment in a Trust is returned to the shareholder. A return of capital does not necessarily reflect a Trust’s investment performance and should not be confused with “yield” or “income.” When distributions exceed total return performance, the difference will reduce a Trust’s net asset value per share.

Section 19(a) notices for the Trusts, as applicable, are available on the BlackRock website at blackrock.com.

Section 19(b) Disclosure

The Trusts, acting pursuant to a U.S. Securities and Exchange Commission (“SEC”) exemptive order and with the approval of each Trust’s Board of Trustees (the “Board”), each has adopted a managed distribution plan, consistent with its investment objectives and policies, to support a level distribution of income, capital gains and/or return of capital (the “Plan”). In accordance with the Plans, the Trusts currently distribute the following fixed amounts per share on a monthly basis:

Trust Name	Amount Per  Common Share
BGR	$	0.065700
CII		0.099500
BDJ		0.056200
BOE		0.063000
BGY		0.033800
BMEZ		0.145000
BME		0.213000
BIGZ		0.070000
BCX		0.051800
BSTZ		0.161300
BST		0.250000
BUI		0.121000

The fixed amounts distributed per share are subject to change at the discretion of each Trust’s Board. Under its Plan, each Trust will distribute all available net income to its shareholders as required by the Internal Revenue Code of 1986, as amended (the “Code”). If sufficient income (inclusive of net income and short-term capital gains) is not earned on a monthly basis, the Trusts will distribute long-term capital gains and/or return of capital to shareholders in order to maintain a level distribution. Each monthly distribution to shareholders is expected to be at the fixed amount established by the Board; however, each Trust may make additional distributions from time to time, including additional capital gain distributions at the end of the taxable year, if required to meet requirements imposed by the Code and/or the Investment Company Act of 1940, as amended (the “1940 Act”).

Shareholders should not draw any conclusions about each Trust’s investment performance from the amount of these distributions or from the terms of the Plan. Each Trust’s total return performance is presented in its financial highlights table.

2 2 0 2 3   B L A C K R O C K  S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Supplemental Information  (unaudited)  (continued)

The Board may amend, suspend or terminate a Trust’s Plan at any time without prior notice to the Trust’s shareholders if it deems such actions to be in the best interests of the Trust or its shareholders. The suspension or termination of the Plan could have the effect of creating a trading discount (if the Trust’s stock is trading at or above net asset value) or widening an existing trading discount. The Trusts are subject to risks that could have an adverse impact on their ability to maintain level distributions. Examples of potential risks include, but are not limited to, economic downturns impacting the markets, changes in interest rates, decreased market volatility, companies suspending or decreasing corporate dividend distributions and changes in the Code. Please refer to BDJ, BME, BST and BUI’s prospectuses for a more complete description of each Trust’s risks.

S U P P L E M E N T A L   I N F O R M A T I O N 3

The Markets in Review

Dear Shareholder,

Despite an uncertain economic landscape during the 12-month reporting period ended June 30, 2023, the resilience of the U.S. economy in the face of ever tighter financial conditions provided an encouraging backdrop for investors. Inflation remained elevated as labor costs grew rapidly and unemployment rates reached the lowest levels in decades. However, inflation moderated substantially as the period continued, while ongoing strength in consumer spending backstopped the economy.

Equity returns were strong, as continued job growth eased investors’ concerns about the economy’s durability. The U.S. economy resumed growth in the third quarter of 2022 and continued to expand thereafter. Most major classes of equities advanced significantly, including large- and small-capitalization U.S. stocks and international equities from developed markets. Emerging market equities also gained, although at a substantially slower pace, pressured by high interest rates and falling commodities prices.

The 10-year U.S. Treasury yield rose during the reporting period, driving its price down, as investors reacted to elevated inflation and attempted to anticipate future interest rate changes. The corporate bond market also faced inflationary headwinds, although high-yield corporate bond prices fared significantly better than investment-grade bonds as demand from yield-seeking investors remained strong.

The U.S. Federal Reserve (the “Fed”), acknowledging that inflation has been more persistent than expected, raised interest rates seven times. Furthermore, the Fed wound down its bond-buying programs and incrementally reduced its balance sheet by not replacing securities that reach maturity. However, the Fed declined to raise interest rates at its June 2023 meeting, which made it the first meeting without a rate increase since the tightening cycle began in early 2022.

Supply constraints have become an embedded feature of the new macroeconomic environment, making it difficult for developed economies to increase production without sparking higher inflation. Geopolitical fragmentation and an aging population exacerbate these constraints, keeping the labor market tight and wage growth high. Although the Fed has decelerated the pace of interest rate hikes and most recently opted for a pause, we believe that the new economic regime means that the Fed will need to maintain high rates for an extended period to keep inflation under control. Furthermore, ongoing structural changes may mean that the Fed will be hesitant to cut interest rates in the event of faltering economic activity lest inflation accelerate again. We believe investors should expect a period of higher volatility as markets adjust to the new economic reality and policymakers attempt to adapt.

While we favor an overweight to developed market equities in the long term, we prefer an underweight stance in the near term. Expectations for corporate earnings remain elevated, which seems inconsistent with macroeconomic constraints. Nevertheless, we are overweight on emerging market stocks in the near-term as growth trends for emerging markets appear brighter. We also believe that stocks with an A.I. tilt should benefit from an investment cycle that is set to support revenues and margins. We are neutral on credit overall amid tightening credit and financial conditions, however there are selective opportunities in the near term. For fixed income investing with a six- to twelve-month horizon, we see the most attractive investments in short-term U.S. Treasuries, U.S. inflation-linked bonds, U.S. mortgage-backed securities, and emerging market bonds denominated in local currency.

Overall, our view is that investors need to think globally, position themselves to be prepared for a decarbonizing economy, and be nimble as market conditions change. We encourage you to talk with your financial advisor and visit blackrock.com for further insight about investing in today’s markets.

Sincerely,

Rob Kapito

President, BlackRock Advisors, LLC

Rob Kapito

President, BlackRock Advisors, LLC

Total Returns as of June 30, 2023
	6-Month		12-Month
U.S. large cap equities (S&P 500® Index)		16.89%		19.59%
U.S. small cap equities (Russell 2000® Index)		8.09		12.31
International equities (MSCI Europe, Australasia, Far East Index)		11.67		18.77
Emerging market equities (MSCI Emerging Markets Index)		4.89		1.75
3-month Treasury bills (ICE BofA 3-Month U.S. Treasury Bill Index)		2.25		3.60
U.S. Treasury securities (ICE BofA 10-Year U.S. Treasury Index)		1.70		(3.97)
U.S. investment grade bonds (Bloomberg U.S. Aggregate Bond Index)		2.09		(0.94)
Tax-exempt municipal bonds (Bloomberg Municipal Bond Index)		2.67		3.19
U.S. high yield bonds (Bloomberg U.S. Corporate High Yield 2% Issuer Capped Index)		5.38		9.07
Past performance is not an indication of future results. Index performance is shown for illustrative purposes only. You cannot invest directly in an index.

4 T H I S   P A G E   I S   N O T   P A R T   O F   Y O U R   F U N D   R E P O R T

Table of Contents

	Page
Supplemental Information		2
The Markets in Review		4
Option Over-Writing Strategy		6
Derivative Financial Instruments		6
Semi-Annual Report:
Trust Summary		7
Financial Statements:
Schedules of Investments		33
Statements of Assets and Liabilities		123
Statements of Operations		126
Statements of Changes in Net Assets		129
Statements of Cash Flows		135
Financial Highlights		138
Notes to Financial Statements		150
Disclosure of Investment Advisory Agreement and Sub-Advisory Agreement		164
Additional Information		169
Glossary of Terms Used in this Report		172

5

Option Over‑Writing Strategy

Overview

In general, the goal of each of the Trusts is to provide total return through a combination of current income and realized and unrealized gains (capital appreciation). The Trusts seek to pursue these goals primarily by investing in a portfolio of equity securities and also by employing a strategy of writing (selling) call and put options in an effort to generate current gains from option premiums and to enhance each Trust’s risk-adjusted return. Each Trust’s objectives cannot be achieved in all market conditions.

Each Trust primarily writes single stock covered call options and may also from time to time write single stock put options. When writing (selling) a covered call option, a Trust holds an underlying equity security and enters into an option transaction which allows the counterparty to purchase the equity security at an agreed-upon price (“strike price”) within an agreed-upon time period. The Trust receives cash premiums from the counterparties upon writing (selling) the option, which along with net investment income and net realized gains, if any, are generally available to support current or future distributions paid by the Trust. During the option term, the counterparty may elect to exercise the option if the market value of the equity security rises above the strike price, and the Trust is obligated to sell the equity security to the counterparty at the strike price, realizing a gain or loss. Premiums received increase gains or reduce losses realized on the sale of the equity security. If the option remains unexercised upon its expiration, the Trust realizes gains equal to the premiums received. Alternatively, an option may be closed out by an offsetting purchase or sale of an option prior to expiration. The Trust realizes a capital gain from a closing purchase or sale transaction if the premium paid is less than the premium received from writing the option. The Trust realizes a capital loss from a closing purchase or sale transaction if the premium received is less than the premium paid to purchase the option.

Writing covered call options entails certain risks, which include, but are not limited to, the following: an increase in the value of the underlying equity security above the strike price can result in the exercise of a written option (sale by a Trust to the counterparty) when the Trust might not otherwise have sold the security; exercise of the option by the counterparty may result in a sale below the current market value and a gain or loss being realized by the Trust; and limiting the potential appreciation that could be realized on the underlying equity security to the extent of the strike price of the option. The premium that a Trust receives from writing a covered call option may not be sufficient to offset the potential appreciation on the underlying equity security above the strike price of the option that could have otherwise been realized by the Trust. As such, an option over-writing strategy may outperform the general equity market in flat or falling markets but underperform in rising markets.

Option Over-Writing Strategy Illustration

To illustrate these concepts, assume the following: (1) a common stock purchased at and currently trading at $37.15 per share; (2) a three-month call option is written by a Trust with a strike price of $40 (i.e., 7.7% higher than the current market price); and (3) the Trust receives $2.45, or 6.6% of the common stock’s value, as a premium. If the stock price remains unchanged, the option expires and there would be a 6.6% return for the three-month period. If the stock were to decline in price by 6.6% (i.e., decline to $34.70 per share), the option strategy would “break-even” from an economic perspective resulting in neither a gain nor a loss. If the stock were to climb to a price of $40 or above, the option would be exercised and the stock would return 7.7% coupled with the option premium received of 6.6% for a total return of 14.3%. Under this scenario, the Trust loses the benefit of any appreciation of the stock above $40, and thus is limited to a 14.3% total return. The premium from writing the call option serves to offset some of the unrealized loss on the stock in the event that the price of the stock declines, but if the stock were to decline more than 6.6% under this scenario, the Trust’s downside protection is eliminated and the stock could eventually become worthless.

Each Trust intends to write covered call and other options to varying degrees depending upon market conditions. Please refer to each Trust’s Schedule of Investments and the Notes to Financial Statements for details of written options.

Derivative Financial Instruments

The Trusts may invest in various derivative financial instruments. These instruments are used to obtain exposure to a security, commodity, index, market, and/or other assets without owning or taking physical custody of securities, commodities and/or other referenced assets or to manage market, equity, credit, interest rate, foreign currency exchange rate, commodity and/or other risks. Derivative financial instruments may give rise to a form of economic leverage and involve risks, including the imperfect correlation between the value of a derivative financial instrument and the underlying asset, possible default of the counterparty to the transaction or illiquidity of the instrument. Pursuant to Rule 18f-4 under the 1940 Act, among other things, the Trusts must either use derivative financial instruments with embedded leverage in a limited manner or comply with an outer limit on fund leverage risk based on value-at-risk. The Trusts’ successful use of a derivative financial instrument depends on the investment adviser’s ability to predict pertinent market movements accurately, which cannot be assured. The use of these instruments may result in losses greater than if they had not been used, may limit the amount of appreciation a Trust can realize on an investment and/or may result in lower distributions paid to shareholders. The Trusts’ investments in these instruments, if any, are discussed in detail in the Notes to Financial Statements.

6 2 0 2 3   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Trust Summary  as of June 30, 2023      BlackRock Energy and Resources Trust (BGR)

Investment Objective

BlackRock Energy and Resources Trust’s (BGR) (the “Trust”) investment objective is to provide total return through a combination of current income and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of energy and natural resources companies and equity derivatives with exposure to the energy and natural resources industry. The Trust may invest directly in such securities or synthetically through the use of derivatives. The Trust seeks to pursue this goal primarily by investing in a portfolio of equity securities and also by employing a strategy of writing (selling) call and put options.

No assurance can be given that the Trust’s investment objective will be achieved.

Trust Information

Symbol on New York Stock Exchange	BGR
Initial Offering Date	December 29, 2004
Current Distribution Rate on Closing Market Price as of June 30, 2023 ($12.04)(a)	6.55%
Current Monthly Distribution per Common Share(b)	$0.065700
Current Annualized Distribution per Common Share(b)	$0.788400

^(a) Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate may consist of income, net realized gains and/or a return of capital. Past performance is not an indication of future results.

^(b) The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain.

Market Price and Net Asset Value Per Share Summary

	06/30/23		12/31/22		Change			High		Low
Closing Market Price	$	12.04	$	12.53		(3.91	)%	$	13.36	$	11.23
Net Asset Value		13.66		14.21		(3.87	)		14.91		12.71

Performance

Returns for the period ended June 30, 2023 were as follows:

				Average Annual Total Returns
	6-month			1 Year			5 Years			10 Years
Trust at NAV(a)(b)		(0.87	)%		15.72	%		3.56	%		1.41	%
Trust at Market Price(a)(b)		(0.92	)		16.22			1.95			1.12
MSCI World Energy Call Overwrite Index(c)		(2.68	)		12.49			N/A			N/A
MSCI World Energy Index(d)		(3.91	)		13.18			3.46			2.77

^(a) All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.

^(b)  The Trust’s discount to NAV widened during the period, which accounts for the difference between performance based on market price and performance based on NAV.

^(c)  An index that incorporates an option overlay component on the MSCI World Energy Index with a 33% overwrite level. The benchmark commenced on December 31, 2018 and therefore the benchmark does not have 5- and 10-year returns.

^(d)  An index that is designed to capture the large- and mid-cap segments across developed markets countries. All securities in the index are classified in the energy sector as per the Global Industry Classification Standard.

Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles. Past performance is not an indication of future results.

The Trust is presenting the performance of one or more indices for informational purposes only. The Trust is actively managed and does not seek to track or replicate the performance of any index. The index performance shown is not intended to be indicative of the Trust’s investment strategies, portfolio components or past or future performance.

More information about the Trust’s historical performance can be found in the “Closed End Funds” section of blackrock.com.

The following discussion relates to the Trust’s absolute performance based on NAV:

What factors influenced performance?

Stock selection in the exploration and production (“E&P”) and integrated oil sub-sectors contributed to the Trust’s outperformance in the semiannual period. At the individual stock level, the Canadian E&P companies Tourmaline Oil Corp., Arc Resources Ltd. and Canadian Natural Resources Ltd. outperformed their United States shale-focused peers. The Trust’s zero weightings in the underperforming stocks Devon Energy Corp. and Neste Oyj also contributed to relative performance.

An underweight in oilfield services companies detracted from results. The sub-sector’s performance was supported by expectations for increased merger and acquisition activity following Patterson-UTI Energy Inc.’s announced merger with NexTier Oilfield Solutions, Inc. Among individual holdings in the sector, an overweight in Patterson-UTI contributed, while a zero weighting in Baker Hughes Co. detracted. A position in BP PLC, which fell from its highs of early 2023 after announcing a reduced pace of share buybacks, also detracted.

T R U S T    S U M M A R Y 7

Trust Summary  as of June 30, 2023 (continued)      BlackRock Energy and Resources Trust (BGR)

The Trust used an options overlay strategy in which calls were written on a portion of the portfolio’s holdings. This strategy contributed to results in the reporting period. The Trust’s practice of maintaining a specified level of monthly distributions to shareholders did not have a material impact on the Trust’s investment strategy.

Describe recent portfolio activity.

The investment adviser sought to take advantage of market volatility by adjusting the portfolio’s positioning and selectively adding to some higher-beta E&P companies following share price weakness.

Describe portfolio positioning at period end.

The investment advisor maintained a bias towards higher-quality international oil producers and selective exposure to the United States shale industry. The investment adviser believed valuations remained attractive given that energy companies are expected to maintain capital discipline and deliver high free cash flows.

As of June 30, 2023, the Trust had in place an option overwriting program whereby 32.0% of the underlying equities were overwritten with call options on individual stocks. These call options were typically written at prices above the prevailing market prices (estimated to be 3.2% out of the money) and for maturities averaging 49 days.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

Overview of the Trust’s Total Investments

TEN LARGEST HOLDINGS

Security(a)	Percent of Total Investments
Exxon Mobil Corp.		18.8	%
Shell PLC		10.7
TotalEnergies SE		6.9
ConocoPhillips		6.8
BP PLC		6.8
Chevron Corp.		4.8
Canadian Natural Resources Ltd.		4.5
Williams Cos., Inc.		4.4
EOG Resources, Inc.		4.2
Hess Corp.		3.7

INDUSTRY ALLOCATION

Industry(a)(b)	Percentage of Total Investments
Oil, Gas & Consumable Fuels		95.5	%
Energy Equipment & Services		4.0
Food Products		0.5

^(a)  Excludes short-term securities.

^(b)  For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

8 2 0 2 3   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Trust Summary  as of June 30, 2023       BlackRock Enhanced Capital and Income Fund, Inc. (CII)

Investment Objective

BlackRock Enhanced Capital and Income Fund, Inc.’s (CII) (the “Trust”) investment objective is to provide current income and capital appreciation. The Trust seeks to achieve its investment objective by investing in a portfolio of equity securities of U.S. and foreign issuers. The Trust may invest directly in such securities or synthetically through the use of derivatives. The Trust also seeks to achieve its investment objective by employing a strategy of writing (selling) call and put options.

No assurance can be given that the Trust’s investment objective will be achieved.

Trust Information

Symbol on New York Stock Exchange	CII
Initial Offering Date	April 30, 2004
Current Distribution Rate on Closing Market Price as of June 30, 2023 ($18.51)(a)	6.45%
Current Monthly Distribution per Common Share(b)	$0.099500
Current Annualized Distribution per Common Share(b)	$1.194000

^(a)  Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. Past performance is not an indication of future results.

^(b)  The distribution rate is not constant and is subject to change.

Market Price and Net Asset Value Per Share Summary

	06/30/23		12/31/22		Change			High		Low
Closing Market Price	$	18.51	$	17.12		8.12	%	$	18.98	$	16.88
Net Asset Value		19.18		17.55		9.29			19.18		17.42

Performance

Returns for the period ended June 30, 2023 were as follows:

				Average Annual Total Returns
	6-month			1 Year			5 Years			10 Years
Trust at NAV(a)(b)		12.93	%		16.93	%		10.19	%		11.18	%
Trust at Market Price(a)(b)		11.73			18.36			10.39			12.01
MSCI USA Call Overwrite Index(c)		15.47			16.69			N/A			N/A
Russell 1000® Index(d)		16.68			19.36			11.92			12.64

^(a) All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.

^(b)  The Trust’s discount to NAV widened during the period, which accounts for the difference between performance based on market price and performance based on NAV.

^(c)  An index that incorporates an option overlay component on the MSCI USA Index with a 55% overwrite level. The benchmark commenced on December 31, 2018 and therefore the benchmark does not have 5- and 10-year returns.

^(d)  An index that measures the performance of the large-cap segment of the U.S. equity universe. It is a subset of the Russell 3000^® Index and includes approximately 1,000 of the largest securities based on a combination of their market capitalization and current index membership. The index represents approximately 93% of the U.S. market.

Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles. Past performance is not an indication of future results.

The Trust is presenting the performance of one or more indices for informational purposes only. The Trust is actively managed and does not seek to track or replicate the performance of any index. The index performance shown is not intended to be indicative of the Trust’s investment strategies, portfolio components or past or future performance.

More information about the Trust’s historical performance can be found in the “Closed End Funds” section of blackrock.com.

The following discussion relates to the Trust’s relative performance based on NAV:

What factors influenced performance?

Investment decisions within the information technology (“IT”) sector detracted the most from the Trust’s relative returns. Notably, stock selection and an underweight position to the semiconductors and semiconductor equipment industry proved costly, as did positioning among technology hardware, storage and peripherals companies. Within the consumer discretionary sector, stock selection detracted from performance, specifically in the automobiles and specialty retail industries. Other detractors included stock selection in the materials and industrials sectors.

Conversely, the largest contribution to the Trust’s relative performance came from investment decisions in the communication services sector. Most notably, stock selection and an overweight allocation to the interactive media & services industry boosted relative return, as did an underweight allocation to entertainment companies. Stock selection in the healthcare sector, specifically within the pharmaceuticals industry, also proved beneficial. Avoiding exposure to the utilities sector entirely added to relative performance, as did investment decisions within energy.

T R U S T    S U M M A R Y 9

Trust Summary  as of June 30, 2023 (continued)      BlackRock Enhanced Capital and Income Fund, Inc. (CII)

The Trust utilized an options overlay strategy in which calls are written on a portion of the portfolio’s holdings. The Trust’s options overlay strategy detracted from relative performance for the six-month period. The Trust’s practice of maintaining a specified level of monthly distributions did not have a material impact on the Trust’s investment strategy.

Describe recent portfolio activity.

During the reporting period, a combination of portfolio trading activity and market price changes resulted in the Trust adding exposure to the IT, communication services, and consumer discretionary sectors. The Trust reduced exposure to financials, industrials, and real estate.

Describe portfolio positioning at period end.

At reporting period end, the Trust’s largest sector overweight positions in the public equity portion of the portfolio were in the communication services and consumer discretionary sectors, while the largest underweight positions were in IT and utilities.

As of June 30, 2023, the Trust had an options overwriting program in place whereby 58% of the underlying equities were overwritten with call options. These call options were typically written at levels above prevailing market prices (estimated to be 3.1% out of the money) with an average time until expiration of 52 days.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

Overview of the Trust’s Total Investments

TEN LARGEST HOLDINGS

Security(a)	Percent of Total Investments
Microsoft Corp.		8.6	%
Amazon.com, Inc.		5.1
Apple, Inc.		5.0
Alphabet, Inc.		5.0
Meta Platforms, Inc.		3.0
Comcast Corp.		2.9
Berkshire Hathaway, Inc.		2.7
Applied Materials, Inc.		2.3
UnitedHealth Group, Inc.		2.1
Sanofi		2.1

SECTOR ALLOCATION

Sector(a)(b)	Percent of Total Investments
Information Technology		23.0	%
Health Care		14.7
Financials		13.7
Consumer Discretionary		12.9
Communication Services		12.7
Consumer Staples		7.3
Industrials		6.9
Materials		4.5
Energy		4.3
Real Estate		—	(c)

^(a)  Excludes short-term securities.

^(b)  For Trust compliance purposes, the Trust’s sector classifications refer to one or more of the sector sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such sector sub-classifications for reporting ease.

^(c)  Rounds to less than 0.1%.

10 2 0 2 3   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Trust Summary  as of June 30, 2023       BlackRock Enhanced Equity Dividend Trust (BDJ)

Investment Objective

BlackRock Enhanced Equity Dividend Trust’s (BDJ) (the “Trust”) primary investment objective is to provide current income and current gains, with a secondary investment objective of long-term capital appreciation. The Trust seeks to achieve its investment objectives by investing in common stocks that pay dividends and have the potential for capital appreciation and by utilizing an option writing strategy to enhance distributions to its shareholders. The Trust invests, under normal market conditions, at least 80% of its total assets in dividend paying equities and may invest up to 20% of its total assets in equity securities of issuers that do not pay dividends. The Trust may invest directly in such securities or synthetically through the use of derivatives.

No assurance can be given that the Trust’s investment objectives will be achieved.

Trust Information

Symbol on New York Stock Exchange	BDJ
Initial Offering Date	August 31, 2005
Current Distribution Rate on Closing Market Price as of June 30, 2023 ($ 8.34)(a)	8.09%
Current Monthly Distribution per Common Share(b)	$0.056200
Current Annualized Distribution per Common Share(b)	$0.674400

^(a)  Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. Past performance is not an indication of future results.

^(b)  The distribution rate is not constant and is subject to change.

Market Price and Net Asset Value Per Share Summary

	06/30/23		12/31/22		Change			High		Low
Closing Market Price	$	8.34	$	9.01		(7.44	)%	$	9.36	$	8.03
Net Asset Value		8.83		8.74		1.03			9.15		8.23

Performance

Returns for the period ended June 30, 2023 were as follows:

				Average Annual Total Returns
	6-month			1 Year			5 Years			10 Years
Trust at NAV(a)(b)		5.07	%		10.06	%		7.27	%		8.48	%
Trust at Market Price(a)(b)		(3.73	)		7.01			7.05			9.08
MSCI USA Value Call Overwrite Index(c)		1.14			5.09			N/A			N/A
Russell 1000® Value Index(d)		5.12			11.54			8.11			9.22

^(a)  All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.

^(b)  The Trust moved from a premium to NAV to a discount during the period, which accounts for the difference between performance based on market price and performance based on NAV.

^(c)  An index that incorporates an option overlay component on the MSCI USA Value Index with a 55% overwrite level. The benchmark commenced on December 31, 2018 and therefore the benchmark does not have 5- and 10-year returns.

^(d)  An index that measures the performance of the large-cap value segment of the U.S. equity universe. It includes those Russell 1000 companies with lower price-to-book ratios and lower expected growth values.

Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.

Past performance is not an indication of future results.

The Trust is presenting the performance of one or more indices for informational purposes only. The Trust is actively managed and does not seek to track or replicate the performance of any index. The index performance shown is not intended to be indicative of the Trust’s investment strategies, portfolio components or past or future performance.

More information about the Trust’s historical performance can be found in the “Closed End Funds” section of blackrock.com.

The following discussion relates to the Trust’s relative performance based on NAV:

What factors influenced performance?

The largest contributor to the Trust’s relative performance for the period was security selection in the healthcare sector. Specifically, stock decisions in the pharmaceuticals and healthcare equipment and supplies industries boosted relative results. Security selection in energy was also a key contributor, with decisions in the oil, gas and consumable fuels industry proving to be beneficial. Other notable contributors included stock selection within the financials and communication services sectors.

Conversely, the largest detractor from relative returns came from stock selection in the information technology (“IT”) sector. Particularly, stock selection in semiconductors proved costly, as did the Trust’s decision not to invest in the electronic equipment, instruments and components industry. Stock selection in consumer staples also hurt performance, with stock decisions in the consumer staples distribution and retail industry weighing on relative return. Other notable detractors included selection decisions in the materials and consumer discretionary sectors.

T R U S T    S U M M A R Y 11

Trust Summary  as of June 30, 2023 (continued)      BlackRock Enhanced Equity Dividend Trust (BDJ)

The Trust utilized an options overlay strategy in which calls are written on a portion of the portfolio’s holdings. The Trust’s options overlay strategy contributed to relative performance. The Trust’s practice of maintaining a specified level of monthly distributions did not have a material impact on the Trust’s investment strategy.

Describe recent portfolio activity.

During the period, a combination of portfolio trading activity and market price changes resulted in the Trust adding exposure to the healthcare, energy, and IT sectors. The Trust reduced exposure to the financials, consumer staples, and utilities sectors.

Describe portfolio positioning at period end.

At reporting period end, the Trust’s largest absolute allocations were to the financials, healthcare, and industrials sectors. Relative to the benchmark, the Trust’s most significant overweight exposures were to the financials, healthcare, and communication services sectors. The Trust maintained its most significant relative underweight sector exposures to real estate, IT, and materials.

As of June 30, 2023, the Trust had an options overwriting program in place whereby 49% of the underlying equities were overwritten with call options. These call options were typically written at levels above prevailing market prices (estimated to be 2.8% out of the money) with an average time until expiration of 51 days.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

Overview of the Trust’s Total Investments

TEN LARGEST HOLDINGS

Security(a)	Percent of Total Investments
Wells Fargo & Co.		3.1	%
Laboratory Corp. of America Holdings		3.1
Citigroup, Inc.		2.7
Cognizant Technology Solutions Corp.		2.6
Baxter International, Inc.		2.6
American International Group, Inc.		2.5
Kraft Heinz Co.		2.4
Medtronic PLC		2.4
Shell PLC		2.3
Cisco Systems, Inc.		2.3

SECTOR ALLOCATION

Sector(a)(b)	Percent of Total Investments
Financials		24.0	%
Health Care		22.0
Industrials		9.4
Consumer Staples		9.1
Energy		9.0
Information Technology		8.9
Communication Services		6.2
Consumer Discretionary		5.8
Utilities		3.6
Materials		2.0

^(a)  Excludes short-term securities.

^(b)  For Trust compliance purposes, the Trust’s sector classifications refer to one or more of the sector sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such sector sub-classifications for reporting ease.

12 2 0 2 3   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Trust Summary  as of June 30, 2023       BlackRock Enhanced Global Dividend Trust (BOE)

Investment Objective

BlackRock Enhanced Global Dividend Trust’s (BOE) (the “Trust”) primary investment objective is to provide current income and current gains, with a secondary investment objective of long-term capital appreciation. The Trust seeks to achieve its investment objectives by investing primarily in equity securities issued by companies located in countries throughout the world and by employing a strategy of writing (selling) call and put options. Under normal circumstances, the Trust invests at least 80% of its net assets in dividend-paying equity securities and at least 40% of its assets outside of the U.S. (unless market conditions are not deemed favorable by Trust management, in which case the Trust would invest at least 30% of its assets outside of the U.S.). The Trust may invest in securities of companies of any market capitalization, but intends to invest primarily in securities of large capitalization companies. The Trust may invest directly in such securities or synthetically through the use of derivatives.

No assurance can be given that the Trust’s investment objectives will be achieved.

Trust Information

Symbol on New York Stock Exchange	BOE
Initial Offering Date	May 31, 2005
Current Distribution Rate on Closing Market Price as of June 30, 2023 ($ 10.07)(a)	7.51%
Current Monthly Distribution per Common Share(b)	$0.063000
Current Annualized Distribution per Common Share(b)	$0.756000

^(a)  Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate may consist of income, net realized gains and/or a return of capital. Past performance is not an indication of future results.

^(b)  The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain.

Market Price and Net Asset Value Per Share Summary

	06/30/23		12/31/22		Change			High		Low
Closing Market Price	$	10.07	$	9.56		5.33	%	$	10.59	$	9.42
Net Asset Value		11.59		10.97		5.65			11.71		10.79

Performance

Returns for the period ended June 30, 2023 were as follows:

				Average Annual Total Returns
	6-month			1 Year			5 Years			10 Years
Trust at NAV(a)(b)		9.67	%		12.00	%		6.85	%		6.16	%
Trust at Market Price(a)(b)		9.34			11.26			5.32			5.99
MSCI ACWI Call Overwrite Index(c)		11.81			13.32			N/A			N/A
MSCI ACWI(d)		13.93			16.53			8.10			8.75

^(a)  All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.

^(b)  The Trust’s discount to NAV widened during the period, which accounts for the difference between performance based on market price and performance based on NAV.

^(c)  An index that incorporates an option overlay component on the MSCI ACWI Index with a 45% overwrite level. The benchmark commenced on December 31, 2018 and therefore the benchmark does not have 5- and 10-year returns.

^(d)  An index that captures large- and mid-cap representation across certain developed and emerging markets.

Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.

Past performance is not an indication of future results.

The Trust is presenting the performance of one or more indices for informational purposes only. The Trust is actively managed and does not seek to track or replicate the performance of any index. The index performance shown is not intended to be indicative of the Trust’s investment strategies, portfolio components or past or future performance.

More information about the Trust’s historical performance can be found in the “Closed End Funds” section of blackrock.com.

The following discussion relates to the Trust’s relative performance based on NAV:

What factors influenced performance?

An underweight allocation to, and stock selection within, the information technology (“IT”) sector detracted the most from relative returns, particularly within the semiconductors and semiconductor equipment industry. Stock selection within communication services and an underweight allocation to consumer discretionary stocks also detracted.

Among individual security decisions, the Trust’s lack of a position in Nvidia was the biggest detractor from relative performance, as companies linked to generative artificial intelligence (“AI”) performed strongly as investor sentiment grew favorable amid the potential implications of the technology for businesses across the economy. Citizens Financial Group also detracted, given the backdrop of tightening credit conditions and expectations for stricter regulation following the collapses of SVB Financial and Signature Bank in the first quarter 2023. Apple was a key detractor from performance due to the Trust’s average underweight position following its mid-March 2023 purchase

T R U S T    S U M M A R Y 13

Trust Summary  as of June 30, 2023 (continued)      BlackRock Enhanced Global Dividend Trust (BOE)

of the stock, as the IT sector maintained a rather defensive posture during the first quarter. Lastly, International Flavors and Fragrances guided lower on full-year growth for 2023, given an uncertain market environment that has led to weaker sales volume and an industry-wide consumer destocking in the United States.

Conversely, stock selection among financials was the most significant contributor to the Trust’s relative performance. Stock selection within healthcare and an underweight allocation to utilities also contributed. At the individual stock level, Inditex was the top contributor, as the Spanish clothing retailer reported a greater-than-expected rise in profit due to robust sales of summer clothes. The retailer sported high profit margins and sales growth both in-store and online, and its strong performance stemmed from its strategic decision to maintain higher prices in markets outside the Eurozone. Also, Taiwan Semiconductor Manufacturing contributed, as the outlook for semiconductors strengthened on demand from the buildout of generative AI capabilities. Lastly, Microsoft was a key contributor to relative performance, following the strong rally in IT during the reporting period. The software company tapped into positive sentiment surrounding AI with the launch of new tools for developers to integrate generative AI into their business software, reflecting Big Tech’s race to commercialize AI technology.

The Trust utilized an options overlay strategy in which calls are written on a portion of the portfolio’s holdings. The Trust’s options overlay strategy contributed positively to relative performance. The Trust’s practice of maintaining a specified level of monthly distributions to shareholders did not have a material impact on the Trust’s investment strategy.

Describe recent portfolio activity.

During the period, the Trust added exposure to the IT, communication services, and energy sectors. Conversely, the Trust reduced its exposure to the consumer discretionary sector, particularly in the specialty retail space. The Trust also reduced exposure to financials, notably within the bank industry.

Describe portfolio positioning at period end.

At period end, the Trust’s largest sector exposures were in IT, healthcare, and financials. Regionally, the majority of the portfolio was listed in the United States, with significant exposure in Europe.

As of June 30, 2023, the Trust had an options overwriting program in place whereby 43% of the underlying equities were overwritten with call options. These call options were typically written at levels above prevailing market prices (estimated to be 2.8% out of the money) with an average time until expiration of 53 days.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

Overview of the Trust’s Total Investments

TEN LARGEST HOLDINGS

Security(a)	Percent of Total Investments
Microsoft Corp.		4.8	%
Apple, Inc.		3.7
Mondelez International, Inc.		3.0
Sanofi		2.9
Reckitt Benckiser Group PLC		2.8
Accenture PLC		2.8
Taiwan Semiconductor Manufacturing Co. Ltd.		2.8
AstraZeneca PLC		2.7
Paychex, Inc.		2.6
Philip Morris International, Inc.		2.6

GEOGRAPHIC ALLOCATION

Country/Geographic Region(a)	Percentage of Total Investments
United States		49.0	%
United Kingdom		13.3
France		9.1
Switzerland		5.0
Ireland		4.7
Taiwan		4.2
Netherlands		3.5
Canada		2.3
Mexico		2.0
Denmark		2.0
Japan		1.5
Singapore		1.3
Indonesia		1.1
Spain		1.0
India		—	(b)

^(a)  Excludes short-term securities.

^(b)  Rounds to less than 0.1%.

14 2 0 2 3   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Trust Summary  as of June 30, 2023       BlackRock Enhanced International Dividend Trust (BGY)

Investment Objective

BlackRock Enhanced International Dividend Trust’s (BGY) (the “Trust”) primary investment objective is to provide current income and current gains, with a secondary objective of long-term capital appreciation. The Trust seeks to achieve its investment objectives by investing primarily in equity securities issued by companies of any market capitalization located in countries throughout the world and by employing a strategy of writing (selling) call and put options. The Trust invests, under normal circumstances, at least 80% of its net assets in dividend-paying equity securities issued by non-U.S. companies of any market capitalization, but intends to invest primarily in securities of large capitalization companies. The Trust may invest directly in such securities or synthetically through the use of derivatives.

No assurance can be given that the Trust’s investment objectives will be achieved.

Trust Information

Symbol on New York Stock Exchange	BGY
Initial Offering Date	May 30, 2007
Current Distribution Rate on Closing Market Price as of June 30, 2023 ($ 5.44)(a)	7.46%
Current Monthly Distribution per Common Share(b)	$0.033800
Current Annualized Distribution per Common Share(b)	$0.405600

^(a)  Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate may consist of income, net realized gains and/or a return of capital. Past performance is not an indication of future results.

^(b)  The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain.

Market Price and Net Asset Value Per Share Summary

	06/30/23		12/31/22		Change			High		Low
Closing Market Price	$	5.44	$	5.02		8.37	%	$	5.64	$	5.02
Net Asset Value		6.24		5.78		7.96			6.40		5.78

Performance

Returns for the period ended June 30, 2023 were as follows:

				Average Annual Total Returns
	6-month			1 Year			5 Years			10 Years
Trust at NAV(a)(b)		12.03	%		18.53	%		7.19	%		5.17	%
Trust at Market Price(a)(b)		12.45			16.19			6.45			4.87
MSCI ACWI ex USA Call Overwrite Index(c)		6.62			8.64			N/A			N/A
MSCI ACWI ex USA Index(d)		9.47			12.72			3.52			4.75

^(a)  All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.

^(b)  The Trust’s discount to NAV narrowed during the period, which accounts for the difference between performance based on market price and performance based on NAV.

^(c)  An index that incorporates an option overlay component on the MSCI ACWI ex USA Index with a 45% overwrite level. The benchmark commenced on December 31, 2018 and therefore the benchmark does not have 5- and 10-year returns.

^(d)  An index that captures large- and mid-cap representation across certain developed markets countries (excluding the U.S.) and certain emerging markets countries.

Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.

Past performance is not an indication of future results.

The Trust is presenting the performance of one or more indices for informational purposes only. The Trust is actively managed and does not seek to track or replicate the performance of any index. The index performance shown is not intended to be indicative of the Trust’s investment strategies, portfolio components or past or future performance.

More information about the Trust’s historical performance can be found in the “Closed End Funds” section of blackrock.com.

The following discussion relates to the Trust’s relative performance based on NAV:

What factors influenced performance?

From a sector perspective, the Trust’s stock selection in healthcare, consumer discretionary, and materials stocks contributed the most to returns. Among individual stocks, Inditex was the top contributor, as the Spanish clothing company’s top-line growth remained extremely strong as it executed its business strategy well. Inditex continues to make good capital allocation decisions, in terms of both disciplined space management and cash deployment, and the current economics of the online business are better than expected. French luxury goods company LVMH also contributed to performance. Discretionary spending has remained strong overall among affluent consumers, leading to continued growth in margins in the luxury retail industry. Lastly, Ferguson also contributed, as the British-American plumbing and HVAC company reported quarterly results in line with expectations and exhibited solid fundamental performance even in a challenging macroeconomic environment.

By contrast, underweight positions in information technology were the most significant detractors from relative performance. An overweight allocation to financials and stock selection in consumer staples also detracted. Among individual stocks, Budweiser Brewing Company APAC was the leading detractor, as it came under pressure during the

T R U S T    S U M M A R Y 15

Trust Summary  as of June 30, 2023 (continued)      BlackRock Enhanced International Dividend Trust (BGY)

period due to increasing concerns about the strength of China’s reopening, given the company’s sizable exposure to the on-premise and nightlife distribution channels in China. Diageo also detracted, as its financial reports showed a significant slowdown for the spirits company in the U.S. market, as volumes fell 6%. Diageo’s guidance was also marginally weaker as price and volume trends normalized. Management did reiterate medium-term growth targets, though, suggesting that Diageo expects any U.S. slowdown to be short-lived. Singapore’s United Overseas Bank also detracted amid broader concerns in the banking sector globally.

The Trust utilized an options overlay strategy in which calls are written on a portion of the portfolio’s holdings. The Trust’s options overlay strategy contributed to relative performance for the reporting period. The Trust’s practice of maintaining a specified level of monthly distributions did not have a material impact on the Trust’s investment strategy.

Describe recent portfolio activity.

During the period, the Trust reduced its exposure to consumer staples stocks as it sold its sole position in the personal care products industry. The Trust also reduced exposure to industrials, notably through the sale of its position in the electrical equipment industry. Conversely, the Trust added exposure to the materials, energy, and communication services sectors.

Describe portfolio positioning at period end.

At period end, the Trust’s largest sector exposures were in healthcare, communication services, and industrials. Regionally, the majority of the portfolio’s securities were listed in Europe, with particularly significant exposure in Europe excluding the United Kingdom.

As of June 30, 2023, the Trust had an options overwriting program in place whereby 43% of the underlying equities were overwritten with call options. These call options were typically written at levels above prevailing market prices (estimated to be 2.9% out of the money) with an average time until expiration of 52 days.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

Overview of the Trust’s Total Investments

TEN LARGEST HOLDINGS

Security(a)	Percent of Total Investments
Taiwan Semiconductor Manufacturing Co. Ltd.		4.0	%
Lonza Group AG		3.6
KDDI Corp.		3.4
Kering SA		3.3
Otis Worldwide Corp.		3.3
Symrise AG		3.2
Sanofi		3.2
HDFC Bank Ltd.		3.2
Industria de Diseno Textil SA		3.2
Novo Nordisk A/S		3.1

GEOGRAPHIC ALLOCATION

Country/Geographic Region(a)	Percentage of Total Investments
United Kingdom		17.7	%
France		13.0
United States		10.1
Netherlands		8.5
Japan		6.9
Taiwan		6.2
Switzerland		5.5
Germany		5.3
Singapore		3.9
India		3.2
Spain		3.1
Denmark		3.0
China		2.9
Mexico		2.7
Canada		2.0
Italy		2.0
Indonesia		2.0
Sweden		2.0

^(a)  Excludes short-term securities.

16 2 0 2 3   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Trust Summary  as of June 30, 2023       BlackRock Health Sciences Term Trust (BMEZ)

Investment Objective

BlackRock Health Sciences Term Trust’s (BMEZ) (the “Trust”) (formerly known as BlackRock Health Sciences Trust II) investment objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation. Under normal market conditions, the Trust will invest at least 80% of its total assets in equity securities of companies principally engaged in the health sciences group of industries and equity derivatives with exposure to the health sciences group of industries. Equity derivatives in which the Trust invests include purchased and sold (written) call and put options on equity securities of companies in the health sciences group of industries.

On March 31, 2023 the Board approved a proposal to change the name of BlackRock Health Sciences Trust II, effective as of April 5, 2023, to BlackRock Health Sciences Term Trust. There were no changes to the Trust’s investment policies or strategies in conjunction with the name change.

No assurance can be given that the Trust’s investment objective will be achieved.

Trust Information

Symbol on New York Stock Exchange	BMEZ
Initial Offering Date	January 30, 2020
Current Distribution Rate on Closing Market Price as of June 30, 2023 ($16.42)(a)	10.60%
Current Monthly Distribution per Common Share(b)	$0.145000
Current Annualized Distribution per Common Share(b)	$1.740000

^(a)  Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate may consist of income, net realized gains and/or a return of capital. Past performance is not an indication of future results.

^(b)  The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain.

Market Price and Net Asset Value Per Share Summary

	06/30/23		12/31/22		Change			High		Low
Closing Market Price	$	16.42	$	15.43		6.42	%	$	16.99	$	15.22
Net Asset Value		19.06		18.76		1.60			19.72		17.93

Performance

Returns for the period ended June 30, 2023 were as follows:

			Average Annual Total Returns
	6-month			1 Year		Since Inception	(a)
Trust at NAV(b)(c)	7.11	%		12.12	%	6.20	%
Trust at Market Price(b)(c)	12.18			11.18		1.66
MSCI Custom ACWI SMID Growth HC Call Overwrite Index(d)	3.61			6.52		(9.81	)
MSCI ACWI(e)	13.93			16.53		7.50

^(a)  BMEZ commenced operations on January 30, 2020.

^(b)  All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.

^(c)  The Trust’s discount to NAV narrowed during the period, which accounts for the difference between performance based on market price and performance based on NAV.

^(d)  An index representing the Health Care sector stocks within the MSCI ACWI SMID Cap Growth Index and incorporating an option overlay component with a 25% overwrite level. The MSCI ACWI SMID Cap Growth Index captures mid- and small-cap securities exhibiting overall growth style characteristics across certain developed and emerging markets countries. The index commenced on March 31, 2022 and therefore the since inception return presented is for the period March 31, 2022 through the current reporting period.

^(e)  An index that captures large- and mid-cap representation across certain developed and emerging markets.

Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.

Past performance is not an indication of future results.

The Trust is presenting the performance of one or more indices for informational purposes only. The Trust is actively managed and does not seek to track or replicate the performance of any index. The index performance shown is not intended to be indicative of the Trust’s investment strategies, portfolio components or past or future performance.

More information about the Trust’s historical performance can be found in the “Closed End Funds” section of blackrock.com.

The following discussion relates to the Trust’s relative performance based on NAV:

What factors influenced performance?

Security selection in the biotechnology and medical devices & supplies sub-sectors made the largest sector-level contributions to relative performance.

T R U S T    S U M M A R Y 17

Trust Summary  as of June 30, 2023 (continued)      BlackRock Health Sciences Term Trust (BMEZ)

An out-of-benchmark position in Intuitive Surgical, Inc. was the leading contributor at the individual stock level. The surgical robot manufacturer benefited from recovering elective procedure volumes in the post-COVID environment. An overweight position in the medication and drug delivery device manufacturer Gerresheimer AG, which benefited from headlines regarding weight loss treatments, was also a top contributor. An out-of-benchmark position in Abcam PLC further contributed to results. The United Kingdom-based antibody researcher indicated that it is exploring a potential sale, boosting its stock.

An underweight in the healthcare providers and services sub-sector detracted from relative performance, as did stock selection in the category. An underweight in the orthodontics company Align Technology, Inc., which rallied after reporting strong earnings, was the largest detractor at the individual security level. An overweight position in the biopharmaceutical company Rhythm Pharmaceuticals, Inc. also detracted amid questions about its near-term product pipeline. An overweight position in Novocure, a United States-based oncology treatment provider, was another notable detractor. The company released weaker-than-expected clinical trial data for its electric field-based lung cancer treatment in June 2023, weighing on its shares.

The Trust used an options overlay strategy in which calls were written on a portion of the portfolio’s holdings. This strategy detracted to relative performance. The Trust’s practice of maintaining a specified level of monthly distributions to shareholders did not have a material impact on the Trust’s investment strategy.

Describe recent portfolio activity.

The Trust’s allocations to the medical devices and supplies (40% to 44%) and healthcare providers and services (6% to 8%) sub-sectors increased, while its weightings in the biotechnology (40% to 38%) and pharmaceuticals (7% to 6%) sub-sectors decreased.

Describe portfolio positioning at period end.

The investment adviser continued to seek opportunities in companies with attractive valuations, stable growth, and promising product pipelines over the medium to long term. It also considered new innovations and technological developments for selective growth opportunities in the biotechnology, pharmaceuticals and medical devices industries.

The investment adviser was encouraged by the healthcare sector’s resilience in the midst of the extraordinary macroeconomic and geopolitical challenges that characterized the first half of the reporting period believing the longer-term, secular drivers for the sector—innovation in medical technology and aging demographics in both developed and developing countries—remained in place. The investment adviser continued to identify investment opportunities in stable, cash-flow generating companies across the sector.

The Trust’s largest overweight positions in the biotechnology and medical devices and supplies sub-sectors, where it saw compelling innovation and new products.

As of June 30, 2023, the Trust had in place an option overwriting program whereby 24% of the underlying equities were overwritten with call options on individual stocks. These call options were typically written at prices above the prevailing market prices (estimated to be 7.6% out of the money) and for maturities averaging 57 days.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

Overview of the Trust’s Total Investments

TEN LARGEST HOLDINGS

Security(a)	Percent of Total Investments
Vertex Pharmaceuticals, Inc.		3.1	%
Alcon, Inc.		3.0
West Pharmaceutical Services, Inc.		2.5
Intuitive Surgical, Inc.		2.3
Dexcom, Inc.		2.3
Align Technology, Inc.		2.1
Stryker Corp.		1.9
Cooper Cos., Inc.		1.9
Penumbra, Inc.		1.8
AmerisourceBergen Corp.		1.8

INDUSTRY ALLOCATION

Industry(a)(b)	Percentage of Total Investments
Biotechnology		39.1	%
Health Care Equipment & Supplies		31.4
Life Sciences Tools & Services		13.4
Health Care Providers & Services		7.2
Pharmaceuticals		6.3
Health Care Technology		1.0
Other*		1.6

^(a)  Excludes short-term securities.

^(b)  For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

* Includes one or more investment categories that individually represents less than 1.0% of the Trust’s total investments. Please refer to the Schedule of Investments for details.

18 2 0 2 3   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Trust Summary  as of June 30, 2023       BlackRock Health Sciences Trust (BME)

Investment Objective

BlackRock Health Sciences Trust’s (BME) (the “Trust”) investment objective is to provide total return through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of companies engaged in the health sciences and related industries and equity derivatives with exposure to the health sciences industry. The Trust seeks to pursue this goal primarily by investing in a portfolio of equity securities and by employing a strategy of writing (selling) call and put options.

No assurance can be given that the Trust’s investment objective will be achieved.

Trust Information

Symbol on New York Stock Exchange	BME
Initial Offering Date	March 31, 2005
Current Distribution Rate on Closing Market Price as of June 30, 2023 ($40.64)(a)	6.29%
Current Monthly Distribution per Common Share(b)	$0.213000
Current Annualized Distribution per Common Share(b)	$2.556000

^(a)  Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate may consist of income, net realized gains and/or a return of capital. Past performance is not an indication of future results.

^(b)  The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain.

Market Price and Net Asset Value Per Share Summary

	06/30/23		12/31/22		Change			High		Low
Closing Market Price	$	40.64	$	43.58		(6.75	)%	$	43.68	$	39.34
Net Asset Value		42.83		43.30		(1.09	)		43.30		40.12

Performance

Returns for the period ended June 30, 2023 were as follows:

				Average Annual Total Returns
	6-month			1 Year			5 Years			10 Years
Trust at NAV(a)(b)		2.00	%		8.51	%		9.49	%		12.21	%
Trust at Market Price(a)(b)		(3.83	)		1.87			7.18			11.67
MSCI USA Investable Market Index Health Care Call Overwrite Index(c)		(0.84	)		5.44			N/A			N/A
Russell 3000® Health Care Index(d)		0.06			6.34			10.49			12.51

^(a)  All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.

^(b)  The Trust moved from a premium to NAV to a discount during the period, which accounts for the difference between performance based on market price and performance based on NAV.

^(c)  An index that incorporates an option overlay component on the MSCI USA IMI Health Care Index with a 33% overwrite level. The benchmark commenced on December 31, 2018 and therefore the benchmark does not have 5- and 10-year returns.

^(d)  An unmanaged index that features companies involved in medical services or health care in the Russell 3000^® Index, which includes the largest 3,000 U.S. companies as determined by total market capitalization.

Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.

Past performance is not an indication of future results.

The Trust is presenting the performance of one or more indices for informational purposes only. The Trust is actively managed and does not seek to track or replicate the performance of any index. The index performance shown is not intended to be indicative of the Trust’s investment strategies, portfolio components or past or future performance.

More information about the Trust’s historical performance can be found in the “Closed End Funds” section of blackrock.com.

The following discussion relates to the Trust’s relative performance based on NAV:

What factors influenced performance?

Stock selection in the pharmaceuticals and medical devices and supplies sub-sectors made the largest sector-level contributions to relative performance.

An underweight in Pfizer, Inc. was the leading contributor at the individual stock level. The company stated that its 2023 revenues could potentially decrease by 33% as demand for its COVID-19 products wanes. A zero weighting in CVS Corp. also contributed to returns. Shares of the healthcare services company declined on concerns about its ability to integrate its acquisitions into its core business. An overweight in Boston Scientific Corp. was another top contributor in the reporting period. The medical device manufacturer reported strong earnings and revenue growth as elective procedure volumes continued to increase. Hospital staffing shortages and COVID-19 restrictions created a difficult environment for patients to receive non-urgent procedures, but individuals increasingly have sought elective surgeries as these headwinds have eased.

At a sub-sector level, an underweight in the pharmaceuticals industry and security selection in the health care providers and services sub-sector were the largest detractors.

T R U S T    S U M M A R Y 19

Trust Summary  as of June 30, 2023 (continued)      BlackRock Health Sciences Trust (BME)

An overweight position in Novocure Ltd. was the most notable detractor among the Trust’s individual holdings. The company released weaker-than-expected clinical trial data for its electric field-based lung cancer treatment in June 2023, weighing on its shares. A zero weighting in the healthcare technology provider Veeva Systems, Inc., which reported strong earnings, also detracted from relative performance. An underweight position in HCA Healthcare Corp was a further detractor of note. The hospital operator reported robust earnings due in part to reduced pressure from labor shortages.

The Trust made use of options, principally writing call options on individual stocks, to seek enhanced income returns while continuing to participate in the performance of the underlying equities. The option overlay strategy contributed to results. The Trust’s practice of maintaining a specified level of monthly distributions to shareholders did not have a material impact on the Trust’s investment strategy.

Describe recent portfolio activity.

The Trust’s allocation to the medical devices and supplies (31% to 38%) sub-sector increased during the period, while its weightings in the pharmaceuticals (24% to 20%) and healthcare providers and supplies (21% to 17%) sub-sectors decreased. The Trust’s allocation to the biotechnology industry remained steady at 21%.

Describe portfolio positioning at period end.

The investment adviser continued to seek opportunities in companies with attractive valuations, stable growth, and promising product pipelines over the medium to long term. It also considered new innovations and technological developments for selective growth opportunities in the biotechnology, pharmaceuticals and medical devices industries.

The investment adviser was encouraged by the healthcare sector’s resilience in the midst of the extraordinary macroeconomic and geopolitical challenges that characterized the first half of the year believing the longer-term, secular drivers for the sector—innovation in medical technology and aging demographics in both developed and developing countries—remained in place. The investment adviser continued to identify investment opportunities in stable, cash-flow generating companies across the sector.

As of June 30, 2023, the Trust’s largest overweight was in the medical devices and supplies sub-sector believing hospitals are particularly attractive in the post-COVID environment. The Trust also held a large overweight position in the biotechnology sub-sector. It continued to emphasize compelling areas of innovation within the category, especially in oncology. The Trust’s largest underweight was in the pharmaceuticals industry, where many flagship medications may face increased competition from biosimilars due to patent expirations.

As of June 30, 2023, the Trust had in place an option overwriting program whereby 36% of the underlying equities were overwritten with call options on individual stocks. These call options were typically written at prices above the prevailing market prices (estimated to be 4.9% out of the money) and for maturities averaging 55 days.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

Overview of the Trust’s Total Investments

TEN LARGEST HOLDINGS

Security(a)	Percent of Total Investments
UnitedHealth Group, Inc.		8.2	%
Eli Lilly & Co.		6.5
Merck & Co., Inc.		4.9
Boston Scientific Corp.		4.2
Intuitive Surgical, Inc.		3.8
Thermo Fisher Scientific, Inc.		3.7
Stryker Corp.		3.6
Vertex Pharmaceuticals, Inc.		3.0
AbbVie, Inc.		2.7
Johnson & Johnson		2.6

INDUSTRY ALLOCATION

Industry(a)(b)	Percentage of Total Investments
Health Care Equipment & Supplies		29.5	%
Biotechnology		22.1
Pharmaceuticals		20.4
Health Care Providers & Services		17.8
Life Sciences Tools & Services		10.0
Health Care Technology		0.2

^(a)  Excludes short-term securities.

^(b)  For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

20 2 0 2 3   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Trust Summary  as of June 30, 2023      BlackRock Innovation and Growth Term Trust (BIGZ)

Investment Objective

BlackRock Innovation and Growth Term Trust’s (BIGZ) (the “Trust”) (formerly known as BlackRock Innovation and Growth Trust) investment objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation. The Trust will invest primarily in equity securities issued by mid-and small-capitalization companies that the Trust’s adviser believes have above-average earnings growth potential. In selecting investments for the Trust, the Trust’s adviser focuses on mid- and small-capitalization growth companies that are “innovative.” These are companies that have introduced, or are seeking to introduce, a new product or service that potentially changes the marketplace. The Trust utilizes an option writing (selling) strategy in an effort to generate current gains from options premiums and to enhance the Trust’s risk-adjusted returns.

On March 31, 2023 the Board approved a proposal to change the name of BlackRock Innovation and Growth Trust, effective as of April 5, 2023, to BlackRock Innovation and Growth Term Trust. There were no changes to the Trust’s investment policies or strategies in conjunction with the name change.

No assurance can be given that the Trust’s investment objective will be achieved.

Trust Information

Symbol on New York Stock Exchange	BIGZ
Initial Offering Date	March 29, 2021
Current Distribution Rate on Closing Market Price as of June 30, 2023 ($7.85)(a)	10.70%
Current Monthly Distribution per Common Share(b)	$0.070000
Current Annualized Distribution per Common Share(b)	$0.840000

^(a)  Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate may consist of income, net realized gains and/or a return of capital. Past performance is not an indication of future results.

^(b)  The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain.

Market Price and Net Asset Value Per Share Summary

	06/30/23		12/31/22		Change			High		Low
Closing Market Price	$	7.85	$	6.81		15.27	%	$	8.07	$	6.81
Net Asset Value		9.38		8.82		6.35			9.97		8.68

Performance

Returns for the period ended June 30, 2023 were as follows:

			Average Annual Total Returns
	6‑month			1 Year		Since Inception	(a)
Trust at NAV(b)(c)	12.30	%		10.26	%	(21.77	)%
Trust at Market Price(b)(c)	21.72			10.29		(27.71	)
MSCI USA SMID Growth Call Overwrite Index (d)	14.25			19.74		(1.40	)
Russell 2500™ Growth Index(e)	13.38			18.58		(5.17	)

^(a)  BIGZ commenced operations on March 29, 2021.

^(b)  All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.

^(c)  The Trust’s discount to NAV narrowed during the period, which accounts for the difference between performance based on market price and performance based on NAV.

^(d) A custom benchmark that is made up of the MSCI USA SMID Growth Index, MSCI USA SMID Growth 25% Call Overwrite Cash and MSCI USA SMID Growth 25% Call Overwrite Option. The MSCI USA SMID Growth Index captures mid and small cap representations of securities exhibiting overall growth style characteristics in the U.S.

^(e) An index that measures the performance of the small to mid-cap growth segment of the U.S. equity universe. It includes those Russell 2500 companies with higher growth earning potential as defined by FTSE Russell’s leading style methodology.

Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.

Past performance is not an indication of future results.

The Trust is presenting the performance of one or more indices for informational purposes only. The Trust is actively managed and does not seek to track or replicate the performance of any index. The index performance shown is not intended to be indicative of the Trust’s investment strategies, portfolio components or past or future performance.

More information about the Trust’s historical performance can be found in the “Closed End Funds” section of blackrock.com.

T R U S T    S U M M A R Y 21

Trust Summary  as of June 30, 2023 (continued)      BlackRock Innovation and Growth Term Trust (BIGZ)

The following discussion relates to the Trust’s relative performance based on NAV:

What factors influenced performance?

Positioning in the energy sector was the largest contributor to relative performance at the sector level, particularly due to the Trust’s decision to avoid investing in the oil, gas and consumable fuels industry. Within information technology (“IT”), a substantial overweight allocation to the semiconductors and semiconductor equipment industry proved beneficial, as an overweight allocation to Entegris Inc. boosted relative returns due to its status as a leading manufacturer of critical materials used in the semiconductor device fabrication process. Elsewhere, stock selection in industrials contributed to performance, most notably in the ground transportation and air freight and logistics industries. An overweight position in American less-than-truckload freight shipping specialist Saia Inc. led performance in the sector.

By contrast, the largest detractor from relative performance from a sector perspective was the Trust’s security selection within the healthcare sector. Most notably, the Trust’s decision to have an overweight position in the life sciences tools and services industry affected relative results negatively. Within this space, Azenta Inc. and Repligen Corp. were the most significant detractors among individual stocks, as both suffered significant share-price declines during the period. Elsewhere, an overweight position to the entertainment sub-sector within communication services also weighed on relative performance. Specifically, an off-benchmark position in upscale camping experience provider Under Canvas Inc. detracted. Stock selection in the consumer discretionary sector also detracted from performance, most notably through the Trust’s overweight exposure to fitness center chain Planet Fitness Inc. within the hotels, restaurants and leisure sub-sector.

The Trust utilized an options overlay strategy in which calls are written on a portion of the portfolio’s holdings. The Trust’s options overlay strategy contributed to relative performance for the period. The Trust’s practice of maintaining a specified level of monthly distributions did not have a material impact on the Trust’s investment strategy. However, the Trust’s distributions during the period were classified as a return of capital, which reduced the Trust’s net asset value.

Describe recent portfolio activity.

Due to a combination of market changes and portfolio activity, the Trust’s exposure to IT and financials increased. Conversely, the Trust’s exposure to the consumer discretionary and communication services sectors decreased. The Trust did not add new positions in any privately held companies during the period.

Describe portfolio positioning at period end.

At period end, the Trust’s largest sector overweight positions in the public equity portion of the portfolio were in the IT and consumer discretionary sectors, while the largest underweight positions were in industrials and materials.

As of June 30, 2023, the Trust had an options overwriting program in place whereby 12.0% of the underlying equities were overwritten with call options. These call options were typically written at levels above prevailing market prices (estimated to be 6.7% out of the money) with an average time until expiration of 58 days.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

22 2 0 2 3   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Trust Summary  as of June 30, 2023 (continued)      BlackRock Innovation and Growth Term Trust (BIGZ)

Overview of the Trust’s Total Investments

TEN LARGEST HOLDINGS

Security(a)	Percent of Total Investments
Monolithic Power Systems, Inc.		3.0	%
Axon Enterprise, Inc.		2.9
Saia, Inc.		2.8
Entegris, Inc.		2.8
Tradeweb Markets, Inc.		2.6
West Pharmaceutical Services, Inc.		2.3
Lattice Semiconductor Corp.		2.3
HEICO Corp.		2.2
MongoDB, Inc.		2.2
HubSpot, Inc.		2.2

INDUSTRY ALLOCATION

Industry(a)(b)	Percentage of Total Investments
Software		20.6	%
Semiconductors & Semiconductor Equipment		11.8
Life Sciences Tools & Services		8.2
Capital Markets		7.7
IT Services		7.0
Hotels, Restaurants & Leisure		5.5
Aerospace & Defense		5.3
Diversified Consumer Services		4.2
Automobile Components		3.3
Health Care Equipment & Supplies		3.0
Ground Transportation		2.8
Interactive Media & Services		2.8
Machinery		1.8
Entertainment		1.8
Construction & Engineering		1.6
Health Care Technology		1.6
Air Freight & Logistics		1.5
Health Care Providers & Services		1.4
Wireless Telecommunication Services		1.2
Food Products		1.2
Professional Services		1.1
Biotechnology		1.0
Building Products		1.0
Other*		2.6

^(a)  Excludes short-term securities.

^(b)  For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

* Includes one or more investment categories that individually represents less than 1.0% of the Trust’s total investments. Please refer to the Schedule of Investments for details.

T R U S T    S U M M A R Y 23

Trust Summary  as of June 30, 2023      BlackRock Resources & Commodities Strategy Trust (BCX)

Investment Objective

BlackRock Resources & Commodities Strategy Trust’s (BCX) (the “Trust”) primary investment objective is to seek high current income and current gains, with a secondary objective of capital appreciation. The Trust will seek to achieve its investment objectives, under normal market conditions, by investing at least 80% of its total assets in equity securities issued by commodity or natural resources companies, derivatives with exposure to commodity or natural resources companies or investments in securities and derivatives linked to the underlying price movement of commodities or natural resources. While permitted, the Trust does not currently expect to invest in securities and derivatives linked to the underlying price movement of commodities or natural resources. The Trust seeks to pursue this goal primarily by investing in a portfolio of equity securities and also by employing a strategy of writing (selling) call and put options.

No assurance can be given that the Trust’s investment objectives will be achieved.

Trust Information

Symbol on New York Stock Exchange	BCX
Initial Offering Date	March 30, 2011
Current Distribution Rate on Closing Market Price as of June 30, 2023 ($9.07)(a)	6.85%
Current Monthly Distribution per Common Share(b)	$0.051800
Current Annualized Distribution per Common Share(b)	$0.621600

^(a)  Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate may consist of income, net realized gains and/or a return of capital. Past performance is not an indication of future results.

^(b)  The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain.

Market Price and Net Asset Value Per Share Summary

	06/30/23		12/31/22		Change			High		Low
Closing Market Price	$	9.07	$	9.97		(9.03	)%	$	10.56	$	8.72
Net Asset Value		10.61		11.23		(5.52	)		11.90		10.03

Performance

Returns for the period ended June 30, 2023 were as follows:

			Average Annual Total Returns
	6-month			1 Year		5 Years		10 Years
Trust at NAV(a)(b)	(2.42	)%		13.56	%	7.64	%	5.70	%
Trust at Market Price(a)(b)	(6.04	)		7.57		6.49		5.08
MSCI ACWI Select Liquidity Natural Resources Call Overwrite Index(c)	(3.25	)		9.44		N/A		N/A
S&P Global Natural Resources Net Index(d)	(3.49	)		7.64		5.18		5.10

^(a)  All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.

^(b)  The Trust’s discount to NAV widened during the period, which accounts for the difference between performance based on market price and performance based on NAV.

^(c)  An index that incorporates an option overlay component on the MSCI ACWI Select Liquidity Natural Resources Index with a 33% overwrite level. The benchmark commenced on December 31, 2018 and therefore the benchmark does not have 5- and 10-year returns.

^(d)  An index that includes approximately 90 of the largest publicly-traded companies in the natural resources and commodities businesses that meet specific investability requirements across three primary commodity-related sectors: agribusiness, energy, and metals and mining.

Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.

Past performance is not an indication of future results.

The Trust is presenting the performance of one or more indices for informational purposes only. The Trust is actively managed and does not seek to track or replicate the performance of any index. The index performance shown is not intended to be indicative of the Trust’s investment strategies, portfolio components or past or future performance.

More information about the Trust’s historical performance can be found in the “Closed End Funds” section of blackrock.com.

The following discussion relates to the Trust’s absolute performance based on NAV:

What factors influenced performance?

An overweight position in Teck Resources, Ltd., which rallied after receiving a takeover bid from Glencore PLC, was the leading contributor to performance. An overweight position in the gold royalty company Wheaton Precious Metals Corp. also contributed to results on the strength of rising gold prices. Kerry Group PLC, a nutrition company that reported a strong increase in revenues, was a further contributor of note.

On the other hand, an overweight position in Glencore detracted as easing supply constraints in the energy sector contributed to a decline in coal prices. CF Industries Holdings Ltd. also underperformed, as fertilizer prices declined amid a normalization of global supply chains. Weakness in exploration and production companies within the energy sector, particularly ConocoPhillips, also detracted.

24 2 0 2 3   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Trust Summary  as of June 30, 2023 (continued)      BlackRock Resources & Commodities Strategy Trust (BCX)

The Trust used an options overlay strategy in which calls were written on a portion of the portfolio’s holdings. This strategy contributed to results in the reporting period. The Trust’s practice of maintaining a specified level of monthly distributions to shareholders did not have a material impact on the Trust’s investment strategy.

Describe recent portfolio activity.

The investment adviser maintained overweight positions in the energy and mining sectors, and it continued to have an underweight in agriculture.

Describe portfolio positioning at period end.

In the energy sector, the investment adviser maintained a bias toward higher-quality oil producers that it expects to benefit from long-term strength in energy prices, a potentially resurgent oilfield services sector and the need for increased liquified natural gas output to replace Russian gas exports into Europe. The investment adviser continued to prefer large-cap integrated companies, and it also added to positions in the midstream industry. In the mining sector, the investment adviser focused on companies with stronger balance sheets and lower costs. The Trust remained underweight in paper and packaging stocks in the agriculture sector, with a corresponding overweight in companies in the agricultural equipment and health and wellness space that it believed to have more attractive growth opportunities.

As of June 30, 2023, the Trust had in place an option overwriting program whereby 32.0% of the underlying equities were overwritten with call options on individual stocks. These call options were typically written at prices above the prevailing market prices (estimated to be 4.5% out of the money) and for maturities averaging 50 days.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

Overview of the Trust’s Total Investments

TEN LARGEST HOLDINGS

Security(a)	Percent of Total Investments
Shell PLC		8.0	%
Exxon Mobil Corp.		6.6
Glencore PLC		5.7
TotalEnergies SE		5.5
BP PLC		5.4
BHP Group Ltd.		4.5
Teck Resources Ltd.		3.9
Wheaton Precious Metals Corp.		3.8
Vale SA		3.7
Deere & Co.		2.9

INDUSTRY ALLOCATION

Industry(a)(b)	Percentage of Total Investments
Oil, Gas & Consumable Fuels		38.8	%
Metals & Mining		34.9
Chemicals		10.3
Food Products		7.1
Machinery		5.4
Energy Equipment & Services		1.2
Containers & Packaging		1.2
Paper & Forest Products		1.1

^(a)  Excludes short-term securities.

^(b)  For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

T R U S T    S U M M A R Y 25

Trust Summary  as of June 30, 2023       BlackRock Science and Technology Term Trust (BSTZ)

Investment Objective

BlackRock Science and Technology Term Trust’s (BSTZ) (the “Trust”) (formerly known as BlackRock Science and Technology Trust II) investment objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities issued by U.S. and non-U.S. science and technology companies in any market capitalization range, selected for their rapid and sustainable growth potential from the development, advancement and use of science and/or technology. The Trust seeks to pursue this goal primarily by investing in a portfolio of equity securities and also by employing a strategy of writing (selling) call and put options.

On March 31, 2023 the Board approved a proposal to change the name of BlackRock Science and Technology Trust II, effective as of April 5, 2023, to BlackRock Science and Technology Term Trust. There were no changes to the Trust’s investment policies or strategies in conjunction with the name change.

No assurance can be given that the Trust’s investment objective will be achieved.

Trust Information

Symbol on New York Stock Exchange	BSTZ
Initial Offering Date	June 27, 2019
Current Distribution Rate on Closing Market Price as of June 30, 2023 ($18.11)(a)	10.69%
Current Monthly Distribution per Common Share(b)	$0.161300
Current Annualized Distribution per Common Share(b)	$1.935600

^(a)  Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate may consist of income, net realized gains and/or a return of capital. Past performance is not an indication of future results.

^(b)  The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain.

Market Price and Net Asset Value Per Share Summary

	06/30/23		12/31/22		Change			High		Low
Closing Market Price	$	18.11	$	15.64		15.79	%	$	19.04	$	15.64
Net Asset Value		21.50		19.53		10.09			21.69		19.30

Performance

Returns for the period ended June 30, 2023 were as follows:

			Average Annual Total Returns
	6-month			1 Year		Since Inception	(a)
Trust at NAV(b)(c)	16.60	%		5.98	%	10.28	%
Trust at Market Price(b)(c)	22.64			4.26		5.66
MSCI Custom ACWI SMID Growth IT Call Overwrite Index(d)	19.92			21.62		(4.10	)
MSCI ACWI(e)	13.93			16.53		8.81

^(a)  BSTZ commenced operations on June 27, 2019.

^(b)  All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.

^(c)  The Trust’s discount to NAV narrowed during the period, which accounts for the difference between performance based on market price and performance based on NAV.

^(d)  An index representing the Information Technology (IT) sector stocks within the MSCI ACWI SMID Cap Growth Index and incorporating an option overlay component with a 25% overwrite level. An index that captures mid- and small-cap securities exhibiting overall growth style characteristics across certain developed and emerging markets. The index commenced on March 31, 2022 and therefore the since inception return presented is for the period March 31, 2022 through the current reporting period.

^(e)  An index that captures large- and mid-cap representation across certain developed and emerging markets.

Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.

Past performance is not an indication of future results.

The Trust is presenting the performance of one or more indices for informational purposes only. The Trust is actively managed and does not seek to track or replicate the performance of any index. The index performance shown is not intended to be indicative of the Trust’s investment strategies, portfolio components or past or future performance.

More information about the Trust’s historical performance can be found in the “Closed End Funds” section of blackrock.com.

26 2 0 2 3   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Trust Summary  as of June 30, 2023 (continued)      BlackRock Science and Technology Term Trust (BSTZ)

The following discussion relates to the Trust’s relative performance based on NAV:

What factors influenced performance?

The largest detractor from the Trust’s relative performance was security selection within the software and new industries sub-sectors. At the individual position level, the Trust’s off-benchmark position in privately held Think & Learn as the most significant detractor, as weakness across the educational technology industry combined with idiosyncratic governance challenges at the company weighed on the privately held company’s valuation. Elsewhere, the Trust’s lack of a position in data analytics company Palantir Technologies was another notable detractor. In its first-quarter 2023 financial results, Palantir announced strong revenue growth and posted the second quarter of positive net income in its history, showing a path toward sustainable profitability. Lastly, not holding a position in Advantest was also a key detractor. The Japanese manufacturer’s stock climbed as optimism around artificial intelligence (“AI”) grew, which could lead to increased demand for Advantest’s chip-testing devices.

Conversely, an overweight allocation to the semiconductors sub-sector and security selection within the hardware sub-sector were the most significant contributors to the Trust’s relative performance. An off-benchmark position in Nvidia was the largest contributor at the individual position level, as the semiconductor designer’s stock jumped on optimism surrounding surging demand for its graphics processing units (“GPUs”), which are used extensively in artificial intelligence (“AI”) applications. First-quarter 2023 financial results showed substantial incremental revenue from generative AI, and Nvidia substantially upgraded its guidance for the remainder of the year. Elsewhere, an off-benchmark position in Tesla also contributed, as the electric vehicle (“EV”) maker’s stock appreciated after the company reported record revenue for 2022 and revealed that demand growth for its EVs continued to outpace supply growth. Tiered pricing appeared as an effective tool for supporting sales growth. Lastly, the Trust’s lack of a position in EPAM Systems was a key contributor, as the engineering software company experienced softening enterprise demand for its non-critical software tools. The company cut its guidance for earnings and profit margins for the remainder of the year.

The Trust utilized an options overlay strategy in which calls are written on a portion of the portfolio’s holdings. The Trust’s options overlay strategy detracted from relative performance. The Trust’s practice of maintaining a specified level of monthly distributions did not have a material impact on the Trust’s investment strategy.

Describe recent portfolio activity.

During the reporting period, the Trust increased its exposure to the semiconductors sub-sector, including companies that stand to benefit from increased capital expenditures on GPUs for generative AI. The Trust trimmed select holdings in the software and services sub-sectors, as enterprise IT spending appears weak in the near-term. From a regional perspective, the Trust reduced its exposure to Chinese equities, reflecting caution about the pace of the economic recovery in the region as well as geopolitical uncertainty. The Trust did not make any new investments in privately held technology companies during the period.

Describe portfolio positioning at period end.

The Trust continued to perform due diligence on multiple new opportunities with the expectation of managing exposure to private investments over the coming quarters, given the current allocation to private equity. As of June 30, 2023, the Trust held 22 private investments, comprising 32.9% of total assets for a total commitment of approximately $546 million. The Trust continued to seek opportunities to harvest the illiquidity premium by taking advantage of the “closed” structure and adding exposure to private investments as capacity increases.

At period end, the Trust held 33% of assets in semiconductors, 25% in software, 13% in hardware, 11% in internet, 11% in services, 5% in new industries, and 3% in content & infrastructure. These industry exposures were the result of bottom-up stock selection.

As of June 30, 2023, the Trust had an options overwriting program in place whereby 29.0% of the underlying equities were overwritten with call options. These call options were typically written at levels above prevailing market prices (estimated to be 6.4% out of the money) with an average time until expiration of 51 days.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

T R U S T    S U M M A R Y 27

Trust Summary  as of June 30, 2023 (continued)      BlackRock Science and Technology Term Trust (BSTZ)

Overview of the Trust’s Total Investments

TEN LARGEST HOLDINGS

Security(a)	Percent of Total Investments
NVIDIA Corp.		4.1	%
ByteDance Ltd.		3.2
SambaNova Systems, Inc.		3.1
Synopsys, Inc.		3.1
Databricks, Inc.		3.0
Tesla, Inc.		2.9
PsiQuantum Corp.		2.5
GrubMarket, Inc.		2.5
Lattice Semiconductor Corp.		2.3
Monolithic Power Systems, Inc.		2.0

INDUSTRY ALLOCATION

Industry(a)(b)	Percentage of Total Investments
Semiconductors & Semiconductor Equipment		28.8	%
Software		23.8
IT Services		11.3
Electronic Equipment, Instruments & Components		6.9
Entertainment		3.8
Financial Services		3.2
Automobiles		2.9
Professional Services		2.6
Consumer Staples Distribution & Retail		2.5
Broadline Retail		2.4
Technology Hardware, Storage & Peripherals		2.0
Communications Equipment		1.8
Diversified Consumer Services		1.7
Media		1.6
Hotels, Restaurants & Leisure		1.2
Other*		3.5

^(a)  Excludes short-term securities.

^(b) For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

* Includes one or more investment categories that individually represents less than 1.0% of the Trust’s total investments. Please refer to the Consolidated Schedule of Investments for details.

28 2 0 2 3   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Trust Summary  as of June 30, 2023      BlackRock Science and Technology Trust (BST)

Investment Objective

BlackRock Science and Technology Trust’s (BST) (the “Trust”) investment objective is to provide income and total return through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of U.S. and non-U.S. science and technology companies in any market capitalization range, selected for their rapid and sustainable growth potential from the development, advancement and use of science and/or technology (high growth science and technology stocks), and/or potential to generate current income from advantageous dividend yields (cyclical science and technology stocks). The Trust seeks to pursue this goal primarily by investing in a portfolio of equity securities and also by employing a strategy of writing (selling) call and put options.

No assurance can be given that the Trust’s investment objective will be achieved.

Trust Information

Symbol on New York Stock Exchange	BST
Initial Offering Date	October 30, 2014
Current Distribution Rate on Closing Market Price as of June 30, 2023 ($34.44)(a)	8.71%
Current Monthly Distribution per Common Share(b)	$0.250000
Current Annualized Distribution per Common Share(b)	$3.000000

^(a)  Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate may consist of income, net realized gains and/or a return of capital. Past performance is not an indication of future results.

^(b) The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain.

Market Price and Net Asset Value Per Share Summary

	06/30/23		12/31/22		Change			High		Low
Closing Market Price	$	34.44	$	28.37		21.40	%	$	34.44	$	28.37
Net Asset Value		34.14		29.11		17.28			34.26		28.82

Performance

Returns for the period ended June 30, 2023 were as follows:

			Average Annual Total Returns
	6-month			1 Year		5 Years		Since Inception	(a)
Trust at NAV(b)(c)	22.90	%		11.69	%	10.41	%	14.99	%
Trust at Market Price(b)(c)	27.21			16.39		8.95		14.49
MSCI ACWI Information Technology Call Overwrite Index(d)	33.87			29.22		N/A		N/A
MSCI ACWI Information Technology Index(e)	36.90			34.28		17.71		17.85

^(a)  BST commenced operations on October 30, 2014.

^(b) All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.

^(c) The Trust moved from a discount to NAV to a premium during the period, which accounts for the difference between performance based on market price and performance based on NAV.

^(d) An index that incorporates an option overlay component on the MSCI ACWI IT Index with a 33% overwrite level. The benchmark commenced on December 31, 2018 and therefore the benchmark does not have 5- and 10-year returns.

^(e) An index that includes large- and mid-cap securities across certain Developed Markets countries and certain Emerging Markets countries. All securities in the index are classified in the Information Technology sector as per the Global Industry Classification Standard.

Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.

Past performance is not an indication of future results.

The Trust is presenting the performance of one or more indices for informational purposes only. The Trust is actively managed and does not seek to track or replicate the performance of any index. The index performance shown is not intended to be indicative of the Trust’s investment strategies, portfolio components or past or future performance.

More information about the Trust’s historical performance can be found in the “Closed End Funds” section of blackrock.com.

T R U S T    S U M M A R Y 29

Trust Summary  as of June 30, 2023 (continued)      BlackRock Science and Technology Trust (BST)

The following discussion relates to the Trust’s relative performance based on NAV:

What factors influenced performance?

The largest detractor from the Trust’s relative performance was security selection within the software and semiconductor sub-sectors. At the individual position level, the Trust’s underweight position in Apple was the largest detractor, as the company’s stock benefited from the rotation toward mega-cap technology stocks as part of a broader flight to quality in equity markets. Additionally, iPhone sales held up better than anticipated despite macroeconomic headwinds. Elsewhere, an underweight position in Nvidia was another notable detractor. The semiconductor designer’s stock jumped on optimism surrounding anticipated demand for its graphics processing units (“GPUs”), which are used extensively in artificial intelligence (“AI”) applications. First-quarter 2023 financial results showed incremental revenue from generative AI, and Nvidia substantially upgraded its guidance for the remainder of the period. Lastly, an off-benchmark position in privately held Bolt Financial was among the largest detractors from relative performance. The financial software company’s valuation fell along with its publicly traded fintech peers amid weak demand in the industry.

Conversely, security selection within the hardware sub-sector was the most significant contributor to the Trust’s relative performance. Among individual positions, an off-benchmark position in Tesla was the largest contributor, as the electric vehicle (“EV”) maker’s stock appreciated after the company reported record revenue for 2022 and revealed that demand growth for its EVs continued to outpace supply growth. Tiered pricing appeared as an effective tool for supporting sales growth. Elsewhere, an off-benchmark position in Meta Platforms notably contributed to relative performance, as investors rewarded the social media company’s stock for committing to cost discipline by reducing headcount and cutting operating expenses. Lastly, an overweight position in MongoDB was a key contributor to performance. The data management company saw its stock climb after reporting positive earnings results and boosting full-year guidance due to strong customer acquisition and retention metrics.

The Trust utilized an options overlay strategy in which calls are written on a portion of the portfolio’s holdings. The Trust’s options overlay strategy detracted to relative performance. The Trust’s practice of maintaining a specified level of monthly distributions did not have a material impact on the Trust’s investment strategy.

Describe recent portfolio activity.

During the reporting period, the Trust increased its exposure to the semiconductors sub-sector, including companies that stand to benefit from increased capital expenditures on GPUs for generative AI. The Trust trimmed select holdings in the services sub-sector, as enterprise IT spending appears weak in the near-term. From a regional perspective, the Trust reduced its exposure to Chinese equities, reflecting caution about the pace of the economic recovery in the region as well as geopolitical uncertainty. The Trust did not make any additional investments in privately held technology companies during the period.

Describe portfolio positioning at period end.

At period end, the Trust held 28% of its net asset value in the software sub-sector, 26% in semiconductors, 16% in internet, 14% in hardware, 11% in services, 4% in new industries, and 1% in content & infrastructure. These industry exposures were the result of bottom-up stock selection.

As of June 30, 2023, the Trust had an options overwriting program in place whereby 34.7% of the underlying equities were overwritten with call options. These call options were typically written at levels above prevailing market prices (estimated to be 5.0% out of the money) with an average time until expiration of 47 days.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

Overview of the Trust’s Total Investments

TEN LARGEST HOLDINGS

Security(a)	Percent of Total Investments
Microsoft Corp.		8.6	%
Apple, Inc.		8.2
NVIDIA Corp.		5.9
ASML Holding NV		2.7
Tesla, Inc.		2.4
Cadence Design Systems, Inc.		2.4
Mastercard, Inc.		2.3
Broadcom, Inc.		2.2
Amazon.com, Inc.		1.9
Meta Platforms, Inc.		1.9

INDUSTRY ALLOCATION

Industry(a)(b)	Percentage of Total Investments
Software		26.5	%
Semiconductors & Semiconductor Equipment		24.8
IT Services		9.6
Technology Hardware, Storage & Peripherals		8.6
Financial Services		6.4
Interactive Media & Services		4.5
Broadline Retail		3.5
Automobiles		2.4
Entertainment		2.3
Diversified Consumer Services		2.1
Electronic Equipment, Instruments & Components		1.8
Consumer Staples Distribution & Retail		1.4
Professional Services		1.0
Other*		5.1

^(a)  Excludes short-term securities.

^(b)  For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

* Includes one or more investment categories that individually represents less than 1.0% of the Trust’s total investments. Please refer to the Consolidated Schedule of Investments for details.

30 2 0 2 3   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Trust Summary  as of June 30, 2023       BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI)

Investment Objective

BlackRock Utilities, Infrastructure & Power Opportunities Trust’s (BUI) (the “Trust”) investment objective is to provide total return through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities issued by companies that are engaged in the Utilities, Infrastructure and Power Opportunities business segments anywhere in the world and by employing a strategy of writing (selling) call and put options. The Trust considers the “Utilities” business segment to include products, technologies and services connected to the management, ownership, operation, construction, development or financing of facilities used to generate, transmit or distribute electricity, water, natural resources or telecommunications, the “Infrastructure” business segment to include companies that own or operate infrastructure assets or that are involved in the development, construction, distribution or financing of infrastructure assets and the “Power Opportunities” business segment to include companies with a significant involvement in, supporting, or necessary to renewable energy technology and development, alternative fuels, energy efficiency, automotive and sustainable mobility and technologies that enable or support the growth and adoption of new power and energy sources. Under normal circumstances, the Trust invests a substantial amount of its total assets in foreign issuers, issuers that primarily trade in a market located outside the United States or issuers that do a substantial amount of business outside the United States. The Trust may invest directly in such securities or synthetically through the use of derivatives.

No assurance can be given that the Trust’s investment objective will be achieved.

Trust Information

Symbol on New York Stock Exchange	BUI
Initial Offering Date	November 25, 2011
Current Distribution Rate on Closing Market Price as of June 30, 2023 ($22.04)(a)	6.59%
Current Monthly Distribution per Common Share(b)	$0.121000
Current Annualized Distribution per Common Share(b)	$1.452000

^(a) Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. Past performance is not an indication of future results.

^(b) The distribution rate is not constant and is subject to change.

Market Price and Net Asset Value Per Share Summary

	06/30/23		12/31/22		Change			High		Low
Closing Market Price	$	22.04	$	20.77		6.11	%	$	23.98	$	20.77
Net Asset Value		22.96		22.37		2.64			23.39		21.90

Performance

Returns for the period ended June 30, 2023 were as follows:

			Average Annual Total Returns
	6-month			1 Year		5 Years		10 Years
Trust at NAV(a)(b)	5.97	%		13.18	%	9.52	%	8.96	%
Trust at Market Price(a)(b)	9.56			7.55		8.90		9.44
MSCI World Select Energy, Utilities and Industry Call Overwrite Index(c)	8.68			11.62		N/A		N/A
MSCI ACWI(d)	13.93			16.53		8.10		8.75

^(a)  All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.

^(b)  The Trust’s discount to NAV narrowed during the period, which accounts for the difference between performance based on market price and performance based on NAV.

^(c)  An index that incorporates an option overlay component on the MSCI World Select Energy, Utilities and Industry Index with a 33% overwrite level. The benchmark commenced on December 31, 2018 and therefore the benchmark does not have 5- and 10-year returns.

^(d)  An index that captures large- and mid-cap representation across certain developed and emerging markets.

Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.

Past performance is not an indication of future results.

The Trust is presenting the performance of one or more indices for informational purposes only. The Trust is actively managed and does not seek to track or replicate the performance of any index. The index performance shown is not intended to be indicative of the Trust’s investment strategies, portfolio components or past or future performance.

More information about the Trust’s historical performance can be found in the “Closed End Funds” section of blackrock.com.

The following discussion relates to the Trust’s relative performance based on NAV:

What factors influenced performance?

The largest detractors from relative returns were the Trust’s positions in clean power utility NextEra Energy and United States based rooftop solar company Sunrun. NextEra’s share price fell following an unexpected announcement of a change in management at its regulated utility subsidiary. Sunrun felt pressure from the collapse of SVB Financial’s Silicon Valley Bank, which could prompt a tightening of financial conditions more broadly.

T R U S T    S U M M A R Y 31

Trust Summary  as of June 30, 2023 (continued)      BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI)

Conversely, the most significant contributor to relative returns came from the interest among investors in areas related to artificial intelligence (“AI”), particularly among semiconductor companies. The Trust’s holdings in Infineon Technologies and STMicroelectronics benefited as a result. Data center and power management companies Eaton and Schneider Electric also outperformed, as investors expected increased demand for data centers to support AI efforts. Both companies reported bottom-line financial results above consensus forecasts. Power infrastructure specialist Quanta also performed strongly after reporting financial results that were stronger than expected and raising its earnings guidance for the remainder of 2023.

The Trust utilized an options overlay strategy in which calls are written on a portion of the portfolio’s holdings. The Trust’s options overlay strategy detracted from relative performance for the six-month period. The Trust’s practice of maintaining a specified level of monthly distributions to shareholders did not have a material impact on the Trust’s investment strategy.

Describe recent portfolio activity.

During the period, the Trust added to its positions in clean power utility companies. It also purchased new positions, one in the electric vehicle supply chain business focused on batteries, and another in freight and logistics. The Trust also increased its exposure to select semiconductor manufacturers early in the period.

Describe portfolio positioning at period end.

At period end, the utilities sector accounted for 49.1% of the Trust’s assets. The Trust had 28.7% and 10.0% of its assets invested in the industrials and energy sectors respectively, and the remainder was invested in other infrastructure- and power-related sectors.

As of June 30, 2023, the Trust had an options overwriting program in place whereby 34% of the underlying equities were overwritten with call options. These call options were typically written at levels above prevailing market prices (estimated to be 2.8% out of the money) with an average time until expiration of 53 days.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

Overview of the Trust’s Total Investments

TEN LARGEST HOLDINGS

Security(a)	Percent of Total Investments
NextEra Energy, Inc.		8.1	%
Enel SpA		4.8
RWE AG		4.2
Vinci SA		3.4
Waste Management, Inc.		3.2
Williams Cos., Inc.		3.1
Sempra Energy		2.9
Cheniere Energy, Inc.		2.7
Atlas Copco AB		2.6
American Electric Power Co., Inc.		2.6

INDUSTRY ALLOCATION

Industry(a)(b)	Percentage of Total Investments
Electric Utilities		31.0	%
Oil, Gas & Consumable Fuels		10.2
Multi-Utilities		10.2
Independent Power and Renewable Electricity Producers		8.8
Electrical Equipment		5.7
Building Products		5.7
Semiconductors & Semiconductor Equipment		5.6
Machinery		5.5
Commercial Services & Supplies		5.3
Construction & Engineering		5.3
Chemicals		4.1
Electronic Equipment, Instruments & Components		1.6
Ground Transportation		1.0

^(a)  Excludes short-term securities.

^(b)  For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

32 2 0 2 3   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Schedule of Investments (unaudited) June 30, 2023 BlackRock Energy and Resources Trust (BGR) (Percentages shown are based on Net Assets)

Security	Shares		Value
Common Stocks
Energy Equipment & Services — 3.9%
Schlumberger NV(a)		264,350	$	12,984,872
Tenaris SA		133,100		1,991,049
				14,975,921
Food Products — 0.5%
Darling Ingredients, Inc.(a)(b)		29,524		1,883,336
Oil, Gas & Consumable Fuels — 94.8%
ARC Resources Ltd.		368,380		4,913,587
BP PLC		4,394,600		25,587,005
Canadian Natural Resources Ltd.		298,109		16,760,263
Cenovus Energy, Inc.		579,006		9,834,033
Cheniere Energy, Inc.(a)		79,100		12,051,676
Chevron Corp.(a)		114,320		17,988,252
ConocoPhillips(a)		248,993		25,798,125
Diamondback Energy, Inc.(a)		59,650		7,835,624
Eni SpA		550,750		7,928,810
EOG Resources, Inc.(a)		137,929		15,784,595
Exxon Mobil Corp.(a)(c)		661,895		70,988,239
Gazprom PJSC(d)		879,200		98
Hess Corp.(a)		102,440		13,926,718
Kinder Morgan, Inc.(a)		587,500		10,116,750
Kosmos Energy Ltd.(a)(b)		466,934		2,796,935
Marathon Petroleum Corp.(a)		92,575		10,794,245
Santos Ltd.		230,436		1,152,984
Shell PLC, ADR(a)		667,722		40,317,054
TC Energy Corp.		156,350		6,318,912
TotalEnergies SE		455,498		26,147,691
Tourmaline Oil Corp.		145,233		6,843,136
Valero Energy Corp.(a)		81,374		9,545,170
Williams Cos., Inc.(a)		511,232		16,681,500
				360,111,402
Total Long-Term Investments — 99.2% (Cost: $265,831,324)				376,970,659

Security	Shares		Value
Short-Term Securities
Money Market Funds — 1.5%
BlackRock Liquidity Funds, T-Fund, Institutional Class, 4.98%(e)(f)		5,580,127	$	5,580,127
Total Short-Term Securities — 1.5% (Cost: $5,580,127)				5,580,127
Total Investments Before Options Written — 100.7% (Cost: $271,411,451)				382,550,786
Options Written — (0.7)% (Premiums Received: $(2,918,083))				(2,556,321	)
Total Investments, Net of Options Written — 100.0% (Cost: $268,493,368)				379,994,465
Other Assets Less Liabilities — 0.0%				48,033
Net Assets — 100.0%			$	380,042,498

^(a)  All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.

^(b)  Non-income producing security.

^(c)  All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives.

^(d)  Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy.

^(e)  Affiliate of the Trust.

^(f)  Annualized 7-day yield as of period end.

For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

Affiliates

Investments in issuers considered to be affiliate(s) of the Trust during the six months ended June 30, 2023 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

Affiliated Issuer	Value at 12/31/22		Purchases at Cost		Proceeds from Sales			Net Realized Gain (Loss)		Change in Unrealized Appreciation (Depreciation)		Value at 06/30/23		Shares Held at 06/30/23		Income		Capital Gain Distributions from Underlying Funds
BlackRock Liquidity Funds, T-Fund, Institutional Class	$	7,695,475	$	—	$	(2,115,348	)(a)	$	—	$	—	$	5,580,127		5,580,127	$	154,603	$	—

^(a)  Represents net amount purchased (sold).

Derivative Financial Instruments Outstanding as of Period End

Exchange-Traded Options Written

Description

Number of Contracts

Expiration Date

Exercise Price

Notional Amount (000)

Value

Call

ConocoPhillips

208

07/07/23

USD

102.00

USD

2,155

$

(46,800

)

S C H E D U L E   O F   I N V E S T M E N T S 33

Schedule of Investments (unaudited) (continued) June 30, 2023 BlackRock Energy and Resources Trust (BGR)

Exchange-Traded Options Written (continued)

Description	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call (continued)
Exxon Mobil Corp.		301		07/07/23		USD	111.62		USD	3,228	$	(3,043	)
Hess Corp.		170		07/07/23		USD	133.00		USD	2,311		(63,750	)
Shell PLC, ADR		414		07/07/23		USD	58.00		USD	2,500		(102,465	)
Diamondback Energy, Inc.		97		07/11/23		USD	137.00		USD	1,274		(5,556	)
Cheniere Energy, Inc.		86		07/14/23		USD	150.00		USD	1,310		(34,400	)
ConocoPhillips		438		07/14/23		USD	108.00		USD	4,538		(20,367	)
Exxon Mobil Corp.		337		07/14/23		USD	112.00		USD	3,614		(9,436	)
Hess Corp.		52		07/14/23		USD	139.00		USD	707		(8,320	)
Kinder Morgan, Inc.		488		07/14/23		USD	17.50		USD	840		(3,416	)
Schlumberger NV		173		07/14/23		USD	50.00		USD	850		(13,062	)
Shell PLC, ADR		728		07/14/23		USD	60.00		USD	4,396		(81,900	)
Valero Energy Corp.		138		07/14/23		USD	119.00		USD	1,619		(26,841	)
Williams Cos., Inc.		515		07/14/23		USD	31.00		USD	1,680		(87,550	)
Arc Resources Ltd.		515		07/21/23		CAD	17.00		CAD	910		(36,932	)
Canadian Natural Resources Ltd.		249		07/21/23		CAD	78.00		CAD	1,855		(7,894	)
Cenovus Energy, Inc.		1,429		07/21/23		CAD	22.50		CAD	3,215		(71,194	)
Cheniere Energy, Inc.		47		07/21/23		USD	150.00		USD	716		(22,795	)
Darling Ingredients, Inc.		74		07/21/23		USD	65.00		USD	472		(9,805	)
Diamondback Energy, Inc.		91		07/21/23		USD	135.00		USD	1,195		(15,243	)
EOG Resources, Inc.		249		07/21/23		USD	117.50		USD	2,850		(34,860	)
Exxon Mobil Corp.		77		07/21/23		USD	115.00		USD	826		(1,463	)
Kinder Morgan, Inc.		640		07/21/23		USD	17.00		USD	1,102		(27,520	)
Marathon Petroleum Corp.		132		07/21/23		USD	115.00		USD	1,539		(51,810	)
Schlumberger NV		234		07/21/23		USD	50.00		USD	1,149		(28,899	)
TC Energy Corp.		262		07/21/23		CAD	56.00		CAD	1,403		(1,780	)
Tourmaline Oil Corp.		348		07/21/23		CAD	62.50		CAD	2,172		(42,950	)
Cheniere Energy, Inc.		124		07/28/23		USD	155.00		USD	1,889		(34,100	)
Chevron Corp.		374		07/28/23		USD	160.00		USD	5,885		(99,110	)
ConocoPhillips		172		07/28/23		USD	104.00		USD	1,782		(48,160	)
EOG Resources, Inc.		211		07/28/23		USD	113.00		USD	2,415		(84,400	)
Exxon Mobil Corp.		539		07/28/23		USD	108.00		USD	5,781		(133,402	)
Hess Corp.		110		07/28/23		USD	141.00		USD	1,495		(27,775	)
Marathon Petroleum Corp.		175		07/28/23		USD	115.00		USD	2,041		(77,875	)
Schlumberger NV		335		07/28/23		USD	49.00		USD	1,646		(64,822	)
Shell PLC, ADR		510		07/28/23		USD	63.00		USD	3,079		(24,225	)
Valero Energy Corp.		137		07/28/23		USD	115.00		USD	1,607		(78,432	)
Williams Cos., Inc.		557		07/28/23		USD	31.40		USD	1,817		(85,680	)
Exxon Mobil Corp.		540		08/04/23		USD	109.00		USD	5,792		(129,600	)
Schlumberger NV		130		08/04/23		USD	50.00		USD	639		(22,100	)
Shell PLC, ADR		551		08/04/23		USD	61.00		USD	3,327		(77,140	)
Williams Cos., Inc.		556		08/04/23		USD	31.40		USD	1,814		(94,073	)
Arc Resources Ltd.		273		08/18/23		CAD	18.00		CAD	482		(14,528	)
Canadian Natural Resources Ltd.		746		08/18/23		CAD	76.00		CAD	5,556		(126,422	)
Cenovus Energy, Inc.		359		08/18/23		CAD	23.00		CAD	808		(26,557	)
Darling Ingredients, Inc.		23		08/18/23		USD	64.75		USD	147		(7,199	)
Exxon Mobil Corp.		390		08/18/23		USD	110.00		USD	4,183		(94,770	)
Kinder Morgan, Inc.		810		08/18/23		USD	17.00		USD	1,395		(41,715	)
TC Energy Corp.		253		08/18/23		CAD	56.00		CAD	1,355		(8,785	)
Tourmaline Oil Corp.		131		08/18/23		CAD	62.00		CAD	818		(33,374	)
Arc Resources Ltd.		427		09/15/23		CAD	18.00		CAD	755		(30,299	)
											$	(2,324,594	)

34 2 0 2 3   B L A C K R O C K  S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Schedule of Investments (unaudited) (continued) June 30, 2023 BlackRock Energy and Resources Trust (BGR)

OTC Options Written

Description	Counterparty	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call
BP PLC	Morgan Stanley & Co. International PLC		720,900		07/11/23		GBP	4.97		GBP	3,305	$	(760	)
Tenaris SA	Morgan Stanley & Co. International PLC		12,000		07/11/23		EUR	13.00		EUR	165		(10,088	)
TotalEnergies SE	UBS AG		32,000		07/11/23		EUR	58.79		EUR	1,683		(72	)
Santos Ltd.	UBS AG		117,400		07/13/23		AUD	7.48		AUD	882		(11,857	)
TotalEnergies SE	Barclays Bank PLC		115,900		07/13/23		EUR	54.14		EUR	6,097		(26,969	)
Tenaris SA	Morgan Stanley & Co. International PLC		70,300		07/25/23		EUR	12.94		EUR	964		(71,033	)
Santos Ltd.	UBS AG		111,200		07/26/23		AUD	7.83		AUD	835		(5,448	)
BP PLC	Barclays Bank PLC		618,600		08/02/23		GBP	5.02		GBP	2,836		(12,711	)
Eni SpA	Goldman Sachs International		130,200		08/03/23		EUR	12.92		EUR	1,718		(67,531	)
Eni SpA	JPMorgan Chase Bank N.A.		51,500		08/14/23		EUR	13.07		EUR	679		(25,258	)
												$	(231,727	)

Balances Reported in the Statements of Assets and Liabilities for Options Written

Description	Swap Premiums Paid		Swap Premiums Received		Unrealized Appreciation		Unrealized Depreciation			Value
Options Written	$	N/A	$	N/A	$	896,114	$	(534,352	)	$	(2,556,321	)

Derivative Financial Instruments Categorized by Risk Exposure

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

	Commodity Contracts		Credit   Contracts		Equity Contracts		Foreign Currency   Exchange Contracts		Interest Rate   Contracts		Other   Contracts		Total
Liabilities — Derivative Financial Instruments
Options written
Options written at value	$	—	$	—	$	2,556,321	$	—	$	—	$	—	$	2,556,321

For the period ended June 30, 2023, the effect of derivative financial instruments in the Statements of Operations was as follows:

	Commodity Contracts		Credit   Contracts		Equity Contracts			Foreign Currency   Exchange Contracts		Interest Rate   Contracts		Other   Contracts		Total
Net Realized Gain (Loss) from:
Options purchased(a)	$	—	$	—	$	(734,586	)	$	—	$	—	$	—	$	(734,586	)
Options written		—		—		10,781,255			—		—		—		10,781,255
	$	—	$	—	$	10,046,669		$	—	$	—	$	—	$	10,046,669
Net Change in Unrealized Appreciation (Depreciation) on:
Options written	$	—	$	—	$	(2,063,487	)	$	—	$	—	$	—	$	(2,063,487	)

^(a)  Options purchased are included in net realized gain (loss) from investments — unaffiliated.

Average Quarterly Balances of Outstanding Derivative Financial Instruments

Options:
Average value of option contracts purchased	$	—	(a)
Average value of option contracts written	$	2,801,514

^(a)  Derivative not held at any quarter-end. The risk exposure table serves as an indicator of activity during the period.

For more information about the Trust’s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.

S C H E D U L E    O F   I N V E S T M E N T S 35

Schedule of Investments (unaudited) (continued) June 30, 2023 BlackRock Energy and Resources Trust (BGR)

Derivative Financial Instruments — Offsetting as of Period End

The Trust’s derivative assets and liabilities (by type) were as follows:

	Assets		Liabilities
Derivative Financial Instruments
Options	$	—	$	2,556,321
Total derivative assets and liabilities in the Statements of Assets and Liabilities		—		2,556,321
Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”)		—		(2,324,594	)
Total derivative assets and liabilities subject to an MNA	$	—	$	231,727

The following table presents the Trust’s derivative liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral pledged by the Trust:

Counterparty		Derivative Liabilities Subject to an MNA by   Counterparty		Derivatives Available for Offset		Non-Cash Collateral Pledged	(a)		Cash     Collateral Pledged		Net Amount of Derivative Liabilities	(b)
Barclays Bank PLC	$	39,680	$	—	$	—		$	—	$	39,680
Goldman Sachs International		67,531		—		—			—		67,531
JPMorgan Chase Bank N.A.		25,258		—		—			—		25,258
Morgan Stanley & Co. International PLC		81,881		—		(81,881	)		—		—
UBS AG		17,377		—		—			—		17,377
	$	231,727	$	—	$	(81,881	)	$	—	$	149,846

^(a)  Excess of collateral received/pledged, if any, from the individual counterparty is not shown for financial reporting purposes.

^(b)  Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.

Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of financial instruments. For a description of the input levels and information about the Trust’s policy regarding valuation of financial instruments, refer to the Notes to Financial Statements.

The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust’s financial instruments into major categories is disclosed in the Schedule of Investments above.

	Level 1			Level 2			Level 3		Total
Assets
Investments
Long-Term Investments
Common Stocks
Energy Equipment & Services	$	12,984,872		$	1,991,049		$	—	$	14,975,921
Food Products		1,883,336			—			—		1,883,336
Oil, Gas & Consumable Fuels		299,294,814			60,816,490			98		360,111,402
Short-Term Securities
Money Market Funds		5,580,127			—			—		5,580,127
	$	319,743,149		$	62,807,539		$	98	$	382,550,786
Derivative Financial Instruments(a)
Liabilities
Equity Contracts	$	(2,129,043	)	$	(427,278	)	$	—	$	(2,556,321	)

^(a)  Derivative financial instruments are options written. Options written are shown at value.

See notes to financial statements.

36 2 0 2 3   B L A C K R O C K  S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Schedule of Investments (unaudited) June 30, 2023      BlackRock Enhanced Capital and Income Fund, Inc. (CII) (Percentages shown are based on Net Assets)

Security	Shares		Value
Common Stocks
Automobile Components — 1.5%
Aptiv PLC(a)		126,010	$	12,864,361
Automobiles — 1.6%
General Motors Co.(b)		341,631		13,173,291
Banks — 1.7%
JPMorgan Chase & Co.(b)		99,251		14,435,065
Beverages — 1.5%
Monster Beverage Corp.(a)		216,910		12,459,310
Broadline Retail — 5.2%
Amazon.com, Inc.(a)(b)		335,180		43,694,065
Building Products — 0.8%
Allegion PLC		56,430		6,772,729
Capital Markets — 2.9%
Intercontinental Exchange, Inc.(b)		126,827		14,341,597
LPL Financial Holdings, Inc.		47,640		10,358,365
				24,699,962
Chemicals — 3.3%
Axalta Coating Systems Ltd.(a)		327,975		10,760,860
Corteva, Inc.(b)		301,838		17,295,317
				28,056,177
Communications Equipment — 1.4%
Ciena Corp.(a)		285,002		12,109,735
Consumer Staples Distribution & Retail(b) — 2.9%
Dollar General Corp.		73,048		12,402,089
Dollar Tree, Inc.(a)		86,262		12,378,597
				24,780,686
Containers & Packaging — 1.2%
Sealed Air Corp.(b)		246,250		9,850,000
Entertainment — 1.0%
World Wrestling Entertainment, Inc., Class A(b)		80,044		8,682,373
Financial Services — 6.2%
Berkshire Hathaway, Inc., Class B(a)(b)		68,608		23,395,328
FleetCor Technologies, Inc.(a)		58,480		14,683,158
Visa, Inc., Class A(b)		21,280		5,053,574
Voya Financial, Inc.		125,650		9,010,362
				52,142,422
Food Products — 1.7%
Mondelez International, Inc., Class A(b)		198,980		14,513,601
Health Care Equipment & Supplies — 1.3%
Medtronic PLC		122,460		10,788,726
Health Care Providers & Services — 7.6%
Elevance Health, Inc.		22,105		9,821,030
Humana, Inc.(b)		21,748		9,724,183
Laboratory Corp. of America Holdings(b)		63,675		15,366,688
Tenet Healthcare Corp.(a)		137,120		11,158,826
UnitedHealth Group, Inc.(b)		37,553		18,049,474
				64,120,201
Health Care Technology — 1.0%
Veeva Systems, Inc., Class A(a)(b)		40,976		8,102,184

Security	Shares		Value
Hotels, Restaurants & Leisure — 1.0%
Las Vegas Sands Corp.(a)(b)		148,428	$	8,608,824
Household Durables — 1.3%
Sony Group Corp., ADR		126,340		11,375,654
Insurance — 3.0%
Fidelity National Financial, Inc.		238,540		8,587,440
Progressive Corp.		68,340		9,046,166
Reinsurance Group of America, Inc.(b)		56,480		7,833,211
				25,466,817
Interactive Media & Services(a) — 8.0%
Alphabet, Inc., Class A		354,280		42,407,315
Meta Platforms, Inc., Class A(b)		88,949		25,526,584
				67,933,899
IT Services — 1.5%
Cognizant Technology Solutions Corp., Class A		199,360		13,014,221
Life Sciences Tools & Services — 1.2%
Avantor, Inc.(a)		493,590		10,138,339
Machinery(b) — 5.0%
Caterpillar, Inc.		64,230		15,803,792
Fortive Corp.		231,873		17,337,144
Otis Worldwide Corp.		103,577		9,219,389
				42,360,325
Media(b) — 3.7%
Comcast Corp., Class A		596,952		24,803,356
Fox Corp., Class A		196,008		6,664,272
				31,467,628
Oil, Gas & Consumable Fuels — 4.3%
BP PLC, ADR(c)		332,140		11,721,221
ConocoPhillips(b)		130,218		13,491,887
EQT Corp.(b)		273,977		11,268,674
				36,481,782
Personal Care Products — 1.2%
Unilever PLC, ADR(b)		197,048		10,272,112
Pharmaceuticals — 3.8%
Novo Nordisk A/S, ADR(b)		89,033		14,408,210
Sanofi, ADR		334,050		18,005,295
				32,413,505
Professional Services — 1.2%
Dun & Bradstreet Holdings, Inc.		859,540		9,944,878
Semiconductors & Semiconductor Equipment — 6.5%
Advanced Micro Devices, Inc.(a)		112,810		12,850,187
Analog Devices, Inc.(b)		64,070		12,481,477
Applied Materials, Inc.(b)		137,120		19,819,325
Marvell Technology, Inc.		165,720		9,906,742
				55,057,731
Software — 8.6%
Microsoft Corp.(b)		214,161		72,930,387
Specialty Retail — 1.7%
Ross Stores, Inc.(b)		126,968		14,236,922
Technology Hardware, Storage & Peripherals — 5.1%
Apple, Inc.(b)		220,458		42,762,238

S C H E D U L E   O F   I N V E S T M E N T S 37

Schedule of Investments (unaudited) (continued) June 30, 2023      BlackRock Enhanced Capital and Income Fund, Inc. (CII) (Percentages shown are based on Net Assets)

Security	Shares		Value
Textiles, Apparel & Luxury Goods — 0.7%
Skechers USA, Inc., Class A(a)		118,530	$	6,241,790
Total Long-Term Investments — 100.6% (Cost: $560,929,271)				851,951,940
Short-Term Securities
Money Market Funds — 1.6%
BlackRock Liquidity Funds, T-Fund, Institutional Class, 4.98%(d)(e)		13,210,705		13,210,705
SL Liquidity Series, LLC, Money Market Series, 5.28%(d)(e)(f)		36		36
Total Short-Term Securities — 1.6% (Cost: $13,210,741)				13,210,741
Total Investments Before Options Written — 102.2% (Cost: $574,140,012)				865,162,681
Options Written — (2.1)% (Premiums Received: $(12,842,348))				(17,316,604	)
Total Investments, Net of Options Written — 100.1% (Cost: $561,297,664)				847,846,077
Liabilities in Excess of Other Assets — (0.1)%				(1,184,989	)
Net Assets — 100.0%			$	846,661,088

^(a)  Non-income producing security.

^(b)  All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.

^(c)  All or a portion of this security is on loan.

^(d)  Affiliate of the Trust.

^(e)  Annualized 7-day yield as of period end.

^(f) All or a portion of this security was purchased with the cash collateral from loaned securities.

For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

Affiliates

Investments in issuers considered to be affiliate(s) of the Trust during the six months ended June 30, 2023 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

Affiliated Issuer	Value at 12/31/22		Purchases at Cost			Proceeds from Sales			Net Realized Gain (Loss)			Change in Unrealized Appreciation (Depreciation)		Value at 06/30/23		Shares Held at 06/30/23		Income			Capital Gain Distributions from Underlying Funds
BlackRock Liquidity Funds, T-Fund, Institutional Class	$	14,661,156	$	—		$	(1,450,451	)(a)	$	—		$	—	$	13,210,705		13,210,705	$	275,672		$	—
SL Liquidity Series, LLC, Money Market Series		—		550	(a)		—			(514	)		—		36		36		5,638	(b)		—
									$	(514	)	$	—	$	13,210,741			$	281,310		$	—

^(a)  Represents net amount purchased (sold).

^(b)  All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities.

Derivative Financial Instruments Outstanding as of Period End

Exchange-Traded Options Written

Description	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call
Alphabet, Inc., Class A		322		07/07/23		USD	124.34		USD	3,854	$	(5,141	)
Amazon.com, Inc.		384		07/07/23		USD	123.00		USD	5,006		(286,080	)
Analog Devices, Inc.		148		07/07/23		USD	185.00		USD	2,883		(150,960	)
Apple, Inc.		370		07/07/23		USD	185.00		USD	7,177		(339,475	)
Applied Materials, Inc.		364		07/07/23		USD	147.00		USD	5,261		(30,940	)
BP PLC, ADR		459		07/07/23		USD	36.00		USD	1,620		(4,590	)
Caterpillar, Inc.		104		07/07/23		USD	215.00		USD	2,559		(325,520	)
ConocoPhillips		77		07/07/23		USD	102.00		USD	798		(17,325	)

38 2 0 2 3   B L A C K R O C K  S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Schedule of Investments (unaudited) (continued) June 30, 2023 BlackRock Enhanced Capital and Income Fund, Inc. (CII)

Exchange-Traded Options Written (continued)

Description	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call (continued)
Elevance Health, Inc.		36		07/07/23		USD	475.00		USD	1,599	$	(1,260	)
EQT Corp.		319		07/07/23		USD	38.00		USD	1,312		(101,282	)
Fox Corp., Class A		684		07/07/23		USD	34.00		USD	2,326		(23,940	)
General Motors Co.		283		07/07/23		USD	38.00		USD	1,091		(24,338	)
Microsoft Corp.		159		07/07/23		USD	340.00		USD	5,415		(55,253	)
Mondelez International, Inc., Class A		377		07/07/23		USD	75.00		USD	2,750		(3,770	)
UnitedHealth Group, Inc.		144		07/07/23		USD	485.00		USD	6,921		(28,224	)
Cognizant Technology Solutions Corp., Class A		189		07/10/23		USD	62.00		USD	1,234		(64,600	)
Alphabet, Inc., Class A		153		07/14/23		USD	125.00		USD	1,831		(7,344	)
Amazon.com, Inc.		380		07/14/23		USD	129.00		USD	4,954		(130,150	)
Analog Devices, Inc.		61		07/14/23		USD	180.00		USD	1,188		(93,635	)
Apple, Inc.		330		07/14/23		USD	185.00		USD	6,401		(311,850	)
Applied Materials, Inc.		539		07/14/23		USD	141.00		USD	7,791		(278,932	)
BP PLC, ADR		272		07/14/23		USD	36.00		USD	960		(6,936	)
ConocoPhillips		216		07/14/23		USD	108.00		USD	2,238		(10,044	)
Dollar General Corp.		266		07/14/23		USD	160.00		USD	4,516		(268,660	)
Dollar Tree, Inc.		211		07/14/23		USD	138.00		USD	3,028		(130,292	)
EQT Corp.		326		07/14/23		USD	37.00		USD	1,341		(138,550	)
General Motors Co.		37		07/14/23		USD	36.00		USD	143		(10,138	)
Las Vegas Sands Corp.		296		07/14/23		USD	59.00		USD	1,717		(24,124	)
Marvell Technology, Inc.		331		07/14/23		USD	61.00		USD	1,979		(36,079	)
Meta Platforms, Inc., Class A		165		07/14/23		USD	285.00		USD	4,735		(122,925	)
Microsoft Corp.		367		07/14/23		USD	330.00		USD	12,498		(438,565	)
Mondelez International, Inc., Class A		356		07/14/23		USD	73.00		USD	2,597		(23,140	)
Ross Stores, Inc.		187		07/14/23		USD	107.00		USD	2,097		(104,720	)
Advanced Micro Devices, Inc.		190		07/21/23		USD	113.00		USD	2,164		(92,150	)
Alphabet, Inc., Class A		131		07/21/23		USD	120.00		USD	1,568		(34,650	)
Alphabet, Inc., Class A		1,012		07/21/23		USD	125.00		USD	12,114		(91,080	)
Amazon.com, Inc.		94		07/21/23		USD	120.00		USD	1,225		(103,635	)
Amazon.com, Inc.		300		07/21/23		USD	130.00		USD	3,911		(107,250	)
Aptiv PLC		444		07/21/23		USD	97.03		USD	4,533		(292,890	)
Avantor, Inc.		482		07/21/23		USD	20.43		USD	990		(38,405	)
Axalta Coating Systems Ltd.		465		07/21/23		USD	33.00		USD	1,526		(30,225	)
Axalta Coating Systems Ltd.		538		07/21/23		USD	32.00		USD	1,765		(65,905	)
Berkshire Hathaway, Inc., Class B		252		07/21/23		USD	325.00		USD	8,593		(437,850	)
Caterpillar, Inc.		104		07/21/23		USD	210.00		USD	2,559		(380,380	)
Ciena Corp.		431		07/21/23		USD	50.00		USD	1,831		(2,155	)
Cognizant Technology Solutions Corp., Class A		203		07/21/23		USD	62.50		USD	1,325		(64,960	)
Comcast Corp., Class A		868		07/21/23		USD	42.50		USD	3,607		(19,530	)
Corteva, Inc.		665		07/21/23		USD	59.00		USD	3,810		(36,324	)
Dollar General Corp.		208		07/21/23		USD	210.00		USD	3,531		(2,080	)
Dollar Tree, Inc.		208		07/21/23		USD	140.00		USD	2,985		(109,200	)
Dun & Bradstreet Holdings, Inc.		498		07/21/23		USD	11.82		USD	576		(15,440	)
Elevance Health, Inc.		62		07/21/23		USD	490.00		USD	2,755		(4,805	)
EQT Corp.		422		07/21/23		USD	38.00		USD	1,736		(148,755	)
Fidelity National Financial, Inc.		851		07/21/23		USD	35.00		USD	3,064		(125,522	)
FleetCor Technologies, Inc.		201		07/21/23		USD	240.00		USD	5,047		(272,355	)
Fortive Corp.		545		07/21/23		USD	66.32		USD	4,075		(475,360	)
Fox Corp., Class A		305		07/21/23		USD	33.00		USD	1,037		(41,938	)
General Motors Co.		463		07/21/23		USD	34.00		USD	1,785		(219,925	)
Humana, Inc.		49		07/21/23		USD	525.00		USD	2,191		(2,573	)
Intercontinental Exchange, Inc.		354		07/21/23		USD	109.00		USD	4,003		(168,846	)
JPMorgan Chase & Co.		83		07/21/23		USD	145.00		USD	1,207		(22,203	)
Laboratory Corp. of America Holdings		164		07/21/23		USD	220.00		USD	3,958		(359,980	)
Las Vegas Sands Corp.		188		07/21/23		USD	60.00		USD	1,090		(20,398	)
LPL Financial Holdings, Inc.		155		07/21/23		USD	220.00		USD	3,370		(70,525	)
Meta Platforms, Inc., Class A		224		07/21/23		USD	250.00		USD	6,428		(851,200	)
Microsoft Corp.		183		07/21/23		USD	330.00		USD	6,232		(261,690	)
Microsoft Corp.		123		07/21/23		USD	340.00		USD	4,189		(87,945	)
Monster Beverage Corp.		813		07/21/23		USD	59.95		USD	4,670		(31,648	)
Otis Worldwide Corp.		483		07/21/23		USD	84.60		USD	4,299		(246,810	)
Progressive Corp.		276		07/21/23		USD	135.00		USD	3,653		(44,160	)

S C H E D U L E    O F   I N V E S T M E N T S 39

Schedule of Investments (unaudited) (continued) June 30, 2023 BlackRock Enhanced Capital and Income Fund, Inc. (CII)

Exchange-Traded Options Written (continued)

Description	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call (continued)
Reinsurance Group of America, Inc.		199		07/21/23		USD	148.51		USD	2,760	$	(12,203	)
Ross Stores, Inc.		402		07/21/23		USD	110.00		USD	4,508		(138,690	)
Sanofi, ADR		1,057		07/21/23		USD	55.00		USD	5,697		(42,280	)
Sanofi, ADR		742		07/21/23		USD	52.50		USD	3,999		(137,270	)
Sealed Air Corp.		757		07/21/23		USD	50.00		USD	3,028		(162,755	)
Skechers USA, Inc., Class A		237		07/21/23		USD	55.00		USD	1,248		(11,850	)
Tenet Healthcare Corp.		95		07/21/23		USD	65.00		USD	773		(157,700	)
Unilever PLC, ADR		553		07/21/23		USD	54.82		USD	2,883		(1,888	)
Veeva Systems, Inc., Class A		166		07/21/23		USD	190.00		USD	3,282		(164,340	)
Visa, Inc., Class A		69		07/21/23		USD	230.00		USD	1,639		(61,928	)
Voya Financial, Inc.		420		07/21/23		USD	72.50		USD	3,012		(42,000	)
World Wrestling Entertainment, Inc., Class A		389		07/21/23		USD	105.00		USD	4,219		(204,225	)
Advanced Micro Devices, Inc.		354		07/28/23		USD	127.00		USD	4,032		(50,976	)
Alphabet, Inc., Class A		186		07/28/23		USD	126.00		USD	2,226		(34,038	)
Amazon.com, Inc.		353		07/28/23		USD	137.00		USD	4,602		(103,958	)
Analog Devices, Inc.		47		07/28/23		USD	195.00		USD	916		(24,675	)
Apple, Inc.		103		07/28/23		USD	185.00		USD	1,998		(110,467	)
Berkshire Hathaway, Inc., Class B		199		07/28/23		USD	345.00		USD	6,786		(62,387	)
BP PLC, ADR		597		07/28/23		USD	36.00		USD	2,107		(31,641	)
Caterpillar, Inc.		209		07/28/23		USD	250.00		USD	5,142		(75,762	)
Comcast Corp., Class A		52		07/28/23		USD	42.00		USD	216		(4,238	)
ConocoPhillips		227		07/28/23		USD	104.00		USD	2,352		(63,560	)
Elevance Health, Inc.		35		07/28/23		USD	450.00		USD	1,555		(28,175	)
Fox Corp., Class A		285		07/28/23		USD	34.00		USD	969		(24,225	)
General Motors Co.		127		07/28/23		USD	39.00		USD	490		(15,748	)
Humana, Inc.		107		07/28/23		USD	470.00		USD	4,784		(35,043	)
Las Vegas Sands Corp.		107		07/28/23		USD	61.00		USD	621		(11,075	)
Meta Platforms, Inc., Class A		94		07/28/23		USD	300.00		USD	2,698		(89,535	)
Microsoft Corp.		278		07/28/23		USD	345.00		USD	9,467		(230,740	)
Mondelez International, Inc., Class A		222		07/28/23		USD	74.00		USD	1,619		(19,980	)
Novo Nordisk A/S, ADR		363		07/28/23		USD	165.00		USD	5,874		(114,345	)
Sony Group Corp., ADR		249		07/28/23		USD	96.00		USD	2,242		(11,205	)
UnitedHealth Group, Inc.		100		07/28/23		USD	490.00		USD	4,806		(75,000	)
Visa, Inc., Class A		136		07/28/23		USD	230.00		USD	3,230		(143,820	)
Advanced Micro Devices, Inc.		189		08/04/23		USD	115.00		USD	2,153		(119,542	)
Alphabet, Inc., Class A		203		08/04/23		USD	121.00		USD	2,430		(82,215	)
Amazon.com, Inc.		372		08/04/23		USD	137.00		USD	4,849		(125,550	)
Apple, Inc.		268		08/04/23		USD	190.00		USD	5,198		(220,430	)
Comcast Corp., Class A		417		08/04/23		USD	42.00		USD	1,733		(37,739	)
EQT Corp.		315		08/04/23		USD	43.00		USD	1,296		(37,958	)
General Motors Co.		456		08/04/23		USD	38.00		USD	1,758		(88,692	)
JPMorgan Chase & Co.		78		08/04/23		USD	146.00		USD	1,134		(23,010	)
Las Vegas Sands Corp.		174		08/04/23		USD	59.00		USD	1,009		(34,539	)
Microsoft Corp.		282		08/04/23		USD	340.00		USD	9,603		(344,040	)
Ross Stores, Inc.		19		08/04/23		USD	108.00		USD	213		(11,020	)
Sony Group Corp., ADR		256		08/04/23		USD	93.00		USD	2,305		(35,200	)
Ciena Corp.		436		08/07/23		USD	46.50		USD	1,853		(22,477	)
Cognizant Technology Solutions Corp., Class A		132		08/07/23		USD	63.75		USD	862		(41,661	)
Comcast Corp., Class A		173		08/11/23		USD	42.00		USD	719		(17,214	)
JPMorgan Chase & Co.		298		08/11/23		USD	144.00		USD	4,334		(131,865	)
Ross Stores, Inc.		217		08/11/23		USD	112.00		USD	2,433		(72,695	)
Alphabet, Inc., Class A		295		08/18/23		USD	130.00		USD	3,531		(49,265	)
Amazon.com, Inc.		295		08/18/23		USD	125.00		USD	3,846		(292,787	)
Apple, Inc.		361		08/18/23		USD	190.00		USD	7,002		(314,972	)
Aptiv PLC		386		08/18/23		USD	110.00		USD	3,941		(80,095	)
Avantor, Inc.		477		08/18/23		USD	22.50		USD	980		(19,080	)
Avantor, Inc.		1,014		08/18/23		USD	20.40		USD	2,083		(124,177	)
Axalta Coating Systems Ltd.		1,130		08/18/23		USD	33.00		USD	3,708		(144,075	)
Ciena Corp.		519		08/18/23		USD	44.32		USD	2,205		(50,074	)
Cognizant Technology Solutions Corp., Class A		267		08/18/23		USD	64.00		USD	1,743		(93,963	)
Comcast Corp., Class A		877		08/18/23		USD	42.50		USD	3,644		(78,053	)
Corteva, Inc.		537		08/18/23		USD	57.90		USD	3,077		(89,375	)

40 2 0 2 3   B L A C K R O C K  S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Schedule of Investments (unaudited) (continued) June 30, 2023      BlackRock Enhanced Capital and Income Fund, Inc. (CII)

Exchange-Traded Options Written (continued)

Description	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call (continued)
Elevance Health, Inc.		10		08/18/23		USD	470.00		USD	444	$	(5,750	)
EQT Corp.		398		08/18/23		USD	39.00		USD	1,637		(143,280	)
Fidelity National Financial, Inc.		480		08/18/23		USD	35.00		USD	1,728		(98,400	)
Fortive Corp.		502		08/18/23		USD	67.45		USD	3,753		(412,491	)
Intercontinental Exchange, Inc.		472		08/18/23		USD	115.00		USD	5,337		(101,480	)
Laboratory Corp. of America Holdings		4		08/18/23		USD	220.00		USD	97		(9,560	)
Laboratory Corp. of America Holdings		251		08/18/23		USD	240.00		USD	6,057		(235,940	)
Las Vegas Sands Corp.		199		08/18/23		USD	62.50		USD	1,154		(22,487	)
LPL Financial Holdings, Inc.		154		08/18/23		USD	220.00		USD	3,348		(145,530	)
Meta Platforms, Inc., Class A		94		08/18/23		USD	300.00		USD	2,698		(115,385	)
Monster Beverage Corp.		616		08/18/23		USD	57.95		USD	3,538		(115,137	)
Novo Nordisk A/S, ADR		215		08/18/23		USD	170.00		USD	3,479		(83,850	)
Otis Worldwide Corp.		278		08/18/23		USD	80.23		USD	2,474		(265,171	)
Progressive Corp.		174		08/18/23		USD	130.00		USD	2,303		(100,920	)
Reinsurance Group of America, Inc.		168		08/18/23		USD	145.00		USD	2,330		(60,480	)
Sealed Air Corp.		575		08/18/23		USD	43.00		USD	2,300		(36,623	)
Tenet Healthcare Corp.		179		08/18/23		USD	85.00		USD	1,457		(43,855	)
Unilever PLC, ADR		405		08/18/23		USD	50.05		USD	2,111		(98,376	)
Medtronic PLC		267		08/29/23		USD	89.00		USD	2,352		(59,375	)
Medtronic PLC		262		09/08/23		USD	89.00		USD	2,308		(64,697	)
Fortive Corp.		480		09/15/23		USD	70.00		USD	3,589		(312,000	)
Sealed Air Corp.		290		09/15/23		USD	41.75		USD	1,160		(39,753	)
											$	(16,829,554	)

OTC Options Written

Description	Counterparty	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call
JPMorgan Chase & Co.	Citibank N.A.		18,700		07/11/23		USD	138.69		USD	2,720	$	(116,588	)
Corteva, Inc.	JPMorgan Chase Bank N.A.		78,600		07/25/23		USD	59.10		USD	4,504		(48,280	)
FleetCor Technologies, Inc.	Citibank N.A.		18,400		07/31/23		USD	246.16		USD	4,620		(165,247	)
Voya Financial, Inc.	Citibank N.A.		39,600		07/31/23		USD	73.46		USD	2,840		(36,103	)
Dun & Bradstreet Holdings, Inc.	JPMorgan Chase Bank N.A.		72,800		08/02/23		USD	12.19		USD	842		(23,386	)
Dun & Bradstreet Holdings, Inc.	JPMorgan Chase Bank N.A.		49,300		08/17/23		USD	10.32		USD	570		(97,446	)
												$	(487,050	)

Balances Reported in the Statements of Assets and Liabilities for Options Written

Description	Swap Premiums Paid		Swap Premiums Received		Unrealized Appreciation		Unrealized Depreciation			Value
Options Written	$	N/A	$	N/A	$	2,754,483	$	(7,228,739	)	$	(17,316,604	)

Derivative Financial Instruments Categorized by Risk Exposure

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

	Commodity Contracts		Credit   Contracts		Equity Contracts		Foreign Currency   Exchange Contracts		Interest Rate   Contracts		Other   Contracts		Total
Liabilities — Derivative Financial Instruments
Options written
Options written at value	$	—	$	—	$	17,316,604	$	—	$	—	$	—	$	17,316,604

S C H E D U L E    O F   I N V E S T M E N T S 41

Schedule of Investments (unaudited) (continued) June 30, 2023 BlackRock Enhanced Capital and Income Fund, Inc. (CII)

For the period ended June 30, 2023, the effect of derivative financial instruments in the Statements of Operations was as follows:

	Commodity Contracts		Credit Contracts		Equity Contracts			Foreign Currency   Exchange Contracts		Interest Rate   Contracts		Other   Contracts		Total
Net Realized Gain (Loss) from:
Options written	$	—	$	—	$	(9,665,066	)	$	—	$	—	$	—	$	(9,665,066	)
Net Change in Unrealized Appreciation (Depreciation) on:
Options written	$	—	$	—	$	(9,874,294	)	$	—	$	—	$	—	$	(9,874,294	)

Average Quarterly Balances of Outstanding Derivative Financial Instruments

Options:
Average value of option contracts written	$	16,946,760

For more information about the Trust’s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.

Derivative Financial Instruments — Offsetting as of Period End

The Trust’s derivative assets and liabilities (by type) were as follows:

	Assets		Liabilities
Derivative Financial Instruments
Options	$	—	$	17,316,604
Total derivative assets and liabilities in the Statements of Assets and Liabilities		—		17,316,604
Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”)		—		(16,829,554	)
Total derivative assets and liabilities subject to an MNA	$	—	$	487,050

The following table presents the Trust’s derivative liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral pledged by the Trust:

Counterparty		Derivative Liabilities Subject to an MNA by Counterparty		Derivatives Available for Offset		Non-Cash Collateral Pledged		Cash Collateral Pledged		Net Amount of Derivative Liabilities	(a)
Citibank N.A.	$	317,938	$	—	$	—	$	—	$	317,938
JPMorgan Chase Bank N.A.		169,112		—		—		—		169,112
	$	487,050	$	—	$	—	$	—	$	487,050

^(a)  Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.

Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of financial instruments. For a description of the input levels and information about the Trust’s policy regarding valuation of financial instruments, refer to the Notes to Financial Statements.

The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust’s financial instruments into major categories is disclosed in the Schedule of Investments above.

	Level 1		Level 2		Level 3		Total
Assets
Investments
Long-Term Investments
Common Stocks	$	851,951,940	$	—	$	—	$	851,951,940

42 2 0 2 3   B L A C K R O C K  S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Schedule of Investments (unaudited) (continued) June 30, 2023      BlackRock Enhanced Capital and Income Fund, Inc. (CII)

Fair Value Hierarchy as of Period End (continued)

	Level 1			Level 2			Level 3		Total
Short-Term Securities
Money Market Funds	$	13,210,705		$	—		$	—	$	13,210,705
	$	865,162,645		$	—		$	—		865,162,645
Investments Valued at NAV(a)										36
									$	865,162,681
Derivative Financial Instruments(b)
Liabilities
Equity Contracts	$	(13,926,649	)	$	(3,389,955	)	$	—	$	(17,316,604	)

^(a)  Certain investments of the Trust were fair valued using NAV as a practical expedient as no quoted market value is available and therefore have been excluded from the fair value hierarchy.

^(b)  Derivative financial instruments are options written. Options written are shown at value.

See notes to financial statements.

S C H E D U L E    O F   I N V E S T M E N T S 43

Consolidated Schedule of Investments (unaudited) June 30, 2023     BlackRock Enhanced Equity Dividend Trust (BDJ) (Percentages shown are based on Net Assets)

Security	Shares		Value
Common Stocks
Aerospace & Defense(a) — 2.8%
L3Harris Technologies, Inc.(b)		169,635	$	33,209,444
Raytheon Technologies Corp.		127,232		12,463,647
				45,673,091
Automobile Components — 0.4%
Lear Corp.(a)		47,800		6,861,690
Automobiles — 2.1%
General Motors Co.(a)(b)		914,947		35,280,356
Banks(a) — 10.2%
Bank of America Corp.		153,081		4,391,894
Citigroup, Inc.		957,550		44,085,602
Citizens Financial Group, Inc.		418,904		10,925,016
First Citizens BancShares, Inc., Class A(b)		24,907		31,966,889
JPMorgan Chase & Co.		181,778		26,437,793
Wells Fargo & Co.		1,193,168		50,924,409
				168,731,603
Beverages — 1.0%
Constellation Brands, Inc., Class A(a)		65,289		16,069,582
Capital Markets — 2.5%
Carlyle Group, Inc.		375,700		12,003,615
Charles Schwab Corp.(a)		70,205		3,979,219
Intercontinental Exchange, Inc.(a)		84,950		9,606,146
Raymond James Financial, Inc.(a)		150,989		15,668,129
				41,257,109
Chemicals — 0.5%
PPG Industries, Inc.(a)		60,439		8,963,104
Communications Equipment — 2.3%
Cisco Systems, Inc.(a)		719,630		37,233,656
Consumer Staples Distribution & Retail — 1.9%
Dollar General Corp.(a)		187,696		31,867,027
Containers & Packaging — 1.4%
Sealed Air Corp.(a)		593,272		23,730,880
Diversified Telecommunication Services(a) — 1.8%
AT&T, Inc.		713,382		11,378,443
Verizon Communications, Inc.		484,060		18,002,191
				29,380,634
Electric Utilities(a) — 2.0%
American Electric Power Co., Inc.		116,849		9,838,686
Exelon Corp.		256,819		10,462,806
PG&E Corp.(c)		763,531		13,193,816
				33,495,308
Entertainment — 0.5%
Activision Blizzard, Inc.(a)(c)		99,436		8,382,455
Financial Services(a) — 3.9%
Apollo Global Management, Inc.		93,384		7,172,825
Equitable Holdings, Inc.		227,446		6,177,434
Fidelity National Information Services, Inc.(b)		575,110		31,458,517
Visa, Inc., Class A		83,611		19,855,940
				64,664,716
Food Products(a) — 2.7%
Kraft Heinz Co.(b)		1,111,094		39,443,837
Mondelez International, Inc., Class A		66,289		4,835,120
				44,278,957

Security	Shares			Value
Ground Transportation — 0.6%
Union Pacific Corp.(a)		45,811		$	9,373,847
Health Care Equipment & Supplies — 7.4%
Baxter International, Inc.(a)		934,402			42,571,355
Koninklijke Philips NV		870,995			18,872,411
Medtronic PLC(a)		436,130			38,423,053
Zimmer Biomet Holdings, Inc.(a)(b)		154,589			22,508,158
					122,374,977
Health Care Providers & Services(a) —8.8%
AmerisourceBergen Corp.		44,126			8,491,166
Cardinal Health, Inc.		314,869			29,777,161
Cigna Group		84,724			23,773,554
Elevance Health, Inc.		52,686			23,407,863
Humana, Inc.		23,368			10,448,534
Laboratory Corp. of America Holdings		204,687			49,397,114
					145,295,392
Household Durables — 2.0%
Newell Brands, Inc.(a)		747,674			6,504,764
Panasonic Holdings Corp.		1,390,500			17,050,203
Sony Group Corp.		105,400			9,514,475
					33,069,442
Industrial Conglomerates — 0.4%
Siemens AG, Registered Shares		42,742			7,125,129
Insurance — 6.9%
Allstate Corp.(a)		95,457			10,408,631
American International Group, Inc.(a)		703,484			40,478,469
Fidelity National Financial, Inc.(a)		498,425			17,943,300
First American Financial Corp.(a)		29,750			1,696,345
Prudential PLC		864,805			12,213,975
Willis Towers Watson PLC(a)		132,095			31,108,373
					113,849,093
Interactive Media & Services — 0.7%
Alphabet, Inc., Class A(a)(c)		93,915			11,241,626
IT Services — 2.6%
Cognizant Technology Solutions Corp., Class A(a)		656,268			42,841,175
Machinery — 1.3%
Fortive Corp.(a)		74,754			5,589,357
Komatsu Ltd.		499,200			13,502,367
Pentair PLC(a)		22,700			1,466,420
					20,558,144
Media(a) — 2.7%
Comcast Corp., Class A		749,197			31,129,135
Fox Corp., Class A		380,307			12,930,438
					44,059,573
Multi-Utilities(a) — 1.5%
Public Service Enterprise Group, Inc.		206,888			12,953,258
Sempra Energy		78,141			11,376,548
					24,329,806
Oil, Gas & Consumable Fuels — 8.9%
BP PLC		5,573,680			32,452,050
ConocoPhillips(a)		105,233			10,903,191
Enterprise Products Partners LP(a)		1,220,258			32,153,798
EQT Corp.(a)		294,416			12,109,330
Formentera Partners Fund II LP(d)(e)		—	(f)		10,037,117
Hess Corp.(a)		77,798			10,576,638
Shell PLC		1,263,772			37,700,422
					145,932,546

44 2 0 2 3   B L A C K R O C K  S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Consolidated Schedule of Investments (unaudited) (continued) June 30, 2023 BlackRock Enhanced Equity Dividend Trust (BDJ) (Percentages shown are based on Net Assets)

Security	Shares		Value
Personal Care Products — 2.0%
Unilever PLC, ADR(a)		635,218	$	33,113,914
Pharmaceuticals — 5.4%
AstraZeneca PLC		102,205		14,651,516
Bayer AG, Registered Shares		404,504		22,391,334
Eli Lilly & Co.(a)		23,037		10,803,892
Novo Nordisk A/S, ADR(a)		59,807		9,678,567
Sanofi		293,812		31,630,553
				89,155,862
Professional Services(a) — 4.2%
Leidos Holdings, Inc.		348,680		30,851,207
Robert Half International, Inc.		65,910		4,957,750
SS&C Technologies Holdings, Inc.		549,700		33,311,820
				69,120,777
Semiconductors & Semiconductor Equipment — 0.5%
Taiwan Semiconductor Manufacturing Co. Ltd., ADR(a)		79,144		7,987,212
Software — 2.1%
Microsoft Corp.(a)		101,563		34,586,264
Specialty Retail — 0.6%
Ross Stores, Inc.(a)		88,225		9,892,669
Technology Hardware, Storage & Peripherals — 1.4%
Samsung Electronics Co. Ltd., GDR, Registered Shares		16,024		22,212,817
Textiles, Apparel & Luxury Goods — 0.5%
Ralph Lauren Corp.(a)		68,473		8,442,721
Tobacco — 1.4%
British American Tobacco PLC, ADR(a)		692,946		23,005,808
Wireless Telecommunication Services — 0.5%
Rogers Communications, Inc., Class B		167,832		7,657,117
Total Long-Term Investments — 98.4%     (Cost: $1,384,197,244)			1,621,096,079

Security	Shares		Value
Short-Term Securities
Money Market Funds — 3.3%
BlackRock Liquidity Funds, T-Fund, Institutional Class, 4.98%(g)(h)		54,579,536	$	54,579,536
Total Short-Term Securities — 3.3% (Cost: $54,579,536)				54,579,536
Total Investments Before Options Written — 101.7% (Cost: $1,438,776,780)				1,675,675,615
Options Written — (1.5)% (Premiums Received: $(19,373,563))				(24,895,659	)
Total Investments, Net of Options Written — 100.2% (Cost: $1,419,403,217)				1,650,779,956
Liabilities in Excess of Other Assets — (0.2)%				(4,025,420	)
Net Assets — 100.0%			$	1,646,754,536

^(a)  All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.

^(b)  All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives.

^(c)  Non-income producing security.

^(d)  All or a portion of the security is held by a wholly-owned subsidiary. See Note 1 of the Notes to Consolidated Financial Statements for details on the wholly-owned subsidiary.

^(e)  Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy.

^(f)  Investment does not issue shares.

^(g)  Affiliate of the Trust.

^(h)  Annualized 7-day yield as of period end.

For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

Affiliates

Investments in issuers considered to be affiliate(s) of the Trust during the six months ended June 30, 2023 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

Affiliated Issuer	Value at 12/31/22		Purchases at Cost			Proceeds from Sales			Net Realized Gain (Loss)			Change in Unrealized Appreciation (Depreciation)		Value at 06/30/23		Shares Held at 06/30/23		Income			Capital Gain Distributions from Underlying Funds
BlackRock Liquidity Funds, T-Fund, Institutional Class	$	76,042,437	$	—		$	(21,462,901	)(a)	$	—		$	—	$	54,579,536		54,579,536	$	1,609,010		$	—
SL Liquidity Series, LLC, Money Market Series(b)		—		232	(a)		—			(232	)		—		—		—		669	(c)		—
									$	(232	)	$	—	$	54,579,536			$	1,609,679		$	—

^(a)  Represents net amount purchased (sold).

^(b)  As of period end, the entity is no longer held.

^(c) All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities.

S C H E D U L E   O F   I N V E S T M E N T S 45

Consolidated Schedule of Investments (unaudited) (continued) June 30, 2023 BlackRock Enhanced Equity Dividend Trust (BDJ)

Derivative Financial Instruments Outstanding as of Period End

Exchange-Traded Options Written

Description	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call
Alphabet, Inc., Class A		60		07/07/23		USD	124.34		USD	718	$	(958	)
American International Group, Inc.		853		07/07/23		USD	57.00		USD	4,908		(78,902	)
AmerisourceBergen Corp.		74		07/07/23		USD	175.00		USD	1,424		(131,350	)
Cigna Group		146		07/07/23		USD	250.00		USD	4,097		(455,520	)
Citigroup, Inc.		733		07/07/23		USD	49.00		USD	3,375		(1,833	)
Constellation Brands, Inc., Class A		84		07/07/23		USD	250.00		USD	2,067		(4,830	)
Elevance Health, Inc.		119		07/07/23		USD	475.00		USD	5,287		(4,165	)
Enterprise Products Partners LP		2,601		07/07/23		USD	26.00		USD	6,854		(105,340	)
EQT Corp.		636		07/07/23		USD	38.00		USD	2,616		(201,930	)
Fox Corp., Class A		1,264		07/07/23		USD	34.00		USD	4,298		(44,240	)
General Motors Co.		286		07/07/23		USD	38.00		USD	1,103		(24,596	)
Hess Corp.		204		07/07/23		USD	133.00		USD	2,773		(76,500	)
Humana, Inc.		79		07/07/23		USD	520.00		USD	3,532		(2,765	)
Kraft Heinz Co.		1,592		07/07/23		USD	38.35		USD	5,652		(6	)
Microsoft Corp.		183		07/07/23		USD	340.00		USD	6,232		(63,592	)
Mondelez International, Inc., Class A		263		07/07/23		USD	75.00		USD	1,918		(2,630	)
PG&E Corp.		538		07/07/23		USD	17.50		USD	930		(4,842	)
PPG Industries, Inc.		101		07/07/23		USD	135.00		USD	1,498		(137,360	)
Taiwan Semiconductor Manufacturing Co. Ltd., ADR		122		07/07/23		USD	104.00		USD	1,231		(3,782	)
Visa, Inc., Class A		93		07/07/23		USD	235.00		USD	2,209		(30,458	)
Cognizant Technology Solutions Corp., Class A		1,019		07/10/23		USD	62.00		USD	6,652		(348,291	)
Alphabet, Inc., Class A		105		07/14/23		USD	125.00		USD	1,257		(5,040	)
American International Group, Inc.		1,082		07/14/23		USD	57.00		USD	6,226		(140,660	)
AT&T, Inc.		1,307		07/14/23		USD	16.00		USD	2,085		(18,298	)
Baxter International, Inc.		1,185		07/14/23		USD	42.00		USD	5,399		(432,525	)
Cisco Systems, Inc.		1,022		07/14/23		USD	51.00		USD	5,288		(83,804	)
Citigroup, Inc.		734		07/14/23		USD	49.00		USD	3,379		(10,276	)
ConocoPhillips		355		07/14/23		USD	108.00		USD	3,678		(16,508	)
Dollar General Corp.		448		07/14/23		USD	160.00		USD	7,606		(452,480	)
Enterprise Products Partners LP		2,037		07/14/23		USD	26.52		USD	5,367		(27,754	)
EQT Corp.		315		07/14/23		USD	37.00		USD	1,296		(133,875	)
General Motors Co.		963		07/14/23		USD	36.00		USD	3,713		(263,862	)
Hess Corp.		201		07/14/23		USD	139.00		USD	2,733		(32,160	)
Kraft Heinz Co.		1,240		07/14/23		USD	38.00		USD	4,402		(3,100	)
Microsoft Corp.		66		07/14/23		USD	330.00		USD	2,248		(78,870	)
Mondelez International, Inc., Class A		101		07/14/23		USD	73.00		USD	737		(6,565	)
PG&E Corp.		538		07/14/23		USD	17.50		USD	930		(11,029	)
Ross Stores, Inc.		78		07/14/23		USD	107.00		USD	875		(43,680	)
Verizon Communications, Inc.		1,331		07/14/23		USD	36.00		USD	4,950		(163,047	)
Visa, Inc., Class A		124		07/14/23		USD	230.00		USD	2,945		(103,540	)
Allstate Corp.		215		07/21/23		USD	120.00		USD	2,344		(2,150	)
Allstate Corp.		310		07/21/23		USD	115.00		USD	3,380		(11,625	)
Alphabet, Inc., Class A		132		07/21/23		USD	125.00		USD	1,580		(11,880	)
American Electric Power Co., Inc.		357		07/21/23		USD	90.50		USD	3,006		(3,496	)
American International Group, Inc.		1,465		07/21/23		USD	55.00		USD	8,430		(446,825	)
AmerisourceBergen Corp.		129		07/21/23		USD	180.00		USD	2,482		(180,600	)
Baxter International, Inc.		2,159		07/21/23		USD	42.50		USD	9,836		(712,470	)
British American Tobacco PLC, ADR		1,271		07/21/23		USD	35.00		USD	4,220		(6,355	)
Carlyle Group, Inc.		853		07/21/23		USD	29.00		USD	2,725		(263,289	)
Cigna Group		80		07/21/23		USD	260.00		USD	2,245		(178,000	)
Citigroup, Inc.		673		07/21/23		USD	48.00		USD	3,098		(26,920	)
Citizens Financial Group, Inc.		582		07/21/23		USD	27.50		USD	1,518		(29,100	)
Citizens Financial Group, Inc.		1,093		07/21/23		USD	30.00		USD	2,851		(13,663	)
Cognizant Technology Solutions Corp., Class A		863		07/21/23		USD	62.50		USD	5,634		(276,160	)
Constellation Brands, Inc., Class A		91		07/21/23		USD	240.00		USD	2,240		(72,345	)
Dollar General Corp.		313		07/21/23		USD	210.00		USD	5,314		(3,130	)
Elevance Health, Inc.		62		07/21/23		USD	490.00		USD	2,755		(4,805	)
Enterprise Products Partners LP		1,030		07/21/23		USD	26.00		USD	2,714		(54,590	)
Enterprise Products Partners LP		1,043		07/21/23		USD	26.33		USD	2,748		(32,668	)
EQT Corp.		28		07/21/23		USD	38.00		USD	115		(9,870	)

46 2 0 2 3   B L A C K R O C K  S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Consolidated Schedule of Investments (unaudited) (continued) June 30, 2023 BlackRock Enhanced Equity Dividend Trust (BDJ)

Exchange-Traded Options Written (continued)

Description	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call (continued)
Equitable Holdings, Inc.		625		07/21/23		USD	25.00		USD	1,698	$	(162,500	)
Exelon Corp.		300		07/21/23		USD	42.00		USD	1,222		(6,750	)
Fidelity National Financial, Inc.		960		07/21/23		USD	35.00		USD	3,456		(141,600	)
Fidelity National Information Services, Inc.		855		07/21/23		USD	57.50		USD	4,677		(34,200	)
First American Financial Corp.		163		07/21/23		USD	60.00		USD	929		(6,113	)
First Citizens BancShares, Inc., Class A		46		07/21/23		USD	1,340.00		USD	5,904		(71,300	)
Fortive Corp.		188		07/21/23		USD	66.32		USD	1,406		(163,978	)
Fox Corp., Class A		791		07/21/23		USD	33.00		USD	2,689		(108,762	)
General Motors Co.		587		07/21/23		USD	34.00		USD	2,263		(278,825	)
Humana, Inc.		49		07/21/23		USD	525.00		USD	2,191		(2,573	)
Intercontinental Exchange, Inc.		132		07/21/23		USD	109.00		USD	1,493		(62,960	)
JPMorgan Chase & Co.		35		07/21/23		USD	145.00		USD	509		(9,363	)
Kraft Heinz Co.		1,404		07/21/23		USD	40.00		USD	4,984		(2,808	)
L3Harris Technologies, Inc.		418		07/21/23		USD	195.00		USD	8,183		(169,290	)
Laboratory Corp. of America Holdings		370		07/21/23		USD	220.00		USD	8,929		(812,150	)
Lear Corp.		174		07/21/23		USD	129.50		USD	2,498		(271,532	)
Leidos Holdings, Inc.		1,720		07/21/23		USD	85.00		USD	15,219		(713,800	)
Medtronic PLC		568		07/21/23		USD	90.00		USD	5,004		(32,376	)
Microsoft Corp.		33		07/21/23		USD	330.00		USD	1,124		(47,190	)
Microsoft Corp.		146		07/21/23		USD	340.00		USD	4,972		(104,390	)
Newell Brands, Inc.		2,069		07/21/23		USD	9.00		USD	1,800		(56,897	)
PG&E Corp.		1,510		07/21/23		USD	17.00		USD	2,609		(77,765	)
PPG Industries, Inc.		104		07/21/23		USD	135.00		USD	1,542		(152,880	)
Public Service Enterprise Group, Inc.		142		07/21/23		USD	64.85		USD	889		(4,386	)
Ralph Lauren Corp.		376		07/21/23		USD	125.00		USD	4,636		(75,200	)
Robert Half International, Inc.		181		07/21/23		USD	70.00		USD	1,361		(96,835	)
Rogers Communications, Inc., Class B		460		07/21/23		CAD	66.00		CAD	2,780		(2,083	)
Sealed Air Corp.		1,039		07/21/23		USD	50.00		USD	4,156		(223,385	)
Sempra Energy		372		07/21/23		USD	150.00		USD	5,416		(17,670	)
SS&C Technologies Holdings, Inc.		781		07/21/23		USD	60.00		USD	4,733		(115,197	)
SS&C Technologies Holdings, Inc.		587		07/21/23		USD	56.96		USD	3,557		(244,294	)
Unilever PLC, ADR		1,505		07/21/23		USD	54.82		USD	7,846		(5,138	)
Visa, Inc., Class A		46		07/21/23		USD	230.00		USD	1,092		(41,285	)
Wells Fargo & Co.		2,491		07/21/23		USD	42.50		USD	10,632		(325,075	)
Willis Towers Watson PLC		249		07/21/23		USD	240.00		USD	5,864		(44,820	)
Willis Towers Watson PLC		281		07/26/23		USD	234.00		USD	6,618		(138,400	)
Alphabet, Inc., Class A		106		07/28/23		USD	126.00		USD	1,269		(19,398	)
American International Group, Inc.		469		07/28/23		USD	58.00		USD	2,699		(57,452	)
AT&T, Inc.		1,308		07/28/23		USD	16.50		USD	2,086		(24,852	)
Bank of America Corp.		841		07/28/23		USD	30.00		USD	2,413		(29,856	)
Baxter International, Inc.		786		07/28/23		USD	43.00		USD	3,581		(263,310	)
Cardinal Health, Inc.		724		07/28/23		USD	93.00		USD	6,847		(249,780	)
Cigna Group		178		07/28/23		USD	280.00		USD	4,995		(132,610	)
CisCo Systems, Inc.		1,408		07/28/23		USD	52.00		USD	7,285		(79,552	)
Citigroup, Inc.		509		07/28/23		USD	47.00		USD	2,343		(44,538	)
Comcast Corp., Class A		1,249		07/28/23		USD	42.00		USD	5,190		(101,793	)
ConocoPhillips		223		07/28/23		USD	104.00		USD	2,311		(62,440	)
Constellation Brands, Inc., Class A		184		07/28/23		USD	255.00		USD	4,529		(24,840	)
Elevance Health, Inc.		62		07/28/23		USD	450.00		USD	2,755		(49,910	)
Eli Lilly & Co.		44		07/28/23		USD	470.00		USD	2,064		(47,410	)
Fox Corp., Class A		36		07/28/23		USD	34.00		USD	122		(3,060	)
General Motors Co.		1,273		07/28/23		USD	39.00		USD	4,909		(157,852	)
Hess Corp.		22		07/28/23		USD	141.00		USD	299		(5,555	)
Kraft Heinz Co.		1,875		07/28/23		USD	37.00		USD	6,656		(20,625	)
Medtronic PLC		676		07/28/23		USD	87.00		USD	5,956		(157,508	)
Microsoft Corp.		33		07/28/23		USD	345.00		USD	1,124		(27,390	)
Novo Nordisk A/S, ADR		219		07/28/23		USD	165.00		USD	3,544		(68,985	)
PG&E Corp.		1,613		07/28/23		USD	17.50		USD	2,787		(59,681	)
Union Pacific Corp.		162		07/28/23		USD	205.00		USD	3,315		(80,190	)
Verizon Communications, Inc.		1,331		07/28/23		USD	37.00		USD	4,950		(99,825	)
Visa, Inc., Class A		46		07/28/23		USD	230.00		USD	1,092		(48,645	)
Visa, Inc., Class A		13		07/28/23		USD	235.00		USD	309		(9,068	)

S C H E D U L E    O F   I N V E S T M E N T S 47

Consolidated Schedule of Investments (unaudited) (continued) June 30, 2023 BlackRock Enhanced Equity Dividend Trust (BDJ)

Exchange-Traded Options Written (continued)

Description	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call (continued)
Zimmer Biomet Holdings, Inc.		365		08/01/23		USD	146.17		USD	5,314	$	(95,050	)
Alphabet, Inc., Class A		68		08/04/23		USD	121.00		USD	814		(27,540	)
AmerisourceBergen Corp.		39		08/04/23		USD	195.00		USD	750		(14,820	)
AT&T, Inc.		1,308		08/04/23		USD	16.00		USD	2,086		(51,012	)
Baxter International, Inc.		1,008		08/04/23		USD	47.00		USD	4,592		(115,920	)
Cardinal Health, Inc.		503		08/04/23		USD	94.00		USD	4,757		(135,810	)
Charles Schwab Corp.		386		08/04/23		USD	58.00		USD	2,188		(71,796	)
Cisco Systems, Inc.		325		08/04/23		USD	51.00		USD	1,682		(57,037	)
Citigroup, Inc.		509		08/04/23		USD	48.00		USD	2,343		(31,049	)
Comcast Corp., Class A		1,011		08/04/23		USD	42.00		USD	4,201		(91,495	)
Eli Lilly & Co.		48		08/04/23		USD	475.00		USD	2,251		(50,040	)
EQT Corp.		425		08/04/23		USD	43.00		USD	1,748		(51,213	)
General Motors Co.		550		08/04/23		USD	38.00		USD	2,121		(106,975	)
JPMorgan Chase & Co.		189		08/04/23		USD	146.00		USD	2,749		(55,755	)
Microsoft Corp.		97		08/04/23		USD	340.00		USD	3,303		(118,340	)
Ross Stores, Inc.		284		08/04/23		USD	108.00		USD	3,184		(164,720	)
Taiwan Semiconductor Manufacturing Co. Ltd., ADR		122		08/04/23		USD	105.00		USD	1,231		(28,548	)
Union Pacific Corp.		89		08/04/23		USD	205.00		USD	1,821		(49,395	)
Visa, Inc., Class A		137		08/04/23		USD	240.00		USD	3,253		(64,390	)
Cognizant Technology Solutions Corp., Class A		863		08/07/23		USD	63.75		USD	5,634		(272,372	)
Public Service Enterprise Group, Inc.		412		08/10/23		USD	61.75		USD	2,580		(87,585	)
Cardinal Health, Inc.		503		08/11/23		USD	94.00		USD	4,757		(169,762	)
Cisco Systems, Inc.		325		08/11/23		USD	52.00		USD	1,682		(26,813	)
Comcast Corp., Class A		611		08/11/23		USD	42.00		USD	2,539		(60,794	)
JPMorgan Chase & Co.		484		08/11/23		USD	144.00		USD	7,039		(214,170	)
Ross Stores, Inc.		123		08/11/23		USD	112.00		USD	1,379		(41,205	)
Alphabet, Inc., Class A		45		08/18/23		USD	130.00		USD	539		(7,515	)
American Electric Power Co., Inc.		163		08/18/23		USD	85.00		USD	1,372		(31,785	)
Apollo Global Management, Inc.		513		08/18/23		USD	77.50		USD	3,940		(151,335	)
British American Tobacco PLC, ADR		1,284		08/18/23		USD	33.25		USD	4,263		(53,100	)
Carlyle Group, Inc.		1,209		08/18/23		USD	34.00		USD	3,863		(54,346	)
Cigna Group		61		08/18/23		USD	280.00		USD	1,712		(71,675	)
Cisco Systems, Inc.		877		08/18/23		USD	52.50		USD	4,538		(103,486	)
Citigroup, Inc.		672		08/18/23		USD	49.00		USD	3,094		(31,248	)
Cognizant Technology Solutions Corp., Class A		864		08/18/23		USD	64.00		USD	5,640		(304,061	)
Comcast Corp., Class A		1,249		08/18/23		USD	42.50		USD	5,190		(111,161	)
Elevance Health, Inc.		46		08/18/23		USD	470.00		USD	2,044		(26,450	)
EQT Corp.		484		08/18/23		USD	39.00		USD	1,991		(174,240	)
Equitable Holdings, Inc.		624		08/18/23		USD	28.00		USD	1,695		(45,188	)
Exelon Corp.		188		08/18/23		USD	42.00		USD	766		(11,280	)
Exelon Corp.		924		08/18/23		USD	40.46		USD	3,764		(105,433	)
Fidelity National Financial, Inc.		1,033		08/18/23		USD	35.00		USD	3,719		(211,765	)
Fidelity National Information Services, Inc.		1,445		08/18/23		USD	56.74		USD	7,904		(199,020	)
First Citizens BancShares, Inc., Class A		90		08/18/23		USD	1,300.00		USD	11,551		(585,900	)
Fortive Corp.		112		08/18/23		USD	67.45		USD	837		(92,030	)
Intercontinental Exchange, Inc.		335		08/18/23		USD	115.00		USD	3,788		(72,025	)
Laboratory Corp. of America Holdings		437		08/18/23		USD	220.00		USD	10,546		(1,044,430	)
Laboratory Corp. of America Holdings		11		08/18/23		USD	240.00		USD	265		(10,340	)
Lear Corp.		88		08/18/23		USD	145.00		USD	1,263		(50,160	)
Medtronic PLC		316		08/18/23		USD	86.25		USD	2,784		(112,269	)
Newell Brands, Inc.		921		08/18/23		USD	9.33		USD	801		(42,467	)
Novo Nordisk A/S, ADR		109		08/18/23		USD	170.00		USD	1,764		(42,510	)
Pentair PLC		124		08/18/23		USD	62.50		USD	801		(52,080	)
PPG Industries, Inc.		130		08/18/23		USD	145.00		USD	1,928		(90,350	)
Public Service Enterprise Group, Inc.		583		08/18/23		USD	62.63		USD	3,650		(102,405	)
Raymond James Financial, Inc.		285		08/18/23		USD	105.00		USD	2,957		(95,475	)
Robert Half International, Inc.		181		08/18/23		USD	80.00		USD	1,361		(25,793	)
Rogers Communications, Inc., Class B		463		08/18/23		CAD	60.00		CAD	2,798		(71,298	)
Sealed Air Corp.		1,263		08/18/23		USD	43.00		USD	5,052		(80,444	)
SS&C Technologies Holdings, Inc.		1,655		08/18/23		USD	61.59		USD	10,029		(314,953	)
Taiwan Semiconductor Manufacturing Co. Ltd., ADR		191		08/18/23		USD	105.00		USD	1,928		(54,340	)
Unilever PLC, ADR		1,988		08/18/23		USD	50.05		USD	10,363		(482,893	)

48 2 0 2 3   B L A C K R O C K  S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Consolidated Schedule of Investments (unaudited) (continued) June 30, 2023      BlackRock Enhanced Equity Dividend Trust (BDJ)

Exchange-Traded Options Written (continued)

Description	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call (continued)
Wells Fargo & Co.		2,281		08/18/23		USD	42.50		USD	9,735	$	(393,472	)
Willis Towers Watson PLC		196		08/18/23		USD	240.00		USD	4,616		(103,880	)
Zimmer Biomet Holdings, Inc.		305		08/18/23		USD	145.00		USD	4,441		(158,600	)
Medtronic PLC		368		08/29/23		USD	89.00		USD	3,242		(81,835	)
Medtronic PLC		470		09/08/23		USD	89.00		USD	4,141		(116,059	)
Fortive Corp.		111		09/15/23		USD	70.00		USD	830		(72,150	)
Raymond James Financial, Inc.		318		09/15/23		USD	103.80		USD	3,300		(158,558	)
Sealed Air Corp.		960		09/15/23		USD	41.75		USD	3,840		(131,595	)
Zimmer Biomet Holdings, Inc.		180		09/15/23		USD	145.00		USD	2,621		(113,400	)
											$	(21,539,204	)

OTC Options Written

Description	Counterparty	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call
Samsung Electronics Co. Ltd., GDR, Registered Shares	UBS AG		1,500		07/06/23		USD	1,277.12		USD	2,079	$	(165,047	)
BP PLC	Morgan Stanley & Co. International PLC		732,200		07/11/23		GBP	4.97		GBP	3,357		(772	)
JPMorgan Chase & Co.	Citibank N.A.		29,100		07/11/23		USD	138.70		USD	4,232		(181,427	)
Prudential PLC	Morgan Stanley & Co. International PLC		282,000		07/11/23		GBP	12.00		GBP	3,136		(3,696	)
Samsung Electronics Co. Ltd., GDR, Registered Shares	UBS AG		1,700		07/11/23		USD	1,273.60		USD	2,357		(195,294	)
Sony Group Corp.	Morgan Stanley & Co. International PLC		33,600		07/11/23		JPY	13,332.80		JPY	437,658		(26,501	)
Koninklijke Philips NV	Goldman Sachs International		217,800		07/13/23		EUR	18.35		EUR	4,325		(363,970	)
Sanofi	Goldman Sachs International		103,700		07/13/23		EUR	97.63		EUR	10,231		(167,055	)
Shell PLC	Morgan Stanley & Co. International PLC		236,500		07/13/23		GBP	23.04		GBP	5,555		(184,367	)
Siemens AG, Registered Shares	Barclays Bank PLC		23,600		07/13/23		EUR	157.94		EUR	3,605		(13,146	)
Sony Group Corp.	UBS AG		24,300		07/13/23		JPY	13,812.30		JPY	316,520		(9,230	)
AstraZeneca PLC	UBS AG		36,500		07/18/23		GBP	122.66		GBP	4,120		(14,695	)
AstraZeneca PLC	UBS AG		19,800		07/18/23		GBP	124.57		GBP	2,235		(4,523	)
Sanofi	Goldman Sachs International		57,900		07/18/23		EUR	97.09		EUR	5,712		(129,526	)
Panasonic Holdings Corp.	BNP Paribas SA		170,000		07/19/23		JPY	1,504.36		JPY	300,787		(303,339	)
Bayer AG, Registered Shares	Goldman Sachs International		75,900		07/25/23		EUR	53.58		EUR	3,850		(13,086	)
Prudential PLC	Morgan Stanley & Co. International PLC		96,800		07/26/23		GBP	11.44		GBP	1,076		(23,570	)
Panasonic Holdings Corp.	Citibank N.A.		116,200		08/01/23		JPY	1,740.44		JPY	205,597		(57,260	)
Komatsu Ltd.	Citibank N.A.		159,700		08/03/23		JPY	3,976.98		JPY	623,292		(84,896	)
Shell PLC	Goldman Sachs International		213,800		08/03/23		GBP	23.39		GBP	5,022		(183,378	)
Panasonic Holdings Corp.	Citibank N.A.		261,500		08/08/23		JPY	1,745.80		JPY	462,681		(134,448	)
Komatsu Ltd.	BNP Paribas SA		114,900		08/10/23		JPY	3,920.70		JPY	448,442		(88,394	)
Samsung Electronics Co. Ltd., GDR, Registered Shares	Morgan Stanley & Co. International PLC		3,100		08/10/23		USD	1,450.05		USD	4,297		(75,511	)
Prudential PLC	JPMorgan Chase Bank N.A.		96,800		08/15/23		GBP	11.27		GBP	1,076		(47,748	)
Shell PLC	Barclays Bank PLC		153,900		08/15/23		GBP	23.66		GBP	3,615		(106,680	)
Bayer AG, Registered Shares	Goldman Sachs International		146,600		08/16/23		EUR	52.05		EUR	7,437		(172,206	)
BP PLC	Morgan Stanley & Co. International PLC		2,333,400		08/16/23		GBP	4.72		GBP	10,697		(249,816	)
Koninklijke Philips NV	UBS AG		130,500		08/16/23		EUR	19.12		EUR	2,591		(203,448	)
Panasonic Holdings Corp.	Societe Generale		217,100		08/16/23		JPY	1,710.21		JPY	384,122		(153,426	)
												$	(3,356,455	)

Balances Reported in the Consolidated Statements of Assets and Liabilities for Options Written

Description	Swap Premiums Paid		Swap Premiums Received		Unrealized Appreciation		Unrealized Depreciation			Value
Options Written	$	N/A	$	N/A	$	4,211,634	$	(9,733,730	)	$	(24,895,659)

S C H E D U L E    O F   I N V E S T M E N T S 49

Consolidated Schedule of Investments (unaudited) (continued) June 30, 2023      BlackRock Enhanced Equity Dividend Trust (BDJ)

Derivative Financial Instruments Categorized by Risk Exposure

As of period end, the fair values of derivative financial instruments located in the Consolidated Statements of Assets and Liabilities were as follows:

	Commodity Contracts		Credit Contracts		Equity Contracts		Foreign Currency Exchange Contracts		Interest Rate Contracts		Other Contracts		Total
Liabilities — Derivative Financial Instruments
Options written
Options written at value	$	—	$	—	$	24,895,659	$	—	$	—	$	—	$	24,895,659

For the period ended June 30, 2023, the effect of derivative financial instruments in the Consolidated Statements of Operations was as follows:

	Commodity Contracts		Credit Contracts		Equity Contracts			Foreign Currency Exchange Contracts		Interest Rate Contracts		Other Contracts		Total
Net Realized Gain (Loss) from:
Options purchased(a)	$	—	$	—	$	(8,278,345	)	$	—	$	—	$	—	$	(8,278,345	)
Options written		—		—		4,987,132			—		—		—		4,987,132
	$	—	$	—	$	(3,291,213	)	$	—	$	—	$	—	$	(3,291,213	)
Net Change in Unrealized Appreciation (Depreciation) on:
Options written	$	—	$	—	$	(13,463,460	)	$	—	$	—	$	—	$	(13,463,460	)

^(a) Options purchased are included in net realized gain (loss) from investments — unaffiliated.

Average Quarterly Balances of Outstanding Derivative Financial Instruments

Options:
Average value of option contracts purchased	$	—(a)
Average value of option contracts written	$	25,918,602

^(a)  Derivative not held at any quarter-end. The risk exposure table serves as an indicator of activity during the period.

For more information about the Trust’s investment risks regarding derivative financial instruments, refer to the Notes to Consolidated Financial Statements.

Derivative Financial Instruments — Offsetting as of Period End

The Trust’s derivative assets and liabilities (by type) were as follows:

	Assets		Liabilities
Derivative Financial Instruments
Options	$	—	$	24,895,659
Total derivative assets and liabilities in the Consolidated Statements of Assets and Liabilities		—		24,895,659
Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”)		—		(21,539,204	)
Total derivative assets and liabilities subject to an MNA	$	—	$	3,356,455

50 2 0 2 3   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Consolidated Schedule of Investments (unaudited) (continued) June 30, 2023 BlackRock Enhanced Equity Dividend Trust (BDJ)

The following table presents the Trust’s derivative liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral pledged by the Trust:

Counterparty		Derivative Liabilities Subject to an MNA by Counterparty		Derivatives Available for Offset		Non-Cash Collateral Pledged	(a)		Cash       Collateral Pledged		Net Amount of Derivative Liabilities	(b)
Barclays Bank PLC	$	119,826	$	—	$	—		$	—	$	119,826
BNP Paribas SA		391,733		—		(391,733	)		—		—
Citibank N.A.		458,031		—		(458,031	)		—		—
Goldman Sachs International		1,029,221		—		(1,029,221	)		—		—
JPMorgan Chase Bank N.A.		47,748		—		(5,096	)		—		42,652
Morgan Stanley & Co. International PLC		564,233		—		(564,233	)		—		—
Societe Generale		153,426		—		(153,426	)		—		—
UBS AG		592,237		—		(592,237	)		—		—
	$	3,356,455	$	—	$	(3,193,977	)	$	—	$	162,478

^(a) Excess of collateral received/pledged, if any, from the individual counterparty is not shown for financial reporting purposes.

^(b)  Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Consolidated Statements of Assets and Liabilities.

Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of financial instruments. For a description of the input levels and information about the Trust’s policy regarding valuation of financial instruments, refer to the Notes to Consolidated Financial Statements.

The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust’s financial instruments into major categories is disclosed in the Consolidated Schedule of Investments above.

	Level 1		Level 2		Level 3		Total
Assets
Investments
Long-Term Investments
Common Stocks
Aerospace & Defense	$	45,673,091	$	—	$	—	$	45,673,091
Automobile Components		6,861,690		—		—		6,861,690
Automobiles		35,280,356		—		—		35,280,356
Banks		168,731,603		—		—		168,731,603
Beverages		16,069,582		—		—		16,069,582
Capital Markets		41,257,109		—		—		41,257,109
Chemicals		8,963,104		—		—		8,963,104
Communications Equipment		37,233,656		—		—		37,233,656
Consumer Staples Distribution & Retail		31,867,027		—		—		31,867,027
Containers & Packaging		23,730,880		—		—		23,730,880
Diversified Telecommunication Services		29,380,634		—		—		29,380,634
Electric Utilities		33,495,308		—		—		33,495,308
Entertainment		8,382,455		—		—		8,382,455
Financial Services		64,664,716		—		—		64,664,716
Food Products		44,278,957		—		—		44,278,957
Ground Transportation		9,373,847		—		—		9,373,847
Health Care Equipment & Supplies		103,502,566		18,872,411		—		122,374,977
Health Care Providers & Services		145,295,392		—		—		145,295,392
Household Durables		6,504,764		26,564,678		—		33,069,442
Industrial Conglomerates		—		7,125,129		—		7,125,129
Insurance		101,635,118		12,213,975		—		113,849,093
Interactive Media & Services		11,241,626		—		—		11,241,626
IT Services		42,841,175		—		—		42,841,175
Machinery		7,055,777		13,502,367		—		20,558,144
Media		44,059,573		—		—		44,059,573
Multi-Utilities		24,329,806		—		—		24,329,806
Oil, Gas & Consumable Fuels		65,742,957		70,152,472		10,037,117		145,932,546
Personal Care Products		33,113,914		—		—		33,113,914
Pharmaceuticals		20,482,459		68,673,403		—		89,155,862
Professional Services		69,120,777		—		—		69,120,777

S C H E D U L E    O F   I N V E S T M E N T S 51

Consolidated Schedule of Investments (unaudited) (continued) June 30, 2023      BlackRock Enhanced Equity Dividend Trust (BDJ)

Fair Value Hierarchy as of Period End (continued)

	Level 1			Level 2			Level 3		Total
Common Stocks (continued)
Semiconductors & Semiconductor Equipment	$	7,987,212		$	—		$	—	$	7,987,212
Software		34,586,264			—			—		34,586,264
Specialty Retail		9,892,669			—			—		9,892,669
Technology Hardware, Storage & Peripherals		—			22,212,817			—		22,212,817
Textiles, Apparel & Luxury Goods		8,442,721			—			—		8,442,721
Tobacco		23,005,808			—			—		23,005,808
Wireless Telecommunication Services		7,657,117			—			—		7,657,117
Short-Term Securities
Money Market Funds		54,579,536			—			—		54,579,536
	$	1,426,321,246		$	239,317,252		$	10,037,117	$	1,675,675,615
Derivative Financial Instruments(a)
Liabilities
Equity Contracts	$	(17,040,391	)	$	(7,855,268	)	$	—	$	(24,895,659	)

^(a)  Derivative financial instruments are options written. Options written are shown at value.

See notes to financial statements.

52 2 0 2 3   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Schedule of Investments  (unaudited) June 30, 2023      BlackRock Enhanced Global Dividend Trust (BOE) (Percentages shown are based on Net Assets)

Security	Shares		Value
Common Stocks
Canada — 2.3%
TELUS Corp.		854,087	$	16,620,768
Denmark — 2.0%
Novo Nordisk A/S, Class B		88,367		14,274,779
France — 9.3%
Air Liquide SA		68,615		12,305,078
EssilorLuxottica SA		82,291		15,517,630
Kering SA		17,738		9,794,909
LVMH Moet Hennessy Louis Vuitton SE		8,731		8,232,566
Sanofi		192,899		20,766,688
				66,616,871
India — 0.1%
AceVector Limited, Series I, (Acquired 08/31/18, Cost: $2,637,143)(a)(b)		566,400		437,040
Indonesia — 1.1%
Bank Rakyat Indonesia Persero Tbk PT		22,422,100		8,186,119
Ireland(c) — 4.8%
Accenture PLC, Class A		65,207		20,121,576
Medtronic PLC		161,221		14,203,570
				34,325,146
Japan — 1.5%
KDDI Corp.		352,200		10,877,033
Mexico — 2.0%
Wal-Mart de Mexico SAB de CV		3,624,607		14,340,035
Netherlands — 3.5%
Koninklijke KPN NV		3,096,591		11,054,747
Shell PLC		477,667		14,388,861
				25,443,608
Singapore — 1.3%
DBS Group Holdings Ltd.		405,168		9,461,794
Spain — 1.0%
Industria de Diseno Textil SA		191,048		7,410,331
Switzerland — 5.0%
Lonza Group AG, Registered Shares		17,163		10,258,540
TE Connectivity Ltd.(c)		76,977		10,789,096
Zurich Insurance Group AG		31,721		15,089,319
				36,136,955
Taiwan — 4.2%
MediaTek, Inc.		480,000		10,625,204
Taiwan Semiconductor Manufacturing Co. Ltd.		1,076,000		19,877,289
				30,502,493
United Kingdom — 13.4%
AstraZeneca PLC		136,569		19,577,740
Ferguson PLC		74,135		11,709,730
Prudential PLC		1,065,116		15,043,044
Reckitt Benckiser Group PLC		267,936		20,135,594
RELX PLC		505,465		16,861,411
Taylor Wimpey PLC		10,188,248		13,309,837
				96,637,356

Security	Shares		Value
United States — 48.4%
AbbVie, Inc.(c)(d)		131,096	$	17,662,576
American Express Co.(c)		70,189		12,226,924
Apple, Inc.(c)(d)		135,913		26,363,045
Assurant, Inc.(c)		89,681		11,274,695
Baker Hughes Co.(c)(d)		504,799		15,956,696
Carrier Global Corp.(c)		310,408		15,430,382
Citizens Financial Group, Inc.(c)		392,831		10,245,033
Intercontinental Exchange, Inc.(c)		160,687		18,170,486
International Flavors & Fragrances, Inc.(c)(d)		173,549		13,812,765
M&T Bank Corp.(c)		87,077		10,776,650
Microsoft Corp.(c)		100,503		34,225,292
Mondelez International, Inc., Class A(c)		294,985		21,516,206
Oracle Corp.		153,421		18,270,907
Otis Worldwide Corp.(c)(d)		173,733		15,463,974
Paychex, Inc.(c)(d)		170,700		19,096,209
Philip Morris International, Inc.(c)(d)		189,817		18,529,936
Republic Services, Inc.(c)		74,667		11,436,744
Synchrony Financial(c)		225,639		7,653,675
United Parcel Service, Inc., Class B(c)(d)		83,321		14,935,289
UnitedHealth Group, Inc.(c)		29,474		14,166,383
Walt Disney Co.(c)(d)(e)		161,930		14,457,110
Williams Cos., Inc.(c)		226,242		7,382,276
				349,053,253
Total Long-Term Investments — 99.9% (Cost: $639,242,116)				720,323,581
Short-Term Securities
Money Market Funds — 1.0%
BlackRock Liquidity Funds, T-Fund, Institutional Class, 4.98%(f)(g)		7,220,667		7,220,667
Total Short-Term Securities — 1.0% (Cost: $7,220,667)				7,220,667
Total Investments Before Options Written — 100.9% (Cost: $646,462,783)				727,544,248
Options Written — (1.0)% (Premiums Received: $(6,795,289))				(7,357,120	)
Total Investments, Net of Options Written — 99.9% (Cost: $639,667,494)				720,187,128
Other Assets Less Liabilities — 0.1%				1,074,434
Net Assets — 100.0%			$	721,261,562

^(a)  Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy.

^(b)  Restricted security as to resale, excluding 144A securities. The Trust held restricted securities with a current value of $437,040, representing 0.1% of its net assets as of period end, and an original cost of $2,637,143.

^(c)  All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.

^(d)  All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives.

^(e)  Non-income producing security.

^(f)  Affiliate of the Trust.

^(g)  Annualized 7-day yield as of period end.

S C H E D U L E   O F   I N V E S T M E N T S 53

Schedule of Investments  (unaudited) (continued) June 30, 2023      BlackRock Enhanced Global Dividend Trust (BOE)

Affiliates

Investments in issuers considered to be affiliate(s) of the Trust during the six months ended June 30, 2023 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

Affiliated Issuer	Value at 12/31/22		Purchases at Cost			Proceeds from Sales			Net Realized Gain (Loss)		Change in Unrealized Appreciation (Depreciation)		Value at 06/30/23		Shares Held at 06/30/23		Income			Capital Gain Distributions from Underlying Funds
BlackRock Liquidity Funds, T-Fund, Institutional Class	$	6,643,752	$	576,915	(a)	$	—		$	—	$	—	$	7,220,667		7,220,667	$	227,151		$	—
SL Liquidity Series, LLC, Money Market Series(b)		—		—			(1,183	)(a)		1,183		—		—		—		2,629	(c)		—
									$	1,183	$	—	$	7,220,667			$	229,780		$	—

^(a)  Represents net amount purchased (sold).

^(b)  As of period end, the entity is no longer held.

^(c)  All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities.

Derivative Financial Instruments Outstanding as of Period End

Exchange-Traded Options Written

Description	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call
American Express Co.		134		07/07/23		USD	165.00		USD	2,334	$	(124,285	)
Apple, Inc.		200		07/07/23		USD	185.00		USD	3,879		(183,500	)
Microsoft Corp.		87		07/07/23		USD	340.00		USD	2,963		(30,232	)
Mondelez International, Inc., Class A		368		07/07/23		USD	75.00		USD	2,684		(3,680	)
United Parcel Service, Inc., Class B		203		07/07/23		USD	175.00		USD	3,639		(98,455	)
UnitedHealth Group, Inc.		33		07/07/23		USD	485.00		USD	1,586		(6,468	)
American Express Co.		181		07/14/23		USD	175.00		USD	3,153		(32,127	)
Microsoft Corp.		146		07/14/23		USD	330.00		USD	4,972		(174,470	)
Mondelez International, Inc., Class A		23		07/14/23		USD	73.00		USD	168		(1,495	)
Walt Disney Co.		293		07/14/23		USD	96.00		USD	2,616		(3,370	)
Williams Cos., Inc.		280		07/14/23		USD	31.00		USD	914		(47,600	)
AbbVie, Inc.		268		07/21/23		USD	150.00		USD	3,611		(1,206	)
Assurant, Inc.		145		07/21/23		USD	129.90		USD	1,823		(14,942	)
Baker Hughes Co.		753		07/21/23		USD	32.00		USD	2,380		(60,240	)
Citizens Financial Group, Inc.		660		07/21/23		USD	27.50		USD	1,721		(33,000	)
Citizens Financial Group, Inc.		1,107		07/21/23		USD	30.00		USD	2,887		(13,838	)
Intercontinental Exchange, Inc.		565		07/21/23		USD	109.00		USD	6,389		(269,486	)
International Flavors & Fragrances, Inc.		322		07/21/23		USD	80.00		USD	2,563		(56,350	)
M&T Bank Corp.		140		07/21/23		USD	125.00		USD	1,733		(58,100	)
M&T Bank Corp.		251		07/21/23		USD	135.00		USD	3,106		(26,355	)
Medtronic PLC		96		07/21/23		USD	90.00		USD	846		(5,472	)
Microsoft Corp.		38		07/21/23		USD	330.00		USD	1,294		(54,340	)
Microsoft Corp.		98		07/21/23		USD	340.00		USD	3,337		(70,070	)
Otis Worldwide Corp.		607		07/21/23		USD	84.60		USD	5,403		(310,173	)
Paychex, Inc.		366		07/21/23		USD	108.89		USD	4,094		(147,686	)
Paychex, Inc.		402		07/21/23		USD	115.00		USD	4,497		(26,130	)
Philip Morris International, Inc.		315		07/21/23		USD	95.00		USD	3,075		(114,975	)
Republic Services, Inc.		168		07/21/23		USD	150.00		USD	2,573		(70,560	)
Synchrony Financial		516		07/21/23		USD	30.00		USD	1,750		(211,560	)
TE Connectivity Ltd.		186		07/21/23		USD	125.00		USD	2,607		(293,880	)
TELUS Corp.		482		07/21/23		CAD	26.00		CAD	1,243		(5,821	)
AbbVie, Inc.		94		07/28/23		USD	140.00		USD	1,266		(6,674	)
Accenture PLC, Class A		146		07/28/23		USD	330.00		USD	4,505		(10,220	)
Medtronic PLC		72		07/28/23		USD	87.00		USD	634		(16,776	)
Microsoft Corp.		120		07/28/23		USD	345.00		USD	4,086		(99,600	)
Mondelez International, Inc., Class A		486		07/28/23		USD	76.00		USD	3,545		(14,580	)
Mondelez International, Inc., Class A		450		07/28/23		USD	74.00		USD	3,282		(40,500	)
UnitedHealth Group, Inc.		99		07/28/23		USD	490.00		USD	4,758		(74,250	)
Walt Disney Co.		369		07/28/23		USD	94.00		USD	3,294		(25,461	)
Williams Cos., Inc.		230		07/28/23		USD	31.40		USD	750		(35,380	)

54 2 0 2 3   B L A C K R O C K  S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Schedule of Investments  (unaudited) (continued) June 30, 2023      BlackRock Enhanced Global Dividend Trust (BOE)

Exchange-Traded Options Written (continued)

Description	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call (continued)
Apple, Inc.		294		08/04/23		USD	190.00		USD	5,703	$	(241,815	)
Oracle Corp.		345		08/04/23		USD	124.00		USD	4,109		(45,540	)
United Parcel Service, Inc., Class B		171		08/04/23		USD	180.00		USD	3,065		(70,537	)
Williams Cos., Inc.		281		08/04/23		USD	31.40		USD	917		(47,544	)
Baker Hughes Co.		765		08/07/23		USD	29.75		USD	2,418		(196,197	)
Accenture PLC, Class A		147		08/11/23		USD	310.00		USD	4,536		(113,190	)
Oracle Corp.		345		08/11/23		USD	124.00		USD	4,109		(53,992	)
AbbVie, Inc.		176		08/18/23		USD	145.00		USD	2,371		(13,992	)
Apple, Inc.		117		08/18/23		USD	190.00		USD	2,269		(102,082	)
Assurant, Inc.		168		08/18/23		USD	130.00		USD	2,112		(51,660	)
Baker Hughes Co.		753		08/18/23		USD	31.60		USD	2,380		(108,064	)
Carrier Global Corp.		698		08/18/23		USD	50.00		USD	3,470		(120,405	)
Intercontinental Exchange, Inc.		33		08/18/23		USD	115.00		USD	373		(7,095	)
International Flavors & Fragrances, Inc.		285		08/18/23		USD	85.00		USD	2,268		(50,587	)
Medtronic PLC		234		08/18/23		USD	86.25		USD	2,062		(83,136	)
Otis Worldwide Corp.		69		08/18/23		USD	80.23		USD	614		(65,816	)
Philip Morris International, Inc.		539		08/18/23		USD	95.00		USD	5,262		(242,550	)
Republic Services, Inc.		168		08/18/23		USD	146.50		USD	2,573		(142,944	)
Synchrony Financial		499		08/18/23		USD	33.70		USD	1,693		(77,965	)
TE Connectivity Ltd.		160		08/18/23		USD	135.00		USD	2,243		(132,000	)
TELUS Corp.		482		08/18/23		CAD	26.00		CAD	1,243		(14,554	)
Medtronic PLC		94		08/29/23		USD	89.00		USD	828		(20,904	)
Medtronic PLC		68		09/08/23		USD	89.00		USD	599		(16,792	)
Carrier Global Corp.		698		09/15/23		USD	50.00		USD	3,470		(157,050	)
Otis Worldwide Corp.		105		09/15/23		USD	90.00		USD	935		(30,450	)
TELUS Corp.		1,531		09/15/23		CAD	26.00		CAD	3,947		(57,207	)
											$	(5,137,375	)

OTC Options Written

Description	Counterparty	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call
Industria de Diseno Textil SA	UBS AG		13,300		07/11/23		EUR	32.16		EUR	472	$	(48,761	)
Lonza Group AG, Registered Shares	Goldman Sachs International		8,200		07/11/23		CHF	605.07		CHF	4,374		(514	)
Novo Nordisk A/S, Class B	Barclays Bank PLC		21,400		07/11/23		DKK	1,191.22		DKK	23,527		(1,632	)
Prudential PLC	Morgan Stanley & Co. International PLC		175,500		07/11/23		GBP	12.00		GBP	1,945		(2,300	)
Zurich Insurance Group AG	Barclays Bank PLC		7,600		07/11/23		CHF	442.18		CHF	3,229		(1,577	)
Taylor Wimpey PLC	UBS AG		881,100		07/12/23		GBP	1.26		GBP	905		(1	)
Wal-Mart de Mexico SAB de CV	Citibank N.A.		799,700		07/12/23		MXN	68.49		MXN	54,156		(45,360	)
Air Liquide SA	Goldman Sachs International		30,900		07/13/23		EUR	159.49		EUR	5,074		(176,547	)
Koninklijke KPN NV	Barclays Bank PLC		789,100		07/13/23		EUR	3.28		EUR	2,580		(23,843	)
Novo Nordisk A/S, Class B	Morgan Stanley & Co. International PLC		10,900		07/13/23		DKK	1,149.69		DKK	11,983		(7,593	)
Reckitt Benckiser Group PLC	Morgan Stanley & Co. International PLC		28,800		07/13/23		GBP	64.10		GBP	1,703		(384	)
RELX PLC	Morgan Stanley & Co. International PLC		33,750		07/13/23		EUR	30.21		EUR	1,031		(20,018	)
Sanofi	Goldman Sachs International		19,500		07/13/23		EUR	97.63		EUR	1,915		(31,414	)
Taylor Wimpey PLC	Goldman Sachs International		766,000		07/13/23		GBP	1.17		GBP	787		(233	)
Zurich Insurance Group AG	Barclays Bank PLC		6,700		07/13/23		CHF	444.02		CHF	2,847		(1,660	)
AstraZeneca PLC	UBS AG		38,000		07/18/23		GBP	124.57		GBP	4,285		(8,680	)
AstraZeneca PLC	UBS AG		16,300		07/18/23		GBP	122.66		GBP	1,838		(6,562	)
Ferguson PLC	Morgan Stanley & Co. International PLC		16,000		07/18/23		GBP	124.80		GBP	1,986		(42,064	)
Reckitt Benckiser Group PLC	Barclays Bank PLC		59,000		07/18/23		GBP	67.68		GBP	3,488		(578	)
Sanofi	Goldman Sachs International		48,100		07/18/23		EUR	97.09		EUR	4,723		(107,603	)
Prudential PLC	Morgan Stanley & Co. International PLC		68,500		07/19/23		GBP	11.63		GBP	759		(7,919	)
KDDI Corp.	BNP Paribas SA		81,300		07/25/23		JPY	4,495.43		JPY	361,785		(40,227	)
Lonza Group AG, Registered Shares	UBS AG		5,000		07/25/23		CHF	612.75		CHF	2,667		(3,004	)
Reckitt Benckiser Group PLC	UBS AG		32,800		07/25/23		GBP	63.72		GBP	1,939		(3,959	)
RELX PLC	Morgan Stanley & Co. International PLC		52,000		07/25/23		EUR	30.46		EUR	1,588		(30,358	)
Shell PLC	Morgan Stanley & Co. International PLC		105,000		07/25/23		EUR	27.03		EUR	2,897		(109,168	)
Wal-Mart de Mexico SAB de CV	Citibank N.A.		415,600		07/25/23		MXN	70.46		MXN	28,144		(17,907	)
KDDI Corp.	UBS AG		112,500		07/26/23		JPY	4,492.08		JPY	500,625		(58,164	)

S C H E D U L E  O F  I N V E S T M E N T S 55

Schedule of Investments  (unaudited) (continued) June 30, 2023      BlackRock Enhanced Global Dividend Trust (BOE)

OTC Options Written (continued)

Description	Counterparty	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call (continued)
MediaTek, Inc.	Morgan Stanley & Co. International PLC		31,919		07/26/23		TWD	775.69		TWD	21,960	$	(851	)
Prudential PLC	Morgan Stanley & Co. International PLC		152,100		07/26/23		GBP	11.44		GBP	1,686		(37,036	)
RELX PLC	Morgan Stanley & Co. International PLC		52,000		07/26/23		EUR	30.29		EUR	1,588		(38,062	)
EssilorLuxottica SA	Barclays Bank PLC		24,500		08/01/23		EUR	171.93		EUR	4,229		(132,548	)
RELX PLC	Barclays Bank PLC		89,700		08/01/23		EUR	30.83		EUR	2,739		(46,189	)
Ferguson PLC	Barclays Bank PLC		13,100		08/02/23		GBP	120.02		GBP	1,626		(102,031	)
Ferguson PLC	Morgan Stanley & Co. International PLC		4,300		08/02/23		GBP	121.58		GBP	534		(27,269	)
Novo Nordisk A/S, Class B	Citibank N.A.		7,500		08/02/23		DKK	1,117.35		DKK	8,246		(32,128	)
Taiwan Semiconductor Manufacturing Co. Ltd.	Morgan Stanley & Co. International PLC		180,000		08/02/23		TWD	601.80		TWD	103,680		(47,365	)
Taylor Wimpey PLC	Citibank N.A.		766,000		08/02/23		GBP	1.12		GBP	787		(11,168	)
DBS Group Holdings Ltd.	Citibank N.A.		71,500		08/03/23		SGD	31.84		SGD	2,253		(28,212	)
MediaTek, Inc.	Morgan Stanley & Co. International PLC		87,000		08/03/23		TWD	711.75		TWD	59,856		(34,778	)
Shell PLC	Goldman Sachs International		62,100		08/03/23		EUR	27.40		EUR	1,714		(56,206	)
EssilorLuxottica SA	UBS AG		12,500		08/08/23		EUR	171.20		EUR	2,158		(83,145	)
Taiwan Semiconductor Manufacturing Co. Ltd.	Morgan Stanley & Co. International PLC		82,000		08/08/23		TWD	582.61		TWD	47,232		(44,141	)
Industria de Diseno Textil SA	Goldman Sachs International		117,000		08/10/23		EUR	35.47		EUR	4,149		(108,714	)
Koninklijke KPN NV	Goldman Sachs International		604,400		08/10/23		EUR	3.27		EUR	1,976		(26,295	)
Taylor Wimpey PLC	Morgan Stanley & Co. International PLC		535,500		08/10/23		GBP	1.14		GBP	550		(7,556	)
Prudential PLC	JPMorgan Chase Bank N.A.		83,300		08/15/23		GBP	11.27		GBP	923		(41,089	)
Wal-Mart de Mexico SAB de CV	JPMorgan Chase Bank N.A.		415,700		08/15/23		MXN	69.16		MXN	28,151		(49,711	)
AstraZeneca PLC	Goldman Sachs International		20,800		08/16/23		GBP	117.36		GBP	2,345		(57,916	)
DBS Group Holdings Ltd.	Citibank N.A.		110,800		08/16/23		SGD	31.68		SGD	3,491		(42,486	)
Kering SA	Goldman Sachs International		6,200		08/16/23		EUR	523.06		EUR	3,135		(81,080	)
LVMH Moet Hennessy Louis Vuitton SE	Goldman Sachs International		4,200		08/16/23		EUR	858.61		EUR	3,625		(146,391	)
MediaTek, Inc.	Bank of America N.A.		48,700		08/16/23		TWD	727.65		TWD	33,506		(18,208	)
Taiwan Semiconductor Manufacturing Co. Ltd.	Morgan Stanley & Co. International PLC		115,000		08/16/23		TWD	592.62		TWD	66,240		(53,588	)
Taylor Wimpey PLC	Morgan Stanley & Co. International PLC		535,500		08/16/23		GBP	1.14		GBP	550		(9,168	)
Taylor Wimpey PLC	Morgan Stanley & Co. International PLC		1,100,600		08/22/23		GBP	1.05		GBP	1,131		(58,384	)
												$	(2,219,745	)

Balances Reported in the Statements of Assets and Liabilities for Options Written

Description	Swap Premiums Paid		Swap Premiums Received		Unrealized Appreciation		Unrealized Depreciation		Value
Options Written	$	N/A	$	N/A	$	2,027,722	$	(2,589,553)	$	(7,357,120)

Derivative Financial Instruments Categorized by Risk Exposure

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

	Commodity Contracts		Credit Contracts		Equity Contracts		Foreign Currency Exchange Contracts		Interest Rate Contracts		Other Contracts		Total
Liabilities — Derivative Financial Instruments
Options written
Options written at value	$	—	$	—	$	7,357,120	$	—	$	—	$	—	$	7,357,120

56 2 0 2 3  B L A C K  R O C K   S E M I - A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Schedule of Investments  (unaudited) (continued) June 30, 2023      BlackRock Enhanced Global Dividend Trust (BOE)

For the period ended June 30, 2023, the effect of derivative financial instruments in the Statements of Operations was as follows:

	Commodity Contracts		Credit Contracts		Equity Contracts			Foreign Currency Exchange Contracts		Interest Rate Contracts		Other Contracts		Total
Net Realized Gain (Loss) from:
Options purchased(a)	$	—	$	—	$	(7,590,001	)	$	—	$	—	$	—	$	(7,590,001	)
Options written		—		—		6,365,169			—		—		—		6,365,169
	$	—	$	—	$	(1,224,832	)	$	—	$	—	$	—	$	(1,224,832	)
Net Change in Unrealized Appreciation (Depreciation) on:
Options written	$	—	$	—	$	(3,947,548	)	$	—	$	—	$	—	$	(3,947,548	)

^(a)  Options purchased are included in net realized gain (loss) from investments — unaffiliated.

Average Quarterly Balances of Outstanding Derivative Financial Instruments

Options:
Average value of option contracts purchased	$	—	(a)
Average value of option contracts written	$	8,216,310

^(a)  Derivative not held at any quarter-end. The risk exposure table serves as an indicator of activity during the period.

For more information about the Trust’s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.

Derivative Financial Instruments — Offsetting as of Period End

The Trust’s derivative assets and liabilities (by type) were as follows:

	Assets		Liabilities
Derivative Financial Instruments
Options	$	—	$	7,357,120
Total derivative assets and liabilities in the Statements of Assets and Liabilities		—		7,357,120
Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”)		—		(5,137,375	)
Total derivative assets and liabilities subject to an MNA	$	—	$	2,219,745

The following table presents the Trust’s derivative liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral pledged by the Trust:

Counterparty		Derivative Liabilities Subject to an MNA by Counterparty		Derivatives Available for Offset		Non-Cash Collateral Pledged(a	)		Cash Collateral Pledged		Net Amount of Derivative Liabilities(b	)
Bank of America N.A.	$	18,208	$	—	$	(18,208	)	$	—	$	—
Barclays Bank PLC		310,058		—		(310,058	)		—		—
BNP Paribas SA		40,227		—		—			—		40,227
Citibank N.A.		177,261		—		(177,261	)		—		—
Goldman Sachs International		792,913		—		(792,913	)		—		—
JPMorgan Chase Bank N.A.		90,800		—		(90,800	)		—		—
Morgan Stanley & Co. International PLC		578,002		—		(578,002	)		—		—
UBS AG		212,276		—		(212,276	)		—		—
	$	2,219,745	$	—	$	(2,179,518	)	$	—	$	40,227

^(a)  Excess of collateral received/pledged, if any, from the individual counterparty is not shown for financial reporting purposes.

^(b)  Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.

S C H E D U L E    O F   I N V E S T M E N T S 57

Schedule of Investments  (unaudited) (continued) June 30, 2023      BlackRock Enhanced Global Dividend Trust (BOE)

Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of financial instruments. For a description of the input levels and information about the Trust’s policy regarding valuation of financial instruments, refer to the Notes to Financial Statements.

The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust’s financial instruments into major categories is disclosed in the Schedule of Investments above.

	Level 1			Level 2			Level 3		Total
Assets
Investments
Long-Term Investments
Common Stocks
Canada	$	16,620,768		$	—		$	—	$	16,620,768
Denmark		—			14,274,779			—		14,274,779
France		—			66,616,871			—		66,616,871
India		—			—			437,040		437,040
Indonesia		—			8,186,119			—		8,186,119
Ireland		34,325,146			—			—		34,325,146
Japan		—			10,877,033			—		10,877,033
Mexico		14,340,035			—			—		14,340,035
Netherlands		—			25,443,608			—		25,443,608
Singapore		—			9,461,794			—		9,461,794
Spain		—			7,410,331			—		7,410,331
Switzerland		10,789,096			25,347,859			—		36,136,955
Taiwan		—			30,502,493			—		30,502,493
United Kingdom		—			96,637,356			—		96,637,356
United States		349,053,253			—			—		349,053,253
Short-Term Securities
Money Market Funds		7,220,667			—			—		7,220,667
	$	432,348,965		$	294,758,243		$	437,040	$	727,544,248
Derivative Financial Instruments(a)
Liabilities
Equity Contracts	$	(3,600,346	)	$	(3,756,774	)	$	—	$	(7,357,120	)

^(a)  Derivative financial instruments are options written. Options written are shown at value.

See notes to financial statements.

58 2 0 2 3   B L A C K R O C K  S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Schedule of Investments  (unaudited)  June 30, 2023      BlackRock Enhanced International Dividend Trust (BGY) (Percentages shown are based on Net Assets)

Security	Shares		Value
Common Stocks
Canada — 2.0%
TELUS Corp.		651,863	$	12,685,433
China — 2.9%
Budweiser Brewing Co. APAC Ltd.(a)		4,826,400		12,489,081
Yum China Holdings, Inc.(b)		100,923		5,702,149
				18,191,230
Denmark — 3.0%
Novo Nordisk A/S, Class B		119,331		19,276,694
France — 13.0%
Air Liquide SA		70,541		12,650,477
EssilorLuxottica SA		65,768		12,401,885
Kering SA		37,887		20,921,170
LVMH Moet Hennessy Louis Vuitton SE		17,294		16,306,724
Sanofi		186,010		20,025,047
				82,305,303
Germany — 5.4%
MTU Aero Engines AG		52,623		13,648,779
Symrise AG		192,507		20,184,839
				33,833,618
India — 3.2%
AceVector Limited, Series I, (Acquired 01/25/22, Cost: $3,948,600)(c)(d)		848,000		654,325
HDFC Bank Ltd.		957,251		19,865,641
				20,519,966
Indonesia — 2.0%
Bank Rakyat Indonesia Persero Tbk PT		33,956,300		12,397,158
Italy — 2.0%
FinecoBank Banca Fineco SpA		935,202		12,588,392
Japan — 6.9%
Daiichi Sankyo Co. Ltd.		170,900		5,430,221
KDDI Corp.		681,000		21,031,401
Sony Group Corp.		189,600		17,115,223
				43,576,845
Mexico — 2.7%
Wal-Mart de Mexico SAB de CV		4,298,658		17,006,784
Netherlands — 8.5%
Heineken NV		152,431		15,675,480
Koninklijke KPN NV		5,283,115		18,860,579
Shell PLC		637,172		19,193,663
				53,729,722
Singapore — 3.9%
DBS Group Holdings Ltd.		477,400		11,148,611
United Overseas Bank Ltd.		653,100		13,552,637
				24,701,248
Spain — 3.1%
Industria de Diseno Textil SA		511,009		19,820,913
Sweden — 1.9%
Epiroc AB, Class A		650,270		12,317,321
Switzerland — 5.5%
Lonza Group AG, Registered Shares		37,625		22,488,934
Zurich Insurance Group AG		25,565		12,160,979
				34,649,913

Security	Shares		Value
Taiwan — 6.2%
MediaTek, Inc.		645,000	$	14,277,618
Taiwan Semiconductor Manufacturing Co. Ltd.		1,356,000		25,049,817
				39,327,435
United Kingdom — 17.8%
AstraZeneca PLC		129,879		18,618,700
BAE Systems PLC		1,094,795		12,908,985
Ferguson PLC		106,107		16,759,754
Prudential PLC		1,363,945		19,263,521
Reckitt Benckiser Group PLC		250,225		18,804,599
RELX PLC		571,799		19,074,195
Smith & Nephew PLC		423,876		6,838,526
				112,268,280
United States(b) — 8.8%
Baker Hughes Co.		599,573		18,952,503
Otis Worldwide Corp.(e)		232,078		20,657,263
Visa, Inc., Class A(e)		66,582		15,811,893
				55,421,659
Total Long-Term Investments — 98.8% (Cost: $537,755,495)				624,617,914
Short-Term Securities
Money Market Funds — 1.3%
BlackRock Liquidity Funds, T-Fund, Institutional Class, 4.98%(f)(g)		8,600,233		8,600,233
Total Short-Term Securities — 1.3%     (Cost: $8,600,233)				8,600,233
Total Investments Before Options Written — 100.1% (Cost: $546,355,728)				633,218,147
Options Written — (0.9)% (Premiums Received: $(6,096,040))				(5,767,908	)
Total Investments, Net of Options Written — 99.2% (Cost: $540,259,688)				627,450,239
Other Assets Less Liabilities — 0.8%				4,996,998
Net Assets — 100.0%			$	632,447,237

^(a)  Security exempt from registration pursuant to Rule 144A under the Securities Act of 1933, as amended. These securities may be resold in transactions exempt from registration to qualified institutional investors.

^(b)  All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.

^(c)  Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy.

^(d)  Restricted security as to resale, excluding 144A securities. The Trust held restricted securities with a current value of $654,325, representing 0.1% of its net assets as of period end, and an original cost of $3,948,600.

^(e)  All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives.

^(f)  Affiliate of the Trust.

^(g)  Annualized 7-day yield as of period end.

S C H E D U L E   O F   I N V E S T M E N T S 59

Schedule of Investments  (unaudited) (continued) June 30, 2023      BlackRock Enhanced International Dividend Trust (BGY)

Affiliates

Investments in issuers considered to be affiliate(s) of the Trust during the six months ended June 30, 2023 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

Affiliated Issuer	Value at 12/31/22		Purchases at Cost			Proceeds from Sales		Net Realized Gain (Loss)		Change in Unrealized Appreciation (Depreciation)		Value at 06/30/23		Shares Held at 06/30/23		Income		Capital Gain Distributions from Underlying Funds
BlackRock Liquidity Funds, T-Fund, Institutional Class	$	5,622,321	$	2,977,912	(a)	$	—	$	—	$	—	$	8,600,233		8,600,233	$	242,490	$	—

^(a)  Represents net amount purchased (sold).

Derivative Financial Instruments Outstanding as of Period End

Exchange-Traded Options Written

Description	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call
Visa, Inc., Class A		37		07/07/23		USD	235.00		USD	879	$	(12,118	)
Visa, Inc., Class A		34		07/14/23		USD	230.00		USD	807		(28,390	)
Baker Hughes Co.		1,000		07/21/23		USD	32.00		USD	3,161		(80,000	)
Otis Worldwide Corp.		201		07/21/23		USD	84.60		USD	1,789		(102,710	)
TELUS Corp.		617		07/21/23		CAD	26.00		CAD	1,591		(7,452	)
Visa, Inc., Class A		187		07/21/23		USD	230.00		USD	4,441		(167,832	)
Yum China Holdings, Inc.		197		07/21/23		USD	65.00		USD	1,113		(1,970	)
Yum China Holdings, Inc.		257		07/21/23		USD	60.00		USD	1,452		(5,783	)
Visa, Inc., Class A		37		07/28/23		USD	230.00		USD	879		(39,127	)
Visa, Inc., Class A		34		07/28/23		USD	235.00		USD	807		(23,715	)
Visa, Inc., Class A		37		08/04/23		USD	240.00		USD	879		(17,390	)
Baker Hughes Co.		1,000		08/07/23		USD	29.75		USD	3,161		(256,467	)
Baker Hughes Co.		1,000		08/18/23		USD	31.60		USD	3,161		(143,511	)
Otis Worldwide Corp.		406		08/18/23		USD	80.23		USD	3,614		(387,264	)
TELUS Corp.		617		08/18/23		CAD	26.00		CAD	1,591		(18,630	)
Otis Worldwide Corp.		437		09/15/23		USD	90.00		USD	3,890		(126,730	)
TELUS Corp.		1,953		09/15/23		CAD	26.00		CAD	5,035		(72,975	)
											$	(1,492,064	)

OTC Options Written

Description	Counterparty	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call
Industria de Diseno Textil SA	UBS AG		142,100		07/11/23		EUR	32.16		EUR	5,051	$	(520,974)
Lonza Group AG, Registered Shares	Goldman Sachs International		9,200		07/11/23		CHF	605.07		CHF	4,922		(577	)
Prudential PLC	Morgan Stanley & Co. International PLC		185,900		07/11/23		GBP	12.00		GBP	2,067		(2,436	)
Zurich Insurance Group AG	Barclays Bank PLC		6,300		07/11/23		CHF	442.18		CHF	2,682		(1,307	)
BAE Systems PLC	UBS AG		246,300		07/12/23		GBP	9.84		GBP	2,287		(3,547	)
Smith & Nephew PLC	Morgan Stanley & Co. International PLC		95,300		07/12/23		GBP	12.94		GBP	1,211		(7,825	)
Wal-Mart de Mexico SAB de CV	Citibank N.A.		466,300		07/12/23		MXN	68.49		MXN	31,578		(26,449	)
Air Liquide SA	Goldman Sachs International		22,400		07/13/23		EUR	159.49		EUR	3,681		(127,982	)
Budweiser Brewing Co. APAC Ltd.	Morgan Stanley & Co. International PLC		893,700		07/13/23		HKD	20.06		HKD	18,121		(67,938	)
Koninklijke KPN NV	Barclays Bank PLC		937,100		07/13/23		EUR	3.28		EUR	3,066		(28,315	)
Novo Nordisk A/S, Class B	Morgan Stanley & Co. International PLC		64,200		07/13/23		DKK	1,149.69		DKK	70,765		(44,724	)
Reckitt Benckiser Group PLC	Morgan Stanley & Co. International PLC		25,650		07/13/23		GBP	64.10		GBP	1,518		(342	)
Sanofi	Goldman Sachs International		18,600		07/13/23		EUR	97.63		EUR	1,835		(29,964	)
Shell PLC	Barclays Bank PLC		70,600		07/13/23		EUR	26.98		EUR	1,949		(63,905	)
United Overseas Bank Ltd.	BNP Paribas SA		74,000		07/13/23		SGD	28.46		SGD	2,077		(7,308	)
Zurich Insurance Group AG	Barclays Bank PLC		5,300		07/13/23		CHF	444.02		CHF	2,257		(1,313	)
AstraZeneca PLC	UBS AG		55,300		07/18/23		GBP	124.57		GBP	6,242		(12,632	)
AstraZeneca PLC	UBS AG		16,100		07/18/23		GBP	122.66		GBP	1,817		(6,482	)
BAE Systems PLC	UBS AG		246,300		07/18/23		GBP	10.28		GBP	2,287		(3,363	)
Budweiser Brewing Co. APAC Ltd.	Bank of America N.A.		751,100		07/18/23		HKD	21.75		HKD	15,230		(16,002	)

60 2 0 2 3  B L A C K R O C K   S E M I - A N N U A L  R E P O R T  T O  S H A R E H O L D E R S

Schedule of Investments  (unaudited) (continued) June 30, 2023      BlackRock Enhanced International Dividend Trust (BGY)

OTC Options Written (continued)

Description	Counterparty	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call (continued)
Ferguson PLC	Morgan Stanley & Co. International PLC		25,400		07/18/23		GBP	124.80		GBP	3,159	$	(66,777	)
Koninklijke KPN NV	Barclays Bank PLC		372,900		07/18/23		EUR	3.36		EUR	1,220		(9,672	)
Reckitt Benckiser Group PLC	Barclays Bank PLC		78,100		07/18/23		GBP	67.68		GBP	4,621		(766	)
Sanofi	Goldman Sachs International		61,800		07/18/23		EUR	97.09		EUR	6,097		(138,251	)
Smith & Nephew PLC	Goldman Sachs International		95,400		07/18/23		GBP	13.49		GBP	1,212		(3,293	)
Prudential PLC	Morgan Stanley & Co. International PLC		154,100		07/19/23		GBP	11.63		GBP	1,714		(17,815	)
Epiroc AB, Class A	Morgan Stanley & Co. International PLC		45,800		07/25/23		SEK	208.40		SEK	9,357		(20,652	)
KDDI Corp.	BNP Paribas SA		107,500		07/25/23		JPY	4,495.44		JPY	479,050		(53,191	)
KDDI Corp.	Citibank N.A.		158,900		07/25/23		JPY	4,522.88		JPY	708,103		(66,115	)
Lonza Group AG, Registered Shares	UBS AG		10,000		07/25/23		CHF	612.75		CHF	5,350		(6,007	)
Reckitt Benckiser Group PLC	UBS AG		37,850		07/25/23		GBP	63.72		GBP	2,240		(4,568	)
RELX PLC	Morgan Stanley & Co. International PLC		48,200		07/25/23		EUR	30.46		EUR	1,473		(28,140	)
Shell PLC	Morgan Stanley & Co. International PLC		82,500		07/25/23		EUR	27.03		EUR	2,277		(85,775	)
Wal-Mart de Mexico SAB de CV	Citibank N.A.		734,100		07/25/23		MXN	70.46		MXN	49,713		(31,630	)
Epiroc AB, Class A	Morgan Stanley & Co. International PLC		32,800		07/26/23		SEK	209.19		SEK	6,701		(14,090	)
KDDI Corp.	UBS AG		108,100		07/26/23		JPY	4,492.08		JPY	481,724		(55,889	)
MediaTek, Inc.	Morgan Stanley & Co. International PLC		49,052		07/26/23		TWD	775.69		TWD	33,817		(1,308	)
Prudential PLC	Morgan Stanley & Co. International PLC		183,300		07/26/23		GBP	11.44		GBP	2,038		(44,633	)
RELX PLC	Morgan Stanley & Co. International PLC		90,000		07/26/23		EUR	30.29		EUR	2,751		(65,877	)
Sony Group Corp.	Citibank N.A.		42,600		07/26/23		JPY	14,030.57		JPY	554,888		(30,744	)
Symrise AG	Morgan Stanley & Co. International PLC		43,300		07/26/23		EUR	97.50		EUR	4,161		(78,760	)
Epiroc AB, Class A	UBS AG		163,400		08/01/23		SEK	212.67		SEK	33,382		(60,471	)
EssilorLuxottica SA	Barclays Bank PLC		29,600		08/01/23		EUR	171.93		EUR	5,115		(160,139	)
MTU Aero Engines AG	Morgan Stanley & Co. International PLC		5,300		08/01/23		EUR	234.89		EUR	1,260		(48,301	)
RELX PLC	Barclays Bank PLC		137,900		08/01/23		EUR	30.83		EUR	4,216		(71,008	)
Ferguson PLC	Barclays Bank PLC		20,200		08/02/23		GBP	120.02		GBP	2,512		(157,330	)
Ferguson PLC	Morgan Stanley & Co. International PLC		2,200		08/02/23		GBP	121.58		GBP	274		(13,952	)
Heineken NV	UBS AG		37,000		08/02/23		EUR	94.55		EUR	3,487		(69,874	)
Shell PLC	Morgan Stanley & Co. International PLC		70,000		08/02/23		EUR	28.07		EUR	1,932		(34,555	)
Taiwan Semiconductor Manufacturing Co. Ltd.	Morgan Stanley & Co. International PLC		133,000		08/02/23		TWD	601.80		TWD	76,521		(34,998	)
Daiichi Sankyo Co. Ltd.	Goldman Sachs International		76,900		08/03/23		JPY	4,670.09		JPY	352,576		(68,284	)
DBS Group Holdings Ltd.	Citibank N.A.		119,400		08/03/23		SGD	31.84		SGD	3,771		(47,113	)
MediaTek, Inc.	Morgan Stanley & Co. International PLC		10,000		08/03/23		TWD	711.75		TWD	6,894		(3,997	)
United Overseas Bank Ltd.	Bank of America N.A.		156,600		08/03/23		SGD	27.57		SGD	4,395		(91,151	)
Sony Group Corp.	Citibank N.A.		42,700		08/04/23		JPY	14,030.57		JPY	556,190		(40,522	)
Symrise AG	Morgan Stanley & Co. International PLC		43,300		08/04/23		EUR	97.50		EUR	4,161		(101,687	)
Epiroc AB, Class A	Citibank N.A.		50,600		08/08/23		SEK	208.08		SEK	10,337		(29,100	)
Taiwan Semiconductor Manufacturing Co. Ltd.	Morgan Stanley & Co. International PLC		197,000		08/08/23		TWD	582.61		TWD	113,342		(106,047	)
FinecoBank Banca Fineco SpA	Goldman Sachs International		210,400		08/10/23		EUR	12.73		EUR	2,595		(62,678	)
Industria de Diseno Textil SA	Goldman Sachs International		87,900		08/10/23		EUR	35.47		EUR	3,124		(81,675	)
Koninklijke KPN NV	Goldman Sachs International		1,067,400		08/10/23		EUR	3.27		EUR	3,492		(46,438	)
Budweiser Brewing Co. APAC Ltd.	Citibank N.A.		527,000		08/15/23		HKD	21.07		HKD	10,686		(45,975	)
Prudential PLC	JPMorgan Chase Bank N.A.		90,400		08/15/23		GBP	11.27		GBP	1,005		(44,591	)
United Overseas Bank Ltd.	Citibank N.A.		63,300		08/15/23		SGD	28.32		SGD	1,776		(9,399	)
Wal-Mart de Mexico SAB de CV	JPMorgan Chase Bank N.A.		734,000		08/15/23		MXN	69.16		MXN	49,706		(87,775	)
Air Liquide SA	Morgan Stanley & Co. International PLC		22,000		08/16/23		EUR	163.29		EUR	3,616		(99,896	)
DBS Group Holdings Ltd.	Citibank N.A.		95,400		08/16/23		SGD	31.68		SGD	3,013		(36,580	)
FinecoBank Banca Fineco SpA	Goldman Sachs International		210,400		08/16/23		EUR	12.73		EUR	2,595		(69,916	)
Heineken NV	Goldman Sachs International		31,500		08/16/23		EUR	95.96		EUR	2,969		(53,425	)
Kering SA	Goldman Sachs International		13,200		08/16/23		EUR	523.06		EUR	6,680		(172,621	)
LVMH Moet Hennessy Louis Vuitton SE	Goldman Sachs International		7,800		08/16/23		EUR	858.61		EUR	6,740		(271,868	)
MediaTek, Inc.	Bank of America N.A.		166,700		08/16/23		TWD	727.65		TWD	114,925		(62,326	)
MTU Aero Engines AG	UBS AG		23,700		08/16/23		EUR	247.25		EUR	5,633		(127,480	)
Taiwan Semiconductor Manufacturing Co. Ltd.	Morgan Stanley & Co. International PLC		144,500		08/16/23		TWD	592.62		TWD	83,137		(67,334	)
												$	(4,275,844	)

S C H E D U L E    O F   I N V E S T M E N T S 61

Schedule of Investments  (unaudited) (continued) June 30, 2023      BlackRock Enhanced International Dividend Trust (BGY)

Balances Reported in the Statements of Assets and Liabilities for Options Written

Description	Swap Premiums Paid		Swap Premiums Received		Unrealized Appreciation		Unrealized Depreciation		Value
Options Written	$	N/A	$	N/A	$	2,045,138	$	(1,717,006)	$	(5,767,908)

Derivative Financial Instruments Categorized by Risk Exposure

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

	Commodity Contracts		Credit Contracts		Equity Contracts		Foreign Currency Exchange Contracts		Interest Rate Contracts		Other Contracts		Total
Liabilities — Derivative Financial Instruments
Options written
Options written at value	$	—	$	—	$	5,767,908	$	—	$	—	$	—	$	5,767,908

For the period ended June 30, 2023, the effect of derivative financial instruments in the Statements of Operations was as follows:

	Commodity Contracts		Credit Contracts		Equity Contracts			Foreign Currency Exchange Contracts		Interest Rate Contracts		Other Contracts		Total
Net Realized Gain (Loss) from:
Options purchased(a)	$	—	$	—	$	(11,196,135	)	$	—	$	—	$	—	$	(11,196,135	)
Options written		—		—		10,247,181			—		—		—		10,247,181
	$	—	$	—	$	(948,954	)	$	—	$	—	$	—	$	(948,954	)
Net Change in Unrealized Appreciation (Depreciation) on:
Options written	$	—	$	—	$	(978,314	)	$	—	$	—	$	—	$	(978,314	)

^(a)  Options purchased are included in net realized gain (loss) from investments — unaffiliated.

Average Quarterly Balances of Outstanding Derivative Financial Instruments

Options:
Average value of option contracts purchased	$	—	(a)
Average value of option contracts written	$	6,277,364

^(a)  Derivative not held at any quarter-end. The risk exposure table serves as an indicator of activity during the period.

For more information about the Trust’s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.

Derivative Financial Instruments — Offsetting as of Period End

The Trust’s derivative assets and liabilities (by type) were as follows:

	Assets		Liabilities
Derivative Financial Instruments
Options	$	—	$	5,767,908
Total derivative assets and liabilities in the Statements of Assets and Liabilities		—		5,767,908
Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”)		—		(1,492,064	)
Total derivative assets and liabilities subject to an MNA	$	—	$	4,275,844

62 2 0 2 3   B L A C K R O C K  S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Schedule of Investments  (unaudited) (continued) June 30, 2023      BlackRock Enhanced International Dividend Trust (BGY)

The following table presents the Trust’s derivative liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral pledged by the Trust:

Counterparty		Derivative Liabilities Subject to an MNA by Counterparty		Derivatives Available for Offset		Non-Cash Collateral Pledged(a	)		Cash Collateral Pledged			Net Amount of Derivative Liabilities(b	)
Bank of America N.A.	$	169,479	$	—	$	(169,479	)	$	—		$	—
Barclays Bank PLC		493,755		—		—			(404,000	)		89,755
BNP Paribas SA		60,499		—		—			—			60,499
Citibank N.A.		363,627		—		(363,627	)		—			—
Goldman Sachs International		1,126,972		—		(980,179	)		—			146,793
JPMorgan Chase Bank N.A.		132,366		—		(8,876	)		—			123,490
Morgan Stanley & Co. International PLC		1,057,859		—		(1,057,859	)		—			—
UBS AG		871,287		—		(871,287	)		—			—
	$	4,275,844	$	—	$	(3,451,307	)	$	(404,000	)	$	420,537

^(a)  Excess of collateral received/pledged, if any, from the individual counterparty is not shown for financial reporting purposes.

^(b)  Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.

Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of financial instruments. For a description of the input levels and information about the Trust’s policy regarding valuation of financial instruments, refer to the Notes to Financial Statements.

The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust’s financial instruments into major categories is disclosed in the Schedule of Investments above.

	Level 1			Level 2			Level 3		Total
Assets
Investments
Long-Term Investments
Common Stocks
Canada	$	12,685,433		$	—		$	—	$	12,685,433
China		5,702,149			12,489,081			—		18,191,230
Denmark		—			19,276,694			—		19,276,694
France		—			82,305,303			—		82,305,303
Germany		—			33,833,618			—		33,833,618
India		—			19,865,641			654,325		20,519,966
Indonesia		—			12,397,158			—		12,397,158
Italy		—			12,588,392			—		12,588,392
Japan		—			43,576,845			—		43,576,845
Mexico		17,006,784			—			—		17,006,784
Netherlands		—			53,729,722			—		53,729,722
Singapore		—			24,701,248			—		24,701,248
Spain		—			19,820,913			—		19,820,913
Sweden		—			12,317,321			—		12,317,321
Switzerland		—			34,649,913			—		34,649,913
Taiwan		—			39,327,435			—		39,327,435
United Kingdom		—			112,268,280			—		112,268,280
United States		55,421,659			—			—		55,421,659
Short-Term Securities
Money Market Funds		8,600,233			—			—		8,600,233
	$	99,416,258		$	533,147,564		$	654,325	$	633,218,147
Derivative Financial Instruments(a)
Liabilities
Equity Contracts	$	(602,112	)	$	(5,165,796	)	$	—	$	(5,767,908	)

^(a)  Derivative financial instruments are options written. Options written are shown at value.

See notes to financial statements.

S C H E D U L E    O F   I N V E S T M E N T S 63

Schedule of Investments  (unaudited) June 30, 2023      BlackRock Health Sciences Term Trust (BMEZ) (Percentages shown are based on Net Assets)

Security	Shares		Value
Common Stocks
Biotechnology — 35.8%
4D Molecular Therapeutics, Inc.(a)		95,330	$	1,722,613
Abbisko Cayman Ltd., (Acquired 10/29/21, Cost: $14,841,983)(b)		10,378,250		3,549,478
Abcam PLC, ADR(a)		976,460		23,893,976
Acumen Pharmaceuticals, Inc.(a)		167,468		805,521
Affinivax, Inc., (Acquired 08/18/22, Cost: $0)(b)(c)		183,164		2,456,229
Alkermes PLC(a)		1,056,985		33,083,630
Allakos, Inc.(a)		136,405		594,726
Alnylam Pharmaceuticals, Inc.(a)(d)		177,747		33,761,265
Annexon, Inc.(a)		237,835		837,179
Antengene Corp. Ltd.		5,019,274		995,507
Apellis Pharmaceuticals, Inc.(a)		172,445		15,709,740
Arcus Biosciences, Inc.(a)		169,790		3,448,435
Arcutis Biotherapeutics, Inc.(a)		372,677		3,551,612
Argenx SE, ADR(a)		18,944		7,383,045
Arrowhead Pharmaceuticals, Inc.(a)		81,025		2,889,352
Aura Biosciences, Inc.(a)		165,565		2,044,728
Bavarian Nordic A/S(a)		75,320		2,145,591
BeiGene Ltd., ADR(a)		68,555		12,223,357
Biogen, Inc.(a)		83,480		23,779,278
Biohaven Ltd.(a)		99,155		2,371,788
BioMarin Pharmaceutical, Inc.(a)		286,338		24,819,778
Biomea Fusion, Inc.(a)(e)		146,215		3,209,419
Black Diamond Therapeutics, Inc.(a)(e)		774,175		3,909,584
Blueprint Medicines Corp.(a)(e)		322,440		20,378,208
Bridgebio Pharma, Inc.(a)		66,595		1,145,434
Cerevel Therapeutics Holdings, Inc.(a)		266,656		8,476,994
Connect Biopharma Holdings Ltd.(a)(e)		1,125,262		1,249,041
CRISPR Therapeutics AG(a)(e)		47,805		2,683,773
CureVac NV(a)(e)		257,233		2,680,368
Decibel Therapeutics, Inc.(a)		793,527		3,055,079
Design Therapeutics, Inc.(a)(e)		196,731		1,239,405
Everest Medicines Ltd.		3,113,667		9,497,977
Exact Sciences Corp.(a)(e)		152,750		14,343,225
Exelixis, Inc.(a)		599,520		11,456,827
Frequency Therapeutics, Inc.(a)		231,775		80,194
Galapagos NV, ADR(a)		74,410		3,025,511
Galecto, Inc.(a)		216,740		546,185
Genmab A/S(a)		34,827		13,197,960
Genmab A/S, ADR(a)(e)		114,086		4,336,409
Gilead Sciences, Inc.		254,765		19,634,739
Halozyme Therapeutics, Inc.(a)		224,005		8,079,860
Horizon Therapeutics PLC(a)		75,466		7,761,678
Immuneering Corp., Class A(a)(e)		696,696		7,064,497
Immunocore Holdings PLC, ADR(a)		59,868		3,589,685
Immunocore Holdings PLC		321,900		19,301,124
ImmunoGen, Inc.(a)		584,344		11,026,571
Incyte Corp.(a)		294,640		18,341,340
Ionis Pharmaceuticals, Inc.(a)(e)		468,285		19,213,734
Iovance Biotherapeutics, Inc.(a)		168,215		1,184,234
IVERIC bio, Inc.(a)		86,080		3,386,387
Karuna Therapeutics, Inc.(a)		21,650		4,694,803
Keros Therapeutics, Inc.(a)		124,317		4,995,057
Kinnate Biopharma, Inc.(a)		196,773		596,222
Kronos Bio, Inc.(a)		284,272		488,948
Legend Biotech Corp., ADR(a)(e)		316,032		21,815,689
LianBio, Series A, ADR(a)		615,188		1,402,629
MacroGenics, Inc.(a)		190,555		1,019,469
Merus NV(a)(e)		354,445		9,332,537

Security	Shares		Value
Biotechnology (continued)
Mirati Therapeutics, Inc.(a)		180,175	$	6,509,723
Monte Rosa Therapeutics, Inc.(a)(e)		764,573		5,237,325
MoonLake Immunotherapeutics(a)(e)		256,816		13,097,616
Morphic Holding, Inc.(a)(e)		153,665		8,809,614
MorphoSys AG(a)		50,810		1,512,207
Neurocrine Biosciences, Inc.(a)		196,010		18,483,743
Nuvalent, Inc., Class A(a)		241,500		10,184,055
Omega Therapeutics, Inc.(a)		151,887		850,567
PMV Pharmaceuticals, Inc.(a)		305,830		1,914,496
Prime Medicine, Inc.(a)(e)		412,139		6,037,836
Protagonist Therapeutics, Inc.(a)		421,725		11,648,045
Prothena Corp. PLC(a)		104,586		7,141,132
PTC Therapeutics, Inc.(a)(e)		225,815		9,183,896
Relay Therapeutics, Inc.(a)		33,915		425,972
Revolution Medicines, Inc.(a)(e)		377,632		10,101,656
Rhythm Pharmaceuticals, Inc.(a)(e)		683,675		11,273,801
Rocket Pharmaceuticals, Inc.(a)		252,097		5,009,167
Sage Therapeutics, Inc.(a)(e)		109,720		5,159,034
Sarepta Therapeutics, Inc.(a)(d)		114,544		13,117,579
Seagen, Inc.(a)(d)(f)		106,455		20,488,329
Tenaya Therapeutics, Inc.(a)		165,729		972,829
TScan Therapeutics, Inc.(a)		1,204,397		3,010,993
Twist Bioscience Corp.(a)		204,550		4,185,093
Ultragenyx Pharmaceutical, Inc.(a)(e)		99,375		4,584,169
United Therapeutics Corp.(a)(d)		55,704		12,296,658
Vaxcyte, Inc.(a)		148,645		7,423,331
Vertex Pharmaceuticals, Inc.(a)(d)(f)		176,460		62,098,039
Viking Therapeutics, Inc.(a)(e)		235,245		3,813,321
Viridian Therapeutics, Inc.(a)		82,300		1,957,917
Voyager Therapeutics, Inc.(a)		164,865		1,887,704
				737,923,471
Electronic Equipment, Instruments & Components — 0.1%
908 Devices, Inc.(a)		274,084		1,880,216
Financial Services — 0.7%
DA32 Life Science Tech Acquisition Corp., Class A(a)(g)		1,496,819		15,357,363
Health Care Equipment & Supplies — 30.2%
Alcon, Inc.		736,189		60,448,479
Align Technology, Inc.(a)		120,220		42,514,601
Bausch & Lomb Corp.(a)(e)		523,547		10,507,588
Becton Dickinson & Co.		40,325		10,646,203
Boston Scientific Corp.(a)		455,830		24,655,845
CONMED Corp.		98,215		13,346,436
ConvaTec Group PLC(h)		4,411,215		11,504,749
Cooper Cos., Inc.		99,160		38,020,919
Dexcom, Inc.(a)		361,853		46,501,729
Glaukos Corp.(a)		110,325		7,856,243
Hologic, Inc.(a)(d)		194,620		15,758,381
Inspire Medical Systems, Inc.(a)		48,555		15,762,895
Insulet Corp.(a)		116,725		33,656,487
Intuitive Surgical, Inc.(a)		136,568		46,698,062
iRhythm Technologies, Inc.(a)		59,920		6,250,854
Masimo Corp.(a)		145,470		23,937,089
Novocure Ltd.(a)		213,335		8,853,403
Nyxoah SA(a)(e)		648,041		5,313,936
Omnicell, Inc.(a)		160,315		11,810,406
Orchestra BioMed Holdings, Inc.(a)(e)		233,344		1,633,408
Penumbra, Inc.(a)		108,648		37,381,431
Pulmonx Corp.(a)		335,566		4,399,270
ResMed, Inc.(d)		69,536		15,193,616

64 2 0 2 3   B L A C K R O C K  S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Schedule of Investments  (unaudited) (continued) June 30, 2023      BlackRock Health Sciences Term Trust (BMEZ) (Percentages shown are based on Net Assets)

Security	Shares		Value
Health Care Equipment & Supplies (continued)
Shockwave Medical, Inc.(a)		53,670	$	15,317,955
SI-BONE, Inc.(a)		204,910		5,528,472
Silk Road Medical, Inc.(a)		204,932		6,658,241
STAAR Surgical Co.(a)		73,525		3,865,209
STERIS PLC		158,875		35,743,697
Straumann Holding AG, Registered Shares		110,675		17,996,413
Stryker Corp.		127,940		39,033,215
Tandem Diabetes Care, Inc.(a)(d)		167,245		4,104,192
				620,899,424
Health Care Providers & Services — 5.1%
Adicon Holdings Ltd.		1,750,000		3,081,930
AmerisourceBergen Corp.		193,455		37,226,546
Chemed Corp.		10,662		5,775,285
Encompass Health Corp.(d)		112,563		7,621,641
Guardant Health, Inc.(a)		196,470		7,033,626
Kindstar Globalgene Technology, Inc.(a)(h)		4,092,500		921,927
McKesson Corp.		38,905		16,624,495
R1 RCM, Inc.(a)(e)		690,615		12,741,847
UnitedHealth Group, Inc.		26,765		12,864,330
				103,891,627
Health Care Technology — 0.1%
Sophia Genetics SA(a)(e)		291,485		1,305,853
Life Sciences Tools & Services — 12.8%
10X Genomics, Inc., Class A(a)(e)		196,435		10,968,930
Avantor, Inc.(a)(d)		664,444		13,647,680
Bio-Rad Laboratories, Inc., Class A(a)		20,190		7,654,433
Bio-Techne Corp.		201,360		16,437,017
Bruker Corp.		185,257		13,694,197
Gerresheimer AG		243,305		27,389,946
IQVIA Holdings, Inc.(a)		127,062		28,559,726
Mettler-Toledo International, Inc.(a)(d)		21,545		28,259,284
Pacific Biosciences of California, Inc.(a)		428,585		5,700,180
QIAGEN NV(a)		645,525		29,067,991
Rapid Micro Biosystems, Inc., Class A(a)		549,778		549,778
Repligen Corp.(a)		69,535		9,836,421
Waters Corp.(a)		77,300		20,603,542
West Pharmaceutical Services, Inc.(f)		134,085		51,283,490
				263,652,615
Pharmaceuticals — 5.7%
Arvinas, Inc.(a)		232,960		5,782,067
Catalent, Inc.(a)(e)		347,125		15,051,340
Novo Nordisk A/S, Class B		61,540		9,941,153
Nuvation Bio, Inc.(a)		200,496		360,893
Pliant Therapeutics, Inc.(a)(e)		134,378		2,434,929
Reata Pharmaceuticals, Inc., Class A(a)(e)		150,760		15,371,490
Roche Holding AG		39,975		12,211,160
Structure Therapeutics, Inc.(a)(e)		164,062		6,820,057
UCB SA		344,377		30,531,932

Security	Shares		Value
Pharmaceuticals (continued)
Ventyx Biosciences, Inc.(a)		29,855	$	979,244
Zoetis, Inc.(d)		101,710		17,515,479
				116,999,744
Total Common Stocks — 90.5% (Cost: $1,749,353,805)				1,861,910,313
	Benefical Interest (000)
Other Interests
Biotechnology — 0.1%
Vividion Therapeutics, Inc.(b)(c)(i)	$	3,810		1,104,762
Total Other Interests — 0.1%
(Cost: $ — )				1,104,762
	Shares
Preferred Securities
Preferred Stocks — 8.1%
Biotechnology(b)(c) — 2.7%
Amunix Pharmaceuticals, Inc., Series B, (Acquired 02/08/22, Cost: $0)		5,657,068		3,563,953
Bright Peak Therapeutics, Inc., Series B, (Acquired 05/14/21, Cost: $8,000,004)		2,048,132		4,219,152
Cellarity, Inc., Series B, (Acquired 01/15/21, Cost: $14,584,998)		2,430,833		9,431,632
Goldfinch Bio, Inc., Series B, (Acquired 06/26/20, Cost: $4,543,847)		3,850,718		1,309,244
Laronde, Inc., Series B, (Acquired 07/28/21, Cost: $13,498,156)		482,077		8,349,574
Mirvie, Inc., Series B, (Acquired 10/15/21, Cost: $6,250,000)		2,793,833		5,783,234
Neurogene, Inc., Series B, (Acquired 12/14/20, Cost: $9,549,916)		3,913,900		9,510,777
NiKang Therapeutics, Inc., Series C, (Acquired 05/20/21, Cost: $7,999,996)		1,394,189		5,674,349
OnKure, Inc., Series C, (Acquired 03/24/23, Cost: $7,022,595)		2,541,380		7,014,209
				54,856,124
Health Care Equipment & Supplies(b)(c) — 0.8%
Exo Imaging, Inc., Series C, (Acquired 06/24/21, Cost: $13,225,003)		2,257,597		6,321,272
Nucleix Ltd., Series AA, (Acquired 03/25/21, Cost: $6,929,998)		2,379,480		7,400,183
Swift Health Systems, Inc., Series D, (Acquired 08/27/21, Cost: $6,441,930)		2,078,042		2,743,015
				16,464,470
Health Care Providers & Services(b) — 2.1%
Adicon Holdings Ltd., (Acquired 12/22/20, Cost: $17,840,000)		10,696,226		17,862,697

S C H E D U L E   O F   I N V E S T M E N T S 65

Schedule of Investments  (unaudited) (continued) June 30, 2023      BlackRock Health Sciences Term Trust (BMEZ) (Percentages shown are based on Net Assets)

Security	Shares		Value
Health Care Providers & Services (continued)
Everly Well, Inc., Series D, (Acquired 11/25/20, Cost: $9,999,986)(c)		382,775	$	7,219,136
Numab Therapeutics AG, Series C, (Acquired 05/07/21, Cost: $7,770,441)(c)		815,851		7,802,564
Quanta Dialysis Technologies Ltd., Series D, (Acquired 06/18/21, Cost: $14,071,890)(c)		115,766,240		9,703,521
				42,587,918
Health Care Technology — 0.9%
Carbon Health Technologies, Inc., Series D2, (Acquired 02/02/23, Cost: $17,100,000)(b)(c)		1,694,781		19,117,130
Life Sciences Tools & Services — 0.4%
Sartorius AG		22,700		7,864,613
Pharmaceuticals(b)(c) — 0.5%
Insitro, Inc.
Series B, (Acquired 05/21/20, Cost: $4,999,999)		802,478		9,252,571
Series C, (Acquired 03/10/21, Cost: $3,600,018)		196,818		2,269,312
				11,521,883
Semiconductors & Semiconductor Equipment — 0.7%
PsiQuantum Corp., Series D, (Acquired 05/21/21, Cost: $14,999,996)(b)(c)		571,947		15,116,559
				167,528,697
Total Preferred Securities — 8.1% (Cost: $198,800,588)				167,528,697
Rights
Health Care Equipment & Supplies — 0.0%
Abiomed, Inc.(c)		98,636		278,154
Total Rights — 0.0% (Cost: $100,609)				278,154
Warrants
Health Care Providers & Services — 0.0%
CareMax, Inc., (Issued/Exercisable 09/15/20, 1 Share for 1 Warrant, Expires 07/16/25, Strike Price USD 11.50)(a)		63,808		21,694
Pharmaceuticals — 0.0%
Nuvation Bio, Inc., (Issued/Exercisable 08/17/20, 1 Share for 1 Warrant, Expires 07/07/27, Strike Price USD 11.50)(a)		68,880		11,393
Total Warrants — 0.0% (Cost: $227,724)				33,087
Total Long-Term Investments — 98.7% (Cost: $1,948,482,726)				2,030,855,013

Security	Shares		Value
Short-Term Securities
Money Market Funds — 5.1%
BlackRock Liquidity Funds, T-Fund, Institutional Class, 4.98%(g)(j)		66,293,156	$	66,293,156
SL Liquidity Series, LLC, Money Market Series, 5.28%(g)(j)(k)		38,936,027		38,936,027
Total Short-Term Securities — 5.1% (Cost: $105,231,453)				105,229,183
Options Purchased — 0.0% (Cost: $187)				150
Total Investments Before Options Written — 103.8% (Cost: $2,053,714,366)				2,136,084,346
Options Written — (1.0)% (Premiums Received: $(17,074,460))				(19,267,653	)
Total Investments, Net of Options Written — 102.8%     (Cost: $2,036,639,906)				2,116,816,693
Liabilities in Excess of Other Assets — (2.8)%				(58,209,171	)
Net Assets — 100.0%			$2,058,607,522

^(a) Non-income producing security.

^(b) Restricted security as to resale, excluding 144A securities. The Trust held restricted securities with a current value of $166,774,553, representing 8.1% of its net assets as of period end, and an original cost of $203,270,756.

^(c) Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy.

^(d) All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.

^(e) All or a portion of this security is on loan.

^(f) All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives.

^(g) Affiliate of the Trust.

^(h) Security exempt from registration pursuant to Rule 144A under the Securities Act of 1933, as amended. These securities may be resold in transactions exempt from registration to qualified institutional investors.

⁽ⁱ⁾ Other interests represent beneficial interests in liquidation trusts and other reorganization or private entities.

^(j) Annualized 7-day yield as of period end.

^(k) All or a portion of this security was purchased with the cash collateral from loaned securities.

For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

66 2 0 2 3   B L A C K R O C K  S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Schedule of Investments  (unaudited) (continued) June 30, 2023      BlackRock Health Sciences Term Trust (BMEZ)

Affiliates

Investments in issuers considered to be affiliate(s) of the Trust during the six months ended June 30, 2023 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

Affiliated Issuer	Value at 12/31/22		Purchases at Cost			Proceeds from Sales			Net Realized Gain (Loss)		Change in Unrealized Appreciation (Depreciation)			Value at 06/30/23		Shares Held at 06/30/23		Income			Capital Gain Distributions from Underlying Funds
BlackRock Liquidity Funds, T-Fund, Institutional Class	$	83,001,707	$	—		$	(16,708,551	)(a)	$	—	$	—		$	66,293,156		66,293,156	$	1,083,366		$	—
DA32 Life Science Tech Acquisition Corp., Class A		14,818,508		—			—			—		538,855			15,357,363		1,496,819		—			—
SL Liquidity Series, LLC, Money Market Series		1,828,050		37,106,765	(a)		—			3,681		(2,469	)		38,936,027		38,936,027		354,806	(b)		—
									$	3,681	$	536,386		$	120,586,546			$	1,438,172		$	—

^(a) Represents net amount purchased (sold).

^(b) All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities.

Derivative Financial Instruments Outstanding as of Period End

Forward Foreign Currency Exchange Contracts

Currency Purchased		Currency Sold			Counterparty	Settlement Date	Unrealized Appreciation (Depreciation)
CHF	5,337,000		USD	5,921,317	BNP Paribas SA	09/14/23	$	85,772
EUR	459,000		USD	493,608	Citibank N.A.	09/14/23		9,016
EUR	44,141,000		USD	47,467,828	Citibank N.A.	09/14/23		868,333
								963,121
JPY	3,713,189,000		USD	26,903,112	UBS AG	09/14/23		(886,235	)
							$	76,886

Exchange-Traded Options Purchased

Description

Number of Contracts

Expiration Date

Exercise Price

Notional Amount (000)

Value

Call

FibroGen, Inc.

30

07/21/23

USD

10.00

USD

8

$

150

Exchange-Traded Options Written

Description	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call
Alcon, Inc.		821		07/05/23		USD	72.60		USD	6,741	$	(785,080	)
Align Technology, Inc.		57		07/07/23		USD	315.00		USD	2,016		(221,445	)
AmerisourceBergen Corp.		115		07/07/23		USD	175.00		USD	2,213		(204,125	)
Reata Pharmaceuticals, Inc., Class A		215		07/07/23		USD	101.00		USD	2,192		(74,712	)
Gilead Sciences, Inc.		407		07/14/23		USD	78.00		USD	3,137		(25,438	)
Intuitive Surgical, Inc.		92		07/14/23		USD	320.00		USD	3,146		(201,480	)
Vertex Pharmaceuticals, Inc.		222		07/14/23		USD	340.00		USD	7,812		(290,820	)
Exelixis, Inc.		958		07/17/23		USD	19.35		USD	1,831		(41,525	)
908 Devices, Inc.		438		07/21/23		USD	10.00		USD	300		(10,950	)
Abcam PLC, ADR		1,562		07/21/23		USD	25.00		USD	3,822		(160,105	)
Alcon, Inc.		713		07/21/23		USD	82.50		USD	5,854		(87,342	)
Align Technology, Inc.		66		07/21/23		USD	320.00		USD	2,334		(234,630	)
Alkermes PLC		885		07/21/23		USD	31.00		USD	2,770		(90,712	)
Alnylam Pharmaceuticals, Inc.		284		07/21/23		USD	210.00		USD	5,394		(26,270	)
AmerisourceBergen Corp.		81		07/21/23		USD	180.00		USD	1,559		(113,400	)
Apellis Pharmaceuticals, Inc.		254		07/21/23		USD	95.00		USD	2,314		(67,945	)

S C H E D U L E    O F   I N V E S T M E N T S 67

Schedule of Investments  (unaudited) (continued) June 30, 2023      BlackRock Health Sciences Term Trust (BMEZ)

Exchange-Traded Options Written (continued)

Description	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call (continued)
Arcutis Biotherapeutics, Inc.		596		07/21/23		USD	10.92		USD	2,150	$	(23,409	)
Arrowhead Pharmaceuticals, Inc.		129		07/21/23		USD	40.00		USD	460		(6,450	)
Avantor, Inc.		448		07/21/23		USD	20.43		USD	920		(35,696	)
Bausch & Lomb Corp.		620		07/21/23		USD	19.63		USD	1,244		(60,186	)
Becton Dickinson & Co.		64		07/21/23		USD	252.95		USD	1,690		(79,611	)
BeiGene Ltd., ADR		94		07/21/23		USD	240.00		USD	1,676		(47,000	)
BioMarin Pharmaceutical, Inc.		581		07/21/23		USD	100.00		USD	5,036		(13,073	)
Biomea Fusion, Inc.		325		07/21/23		USD	40.00		USD	713		(2,438	)
Bio-Techne Corp.		244		07/21/23		USD	85.00		USD	1,992		(20,130	)
Blueprint Medicines Corp.		540		07/21/23		USD	55.00		USD	3,413		(496,800	)
Boston Scientific Corp.		705		07/21/23		USD	53.40		USD	3,813		(106,678	)
Bruker Corp.		332		07/21/23		USD	77.50		USD	2,454		(20,750	)
Catalent, Inc.		555		07/21/23		USD	40.00		USD	2,406		(252,525	)
Catalent, Inc.		555		07/21/23		USD	50.00		USD	2,406		(24,975	)
Cerevel Therapeutics Holdings, Inc.		398		07/21/23		USD	35.00		USD	1,265		(10,945	)
Chemed Corp.		34		07/21/23		USD	560.00		USD	1,842		(8,670	)
CONMED Corp.		314		07/21/23		USD	120.00		USD	4,267		(532,230	)
Dexcom, Inc.		577		07/21/23		USD	124.95		USD	7,415		(336,704	)
Encompass Health Corp.		360		07/21/23		USD	65.00		USD	2,438		(99,900	)
Exact Sciences Corp.		77		07/21/23		USD	85.00		USD	723		(75,460	)
FibroGen, Inc.		30		07/21/23		USD	32.50		USD	8		(150	)
Galapagos NV, ADR		238		07/21/23		USD	45.00		USD	968		(3,570	)
Gilead Sciences, Inc.		204		07/21/23		USD	82.50		USD	1,572		(1,938	)
Glaukos Corp.		91		07/21/23		USD	60.00		USD	648		(105,560	)
Halozyme Therapeutics, Inc.		339		07/21/23		USD	34.89		USD	1,223		(72,901	)
Hologic, Inc.		606		07/21/23		USD	85.00		USD	4,907		(21,210	)
Hologic, Inc.		16		07/21/23		USD	80.00		USD	130		(3,440	)
Immunocore Holdings PLC, ADR		95		07/21/23		USD	60.00		USD	570		(20,663	)
Incyte Corp.		415		07/21/23		USD	68.00		USD	2,583		(5,034	)
Inspire Medical Systems, Inc.		154		07/21/23		USD	310.00		USD	4,999		(310,310	)
Insulet Corp.		108		07/21/23		USD	330.00		USD	3,114		(4,050	)
Intuitive Surgical, Inc.		73		07/21/23		USD	325.00		USD	2,496		(158,410	)
Ionis Pharmaceuticals, Inc.		748		07/21/23		USD	37.50		USD	3,069		(295,460	)
Ionis Pharmaceuticals, Inc.		750		07/21/23		USD	45.00		USD	3,077		(9,375	)
IQVIA Holdings, Inc.		174		07/21/23		USD	210.00		USD	3,911		(281,880	)
Karuna Therapeutics, Inc.		69		07/21/23		USD	240.00		USD	1,496		(5,865	)
Masimo Corp.		170		07/21/23		USD	175.00		USD	2,797		(23,375	)
McKesson Corp.		4		07/21/23		USD	400.00		USD	171		(11,880	)
Mettler-Toledo International, Inc.		34		07/21/23		USD	1,460.00		USD	4,460		(8,330	)
Morphic Holding, Inc.		266		07/21/23		USD	60.00		USD	1,525		(72,485	)
Neurocrine Biosciences, Inc.		158		07/21/23		USD	100.00		USD	1,490		(17,380	)
Omnicell, Inc.		225		07/21/23		USD	75.00		USD	1,658		(59,062	)
Penumbra, Inc.		103		07/21/23		USD	320.00		USD	3,544		(281,705	)
PTC Therapeutics, Inc.		312		07/21/23		USD	65.00		USD	1,269		(149,760	)
QIAGEN NV		1,032		07/21/23		USD	47.25		USD	4,647		(81,129	)
R1 RCM, Inc.		1,105		07/21/23		USD	17.50		USD	2,039		(140,887	)
Repligen Corp.		331		07/21/23		USD	170.00		USD	4,682		(99,300	)
ResMed, Inc.		450		07/21/23		USD	234.21		USD	9,833		(46,400	)
Revolution Medicines, Inc.		661		07/21/23		USD	30.00		USD	1,768		(38,007	)
Rhythm Pharmaceuticals, Inc.		570		07/21/23		USD	22.50		USD	940		(42,750	)
Rhythm Pharmaceuticals, Inc.		636		07/21/23		USD	20.00		USD	1,049		(12,720	)
Rocket Pharmaceuticals, Inc.		403		07/21/23		USD	22.50		USD	801		(5,038	)
Rocket Pharmaceuticals, Inc.		403		07/21/23		USD	25.00		USD	801		(42,315	)
Sage Therapeutics, Inc.		424		07/21/23		USD	52.50		USD	1,994		(14,840	)
Shockwave Medical, Inc.		80		07/21/23		USD	290.00		USD	2,283		(80,800	)
STAAR Surgical Co.		117		07/21/23		USD	65.50		USD	615		(1,325	)
STERIS PLC		254		07/21/23		USD	210.00		USD	5,714		(397,510	)
Stryker Corp.		205		07/21/23		USD	290.00		USD	6,254		(338,250	)
Tandem Diabetes Care, Inc.		268		07/21/23		USD	30.00		USD	658		(2,680	)
Ultragenyx Pharmaceutical, Inc.		159		07/21/23		USD	55.00		USD	733		(4,770	)
United Therapeutics Corp.		84		07/21/23		USD	230.00		USD	1,854		(17,640	)
Vaxcyte, Inc.		325		07/21/23		USD	55.00		USD	1,623		(19,500	)

68 2 0 2 3   B L A C K R O C K  S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Schedule of Investments  (unaudited) (continued) June 30, 2023      BlackRock Health Sciences Term Trust (BMEZ)

Exchange-Traded Options Written  (continued)

Description	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call (continued)
Vertex Pharmaceuticals, Inc.		166		07/21/23		USD	350.00		USD	5,842	$	(122,010	)
Viridian Therapeutics, Inc.		263		07/21/23		USD	30.00		USD	626		(30,245	)
Waters Corp.		155		07/21/23		USD	260.00		USD	4,131		(161,200	)
West Pharmaceutical Services, Inc.		368		07/21/23		USD	360.00		USD	14,075		(920,000	)
Zoetis, Inc.		325		07/21/23		USD	170.00		USD	5,597		(141,375	)
Alkermes PLC		976		07/25/23		USD	30.25		USD	3,055		(163,083	)
Align Technology, Inc.		67		07/28/23		USD	350.00		USD	2,369		(139,360	)
AmerisourceBergen Corp.		148		07/28/23		USD	185.00		USD	2,848		(137,640	)
Biogen, Inc.		152		07/28/23		USD	300.00		USD	4,330		(64,600	)
McKesson Corp.		120		07/28/23		USD	405.00		USD	5,128		(313,800	)
Reata Pharmaceuticals, Inc., Class A		150		07/28/23		USD	98.00		USD	1,529		(112,500	)
UnitedHealth Group, Inc.		85		07/28/23		USD	490.00		USD	4,085		(63,750	)
Vertex Pharmaceuticals, Inc.		176		07/28/23		USD	355.00		USD	6,194		(147,840	)
AmerisourceBergen Corp.		161		08/04/23		USD	190.00		USD	3,098		(99,015	)
AmerisourceBergen Corp.		114		08/04/23		USD	195.00		USD	2,194		(43,320	)
CRISPR Therapeutics AG		160		08/04/23		USD	62.00		USD	898		(34,400	)
Gilead Sciences, Inc.		204		08/04/23		USD	79.00		USD	1,572		(24,378	)
Intuitive Surgical, Inc.		165		08/04/23		USD	330.00		USD	5,642		(344,025	)
10X Genomics, Inc., Class A		628		08/18/23		USD	70.00		USD	3,507		(51,810	)
908 Devices, Inc.		438		08/18/23		USD	10.00		USD	300		(14,235	)
Abcam PLC, ADR		781		08/18/23		USD	25.00		USD	1,911		(187,440	)
Alcon, Inc.		821		08/18/23		USD	80.00		USD	6,741		(369,450	)
Alkermes PLC		637		08/18/23		USD	32.00		USD	1,994		(74,847	)
Alnylam Pharmaceuticals, Inc.		284		08/18/23		USD	220.00		USD	5,394		(78,810	)
Apellis Pharmaceuticals, Inc.		297		08/18/23		USD	95.00		USD	2,706		(163,350	)
Arcutis Biotherapeutics, Inc.		596		08/18/23		USD	11.57		USD	2,150		(16,400	)
Argenx SE, ADR		60		08/18/23		USD	450.00		USD	2,338		(102,300	)
Arrowhead Pharmaceuticals, Inc.		130		08/18/23		USD	40.00		USD	464		(24,375	)
Avantor, Inc.		897		08/18/23		USD	22.50		USD	1,842		(35,880	)
Avantor, Inc.		781		08/18/23		USD	20.40		USD	1,604		(95,644	)
Bausch & Lomb Corp.		621		08/18/23		USD	20.00		USD	1,246		(69,862	)
Becton Dickinson & Co.		65		08/18/23		USD	260.00		USD	1,716		(66,300	)
BeiGene Ltd., ADR		94		08/18/23		USD	230.00		USD	1,676		(20,210	)
Biogen, Inc.		115		08/18/23		USD	305.00		USD	3,276		(52,900	)
BioMarin Pharmaceutical, Inc.		335		08/18/23		USD	105.00		USD	2,904		(24,288	)
Biomea Fusion, Inc.		305		08/18/23		USD	40.00		USD	669		(7,625	)
Bio-Techne Corp.		400		08/18/23		USD	80.50		USD	3,265		(175,463	)
Boston Scientific Corp.		753		08/18/23		USD	57.50		USD	4,073		(28,237	)
Cerevel Therapeutics Holdings, Inc.		455		08/18/23		USD	35.00		USD	1,446		(39,812	)
Cooper Cos., Inc.		317		08/18/23		USD	380.00		USD	12,155		(431,120	)
Dexcom, Inc.		580		08/18/23		USD	131.00		USD	7,454		(262,697	)
Exact Sciences Corp.		411		08/18/23		USD	91.00		USD	3,859		(275,086	)
Exelixis, Inc.		960		08/18/23		USD	20.00		USD	1,835		(52,800	)
Halozyme Therapeutics, Inc.		377		08/18/23		USD	35.73		USD	1,360		(92,570	)
Immunocore Holdings PLC, ADR		96		08/18/23		USD	65.00		USD	576		(19,440	)
Incyte Corp.		527		08/18/23		USD	64.00		USD	3,281		(105,978	)
Inspire Medical Systems, Inc.		1		08/18/23		USD	340.00		USD	32		(1,245	)
Insulet Corp.		265		08/18/23		USD	299.00		USD	7,641		(258,853	)
Intuitive Surgical, Inc.		75		08/18/23		USD	330.00		USD	2,565		(163,875	)
IQVIA Holdings, Inc.		232		08/18/23		USD	230.00		USD	5,215		(146,160	)
iRhythm Technologies, Inc.		191		08/18/23		USD	120.00		USD	1,993		(49,660	)
Legend Biotech Corp., ADR		352		08/18/23		USD	75.00		USD	2,430		(78,320	)
Masimo Corp.		295		08/18/23		USD	165.50		USD	4,854		(226,397	)
Merus NV		622		08/18/23		USD	30.00		USD	1,638		(158,610	)
Mettler-Toledo International, Inc.		34		08/18/23		USD	1,385.00		USD	4,460		(69,185	)
Morphic Holding, Inc.		225		08/18/23		USD	60.00		USD	1,290		(79,312	)
Neurocrine Biosciences, Inc.		469		08/18/23		USD	105.00		USD	4,423		(83,247	)
Omnicell, Inc.		288		08/18/23		USD	75.00		USD	2,122		(120,960	)
Penumbra, Inc.		244		08/18/23		USD	330.50		USD	8,395		(533,274	)
Prothena Corp. PLC		400		08/18/23		USD	80.00		USD	2,731		(73,000	)
Pulmonx Corp.		540		08/18/23		USD	15.00		USD	708		(93,150	)
R1 RCM, Inc.		1,104		08/18/23		USD	17.50		USD	2,037		(187,680	)

S C H E D U L E    O F   I N V E S T M E N T S 69

Schedule of Investments  (unaudited) (continued) June 30, 2023      BlackRock Health Sciences Term Trust (BMEZ)

Exchange-Traded Options Written (continued)

Description	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call (continued)
Reata Pharmaceuticals, Inc., Class A		117		08/18/23		USD	110.00		USD	1,193	$	(42,120	)
Rhythm Pharmaceuticals, Inc.		981		08/18/23		USD	20.00		USD	1,618		(49,050	)
Sage Therapeutics, Inc.		449		08/18/23		USD	60.00		USD	2,111		(49,390	)
Seagen, Inc.		159		08/18/23		USD	200.00		USD	3,060		(58,432	)
Shockwave Medical, Inc.		91		08/18/23		USD	320.00		USD	2,597		(55,055	)
STAAR Surgical Co.		118		08/18/23		USD	60.00		USD	620		(16,520	)
STERIS PLC		254		08/18/23		USD	207.50		USD	5,714		(531,085	)
Stryker Corp.		204		08/18/23		USD	292.00		USD	6,224		(399,168	)
Tandem Diabetes Care, Inc.		268		08/18/23		USD	30.00		USD	658		(19,430	)
Ultragenyx Pharmaceutical, Inc.		159		08/18/23		USD	55.00		USD	733		(25,043	)
United Therapeutics Corp.		94		08/18/23		USD	240.00		USD	2,075		(27,025	)
Viking Therapeutics, Inc.		752		08/18/23		USD	26.00		USD	1,219		(26,320	)
West Pharmaceutical Services, Inc.		62		08/18/23		USD	380.00		USD	2,371		(106,950	)
Bausch & Lomb Corp.		434		08/21/23		USD	18.56		USD	871		(91,973	)
Bruker Corp.		260		09/15/23		USD	82.50		USD	1,922		(71,500	)
Seagen, Inc.		159		09/15/23		USD	200.00		USD	3,060		(76,320	)
											$	(18,169,042	)

OTC Options Written

Description	Counterparty	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call
Straumann Holding AG, Registered Shares	Goldman Sachs International		35,400		07/11/23		CHF	144.61		CHF	5,152	$	(111,304	)
ConvaTec Group PLC	UBS AG		490,000		07/13/23		GBP	2.11		GBP	1,006		(8,812	)
Genmab A/S	Morgan Stanley & Co. International PLC		9,200		07/13/23		DKK	2,806.75		DKK	23,790		(1,747	)
Gerresheimer AG	UBS AG		20,000		07/13/23		EUR	107.43		EUR	2,063		(34,200	)
Roche Holding AG	UBS AG		10,400		07/13/23		CHF	294.44		CHF	2,843		(1,229	)
UCB SA	Morgan Stanley & Co. International PLC		27,600		07/13/23		EUR	83.60		EUR	2,242		(31,648	)
Genmab A/S	UBS AG		1,900		07/18/23		DKK	2,776.72		DKK	4,913		(1,423	)
UCB SA	Goldman Sachs International		27,600		07/19/23		EUR	88.77		EUR	2,242		(10,506	)
Gerresheimer AG	JPMorgan Chase Bank N.A.		14,900		07/25/23		EUR	112.79		EUR	1,537		(18,586	)
Sartorius AG	Goldman Sachs International		7,200		07/25/23		EUR	358.54		EUR	2,286		(8,508	)
UCB SA	Morgan Stanley & Co. International PLC		55,000		07/25/23		EUR	86.63		EUR	4,469		(55,708	)
Gerresheimer AG	UBS AG		14,900		07/26/23		EUR	110.03		EUR	1,537		(30,108	)
MorphoSys AG	Barclays Bank PLC		16,200		07/26/23		EUR	28.88		EUR	442		(11,619	)
Glaukos Corp.	Morgan Stanley & Co. International PLC		26,200		07/31/23		USD	69.83		USD	1,866		(104,427	)
Revolution Medicines, Inc	Citibank N.A.		54,700		07/31/23		USD	25.25		USD	1,463		(134,277	)
Vaxcyte, Inc	Morgan Stanley & Co. International PLC		15,000		07/31/23		USD	54.78		USD	749		(14,921	)
Waters Corp.	Morgan Stanley & Co. International PLC		9,200		07/31/23		USD	278.78		USD	2,452		(29,408	)
Novo Nordisk A/S, Class B	Citibank N.A.		19,700		08/02/23		DKK	1,117.35		DKK	21,715		(84,388	)
ConvaTec Group PLC	UBS AG		411,500		08/03/23		GBP	2.11		GBP	845		(18,960	)
ConvaTec Group PLC	UBS AG		510,000		08/16/23		GBP	2.13		GBP	1,047		(27,909	)
Gerresheimer AG	UBS AG		28,000		08/16/23		EUR	110.39		EUR	2,889		(77,664	)
Genmab A/S, ADR	Morgan Stanley & Co. International PLC		36,500		08/23/23		USD	39.39		USD	1,387		(44,232	)
Alkermes PLC	Citibank N.A.		88,400		08/29/23		USD	33.63		USD	2,767		(77,853	)
Legend Biotech Corp., ADR	UBS AG		49,600		09/08/23		USD	75.79		USD	3,424		(159,174	)
												$	(1,098,611	)

Balances Reported in the Statements of Assets and Liabilities for Options Written

Description	Swap Premiums Paid		Swap Premiums Received		Unrealized Appreciation		Unrealized Depreciation			Value
Options Written	$	N/A	$	N/A	$	4,866,815	$	(7,060,008	)	$	(19,267,653)

70 2 0 2 3   B L A C K R O C K  S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Schedule of Investments  (unaudited) (continued) June 30, 2023      BlackRock Health Sciences Term Trust (BMEZ)

Derivative Financial Instruments Categorized by Risk Exposure

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

	Commodity Contracts		Credit Contracts		Equity Contracts		Foreign Currency Exchange Contracts		Interest Rate Contracts		Other Contracts		Total
Assets — Derivative Financial Instruments
Forward foreign currency exchange contracts
Unrealized appreciation on forward foreign currency exchange contracts	$	—	$	—	$	—	$	963,121	$	—	$	—	$	963,121
Options purchased
Investments at value — unaffiliated		—		—		150		—		—		—		150
	$	—	$	—	$	150	$	963,121	$	—	$	—	$	963,271
Liabilities — Derivative Financial Instruments
Forward foreign currency exchange contracts
Unrealized depreciation on forward foreign currency exchange contracts	$	—	$	—	$	—	$	886,235	$	—	$	—	$	886,235
Options written
Options written at value		—		—		19,267,653		—		—		—		19,267,653
	$	—	$	—	$	19,267,653	$	886,235	$	—	$	—	$	20,153,888

For the period ended June 30, 2023, the effect of derivative financial instruments in the Statements of Operations was as follows:

	Commodity Contracts		Credit Contracts		Equity Contracts			Foreign Currency Exchange Contracts			Interest Rate Contracts		Other Contracts		Total
Net Realized Gain (Loss) from:
Forward foreign currency exchange contracts	$	—	$	—	$	—		$	1,506,894		$	—	$	—	$	1,506,894
Options purchased(a)		—		—		(2,929,435	)		—			—		—		(2,929,435	)
Options written		—		—		10,910,202			—			—		—		10,910,202
	$	—	$	—	$	7,980,767		$	1,506,894		$	—	$	—	$	9,487,661
Net Change in Unrealized Appreciation (Depreciation) on:
Forward foreign currency exchange contracts	$	—	$	—	$	—		$	(4,887,669	)	$	—	$	—	$	(4,887,669	)
Options purchased		—		—		(37	)		—			—		—		(37	)
Options written		—		—		(4,568,856	)		—			—		—		(4,568,856	)
	$	—	$	—	$	(4,568,893	)	$	(4,887,669	)	$	—	$	—	$	(9,456,562	)

^(a) Options purchased are included in net realized gain (loss) from investments — unaffiliated.

Average Quarterly Balances of Outstanding Derivative Financial Instruments

Forward foreign currency exchange contracts:
Average amounts sold — in USD	$	115,944,905
Options:
Average value of option contracts purchased	$	75
Average value of option contracts written	$	19,839,452

For more information about the Trust’s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.

S C H E D U L E    O F   I N V E S T M E N T S 71

Schedule of Investments (unaudited) (continued) June 30, 2023      BlackRock Health Sciences Term Trust (BMEZ)

Derivative Financial Instruments — Offsetting as of Period End

The Trust’s derivative assets and liabilities (by type) were as follows:

	Assets			Liabilities
Derivative Financial Instruments
Forward foreign currency exchange contracts	$	963,121		$	886,235
Options		150			19,267,653
Total derivative assets and liabilities in the Statements of Assets and Liabilities		963,271			20,153,888
Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”)		(150	)		(18,169,042	)
Total derivative assets and liabilities subject to an MNA	$	963,121		$	1,984,846

The following table presents the Trust’s derivative assets and liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral received (and pledged) by the Trust:

Counterparty		Derivative Assets Subject to an MNA by Counterparty		Derivatives Available for Offset	(a)		Non‑Cash Collateral Received		Cash Collateral Received		Net Amount   of Derivative Assets	(b)(c)
BNP Paribas SA	$	85,772	$	—		$	—	$	—	$	85,772
Citibank N.A.		877,349		(296,518	)		—		—		580,831
	$	963,121	$	(296,518	)	$	—	$	—	$	666,603

Counterparty		Derivative Liabilities Subject to an MNA by Counterparty		Derivatives Available for Offset	(a)		Non-Cash Collateral Pledged	(d)		Cash  Collateral Pledged	(d)		Net Amount   of Derivative Liabilities	(b)(e)
Barclays Bank PLC	$	11,619	$	—		$	—		$	—		$	11,619
Citibank N.A.		296,518		(296,518	)		—			—			—
Goldman Sachs International		130,318		—			(130,318	)		—			—
JPMorgan Chase Bank N.A.		18,586		—			(18,586	)		—			—
Morgan Stanley & Co. International PLC		282,091		—			(154,160	)		(16,000	)		111,931
UBS AG		1,245,714		—			(635,198	)		—			610,516
	$	1,984,846	$	(296,518	)	$	(938,262	)	$	(16,000	)	$	734,066

^(a) The amount of derivatives available for offset is limited to the amount of derivative asset and/or liabilities that are subject to an MNA.

^(b) Net amount may also include forward foreign currency exchange contracts that are not required to be collateralized.

^(c) Net amount represents the net amount receivable from the counterparty in the event of default.

^(d) Excess of collateral received/pledged, if any, from the individual counterparty is not shown for financial reporting purposes.

^(e) Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.

Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of financial instruments. For a description of the input levels and information about the Trust’s policy regarding valuation of financial instruments, refer to the Notes to Financial Statements.

The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust’s financial instruments into major categories is disclosed in the Schedule of Investments above.

	Level 1		Level 2		Level 3		Total
Assets
Investments
Long-Term Investments
Common Stocks
Biotechnology	$	685,267,398	$	50,199,844	$	2,456,229	$	737,923,471
Electronic Equipment, Instruments & Components		1,880,216		—		—		1,880,216
Financial Services		15,357,363		—		—		15,357,363
Health Care Equipment & Supplies		591,398,262		29,501,162		—		620,899,424
Health Care Providers & Services		102,969,700		921,927		—		103,891,627

72 2 0 2 3   B L A C K R O C K  S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Schedule of Investments (unaudited) (continued) June 30, 2023      BlackRock Health Sciences Term Trust (BMEZ)

Fair Value Hierarchy as of Period End (continued)

	Level 1			Level 2			Level 3		Total
Common Stocks (continued)
Health Care Technology	$	1,305,853		$	—		$	—	$	1,305,853
Life Sciences Tools & Services		236,262,669			27,389,946			—		263,652,615
Pharmaceuticals		64,315,499			52,684,245			—		116,999,744
Other Interests		—			—			1,104,762		1,104,762
Preferred Securities
Preferred Stocks		—			25,727,310			141,801,387		167,528,697
Rights		—			—			278,154		278,154
Warrants		33,087			—			—		33,087
Short-Term Securities
Money Market Funds		66,293,156			—			—		66,293,156
Options Purchased
Equity Contracts		150			—			—		150
	$	1,765,083,353		$	186,424,434		$	145,640,532		2,097,148,319
Investments Valued at NAV(a)										38,936,027
									$	2,136,084,346
Derivative Financial Instruments(b)
Assets
Foreign Currency Exchange Contracts	$	—		$	963,121		$	—	$	963,121
Liabilities
Equity Contracts		(13,196,508	)		(6,071,145	)		—		(19,267,653	)
Foreign Currency Exchange Contracts		—			(886,235	)		—		(886,235	)
	$	(13,196,508	)	$	(5,994,259	)	$	—	$	(19,190,767	)

^(a)  Certain investments of the Trust were fair valued using NAV as a practical expedient as no quoted market value is available and therefore have been excluded from the fair value hierarchy.

^(b) Derivative financial instruments are forward foreign currency exchange contracts and options written. Forward foreign currency exchange contracts are valued at the unrealized appreciation (depreciation) on the instrument and options written are shown at value.

A reconciliation of Level 3 financial instruments is presented when the Trust had a significant amount of Level 3 investments and derivative financial instruments at the beginning and/or end of the period in relation to net assets. The following table is a reconciliation of Level 3 investments for which significant unobservable inputs were used in determining fair value:

	Common Stocks			Other Interests			Preferred Stocks			Rights		Total
Assets
Opening balance, as of December 31, 2022	$	12,093,187		$	4,076,191		$	158,791,702		$	—	$	174,961,080
Transfers into Level 3(a)		—			—			—			—		—
Transfers out of Level 3(b)		—			—			(22,889,924	)		—		(22,889,924	)
Other(c)		(9,726,707	)		—			9,626,098			100,609		—
Accrued discounts/premiums		—			—			—			—		—
Net realized gain (loss)		—			—			—			—		—
Net change in unrealized appreciation (depreciation)(d)(e)		89,749			(2,971,429	)		(6,249,086	)		177,545		(8,953,221	)
Purchases		—			—			24,122,598			—		24,122,598
Sales		—			—			(21,600,001	)		—		(21,600,001	)
Closing balance, as of June 30, 2023	$	2,456,229		$	1,104,762		$	141,801,387		$	278,154	$	145,640,532
Net change in unrealized appreciation (depreciation) on investments still held at June 30, 2023(e)	$	89,749		$	(2,971,429	)	$	(5,842,670	)	$	177,545	$	(8,546,805	)

^(a) As of December 31, 2022, the Trust used observable inputs in determining the value of certain investments. As of June 30, 2023, the Trust used significant unobservable inputs in determining the value of the same investments. As a result, investments at beginning of period value were transferred from Level 2 to Level 3 in the disclosure hierarchy.

^(b) As of December 31, 2022, the Trust used significant unobservable inputs in determining the value of certain investments. As of June 30, 2023, the Trust used observable inputs in determining the value of the same investments. As a result, investments at beginning of period value were transferred from Level 3 to Level 2 in the disclosure hierarchy.

^(c) Certain Level 3 investments were re-classified between Common Stocks, Preferred Stocks and Rights.

^(d) Included in the related net change in unrealized appreciation (depreciation) in the Statements of Operations.

^(e)  Any difference between net change in unrealized appreciation (depreciation) and net change in unrealized appreciation (depreciation) on investments still held at June 30, 2023 is generally due to investments no longer held or categorized as Level 3 at period end.

S C H E D U L E    O F   I N V E S T M E N T S 73

Schedule of Investments (unaudited) (continued) June 30, 2023      BlackRock Health Sciences Term Trust (BMEZ)

The following table summarizes the valuation approaches used and unobservable inputs utilized by the BlackRock Valuation Committee (the “Valuation Committee”) to determine the value of certain of the Trust’s Level 3 financial instruments as of period end.

		Value	Valuation Approach	Unobservable Inputs	Range of Unobservable Inputs Utilized	(a)	Weighted Average of Unobservable Inputs Based on Fair Value
Assets
Common Stocks	$	2,456,229	Income	Discount Rate	5%		—
Preferred Stocks		141,801,387	Market	Revenue Multiple	3.00x - 8.00x		5.20x
				Volatility	50% - 100%		68%
				Time to Exit	1.0 ‑ 4.0 years		2.3 years
				Market Adjustment Multiple	0.45x - 1.10x		0.88x
			Income	Discount Rate	5% - 5%		5%
Other Interests		1,104,762	Income	Discount Rate	7%		—
Rights		278,154	Income	Discount Rate	4%		—
	$	145,640,532

^(a) A significant change in unobservable input would have resulted in a correlated (inverse) significant change to value.

See notes to financial statements.

74 2 0 2 3   B L A C K R O C K  S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Schedule of Investments  (unaudited) June 30, 2023 BlackRock Health Sciences Trust (BME) (Percentages shown are based on Net Assets)

Security	Shares		Value
Common Stocks
Biotechnology — 21.2%
AbbVie, Inc.		115,564	$	15,569,938
Abcam PLC, ADR(a)		57,415		1,404,945
Affinivax, Inc., (Acquired 08/18/22, Cost: $0)(b)(c)		6,331		84,899
Alkermes PLC(a)		32,331		1,011,960
Alnylam Pharmaceuticals, Inc.(a)		17,051		3,238,667
Amgen, Inc.(d)		61,050		13,554,321
Apellis Pharmaceuticals, Inc.(a)		13,695		1,247,615
Argenx SE, ADR(a)		5,466		2,130,264
BeiGene Ltd., ADR(a)		6,630		1,182,129
Biogen, Inc.(a)		38,487		10,963,022
BioMarin Pharmaceutical, Inc.(a)		26,700		2,314,356
Biomea Fusion, Inc.(a)		9,387		206,045
Blueprint Medicines Corp.(a)		26,725		1,689,020
Cerevel Therapeutics Holdings, Inc.(a)		16,785		533,595
CureVac NV(a)		20,488		213,485
Decibel Therapeutics, Inc.(a)		46,884		180,503
Design Therapeutics, Inc.(a)		13,967		87,992
Exact Sciences Corp.(a)		18,951		1,779,499
Frequency Therapeutics, Inc.(a)		28,060		9,709
Genmab A/S(a)		2,498		946,636
Genmab A/S, ADR(a)(e)		16,911		642,787
Gilead Sciences, Inc.		184,370		14,209,396
Horizon Therapeutics PLC(a)		7,410		762,119
Immuneering Corp., Class A(a)(e)		14,456		146,584
Immunocore Holdings PLC, ADR(a)		9,668		579,693
ImmunoGen, Inc.(a)		18,174		342,943
Incyte Corp.(a)		33,358		2,076,535
Ionis Pharmaceuticals, Inc.(a)		28,425		1,166,278
IVERIC bio, Inc.(a)		12,230		481,128
Karuna Therapeutics, Inc.(a)		2,610		565,979
Legend Biotech Corp., ADR(a)		31,816		2,196,258
Merus NV(a)		14,810		389,947
Mirati Therapeutics, Inc.(a)		15,380		555,679
Moderna, Inc.(a)		15,623		1,898,194
Monte Rosa Therapeutics, Inc.(a)(e)		28,575		195,739
MoonLake Immunotherapeutics(a)		15,432		787,032
Morphic Holding, Inc.(a)		12,685		727,231
Neurocrine Biosciences, Inc.(a)		20,029		1,888,735
Nuvalent, Inc., Class A(a)		13,773		580,807
PMV Pharmaceuticals, Inc.(a)		17,490		109,487
Prime Medicine, Inc.(a)		22,929		335,910
Protagonist Therapeutics, Inc.(a)		27,270		753,197
Prothena Corp. PLC(a)		8,639		589,871
PTC Therapeutics, Inc.(a)		19,555		795,302
Regeneron Pharmaceuticals, Inc.(a)		10,742		7,718,557
Revolution Medicines, Inc.(a)		18,874		504,880
Rhythm Pharmaceuticals, Inc.(a)		48,130		793,664
Rocket Pharmaceuticals, Inc.(a)		17,213		342,022
Sage Therapeutics, Inc.(a)		6,345		298,342
Sarepta Therapeutics, Inc.(a)		22,463		2,572,463
Seagen, Inc.(a)		23,289		4,482,201
Tenaya Therapeutics, Inc.(a)		25,502		149,697
Ultragenyx Pharmaceutical, Inc.(a)		6,140		283,238
Vaxcyte, Inc.(a)		12,030		600,778
Vertex Pharmaceuticals, Inc.(a)(e)		48,713		17,142,592
Viking Therapeutics, Inc.(a)		16,970		275,084
				126,288,949

Security	Shares		Value
Health Care Equipment & Supplies — 28.1%
Abbott Laboratories(d)		119,326	$	13,008,920
Alcon, Inc.		94,504		7,759,723
Align Technology, Inc.(a)		6,080		2,150,131
Bausch & Lomb Corp.(a)(e)		75,830		1,521,908
Baxter International, Inc.		111,827		5,094,838
Becton Dickinson & Co.		40,270		10,631,683
Boston Scientific Corp.(a)		447,569		24,209,007
Cooper Cos., Inc.		12,951		4,965,802
Dexcom, Inc.(a)		54,892		7,054,171
Edwards Lifesciences Corp.(a)		37,566		3,543,601
Envista Holdings Corp.(a)		21,195		717,239
GE HealthCare, Inc.(a)		68,490		5,564,128
Glaukos Corp.(a)		4,880		347,505
Hologic, Inc.(a)		10,990		889,860
IDEXX Laboratories, Inc.(a)		7,185		3,608,523
Inspire Medical Systems, Inc.(a)		5,650		1,834,216
Insulet Corp.(a)		8,555		2,466,749
Intuitive Surgical, Inc.(a)		63,429		21,688,912
iRhythm Technologies, Inc.(a)		2,280		237,850
Masimo Corp.(a)		12,760		2,099,658
Medtronic PLC		144,255		12,708,865
Novocure Ltd.(a)		27,700		1,149,550
Omnicell, Inc.(a)		8,385		617,723
Orchestra BioMed Holdings, Inc.(a)		13,696		95,872
Penumbra, Inc.(a)		17,840		6,138,030
ResMed, Inc.		13,234		2,891,629
STERIS PLC		9,590		2,157,558
Stryker Corp.		68,196		20,805,918
Zimmer Biomet Holdings, Inc.		14,617		2,128,235
				168,087,804
Health Care Providers & Services — 17.1%
Agiliti, Inc.(a)		40,496		668,184
AmerisourceBergen Corp.		59,256		11,402,632
Centene Corp.(a)		29,311		1,977,027
Cigna Group		22,809		6,400,205
Elevance Health, Inc.(d)		12,737		5,658,922
Guardant Health, Inc.(a)		12,702		454,732
HCA Healthcare, Inc.		21,285		6,459,572
Humana, Inc.		11,855		5,300,726
McKesson Corp.		26,075		11,142,108
Quest Diagnostics, Inc.		40,564		5,701,676
UnitedHealth Group, Inc.(d)		97,709		46,962,854
				102,128,638
Life Sciences Tools & Services — 9.7%
10X Genomics, Inc., Class A(a)		9,740		543,882
Agilent Technologies, Inc.		25,861		3,109,785
Avantor, Inc.(a)		78,897		1,620,544
Bio-Techne Corp.		10,625		867,319
Danaher Corp.		43,329		10,398,960
Icon PLC(a)		8,210		2,054,142
Illumina, Inc.(a)		11,735		2,200,195
IQVIA Holdings, Inc.(a)		26,058		5,857,057
Mettler-Toledo International, Inc.(a)		1,055		1,383,780
Nautilus Biotechnology, Inc.(a)		16,560		64,087
QIAGEN NV(a)		31,011		1,396,425
Rapid Micro Biosystems, Inc., Class A(a)		20,561		20,561
Repligen Corp.(a)		8,070		1,141,582

S C H E D U L E   O F   I N V E S T M E N T S 75

Schedule of Investments  (unaudited) (continued) June 30, 2023 BlackRock Health Sciences Trust (BME) (Percentages shown are based on Net Assets)

Security	Shares		Value
Life Sciences Tools & Services (continued)
Thermo Fisher Scientific, Inc.(f)		40,468	$	21,114,179
West Pharmaceutical Services, Inc.		15,420		5,897,688
				57,670,186
Pharmaceuticals — 19.6%
Arvinas, Inc.(a)		13,163		326,706
AstraZeneca PLC		26,401		3,784,694
Bristol-Myers Squibb Co.		39,106		2,500,829
Catalent, Inc.(a)		20,045		869,151
Daiichi Sankyo Co. Ltd.		33,900		1,077,147
Elanco Animal Health, Inc.(a)		51,800		521,108
Eli Lilly & Co.		79,376		37,225,756
Johnson & Johnson(d)		90,509		14,981,050
Merck & Co., Inc.(d)		243,775		28,129,197
Novo Nordisk A/S, Class B		17,765		2,869,753
Pfizer, Inc.(d)		178,976		6,564,840
Pliant Therapeutics, Inc.(a)		12,594		228,203
Reata Pharmaceuticals, Inc., Class A(a)		6,625		675,485
Roche Holding AG		11,601		3,543,756
Sanofi		24,587		2,646,932
Structure Therapeutics, Inc.(a)(e)		13,208		549,057
Zoetis, Inc.		61,919		10,663,071
				117,156,735
Total Common Stocks — 95.7% (Cost: $384,440,043)				571,332,312
	Benefical Interest (000)
Other Interests
Health Care Providers & Services — 0.0%
Afferent Pharmaceuticals, Inc.(b)(c)(g)	$	190		152,128
Total Other Interests — 0.0% (Cost: $ — )				152,128
	Shares
Preferred Securities
Preferred Stocks — 0.7%(b)(c)
Biotechnology — 0.1%
Cellarity, Inc., Series B, (Acquired 01/15/21, Cost: $265,002)		44,167		171,368
Goldfinch Bio, Inc., Series B, (Acquired 06/26/20, Cost: $224,200)		190,000		64,600
Laronde, Inc., Series B, (Acquired 07/28/21, Cost: $590,800)		21,100		365,452
Neurogene, Inc., Series B, (Acquired 12/14/20, Cost: $260,568)		106,790		259,500
				860,920
Health Care Equipment & Supplies — 0.3%
Exo Imaging, Inc., Series C, (Acquired 06/24/21, Cost: $595,999)		101,741		284,875

Security	Shares		Value
Health Care Equipment & Supplies (continued)
Nucleix Ltd., Series AA, (Acquired 03/25/21, Cost: $1,070,001)		367,395	$	1,142,598
Swift Health Systems, Inc., Series D, (Acquired 08/27/21, Cost: $286,998)		92,580		122,206
				1,549,679
Health Care Providers & Services — 0.1%
Quanta Dialysis Technologies Ltd., Series D, (Acquired 06/18/21, Cost: $515,759)		4,243,029		355,650
Health Care Technology — 0.2%
Carbon Health Technologies, Inc., Series D2, (Acquired 02/02/23, Cost: $907,000)		89,892		1,013,982
Pharmaceuticals — 0.0%
Insitro, Inc., Series C, (Acquired 03/10/21, Cost: $560,000)		30,616		353,002
				4,133,233
Total Preferred Securities — 0.7% (Cost: $5,276,327)				4,133,233
Rights
Health Care Equipment & Supplies — 0.0%
Abiomed, Inc.(a)(b)		14,359		40,493
Total Rights — 0.0% (Cost: $14,646)				40,493
Warrants
Health Care Providers & Services — 0.0%
CareMax, Inc., (Issued/Exercisable 09/15/20, 1 Share for 1 Warrant, Expires 07/16/25, Strike Price USD 11.50)(a)		4,201		1,428
Pharmaceuticals — 0.0%
Nuvation Bio, Inc., (Issued/Exercisable 08/17/20, 1 Share for 1 Warrant, Expires 07/07/27, Strike Price USD 11.50)(a)		4,050		670
Total Warrants — 0.0% (Cost: $14,030)				2,098
Total Long-Term Investments — 96.4% (Cost: $389,745,046)				575,660,264

76 2 0 2 3   B L A C K R O C K  S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Schedule of Investments  (unaudited) (continued) June 30, 2023 BlackRock Health Sciences Trust (BME) (Percentages shown are based on Net Assets)

Security	Shares		Value
Short-Term Securities
Money Market Funds — 4.7%
BlackRock Liquidity Funds, T-Fund, Institutional Class, 4.98%(h)(i)		25,514,114	$	25,514,114
SL Liquidity Series, LLC, Money Market Series, 5.28%(h)(i)(j)		2,540,085		2,540,085
Total Short-Term Securities — 4.7% (Cost: $28,054,559)				28,054,199
Total Investments Before Options Written — 101.1% (Cost: $417,799,605)				603,714,463
Options Written — (1.0)% (Premiums Received: $(4,910,324))				(6,153,073	)
Total Investments, Net of Options Written — 100.1% (Cost: $412,889,281)				597,561,390
Liabilities in Excess of Other Assets — (0.1)%				(312,144	)
Net Assets — 100.0%			$	597,249,246

^(a)  Non-income producing security.

^(b)  Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy.

^(c)  Restricted security as to resale, excluding 144A securities. The Trust held restricted securities with a current value of $4,370,260, representing 0.7% of its net assets as of period end, and an original cost of $5,276,327.

^(d)  All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.

^(e)  All or a portion of this security is on loan.

^(f)  All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives.

^(g)  Other interests represent beneficial interests in liquidation trusts and other reorganization or private entities.

^(h)  Affiliate of the Trust.

⁽ⁱ⁾  Annualized 7-day yield as of period end.

^(j)  All or a portion of this security was purchased with the cash collateral from loaned securities.

For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

Affiliates

Investments in issuers considered to be affiliate(s) of the Trust during the six months ended June 30, 2023 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

Affiliated Issuer	Value at 12/31/22		Purchases at Cost			Proceeds from Sales		Net Realized Gain (Loss)		Change in Unrealized Appreciation (Depreciation)			Value at 06/30/23		Shares Held at 06/30/23		Income			Capital Gain Distributions from Underlying Funds
BlackRock Liquidity Funds, T-Fund, Institutional Class	$	23,195,315	$	2,318,799	(a)	$	—	$	—	$	—		$	25,514,114		25,514,114	$	571,208		$	—
SL Liquidity Series, LLC, Money Market Series		675,980		1,863,501	(a)		—		1,229		(625	)		2,540,085		2,540,085		20,778	(b)		—
								$	1,229	$	(625	)	$	28,054,199			$	591,986		$	—

^(a)  Represents net amount purchased (sold).

^(b)  All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities.

Derivative Financial Instruments Outstanding as of Period End

Exchange-Traded Options Written

Description	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call
Alcon, Inc.		136		07/05/23		USD	72.60		USD	1,117	$	(130,050	)
Abbott Laboratories		245		07/07/23		USD	104.00		USD	2,671		(126,175	)
Align Technology, Inc.		15		07/07/23		USD	315.00		USD	530		(58,275	)
AmerisourceBergen Corp.		52		07/07/23		USD	175.00		USD	1,001		(92,300	)
Danaher Corp.		126		07/07/23		USD	235.00		USD	3,024		(78,120	)
Humana, Inc.		32		07/07/23		USD	520.00		USD	1,431		(1,120	)
McKesson Corp.		22		07/07/23		USD	390.00		USD	940		(83,600	)
Pfizer, Inc.		340		07/07/23		USD	39.00		USD	1,247		(510	)
Reata Pharmaceuticals, Inc., Class A		25		07/07/23		USD	101.00		USD	255		(8,687	)
UnitedHealth Group, Inc.		209		07/07/23		USD	485.00		USD	10,045		(40,964	)
AbbVie, Inc.		101		07/14/23		USD	135.00		USD	1,361		(14,796	)
Baxter International, Inc.		177		07/14/23		USD	42.00		USD	806		(64,605	)
Bristol-Myers Squibb Co.		74		07/14/23		USD	68.00		USD	473		(259	)
Eli Lilly & Co.		123		07/14/23		USD	460.00		USD	5,768		(153,750	)

S C H E D U L E   O F   I N V E S T M E N T S 77

Schedule of Investments  (unaudited) (continued) June 30, 2023 BlackRock Health Sciences Trust (BME)

Exchange-Traded Options Written (continued)

Description	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call (continued)
Gilead Sciences, Inc.		141		07/14/23		USD	78.00		USD	1,087	$	(8,812	)
Illumina, Inc.		20		07/14/23		USD	210.00		USD	375		(3,500	)
Intuitive Surgical, Inc.		63		07/14/23		USD	320.00		USD	2,154		(137,970	)
Merck & Co., Inc.		260		07/14/23		USD	114.00		USD	3,000		(65,650	)
Pfizer, Inc.		340		07/14/23		USD	40.00		USD	1,247		(680	)
Thermo Fisher Scientific, Inc.		89		07/14/23		USD	530.00		USD	4,644		(38,270	)
Vertex Pharmaceuticals, Inc.		70		07/14/23		USD	340.00		USD	2,463		(91,700	)
Abbott Laboratories		208		07/21/23		USD	105.00		USD	2,268		(97,760	)
AbbVie, Inc.		105		07/21/23		USD	150.00		USD	1,415		(473	)
Abcam PLC, ADR		109		07/21/23		USD	25.00		USD	267		(11,172	)
Alcon, Inc.		87		07/21/23		USD	82.50		USD	714		(10,657	)
Alkermes PLC		19		07/21/23		USD	31.00		USD	59		(1,948	)
Alnylam Pharmaceuticals, Inc.		29		07/21/23		USD	210.00		USD	551		(2,683	)
AmerisourceBergen Corp.		23		07/21/23		USD	180.00		USD	443		(32,200	)
Amgen, Inc.		118		07/21/23		USD	235.00		USD	2,620		(4,130	)
Apellis Pharmaceuticals, Inc.		26		07/21/23		USD	95.00		USD	237		(6,955	)
Avantor, Inc.		75		07/21/23		USD	20.43		USD	154		(5,976	)
Bausch & Lomb Corp.		107		07/21/23		USD	19.63		USD	215		(10,387	)
Baxter International, Inc.		194		07/21/23		USD	42.50		USD	884		(64,020	)
Becton Dickinson & Co.		48		07/21/23		USD	252.95		USD	1,267		(59,708	)
BioMarin Pharmaceutical, Inc.		52		07/21/23		USD	100.00		USD	451		(1,170	)
Biomea Fusion, Inc.		66		07/21/23		USD	40.00		USD	145		(495	)
Bio-Techne Corp.		20		07/21/23		USD	85.00		USD	163		(1,650	)
Blueprint Medicines Corp.		60		07/21/23		USD	55.00		USD	379		(55,200	)
Boston Scientific Corp.		767		07/21/23		USD	53.40		USD	4,149		(116,059	)
Catalent, Inc.		38		07/21/23		USD	40.00		USD	165		(17,290	)
Catalent, Inc.		38		07/21/23		USD	50.00		USD	165		(1,710	)
Centene Corp.		56		07/21/23		USD	67.50		USD	378		(8,540	)
Cerevel Therapeutics Holdings, Inc.		32		07/21/23		USD	35.00		USD	102		(880	)
Dexcom, Inc.		99		07/21/23		USD	124.95		USD	1,272		(57,771	)
Edwards Lifesciences Corp.		42		07/21/23		USD	88.72		USD	396		(25,756	)
Edwards Lifesciences Corp.		53		07/21/23		USD	90.00		USD	500		(26,765	)
Elevance Health, Inc.		48		07/21/23		USD	490.00		USD	2,133		(3,720	)
Envista Holdings Corp.		80		07/21/23		USD	32.24		USD	271		(16,214	)
Exact Sciences Corp.		37		07/21/23		USD	85.00		USD	347		(36,260	)
Gilead Sciences, Inc.		226		07/21/23		USD	82.50		USD	1,742		(2,147	)
Glaukos Corp.		9		07/21/23		USD	60.00		USD	64		(10,440	)
HCA Healthcare, Inc.		50		07/21/23		USD	285.00		USD	1,517		(99,250	)
Hologic, Inc.		26		07/21/23		USD	85.00		USD	211		(910	)
Hologic, Inc.		15		07/21/23		USD	80.00		USD	121		(3,225	)
Humana, Inc.		15		07/21/23		USD	525.00		USD	671		(788	)
IDEXX Laboratories, Inc.		27		07/21/23		USD	490.00		USD	1,356		(53,595	)
Immunocore Holdings PLC, ADR		18		07/21/23		USD	60.00		USD	108		(3,915	)
Incyte Corp.		63		07/21/23		USD	68.00		USD	392		(764	)
Insulet Corp.		12		07/21/23		USD	330.00		USD	346		(450	)
Intuitive Surgical, Inc.		48		07/21/23		USD	325.00		USD	1,641		(104,160	)
Ionis Pharmaceuticals, Inc.		29		07/21/23		USD	37.50		USD	119		(11,455	)
Ionis Pharmaceuticals, Inc.		79		07/21/23		USD	45.00		USD	324		(988	)
IQVIA Holdings, Inc.		30		07/21/23		USD	210.00		USD	674		(48,600	)
Karuna Therapeutics, Inc.		6		07/21/23		USD	240.00		USD	130		(510	)
Masimo Corp.		16		07/21/23		USD	175.00		USD	263		(2,200	)
McKesson Corp.		45		07/21/23		USD	400.00		USD	1,923		(133,650	)
Medtronic PLC		126		07/21/23		USD	90.00		USD	1,110		(7,182	)
Mettler-Toledo International, Inc.		2		07/21/23		USD	1,460.00		USD	262		(490	)
Moderna, Inc.		41		07/21/23		USD	150.00		USD	498		(882	)
Moderna, Inc.		18		07/21/23		USD	135.00		USD	219		(1,449	)
Morphic Holding, Inc.		31		07/21/23		USD	60.00		USD	178		(8,447	)
Neurocrine Biosciences, Inc.		32		07/21/23		USD	100.00		USD	302		(3,520	)
Omnicell, Inc.		12		07/21/23		USD	75.00		USD	88		(3,150	)
Penumbra, Inc.		30		07/21/23		USD	320.00		USD	1,032		(82,050	)
PTC Therapeutics, Inc.		24		07/21/23		USD	65.00		USD	98		(11,520	)
QIAGEN NV		58		07/21/23		USD	47.25		USD	261		(4,560	)

78 2 0 2 3   B L A C K R O C K  S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Schedule of Investments  (unaudited) (continued) June 30, 2023 BlackRock Health Sciences Trust (BME)

Exchange-Traded Options Written (continued)

Description	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call (continued)
Quest Diagnostics, Inc.		77		07/21/23		USD	135.00		USD	1,082	$	(44,660	)
Regeneron Pharmaceuticals, Inc.		20		07/21/23		USD	785.00		USD	1,437		(2,850	)
Regeneron Pharmaceuticals, Inc.		21		07/21/23		USD	760.00		USD	1,509		(6,772	)
Repligen Corp.		33		07/21/23		USD	170.00		USD	467		(9,900	)
ResMed, Inc.		21		07/21/23		USD	234.21		USD	459		(2,165	)
ResMed, Inc.		29		07/21/23		USD	220.00		USD	634		(14,210	)
Revolution Medicines, Inc.		38		07/21/23		USD	30.00		USD	102		(2,185	)
Rhythm Pharmaceuticals, Inc.		54		07/21/23		USD	22.50		USD	89		(4,050	)
Rhythm Pharmaceuticals, Inc.		44		07/21/23		USD	20.00		USD	73		(880	)
Rocket Pharmaceuticals, Inc.		32		07/21/23		USD	22.50		USD	64		(400	)
Rocket Pharmaceuticals, Inc.		33		07/21/23		USD	25.00		USD	66		(3,465	)
Sage Therapeutics, Inc.		43		07/21/23		USD	52.50		USD	202		(1,505	)
STERIS PLC		18		07/21/23		USD	210.00		USD	405		(28,170	)
Stryker Corp.		233		07/21/23		USD	290.00		USD	7,109		(384,450	)
Ultragenyx Pharmaceutical, Inc.		11		07/21/23		USD	55.00		USD	51		(330	)
Vaxcyte, Inc.		23		07/21/23		USD	55.00		USD	115		(1,380	)
Vertex Pharmaceuticals, Inc.		40		07/21/23		USD	350.00		USD	1,408		(29,400	)
West Pharmaceutical Services, Inc.		48		07/21/23		USD	360.00		USD	1,836		(120,000	)
Zoetis, Inc.		235		07/21/23		USD	170.00		USD	4,047		(102,225	)
Alkermes PLC		22		07/25/23		USD	30.25		USD	69		(3,676	)
AbbVie, Inc.		115		07/28/23		USD	140.00		USD	1,549		(8,165	)
AmerisourceBergen Corp.		95		07/28/23		USD	185.00		USD	1,828		(88,350	)
Amgen, Inc.		113		07/28/23		USD	235.00		USD	2,509		(6,723	)
Baxter International, Inc.		27		07/28/23		USD	43.00		USD	123		(9,045	)
Biogen, Inc.		128		07/28/23		USD	300.00		USD	3,646		(54,400	)
Bristol-Myers Squibb Co.		74		07/28/23		USD	67.00		USD	473		(1,776	)
Centene Corp.		55		07/28/23		USD	68.00		USD	371		(16,362	)
Cigna Group		14		07/28/23		USD	280.00		USD	393		(10,430	)
Eli Lilly & Co.		120		07/28/23		USD	470.00		USD	5,628		(129,300	)
GE HealthCare, Inc.		260		07/28/23		USD	80.00		USD	2,112		(81,900	)
Humana, Inc.		11		07/28/23		USD	470.00		USD	492		(3,603	)
Johnson & Johnson		86		07/28/23		USD	165.00		USD	1,423		(27,305	)
McKesson Corp.		32		07/28/23		USD	425.00		USD	1,367		(31,520	)
Medtronic PLC		65		07/28/23		USD	87.00		USD	573		(15,145	)
Merck & Co., Inc.		223		07/28/23		USD	112.00		USD	2,573		(104,810	)
UnitedHealth Group, Inc.		162		07/28/23		USD	490.00		USD	7,786		(121,500	)
Vertex Pharmaceuticals, Inc.		75		07/28/23		USD	355.00		USD	2,639		(63,000	)
Zimmer Biomet Holdings, Inc.		27		08/01/23		USD	146.17		USD	393		(7,031	)
AmerisourceBergen Corp.		3		08/04/23		USD	190.00		USD	58		(1,845	)
AmerisourceBergen Corp.		52		08/04/23		USD	195.00		USD	1,001		(19,760	)
Baxter International, Inc.		26		08/04/23		USD	47.00		USD	118		(2,990	)
Danaher Corp.		38		08/04/23		USD	240.00		USD	912		(30,400	)
Eli Lilly & Co.		58		08/04/23		USD	475.00		USD	2,720		(60,465	)
Gilead Sciences, Inc.		333		08/04/23		USD	79.00		USD	2,566		(39,793	)
Illumina, Inc.		24		08/04/23		USD	215.00		USD	450		(7,440	)
Intuitive Surgical, Inc.		72		08/04/23		USD	330.00		USD	2,462		(150,120	)
Johnson & Johnson		96		08/04/23		USD	170.00		USD	1,589		(10,752	)
Merck & Co., Inc.		209		08/04/23		USD	116.00		USD	2,412		(56,430	)
Thermo Fisher Scientific, Inc.		72		08/04/23		USD	550.00		USD	3,757		(36,000	)
10X Genomics, Inc., Class A		37		08/18/23		USD	70.00		USD	207		(3,053	)
AbbVie, Inc.		118		08/18/23		USD	145.00		USD	1,590		(9,381	)
Abcam PLC, ADR		55		08/18/23		USD	25.00		USD	135		(13,200	)
Agilent Technologies, Inc.		98		08/18/23		USD	120.00		USD	1,178		(47,040	)
Alcon, Inc.		136		08/18/23		USD	80.00		USD	1,117		(61,200	)
Alkermes PLC		22		08/18/23		USD	32.00		USD	69		(2,585	)
Alnylam Pharmaceuticals, Inc.		35		08/18/23		USD	220.00		USD	665		(9,712	)
Apellis Pharmaceuticals, Inc.		26		08/18/23		USD	95.00		USD	237		(14,300	)
Argenx SE, ADR		20		08/18/23		USD	450.00		USD	779		(34,100	)
Avantor, Inc.		149		08/18/23		USD	22.50		USD	306		(5,960	)
Avantor, Inc.		75		08/18/23		USD	20.40		USD	154		(9,185	)
Bausch & Lomb Corp.		107		08/18/23		USD	20.00		USD	215		(12,037	)
Becton Dickinson & Co.		105		08/18/23		USD	260.00		USD	2,772		(107,100	)

S C H E D U L E    O F   I N V E S T M E N T S 79

Schedule of Investments  (unaudited) (continued) June 30, 2023 BlackRock Health Sciences Trust (BME)

Exchange-Traded Options Written (continued)

Description	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call (continued)
BeiGene Ltd., ADR		19		08/18/23		USD	230.00		USD	339	$	(4,085	)
Biogen, Inc.		18		08/18/23		USD	305.00		USD	513		(8,280	)
BioMarin Pharmaceutical, Inc.		61		08/18/23		USD	105.00		USD	529		(4,423	)
Bio-Techne Corp.		20		08/18/23		USD	80.50		USD	163		(8,773	)
Boston Scientific Corp.		933		08/18/23		USD	57.50		USD	5,047		(34,987	)
Cerevel Therapeutics Holdings, Inc.		31		08/18/23		USD	35.00		USD	99		(2,713	)
Cigna Group		72		08/18/23		USD	280.00		USD	2,020		(84,600	)
Cooper Cos., Inc.		49		08/18/23		USD	380.00		USD	1,879		(66,640	)
Dexcom, Inc.		109		08/18/23		USD	131.00		USD	1,401		(49,369	)
Edwards Lifesciences Corp.		47		08/18/23		USD	87.20		USD	443		(44,689	)
Exact Sciences Corp.		35		08/18/23		USD	91.00		USD	329		(23,426	)
HCA Healthcare, Inc.		30		08/18/23		USD	290.00		USD	910		(61,050	)
Icon PLC		31		08/18/23		USD	240.00		USD	776		(56,420	)
Immunocore Holdings PLC, ADR		18		08/18/23		USD	65.00		USD	108		(3,645	)
Incyte Corp.		63		08/18/23		USD	64.00		USD	392		(12,669	)
Inspire Medical Systems, Inc.		21		08/18/23		USD	340.00		USD	682		(26,145	)
Insulet Corp.		20		08/18/23		USD	299.00		USD	577		(19,536	)
Intuitive Surgical, Inc.		58		08/18/23		USD	330.00		USD	1,983		(126,730	)
IQVIA Holdings, Inc.		69		08/18/23		USD	230.00		USD	1,551		(43,470	)
iRhythm Technologies, Inc.		8		08/18/23		USD	120.00		USD	83		(2,080	)
Johnson & Johnson		161		08/18/23		USD	165.00		USD	2,665		(66,010	)
Legend Biotech Corp., ADR		48		08/18/23		USD	75.00		USD	331		(10,680	)
Masimo Corp.		32		08/18/23		USD	165.50		USD	527		(24,558	)
Medtronic PLC		85		08/18/23		USD	86.25		USD	749		(30,199	)
Merck & Co., Inc.		234		08/18/23		USD	115.00		USD	2,700		(88,920	)
Merus NV		28		08/18/23		USD	30.00		USD	74		(7,140	)
Mettler-Toledo International, Inc.		2		08/18/23		USD	1,385.00		USD	262		(4,070	)
Morphic Holding, Inc.		17		08/18/23		USD	60.00		USD	97		(5,993	)
Neurocrine Biosciences, Inc.		44		08/18/23		USD	105.00		USD	415		(7,810	)
Omnicell, Inc.		19		08/18/23		USD	75.00		USD	140		(7,980	)
Penumbra, Inc.		37		08/18/23		USD	330.50		USD	1,273		(80,865	)
Prothena Corp. PLC		33		08/18/23		USD	80.00		USD	225		(6,023	)
Quest Diagnostics, Inc.		77		08/18/23		USD	140.00		USD	1,082		(32,725	)
Regeneron Pharmaceuticals, Inc.		26		08/18/23		USD	800.00		USD	1,868		(12,090	)
Rhythm Pharmaceuticals, Inc.		84		08/18/23		USD	20.00		USD	139		(4,200	)
Sage Therapeutics, Inc.		20		08/18/23		USD	60.00		USD	94		(2,200	)
Seagen, Inc.		41		08/18/23		USD	200.00		USD	789		(15,067	)
STERIS PLC		18		08/18/23		USD	207.50		USD	405		(37,636	)
Stryker Corp.		14		08/18/23		USD	292.00		USD	427		(27,394	)
Ultragenyx Pharmaceutical, Inc.		11		08/18/23		USD	55.00		USD	51		(1,733	)
Viking Therapeutics, Inc.		64		08/18/23		USD	26.00		USD	104		(2,240	)
West Pharmaceutical Services, Inc.		10		08/18/23		USD	380.00		USD	382		(17,250	)
Zimmer Biomet Holdings, Inc.		28		08/18/23		USD	145.00		USD	408		(14,560	)
Bausch & Lomb Corp.		74		08/21/23		USD	18.56		USD	149		(15,682	)
Medtronic PLC		122		08/29/23		USD	89.00		USD	1,075		(27,130	)
Medtronic PLC		150		09/08/23		USD	89.00		USD	1,322		(37,040	)
Seagen, Inc.		41		09/15/23		USD	200.00		USD	789		(19,680	)
											$	(6,056,130	)

OTC Options Written

Description	Counterparty	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call
Roche Holding AG	Barclays Bank PLC		1,200		07/11/23		CHF	290.77		CHF	328	$	(145	)
Genmab A/S	Morgan Stanley & Co. International PLC		900		07/13/23		DKK	2,806.75		DKK	2,327		(171	)
Novo Nordisk A/S, Class B	Morgan Stanley & Co. International PLC		5,000		07/13/23		DKK	1,149.69		DKK	5,511		(3,483	)
Roche Holding AG	UBS AG		1,000		07/13/23		CHF	294.45		CHF	273		(118	)
Sanofi	Goldman Sachs International		4,700		07/13/23		EUR	97.63		EUR	464		(7,572	)
AstraZeneca PLC	UBS AG		6,700		07/18/23		GBP	124.57		GBP	756		(1,531	)
Sanofi	Goldman Sachs International		4,700		07/18/23		EUR	97.09		EUR	464		(10,514	)

80 2 0 2 3   B L A C K R O C K  S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Schedule of Investments (unaudited) (continued) June 30, 2023      BlackRock Health Sciences Trust (BME)

OTC Options Written (continued)

Description	Counterparty	Number of Contracts		Expiration Date		Exercise Price		Notional Amount (000)		Value
Call (continued)
Roche Holding AG	JPMorgan Chase Bank N.A.		1,300		07/25/23	CHF	296.53	CHF	355	$	(619	)
Glaukos Corp.	Morgan Stanley & Co. International PLC		900		07/31/23	USD	69.83	USD	64		(3,587	)
Revolution Medicines, Inc.	Citibank N.A.		3,300		07/31/23	USD	25.25	USD	88		(8,101	)
Vaxcyte, Inc.	Morgan Stanley & Co. International PLC		2,200		07/31/23	USD	54.78	USD	110		(2,188	)
Novo Nordisk A/S, Class B	Citibank N.A.		1,800		08/02/23	DKK	1,117.35	DKK	1,984		(7,711	)
Daiichi Sankyo Co. Ltd.	Goldman Sachs International		12,900		08/03/23	JPY	4,670.09	JPY	59,145		(11,455	)
AstraZeneca PLC	Goldman Sachs International		3,400		08/16/23	GBP	117.36	GBP	384		(9,467	)
Genmab A/S, ADR	Morgan Stanley & Co. International PLC		6,400		08/23/23	USD	39.39	USD	243		(7,756	)
Alkermes PLC	Citibank N.A.		5,900		08/29/23	USD	33.63	USD	185		(5,196	)
Legend Biotech Corp., ADR	UBS AG		5,400		09/08/23	USD	75.80	USD	373		(17,329	)
										$	(96,943	)

Balances Reported in the Statements of Assets and Liabilities for Options Written

Description

Swap Premiums Paid

Swap Premiums Received

Unrealized Appreciation

Unrealized Depreciation

Value

Options Written

$       N/A

$       N/A

$  1,220,682

$ (2,463,431

)

$ (6,153,073

)

Derivative Financial Instruments Categorized by Risk Exposure

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

	Commodity Contracts		Credit Contracts		Equity Contracts		Foreign Currency Exchange Contracts		Interest Rate Contracts		Other Contracts		Total
Liabilities — Derivative Financial Instruments
Options written
Options written at value	$	—	$	—	$	6,153,073	$	—	$	—	$	—	$	6,153,073

For the period ended June 30, 2023, the effect of derivative financial instruments in the Statements of Operations was as follows:

	Commodity Contracts		Credit Contracts		Equity Contracts			Foreign Currency Exchange Contracts		Interest Rate Contracts		Other Contracts		Total
Net Realized Gain (Loss) from:
Options purchased(a)	$	—	$	—	$	(209,469	)	$	—	$	—	$	—	$	(209,469	)
Options written		—		—		4,698,971			—		—		—		4,698,971
	$	—	$	—	$	4,489,502		$	—	$	—	$	—	$	4,489,502
Net Change in Unrealized Appreciation (Depreciation) on:
Options written	$	—	$	—	$	(3,421,738	)	$	—	$	—	$	—	$	(3,421,738	)

^(a)  Options purchased are included in net realized gain (loss) from investments — unaffiliated.

Average Quarterly Balances of Outstanding Derivative Financial Instruments

Options:
Average value of option contracts purchased	$	—	(a)
Average value of option contracts written	$	5,024,703

^(a)  Derivative not held at any quarter-end. The risk exposure table serves as an indicator of activity during the period.

For more information about the Trust’s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.

S C H E D U L E    O F   I N V E S T M E N T S 81

Schedule of Investments (unaudited) (continued) June 30, 2023      BlackRock Health Sciences Trust (BME)

Derivative Financial Instruments — Offsetting as of Period End

The Trust’s derivative assets and liabilities (by type) were as follows:

	Assets		Liabilities
Derivative Financial Instruments
Options	$	—	$	6,153,073
Total derivative assets and liabilities in the Statements of Assets and Liabilities		—		6,153,073
Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”)		—		(6,056,130	)
Total derivative assets and liabilities subject to an MNA	$	—	$	96,943

The following table presents the Trust’s derivative liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral pledged by the Trust:

Counterparty		Derivative Liabilities Subject to an MNA by Counterparty		Derivatives Available for Offset		Non-Cash Collateral Pledged	(a)		Cash Collateral Pledged		Net Amount of Derivative Liabilities	(b)
Barclays Bank PLC	$	145	$	—	$	—		$	—	$	145
Citibank N.A.		21,008		—		—			—		21,008
Goldman Sachs International		39,008		—		—			—		39,008
JPMorgan Chase Bank N.A.		619		—		(619	)		—		—
Morgan Stanley & Co. International PLC		17,185		—		—			—		17,185
UBS AG		18,978		—		—			—		18,978
	$	96,943	$	—	$	(619	)	$	—	$	96,324

^(a)  Excess of collateral received/pledged, if any, from the individual counterparty is not shown for financial reporting purposes.

^(b)  Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.

Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of financial instruments. For a description of the input levels and information about the Trust’s policy regarding valuation of financial instruments, refer to the Notes to Financial Statements.

The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust’s financial instruments into major categories is disclosed in the Schedule of Investments above.

	Level 1		Level 2		Level 3		Total
Assets
Investments
Long-Term Investments
Common Stocks
Biotechnology	$	125,257,414	$	946,636	$	84,899	$	126,288,949
Health Care Equipment & Supplies		168,087,804		—		—		168,087,804
Health Care Providers & Services		102,128,638		—		—		102,128,638
Life Sciences Tools & Services		57,670,186		—		—		57,670,186
Pharmaceuticals		103,234,453		13,922,282		—		117,156,735
Other Interests		—		—		152,128		152,128
Preferred Securities
Preferred Stocks		—		—		4,133,233		4,133,233
Rights		—		—		40,493		40,493
Warrants		2,098		—		—		2,098
Short-Term Securities
Money Market Funds		25,514,114		—		—		25,514,114
	$	581,894,707	$	14,868,918	$	4,410,753		601,174,378
Investments Valued at NAV(a)								2,540,085
							$	603,714,463

82 2 0 2 3   B L A C K R O C K  S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Schedule of Investments (unaudited) (continued) June 30, 2023      BlackRock Health Sciences Trust (BME)

Fair Value Hierarchy as of Period End (continued)

	Level 1		Level 2		Level 3		Total
Derivative Financial Instruments(b)
Liabilities
Equity Contracts	$	(5,163,792)	$	(989,281)	$	—	$	(6,153,073)

^(a)  Certain investments of the Trust were fair valued using NAV as a practical expedient as no quoted market value is available and therefore have been excluded from the fair value hierarchy.

^(b)  Derivative financial instruments are options written. Options written are shown at value.

See notes to financial statements.

S C H E D U L E    O F   I N V E S T M E N T S 83

Schedule of Investments (unaudited) June 30, 2023      BlackRock Innovation and Growth Term Trust (BIGZ) (Percentages shown are based on Net Assets)

Security	Shares		Value
Common Stocks
Aerospace & Defense — 5.2%
Axon Enterprise, Inc.(a)(b)		323,772	$	63,174,392
HEICO Corp.(c)		269,930		47,761,414
				110,935,806
Air Freight & Logistics — 1.6%
GXO Logistics, Inc.(b)		529,641		33,272,048
Automobile Components — 1.6%
Fox Factory Holding Corp.(b)(c)		317,209		34,420,349
Biotechnology — 1.0%
Halozyme Therapeutics, Inc.(b)		610,181		22,009,229
Broadline Retail — 0.3%
Etsy, Inc.(b)		68,408		5,788,001
Building Products — 1.0%
AZEK Co., Inc.(b)		725,567		21,977,425
Capital Markets — 4.8%
MarketAxess Holdings, Inc.		78,856		20,614,535
TPG, Inc.		913,473		26,728,220
Tradeweb Markets, Inc., Class A(d)		804,964		55,123,935
				102,466,690
Construction & Engineering — 1.6%
Comfort Systems USA, Inc.		207,799		34,120,596
Diversified Consumer Services — 3.9%
Duolingo, Inc.(b)		237,302		33,919,948
Grammarly, Inc., (Acquired 11/17/21, Cost: $26,250,012)(e)(f)		1,001,454		17,164,922
Ideal Image, Class A, (Acquired 05/05/21, Cost: $50,000,000)(e)(f)		6,224		32,480,436
				83,565,306
Entertainment — 0.6%
Kahoot! ASA(b)		4,666,896		12,729,395
Food Products — 0.3%
Freshpet, Inc.(b)(c)		90,230		5,938,036
Ground Transportation — 2.8%
Saia, Inc.(b)		175,878		60,222,386
Health Care Equipment & Supplies(b) — 3.0%
Inmode Ltd.		148,982		5,564,478
Inspire Medical Systems, Inc.		110,525		35,880,836
Insulet Corp.		78,734		22,702,161
				64,147,475
Health Care Providers & Services — 1.4%
Surgery Partners, Inc.(b)		655,839		29,506,197
Health Care Technology(b) — 1.6%
Certara, Inc.		396,935		7,228,186
Doximity, Inc., Class A(c)		407,869		13,875,704
Phreesia, Inc.		419,312		13,002,865
				34,106,755
Hotels, Restaurants & Leisure — 4.3%
Domino’s Pizza, Inc.		19,401		6,537,943
Evolution AB(g)		300,297		38,054,766

Security	Shares		Value
Hotels, Restaurants & Leisure (continued)
Penn Entertainment, Inc.(b)		170,486	$	4,096,779
Planet Fitness, Inc., Class A(b)(d)		624,948		42,146,493
				90,835,981
Industrial REITs — 0.3%
Innovative Industrial Properties, Inc.		33,866		2,472,557
Rexford Industrial Realty, Inc.		88,153		4,603,349
				7,075,906
Interactive Media & Services — 2.3%
Match Group, Inc.(b)(c)		1,035,971		43,355,386
Patreon, Inc., (Acquired 08/19/21, Cost: $11,732,736)(e)(f)		208,333		5,435,408
				48,790,794
IT Services — 5.7%
DigitalOcean Holdings, Inc.(b)		407,658		16,363,392
Globant SA(b)		221,257		39,764,308
MongoDB, Inc.(b)		116,170		47,744,708
Teya Services Ltd., Series C, (Acquired 11/16/21, Cost: $49,999,974)(e)(f)		25,742		17,073,897
				120,946,305
Life Sciences Tools & Services — 8.3%
10X Genomics, Inc., Class A(b)(c)(d)		88,021		4,915,092
Azenta, Inc.(b)		305,275		14,250,237
Bio-Techne Corp.		511,281		41,735,868
Charles River Laboratories International, Inc.(b)		127,516		26,810,239
Olink Holding AB, ADR(b)		65,984		1,237,200
Repligen Corp.(b)		260,878		36,903,802
West Pharmaceutical Services, Inc.		130,655		49,971,618
				175,824,056
Machinery(b) — 1.9%
AutoStore Holdings Ltd.(c)(g)		9,492,782		20,779,611
Chart Industries, Inc.		118,174		18,883,024
				39,662,635
Personal Care Products — 0.1%
Beauty Health Co.(b)		223,147		1,867,740
Professional Services(b) — 1.1%
Fiverr International Ltd.		357,463		9,297,613
Paylocity Holding Corp.(d)		80,236		14,805,949
				24,103,562
Semiconductors & Semiconductor Equipment — 9.6%
Ambarella, Inc.(b)		205,175		17,166,992
ASM International NV		24,372		10,348,453
Entegris, Inc.(a)(c)(d)		541,178		59,973,346
Lattice Semiconductor Corp.(b)(c)		503,092		48,332,048
Monolithic Power Systems, Inc.(a)(d)		120,729		65,221,428
SolarEdge Technologies, Inc.(b)(c)		16,083		4,327,131
				205,369,398
Software — 13.7%
Aspen Technology, Inc.(b)(c)		161,072		26,997,278
Bentley Systems, Inc., Class B		786,253		42,638,500
Bill Holding, Inc.(b)		173,026		20,218,088
Confluent, Inc., Class A(b)		1,134,927		40,074,272
Five9, Inc.(b)		158,993		13,108,973
HubSpot, Inc.(b)		88,402		47,037,820
JFrog Ltd.(b)		847,689		23,480,985

84 2 0 2 3   B L A C K R O C K  S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Schedule of Investments (unaudited) (continued) June 30, 2023      BlackRock Innovation and Growth Term Trust (BIGZ) (Percentages shown are based on Net Assets)

Security	Shares		Value
Software (continued)
PagerDuty, Inc.(b)		334,226	$	7,513,401
SiteMinder Ltd.(b)		8,522,830		16,612,241
Snorkel AI, Inc., (Acquired 06/30/21, Cost: $2,999,997)(e)(f)		199,738		2,211,100
Snyk Ltd., (Acquired 09/02/21, Cost: $25,961,537)(e)(f)		1,809,860		20,795,291
Zscaler, Inc.(b)		213,972		31,304,104
				291,992,053
Textiles, Apparel & Luxury Goods — 0.8%
Figs, Inc., Class A(b)		2,000,216		16,541,786
Total Common Stocks — 78.8% (Cost: $1,747,200,322)				1,678,215,910
Preferred Securities
Preferred Stocks — 21.8%(e)(f)
Aerospace & Defense — 0.1%
SkySafe, Inc., Series B, (Acquired 12/02/21, Cost: $4,999,999)		909,438		2,337,256
Automobile Components — 1.7%
Relativity Space, Inc., Series E, (Acquired 05/27/21, Cost: $50,000,009)		2,189,612		36,435,144
Capital Markets — 2.9%
Anchor Labs, Inc., Series D, (Acquired 11/24/21, Cost: $9,999,995)		428,785		2,765,663
The Production Board LLC, Series A3, (Acquired 06/04/21, Cost: $50,000,001)		16,666,667		42,166,668
Varo Money, Inc., Series E, (Acquired 08/27/21, Cost: $40,000,001)		4,316,904		17,353,954
				62,286,285
Diversified Consumer Services — 0.3%
Grammarly, Inc., Series 3, (Acquired 11/17/21, Cost: $8,750,004)		333,818		5,721,640
Diversified Telecommunication Services — 0.6%
Discord, Inc., Series I, (Acquired 09/13/21, Cost: $17,999,912)		32,690		12,276,496
Entertainment — 1.2%
Under Canvas, Inc., Class A, (Acquired 08/19/21, Cost: $49,999,982)		2,172,486		24,918,414
Food Products — 0.9%
Motif Food Works, Inc., Series B, (Acquired 06/08/21, Cost: $39,999,986)		1,972,240		19,485,731
Hotels, Restaurants & Leisure — 1.3%
Dapper Labs, Inc., Series 7, (Acquired 07/20/21, Cost: $29,999,946)		191,067		8,009,529
Underdog Sports, Inc., Series B, (Acquired 01/11/22, Cost: $14,999,974)		291,061		19,180,920
				27,190,449
Interactive Media & Services — 0.5%
Patreon, Inc., Series D, (Acquired 07/14/21, Cost: $23,333,352)		416,667		10,870,842

Security	Shares		Value
IT Services — 1.4%
Via Transportation, Inc., Series G, (Acquired 11/05/21, Cost: $24,999,974)		549,357	$	25,001,237
Wagestream Holdings Ltd., Series C, (Acquired 02/11/22, Cost: $10,024,684)		762,746		4,804,687
				29,805,924
Semiconductors & Semiconductor Equipment — 2.2%
PsiQuantum Corp., Series D, (Acquired 05/21/21, Cost: $39,999,990)		1,525,192		40,310,825
Rivos, Inc., Series A, (Acquired 12/03/21, Cost: $7,996,292)		2,997,684		7,404,279
				47,715,104
Software — 7.0%
AnyRoad, Inc., Series B, (Acquired 12/07/21, Cost: $14,999,995)		2,745,894		11,642,591
Bolt Financial, Inc., Series E, (Acquired 01/18/22, Cost: $44,999,983)		898,024		22,019,548
Deepgram, Inc., Series B, (Acquired 10/22/21, Cost: $11,999,997)		2,165,400		13,403,826
Dragos, Inc., Series D, (Acquired 09/28/21, Cost: $39,999,959)		900,760		30,625,840
Genesys Cloud Services, Inc., (Acquired 11/24/21, Cost: $30,000,101)		4,651,163		18,883,722
Open Space Labs, Inc., Series D, (Acquired 01/31/22, Cost: $15,000,003)		1,687,916		15,056,211
Snorkel AI, Inc., Series C, (Acquired 06/30/21, Cost: $10,999,994)		732,373		8,107,369
Snyk Ltd., Series F, (Acquired 09/02/21, Cost: $24,038,470)		1,685,092		19,361,707
Validere Technologies, Inc., Series B, (Acquired 10/21/21, Cost: $10,000,000)		4,684,060		9,930,207
				149,031,021
Specialty Retail — 0.5%
Super73, Inc., Series C-1, (Acquired 10/25/22, Cost: $12,000,000)		1,400,669		10,799,158
Wireless Telecommunication Services — 1.2%
Loft Orbital Solutions, Inc., Series B, (Acquired 10/14/21, Cost: $24,999,992)		1,365,305		25,708,693
				464,582,157
Total Preferred Securities — 21.8% (Cost: $662,142,595)				464,582,157
Total Long-Term Investments — 100.6% (Cost: $2,409,342,917)				2,142,798,067

S C H E D U L E   O F   I N V E S T M E N T S 85

Schedule of Investments (unaudited) (continued) June 30, 2023      BlackRock Innovation and Growth Term Trust (BIGZ) (Percentages shown are based on Net Assets)

Security	Shares		Value
Short-Term Securities
Money Market Funds — 2.0%
BlackRock Liquidity Funds, T-Fund, Institutional Class, 4.98%(h)(i)		22,789,372	$	22,789,372
SL Liquidity Series, LLC, Money Market Series, 5.28%(h)(i)(j)		20,792,167		20,792,167
Total Short-Term Securities — 2.0% (Cost: $43,582,102)				43,581,539
Total Investments Before Options Written — 102.6% (Cost: $2,452,925,019)				2,186,379,606
Options Written — (0.7)% (Premiums Received: $(10,673,712))				(15,626,686	)
Total Investments, Net of Options Written — 101.9% (Cost: $2,442,251,307)				2,170,752,920
Liabilities in Excess of Other Assets — (1.9)%				(41,344,001	)
Net Assets — 100.0%			$	2,129,408,919

^(a)  All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives.

^(b)  Non-income producing security.

^(c)  All or a portion of this security is on loan.

^(d)  All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.

^(e)  Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy.

^(f)  Restricted security as to resale, excluding 144A securities. The Trust held restricted securities with a current value of $559,743,211, representing 26.3% of its net assets as of period end, and an original cost of $829,086,851.

^(g)  Security exempt from registration pursuant to Rule 144A under the Securities Act of 1933, as amended. These securities may be resold in transactions exempt from registration to qualified institutional investors.

^(h)  Affiliate of the Trust.

⁽ⁱ⁾  Annualized 7-day yield as of period end.

^(j)  All or a portion of this security was purchased with the cash collateral from loaned securities.

For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

Affiliates

Investments in issuers considered to be affiliate(s) of the Trust during the six months ended June 30, 2023 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

Affiliated Issuer	Value at 12/31/22		Purchases at Cost			Proceeds from Sales		Net Realized Gain (Loss)			Change in Unrealized Appreciation (Depreciation)			Value at 06/30/23		Shares Held at 06/30/23		Income			Capital Gain Distributions from Underlying Funds
BlackRock Liquidity Funds, T-Fund, Institutional Class	$	20,778,628	$	2,010,744	(a)	$	—	$	—		$	—		$	22,789,372		22,789,372	$	254,336		$	—
SL Liquidity Series, LLC, Money Market Series		184,600		20,612,476	(a)		—		(4,346	)		(563	)		20,792,167		20,792,167		38,615	(b)		—
								$	(4,346	)	$	(563	)	$	43,581,539			$	292,951		$	—

^(a)  Represents net amount purchased (sold).

^(b)  All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities.

Derivative Financial Instruments Outstanding as of Period End

Exchange-Traded Options Written

Description	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call
Ambarella, Inc.		218		07/07/23		USD	76.00		USD	1,824	$	(178,760	)
Bill Holding, Inc.		184		07/07/23		USD	101.00		USD	2,150		(299,000	)
Etsy, Inc.		110		07/07/23		USD	91.00		USD	931		(2,365	)
Match Group, Inc.		301		07/07/23		USD	37.00		USD	1,260		(147,490	)
MongoDB, Inc.		47		07/07/23		USD	420.00		USD	1,932		(21,503	)
Penn Entertainment, Inc.		136		07/07/23		USD	28.00		USD	327		(272	)
Domino’s Pizza, Inc.		18		07/14/23		USD	310.00		USD	607		(50,130	)
Match Group, Inc.		700		07/14/23		USD	41.00		USD	2,930		(117,950	)
Zscaler, Inc.		180		07/14/23		USD	145.00		USD	2,633		(90,900	)
Aspen Technology, Inc.		59		07/21/23		USD	185.00		USD	989		(14,308	)
Axon Enterprise, Inc.		259		07/21/23		USD	210.00		USD	5,054		(23,958	)
AZEK Co., Inc.		617		07/21/23		USD	25.00		USD	1,869		(336,265	)
Azenta, Inc.		396		07/21/23		USD	45.00		USD	1,849		(99,000	)
Bio-Techne Corp.		259		07/21/23		USD	85.00		USD	2,114		(21,368	)

86 2 0 2 3   B L A C K R O C K  S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Schedule of Investments (unaudited) (continued) June 30, 2023      BlackRock Innovation and Growth Term Trust (BIGZ)

Exchange-Traded Options Written (continued)

Description	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call (continued)
Chart Industries, Inc.		54		07/21/23		USD	125.50		USD	863	$	(188,532	)
Chart Industries, Inc.		40		07/21/23		USD	150.00		USD	639		(50,000	)
Comfort Systems USA, Inc.		141		07/21/23		USD	160.00		USD	2,315		(83,190	)
Confluent, Inc., Class A		617		07/21/23		USD	27.00		USD	2,179		(524,450	)
Confluent, Inc., Class A		305		07/21/23		USD	28.00		USD	1,077		(227,225	)
DigitalOcean Holdings, Inc.		228		07/21/23		USD	35.80		USD	915		(110,173	)
Doximity, Inc., Class A		326		07/21/23		USD	33.91		USD	1,109		(40,054	)
Duolingo, Inc.		184		07/21/23		USD	150.00		USD	2,630		(58,420	)
Entegris, Inc.		600		07/21/23		USD	93.00		USD	6,649		(1,100,353	)
Figs, Inc., Class A		1,700		07/21/23		USD	8.45		USD	1,406		(68,770	)
Fiverr International Ltd.		350		07/21/23		USD	35.00		USD	910		(2,625	)
Fox Factory Holding Corp.		194		07/21/23		USD	105.50		USD	2,105		(95,950	)
Freshpet, Inc.		72		07/21/23		USD	70.00		USD	474		(7,200	)
Globant SA		134		07/21/23		USD	180.00		USD	2,408		(79,730	)
GXO Logistics, Inc.		307		07/21/23		USD	55.00		USD	1,929		(239,460	)
GXO Logistics, Inc.		117		07/21/23		USD	60.00		USD	735		(41,535	)
GXO Logistics, Inc.		423		07/21/23		USD	65.00		USD	2,657		(34,897	)
Halozyme Therapeutics, Inc.		373		07/21/23		USD	34.89		USD	1,345		(80,212	)
HEICO Corp.		231		07/21/23		USD	180.00		USD	4,087		(38,115	)
Inmode Ltd.		238		07/21/23		USD	40.00		USD	889		(11,305	)
Innovative Industrial Properties, Inc.		54		07/21/23		USD	75.00		USD	394		(7,155	)
Inspire Medical Systems, Inc.		66		07/21/23		USD	310.00		USD	2,143		(132,990	)
Insulet Corp.		50		07/21/23		USD	330.00		USD	1,442		(1,875	)
JFrog Ltd.		264		07/21/23		USD	25.00		USD	731		(70,620	)
JFrog Ltd.		470		07/21/23		USD	27.33		USD	1,302		(68,859	)
MarketAxess Holdings, Inc.		55		07/21/23		USD	310.00		USD	1,438		(26,400	)
Monolithic Power Systems, Inc.		98		07/21/23		USD	431.00		USD	5,294		(1,087,435	)
Olink Holding AB, ADR		52		07/21/23		USD	25.00		USD	98		(26,000	)
Paylocity Holding Corp.		130		07/21/23		USD	200.00		USD	2,399		(18,200	)
Phreesia, Inc.		226		07/21/23		USD	35.00		USD	701		(22,600	)
Planet Fitness, Inc., Class A		600		07/21/23		USD	72.50		USD	4,046		(18,000	)
Repligen Corp.		60		07/21/23		USD	170.00		USD	849		(18,000	)
Rexford Industrial Realty, Inc.		70		07/21/23		USD	55.00		USD	366		(3,150	)
Saia, Inc.		150		07/21/23		USD	300.00		USD	5,136		(673,500	)
Surgery Partners, Inc.		525		07/21/23		USD	45.00		USD	2,362		(90,562	)
TPG, Inc.		661		07/21/23		USD	29.00		USD	1,934		(76,788	)
Tradeweb Markets, Inc., Class A		428		07/21/23		USD	75.00		USD	2,931		(12,840	)
West Pharmaceutical Services, Inc.		104		07/21/23		USD	360.00		USD	3,978		(260,000	)
Lattice Semiconductor Corp.		85		07/27/23		USD	91.00		USD	817		(64,270	)
Ambarella, Inc.		55		07/28/23		USD	93.00		USD	460		(8,525	)
Bill Holding, Inc.		92		07/28/23		USD	125.00		USD	1,075		(33,120	)
Domino’s Pizza, Inc.		13		07/28/23		USD	320.00		USD	438		(30,420	)
Match Group, Inc.		270		07/28/23		USD	43.00		USD	1,130		(36,315	)
Match Group, Inc.		507		07/28/23		USD	46.00		USD	2,122		(28,899	)
MongoDB, Inc.		120		07/28/23		USD	380.00		USD	4,932		(481,800	)
Penn Entertainment, Inc.		136		07/28/23		USD	27.00		USD	327		(2,312	)
Axon Enterprise, Inc.		259		08/04/23		USD	211.00		USD	5,054		(74,001	)
Tradeweb Markets, Inc., Class A		430		08/09/23		USD	75.00		USD	2,945		(27,637	)
SolarEdge Technologies, Inc.		38		08/11/23		USD	290.00		USD	1,022		(43,700	)
10X Genomics, Inc., Class A		140		08/18/23		USD	70.00		USD	782		(11,550	)
Ambarella, Inc.		159		08/18/23		USD	87.50		USD	1,330		(52,470	)
Aspen Technology, Inc.		198		08/18/23		USD	172.00		USD	3,319		(85,088	)
AZEK Co., Inc.		543		08/18/23		USD	30.00		USD	1,645		(104,527	)
Azenta, Inc.		100		08/18/23		USD	50.00		USD	467		(18,250	)
Bio-Techne Corp.		559		08/18/23		USD	80.50		USD	4,563		(245,209	)
Certara, Inc.		385		08/18/23		USD	20.00		USD	701		(97,212	)
Charles River Laboratories International, Inc.		204		08/18/23		USD	210.00		USD	4,289		(240,720	)
Chart Industries, Inc.		95		08/18/23		USD	155.00		USD	1,518		(138,225	)
Comfort Systems USA, Inc.		191		08/18/23		USD	165.00		USD	3,136		(122,240	)
Confluent, Inc., Class A		580		08/18/23		USD	33.00		USD	2,048		(272,600	)
Confluent, Inc., Class A		400		08/18/23		USD	36.00		USD	1,412		(97,885	)
DigitalOcean Holdings, Inc.		424		08/18/23		USD	45.00		USD	1,702		(72,080	)

S C H E D U L E    O F   I N V E S T M E N T S 87

Schedule of Investments (unaudited) (continued) June 30, 2023      BlackRock Innovation and Growth Term Trust (BIGZ)

Exchange-Traded Options Written (continued)

Description	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call (continued)
Doximity, Inc., Class A		326		08/18/23		USD	35.00		USD	1,109	$	(65,200	)
Duolingo, Inc.		200		08/18/23		USD	160.00		USD	2,859		(122,000	)
Entegris, Inc.		479		08/18/23		USD	125.00		USD	5,308		(93,405	)
Figs, Inc., Class A		1,500		08/18/23		USD	8.55		USD	1,241		(113,377	)
Five9, Inc.		260		08/18/23		USD	80.00		USD	2,144		(204,100	)
Fiverr International Ltd.		221		08/18/23		USD	32.00		USD	575		(11,077	)
Fox Factory Holding Corp.		313		08/18/23		USD	96.50		USD	3,396		(437,245	)
Freshpet, Inc.		72		08/18/23		USD	75.00		USD	474		(10,800	)
Globant SA		220		08/18/23		USD	200.00		USD	3,954		(74,800	)
Halozyme Therapeutics, Inc.		603		08/18/23		USD	35.73		USD	2,175		(148,062	)
HEICO Corp.		200		08/18/23		USD	170.00		USD	3,539		(204,000	)
HubSpot, Inc.		64		08/18/23		USD	530.00		USD	3,405		(223,040	)
Inspire Medical Systems, Inc.		110		08/18/23		USD	340.00		USD	3,571		(136,950	)
Insulet Corp.		75		08/18/23		USD	299.00		USD	2,163		(73,260	)
Lattice Semiconductor Corp.		108		08/18/23		USD	95.00		USD	1,038		(79,920	)
MarketAxess Holdings, Inc.		71		08/18/23		USD	290.00		USD	1,856		(19,880	)
MongoDB, Inc.		18		08/18/23		USD	390.00		USD	740		(72,990	)
Monolithic Power Systems, Inc.		101		08/18/23		USD	530.00		USD	5,456		(429,755	)
Olink Holding AB, ADR		53		08/18/23		USD	22.50		USD	99		(26,500	)
PagerDuty, Inc.		534		08/18/23		USD	25.00		USD	1,200		(25,365	)
Planet Fitness, Inc., Class A		400		08/18/23		USD	72.50		USD	2,698		(65,000	)
Repligen Corp.		357		08/18/23		USD	175.00		USD	5,050		(106,207	)
Rexford Industrial Realty, Inc.		71		08/18/23		USD	53.42		USD	371		(12,107	)
Saia, Inc.		151		08/18/23		USD	313.50		USD	5,170		(615,917	)
Surgery Partners, Inc.		525		08/18/23		USD	45.00		USD	2,362		(165,375	)
TPG, Inc.		400		08/18/23		USD	32.50		USD	1,170		(24,000	)
Tradeweb Markets, Inc., Class A		429		08/18/23		USD	75.00		USD	2,938		(98,670	)
West Pharmaceutical Services, Inc.		105		08/18/23		USD	380.00		USD	4,016		(181,125	)
Zscaler, Inc.		162		08/18/23		USD	155.00		USD	2,370		(89,910	)
HubSpot, Inc.		77		09/15/23		USD	520.00		USD	4,097		(374,220	)
											$	(13,793,751	)

OTC Options Written

Description	Counterparty	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call
Bentley Systems, Inc., Class B	Goldman Sachs International		50,000		07/06/23		USD	45.44		USD	2,712		$  (441,672	)
AutoStore Holdings Ltd.	Morgan Stanley & Co. International PLC		267,000		07/11/23		NOK	22.86		NOK	6,273		(24,415	)
Kahoot! ASA	Goldman Sachs International		110,800		07/11/23		NOK	24.63		NOK	3,244		(48,613	)
Lattice Semiconductor Corp.	Citibank N.A.		8,800		07/11/23		USD	85.77		USD	845		(93,336	)
SiteMinder Ltd.	UBS AG		25,000		07/12/23		AUD	3.34		AUD	73		(161	)
AutoStore Holdings Ltd.	Goldman Sachs International		250,000		07/13/23		NOK	24.56		NOK	5,874		(7,950	)
Kahoot! ASA	Morgan Stanley & Co. International PLC		285,000		07/19/23		NOK	25.63		NOK	8,344		(103,526	)
Certara, Inc.	Citibank N.A.		25,000		07/24/23		USD	22.31		USD	455		(10,701	)
AutoStore Holdings Ltd.	Morgan Stanley & Co. International PLC		250,000		07/26/23		NOK	24.58		NOK	5,874		(14,730	)
SiteMinder Ltd.	Citibank N.A.		25,000		07/26/23		AUD	3.22		AUD	73		(987	)
Confluent, Inc., Class A	Morgan Stanley & Co. International PLC		20,700		07/31/23		USD	38.53		USD	731		(20,827	)
Lattice Semiconductor Corp.	Citibank N.A.		56,000		07/31/23		USD	95.73		USD	5,380		(291,428	)
AutoStore Holdings Ltd.	Morgan Stanley & Co. International PLC		250,000		08/01/23		NOK	26.95		NOK	5,874		(6,401	)
SiteMinder Ltd.	Citibank N.A.		36,200		08/02/23		AUD	3.33		AUD	106		(1,312	)
AutoStore Holdings Ltd.	Goldman Sachs International		250,900		08/10/23		NOK	26.77		NOK	5,895		(9,432	)
Kahoot! ASA	UBS AG		351,000		08/10/23		NOK	32.56		NOK	10,276		(27,052	)
Evolution AB	UBS AG		48,100		08/11/23		SEK	1,417.50		SEK	65,741		(152,597	)
Bentley Systems, Inc., Class B	Goldman Sachs International		75,000		08/14/23		USD	53.45		USD	4,067		(223,314	)
Phreesia, Inc.	Citibank N.A.		44,400		08/14/23		USD	31.25		USD	1,377		(99,625	)
AutoStore Holdings Ltd.	Barclays Bank PLC		250,900		08/16/23		NOK	26.04		NOK	5,895		(14,336	)
JFrog Ltd.	Bank of America N.A.		62,200		08/22/23		USD	27.91		USD	1,723		(117,962	)

88 2 0 2 3   B L A C K R O C K  S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Schedule of Investments  (unaudited) (continued) June 30, 2023      BlackRock Innovation and Growth Term Trust (BIGZ)

OTC Options Written (continued)

Description	Counterparty		Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call (continued)
ASM International NV		Barclays Bank PLC		4,000		08/24/23		EUR	414.85		EUR	1,556	$	(52,569	)
TPG, Inc.		BNP Paribas SA		40,000		09/08/23		USD	29.71		USD	1,170		(69,989	)
													$	(1,832,935	)

Balances Reported in the Statements of Assets and Liabilities for Options Written

Description	Swap Premiums Paid		Swap Premiums Received		Unrealized Appreciation		Unrealized Depreciation			Value
Options Written	$	N/A	$	N/A	$	1,928,768	$	(6,881,742	)		$ (15,626,686)

Derivative Financial Instruments Categorized by Risk Exposure

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

	Commodity Contracts		Credit Contracts		Equity Contracts		Foreign Currency Exchange Contracts		Interest Rate Contracts		Other Contracts		Total
Liabilities — Derivative Financial Instruments
Options written
Options written at value	$	—	$	—	$	15,626,686	$	—	$	—	$	—	$	15,626,686

For the period ended June 30, 2023, the effect of derivative financial instruments in the Statements of Operations was as follows:

	Commodity Contracts		Credit Contracts		Equity Contracts			Foreign Currency Exchange Contracts		Interest Rate Contracts		Other Contracts		Total
Net Realized Gain (Loss) from:
Options purchased(a)	$	—	$	—	$	(1,549,151	)	$	—	$	—	$	—	$	(1,549,151	)
Options written		—		—		1,213,830			—		—		—		1,213,830
	$	—	$	—	$	(335,321	)	$	—	$	—	$	—	$	(335,321	)
Net Change in Unrealized Appreciation (Depreciation) on:
Options written	$	—	$	—	$	(10,524,710	)	$	—	$	—	$	—	$	(10,524,710	)

^(a)  Options purchased are included in net realized gain (loss) from investments — unaffiliated.

Average Quarterly Balances of Outstanding Derivative Financial Instruments

Options:
Average value of option contracts purchased	$	—	(a)
Average value of option contracts written	$	14,252,452

^(a)  Derivative not held at any quarter-end. The risk exposure table serves as an indicator of activity during the period.

For more information about the Trust’s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.

S C H E D U L E    O F   I N V E S T M E N T S 89

Schedule of Investments  (unaudited) (continued) June 30, 2023      BlackRock Innovation and Growth Term Trust (BIGZ)

Derivative Financial Instruments — Offsetting as of Period End

The Trust’s derivative assets and liabilities (by type) were as follows:

	Assets		Liabilities
Derivative Financial Instruments Options	$	—	$	15,626,686
Total derivative assets and liabilities in the Statements of Assets and Liabilities		—		15,626,686
Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”)		—		(13,793,751	)
Total derivative assets and liabilities subject to an MNA	$	—	$	1,832,935

The following table presents the Trust’s derivative liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral pledged by the Trust:

Counterparty		Derivative Liabilities Subject to an MNA by Counterparty		Derivatives Available for Offset		Non-Cash Collateral Pledged	(a)		Cash Collateral Pledged		Net Amount of Derivative Liabilities	(b)
Bank of America N.A.	$	117,962	$	—	$	—		$	—	$	117,962
Barclays Bank PLC		66,905		—		—			—		66,905
BNP Paribas SA		69,989		—		—			—		69,989
Citibank N.A.		497,389		—		(497,389	)		—		—
Goldman Sachs International		730,981		—		(730,981	)		—		—
Morgan Stanley & Co. International PLC		169,899		—		(169,899	)		—		—
UBS AG		179,810		—		—			—		179,810
	$	1,832,935	$	—	$	(1,398,269	)	$	—	$	434,666

^(a)  Excess of collateral received/pledged, if any, from the individual counterparty is not shown for financial reporting purposes.

^(b)  Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.

Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of financial instruments. For a description of the input levels and information about the Trust’s policy regarding valuation of financial instruments, refer to the Notes to Financial Statements.

The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust’s financial instruments into major categories is disclosed in the Schedule of Investments above.

	Level 1		Level 2		Level 3		Total
Assets
Investments
Long-Term Investments
Common Stocks
Aerospace & Defense	$	110,935,806	$	—	$	—	$	110,935,806
Air Freight & Logistics		33,272,048		—		—		33,272,048
Automobile Components		34,420,349		—		—		34,420,349
Biotechnology		22,009,229		—		—		22,009,229
Broadline Retail		5,788,001		—		—		5,788,001
Building Products		21,977,425		—		—		21,977,425
Capital Markets		102,466,690		—		—		102,466,690
Construction & Engineering		34,120,596		—		—		34,120,596
Diversified Consumer Services		33,919,948		—		49,645,358		83,565,306
Entertainment		—		12,729,395		—		12,729,395
Food Products		5,938,036		—		—		5,938,036
Ground Transportation		60,222,386		—		—		60,222,386
Health Care Equipment & Supplies		64,147,475		—		—		64,147,475
Health Care Providers & Services		29,506,197		—		—		29,506,197
Health Care Technology		34,106,755		—		—		34,106,755
Hotels, Restaurants & Leisure		52,781,215		38,054,766		—		90,835,981
Industrial REITs		7,075,906		—		—		7,075,906
Interactive Media & Services		43,355,386		—		5,435,408		48,790,794
IT Services		103,872,408		—		17,073,897		120,946,305

90 2 0 2 3   B L A C K R O C K  S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Schedule of Investments  (unaudited) (continued) June 30, 2023      BlackRock Innovation and Growth Term Trust (BIGZ)

Fair Value Hierarchy as of Period End (continued)

	Level 1			Level 2			Level 3		Total
Common Stocks (continued)
Life Sciences Tools & Services	$	175,824,056		$	—		$	—	$	175,824,056
Machinery		18,883,024			20,779,611			—		39,662,635
Personal Care Products		1,867,740			—			—		1,867,740
Professional Services		24,103,562			—			—		24,103,562
Semiconductors & Semiconductor Equipment		195,020,945			10,348,453			—		205,369,398
Software		252,373,421			16,612,241			23,006,391		291,992,053
Textiles, Apparel & Luxury Goods		16,541,786			—			—		16,541,786
Preferred Securities
Preferred Stocks		—			—			464,582,157		464,582,157
Short-Term Securities
Money Market Funds		22,789,372			—			—		22,789,372
	$	1,507,319,762		$	98,524,466		$	559,743,211		2,165,587,439
Investments Valued at NAV(a)										20,792,167
									$	2,186,379,606
Derivative Financial Instruments(b)
Liabilities
Equity Contracts	$	(8,871,490	)	$	(6,755,196	)	$	—	$	(15,626,686	)

^(a)  Certain investments of the Trust were fair valued using NAV as a practical expedient as no quoted market value is available and therefore have been excluded from the fair value hierarchy.

^(b)  Derivative financial instruments are options written. Options written are shown at value.

A reconciliation of Level 3 financial instruments is presented when the Trust had a significant amount of Level 3 investments and derivative financial instruments at the beginning and/or end of the period in relation to net assets. The following table is a reconciliation of Level 3 investments for which significant unobservable inputs were used in determining fair value:

	Common     Stocks			Preferred     Stocks			Total
Assets
Opening balance, as of December 31, 2022	$	102,169,910		$	471,282,347		$	573,452,257
Transfers into Level 3		—			—			—
Transfers out of Level 3		—			—			—
Accrued discounts/premiums		—			—			—
Net realized gain (loss)		—			—			—
Net change in unrealized appreciation (depreciation)(a)(b)		(7,008,856	)		(6,700,190	)		(13,709,046	)
Purchases		—			—			—
Sales		—			—			—
Closing balance, as of June 30, 2023	$	95,161,054		$	464,582,157		$	559,743,211
Net change in unrealized appreciation (depreciation) on investments still held at June 30, 2023(b)	$	(7,008,856	)	$	(6,700,190	)	$	(13,709,046	)

^(a)  Included in the related net change in unrealized appreciation (depreciation) in the Statements of Operations.

^(b)  Any difference between net change in unrealized appreciation (depreciation) and net change in unrealized appreciation (depreciation) on investments still held at June 30, 2023 is generally due to investments no longer held or categorized as Level 3 at period end.

S C H E D U L E    O F   I N V E S T M E N T S 91

Schedule of Investments  (unaudited) (continued) June 30, 2023      BlackRock Innovation and Growth Term Trust (BIGZ)

The following table summarizes the valuation approaches used and unobservable inputs utilized by the BlackRock Valuation Committee (the “Valuation Committee”) to determine the value of certain of the Trust’s Level 3 financial instruments as of period end.

	Value		Valuation Approach		Unobservable Inputs		Range of    Unobservable    Inputs    Utilized(a)		Weighted Average of Unobservable Inputs Based on Fair Value
Assets
Common Stocks	$	95,161,054		Market		Revenue Multiple		2.30x - 25.09x		11.48x
						Gross Profit Multiple		18.00x		—
Preferred Stocks		464,582,157		Market		Revenue Multiple		1.05x - 25.09x		9.53x
						Time to Exit		1.0 ‑ 5.0 years		3.1 years
						Volatility		45% - 100%		68%
						Market Adjustment Multiple		0.80x - 1.10x		0.95x
	$	559,743,211

^(a)  A significant change in unobservable input would have resulted in a correlated (inverse) significant change to value.

See notes to financial statements.

92 2 0 2 3   B L A C K R O C K  S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Schedule of Investments  (unaudited) June 30, 2023      BlackRock Resources & Commodities Strategy Trust (BCX) (Percentages shown are based on Net Assets)

Security	Shares		Value
Common Stocks
Chemicals(a) — 9.9%
Albemarle Corp.		82,387	$	18,379,716
CF Industries Holdings, Inc.		330,113		22,916,444
FMC Corp.		164,846		17,200,032
Nutrien Ltd.		341,937		20,191,380
Sociedad Quimica y Minera de Chile SA, ADR		159,969		11,616,949
				90,304,521
Containers & Packaging — 1.1%
Packaging Corp. of America(a)		31,281		4,134,097
Smurfit Kappa Group PLC		182,189		6,080,572
				10,214,669
Energy Equipment & Services — 1.2%
Schlumberger NV(a)		221,279		10,869,225
Food Products — 6.8%
Archer-Daniels-Midland Co.(a)		264,359		19,974,966
Bunge Ltd.(a)		180,149		16,997,058
Darling Ingredients, Inc.(a)(b)		125,274		7,991,228
Hofseth International, (Acquired 05/26/21, Cost: $10,198,057)(c)(d)		18,993,283		7,662,007
Kerry Group PLC, Class A		99,575		9,718,826
				62,344,085
Machinery(a) — 5.2%
AGCO Corp.(e)		171,009		22,473,992
Deere & Co.		62,048		25,141,229
				47,615,221
Metals & Mining — 33.7%
Alcoa Corp.(a)		218,238		7,404,815
Anglo American PLC		79,302		2,258,004
ArcelorMittal SA, Registered Shares(a)		363,884		9,948,589
Barrick Gold Corp.(a)		237,052		4,013,290
BHP Group Ltd., ADR(a)		669,209		39,931,701
Filo Corp.		110,335		2,149,648
Filo Mining		175,560		3,319,709
First Quantum Minerals Ltd.		765,284		18,104,549
Franco-Nevada Corp.(a)		80,287		11,448,926
Freeport-McMoRan, Inc.(a)(e)		237,961		9,518,440
Glencore PLC		8,912,751		50,534,208
Newmont Corp.(a)		420,482		17,937,762
Norsk Hydro ASA		2,792,496		16,646,796
Polyus PJSC(b)(c)		104,732		21
Stelco Holdings, Inc.		435,274		14,200,825
Teck Resources Ltd., Class B(a)		806,513		33,954,197
Vale SA, ADR(a)		2,448,198		32,854,817
Wheaton Precious Metals Corp.(f)		765,463		33,083,311
				307,309,608
Oil, Gas & Consumable Fuels — 37.5%
BP PLC		8,195,494		47,717,233
Canadian Natural Resources Ltd.		366,839		20,624,396
Cenovus Energy, Inc.		560,932		9,527,058

Security	Shares		Value
Oil, Gas & Consumable Fuels (continued)
Cheniere Energy, Inc.(a)		96,050	$	14,634,178
Chevron Corp.(a)		83,772		13,181,524
ConocoPhillips(a)		242,611		25,136,926
Eni SpA		988,891		14,236,457
EOG Resources, Inc.(a)		95,521		10,931,423
Exxon Mobil Corp.(a)		541,991		58,128,535
Gazprom PJSC(c)		5,430,000		606
Hess Corp.(a)		60,404		8,211,924
Shell PLC, ADR(a)		1,161,523		70,132,768
TotalEnergies SE		847,349		48,641,749
				341,104,777
Paper & Forest Products — 1.1%
Precious Woods Holding AG, Registered Shares(b)		20,000		189,933
UPM-Kymmene OYJ		323,144		9,628,663
				9,818,596
Total Long-Term Investments — 96.5% (Cost: $763,798,215)				879,580,702
Short-Term Securities
Money Market Funds — 4.7%
BlackRock Liquidity Funds, T-Fund, Institutional Class, 4.98%(g)(h)		35,301,139		35,301,139
SL Liquidity Series, LLC, Money Market Series, 5.28%(g)(h)(i)		7,296,133		7,296,133
Total Short-Term Securities — 4.7% (Cost: $42,597,889)				42,597,272
Total Investments Before Options Written — 101.2% (Cost: $806,396,104)				922,177,974
Options Written — (0.6)% (Premiums Received: $(7,646,569))				(5,496,164	)
Total Investments, Net of Options Written — 100.6% (Cost: $798,749,535)				916,681,810
Liabilities in Excess of Other Assets — (0.6)%				(5,889,096	)
Net Assets — 100.0%			$	910,792,714

^(a)  All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.

^(b)  Non-income producing security.

^(c)  Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy.

^(d)  Restricted security as to resale, excluding 144A securities. The Trust held restricted securities with a current value of $7,662,007, representing 0.8% of its net assets as of period end, and an original cost of $10,198,057.

^(e)  All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives.

^(f)  All or a portion of this security is on loan.

^(g)  Affiliate of the Trust.

^(h)  Annualized 7-day yield as of period end.

⁽ⁱ⁾  All or a portion of this security was purchased with the cash collateral from loaned securities.

For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

S C H E D U L E   O F   I N V E S T M E N T S 93

Schedule of Investments  (unaudited)  (continued) June 30, 2023      BlackRock Resources & Commodities Strategy Trust (BCX)

Affiliates

Investments in issuers considered to be affiliate(s) of the Trust during the six months ended June 30, 2023 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

Affiliated Issuer	Value at 12/31/22		Purchases at Cost			Proceeds from Sales		Net Realized Gain (Loss)		Change in Unrealized Appreciation (Depreciation)			Value at 06/30/23		Shares Held at 06/30/23		Income			Capital Gain Distributions from Underlying Funds
BlackRock Liquidity Funds, T-Fund, Institutional Class	$	19,404,102	$	15,897,037	(a)	$	—	$	—	$	—		$	35,301,139		35,301,139	$	704,650		$	—
SL Liquidity Series, LLC, Money Market Series		—		7,293,782	(a)		—		2,968		(617	)		7,296,133		7,296,133		11,156	(b)		—
								$	2,968	$	(617	)	$	42,597,272			$	715,806		$	—

^(a)  Represents net amount purchased (sold).

^(b)  All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities.

Derivative Financial Instruments Outstanding as of Period End

Exchange-Traded Options Written

Description	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call
Alcoa Corp.		143		07/07/23		USD	35.00		USD	485	$	(3,361	)
Archer-Daniels-Midland Co.		272		07/07/23		USD	74.00		USD	2,055		(48,960	)
CF Industries Holdings, Inc.		463		07/07/23		USD	65.00		USD	3,214		(210,665	)
ConocoPhillips		27		07/07/23		USD	102.00		USD	280		(6,075	)
Exxon Mobil Corp.		430		07/07/23		USD	111.62		USD	4,612		(4,346	)
Hess Corp.		95		07/07/23		USD	133.00		USD	1,292		(35,625	)
Newmont Corp.		415		07/07/23		USD	42.00		USD	1,770		(40,255	)
Shell PLC, ADR		1,093		07/07/23		USD	58.00		USD	6,600		(270,517	)
Vale SA, ADR		1,241		07/07/23		USD	13.50		USD	1,665		(22,338	)
Albemarle Corp.		108		07/14/23		USD	220.00		USD	2,409		(80,460	)
Alcoa Corp.		281		07/14/23		USD	38.00		USD	953		(2,529	)
ArcelorMittal SA, Registered Shares		541		07/14/23		USD	29.00		USD	1,479		(5,410	)
Archer-Daniels-Midland Co.		269		07/14/23		USD	74.00		USD	2,033		(57,162	)
Cheniere Energy, Inc.		128		07/14/23		USD	150.00		USD	1,950		(51,200	)
Chevron Corp.		221		07/14/23		USD	160.00		USD	3,477		(24,200	)
ConocoPhillips		574		07/14/23		USD	108.00		USD	5,947		(26,691	)
Exxon Mobil Corp.		693		07/14/23		USD	112.00		USD	7,432		(19,404	)
Hess Corp.		42		07/14/23		USD	139.00		USD	571		(6,720	)
Newmont Corp.		570		07/14/23		USD	43.00		USD	2,432		(41,895	)
Schlumberger NV		237		07/14/23		USD	50.00		USD	1,164		(17,894	)
Shell PLC, ADR		1,153		07/14/23		USD	60.00		USD	6,962		(129,712	)
Teck Resources Ltd., Class B		778		07/14/23		USD	46.00		USD	3,275		(11,281	)
Vale SA, ADR		1,510		07/14/23		USD	14.00		USD	2,026		(19,630	)
AGCO Corp.		296		07/21/23		USD	124.00		USD	3,890		(284,083	)
Alcoa Corp.		192		07/21/23		USD	40.50		USD	651		(3,062	)
Archer-Daniels-Midland Co.		211		07/21/23		USD	77.50		USD	1,594		(12,660	)
BHP Group Ltd., ADR		765		07/21/23		USD	61.50		USD	4,565		(54,993	)
Bunge Ltd.		333		07/21/23		USD	95.00		USD	3,142		(71,595	)
Canadian Natural Resources Ltd.		1,051		07/21/23		CAD	78.00		CAD	7,828		(33,321	)
Cenovus Energy, Inc.		611		07/21/23		CAD	22.50		CAD	1,375		(30,440	)
CF Industries Holdings, Inc.		295		07/21/23		USD	70.00		USD	2,048		(58,262	)
Cheniere Energy, Inc.		227		07/21/23		USD	150.00		USD	3,459		(110,095	)
Darling Ingredients, Inc.		264		07/21/23		USD	65.00		USD	1,684		(34,980	)
EOG Resources, Inc.		158		07/21/23		USD	117.50		USD	1,808		(22,120	)
Exxon Mobil Corp.		44		07/21/23		USD	115.00		USD	472		(836	)
FMC Corp.		304		07/21/23		USD	110.00		USD	3,172		(9,120	)
Franco-Nevada Corp.		149		07/21/23		USD	160.00		USD	2,125		(1,863	)
Packaging Corp. of America		57		07/21/23		USD	135.00		USD	753		(7,268	)
Sociedad Quimica y Minera de Chile SA, ADR		295		07/21/23		USD	80.00		USD	2,142		(5,900	)
Stelco Holdings, Inc.		415		07/21/23		CAD	48.00		CAD	1,794		(4,856	)
Teck Resources Ltd., Class B		740		07/21/23		USD	45.00		USD	3,115		(30,710	)

94 2 0 2 3   B L A C K R O C K  S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Schedule of Investments  (unaudited)  (continued) June 30, 2023      BlackRock Resources & Commodities Strategy Trust (BCX)     

Exchange-Traded Options Written (continued)

Description	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call (continued)
Vale SA, ADR		654		07/21/23		USD	14.00		USD	878	$	(15,042	)
Vale SA, ADR		653		07/21/23		USD	15.00		USD	876		(4,245	)
Albemarle Corp.		88		07/28/23		USD	235.00		USD	1,963		(36,960	)
ArcelorMittal SA, Registered Shares		542		07/28/23		USD	29.00		USD	1,482		(17,615	)
Archer-Daniels-Midland Co.		226		07/28/23		USD	75.00		USD	1,708		(53,675	)
Barrick Gold Corp.		439		07/28/23		USD	18.00		USD	743		(6,805	)
Chevron Corp.		93		07/28/23		USD	160.00		USD	1,463		(24,645	)
ConocoPhillips		188		07/28/23		USD	104.00		USD	1,948		(52,640	)
EOG Resources, Inc.		195		07/28/23		USD	113.00		USD	2,232		(78,000	)
Exxon Mobil Corp.		257		07/28/23		USD	108.00		USD	2,756		(63,607	)
Freeport-McMoRan, Inc.		880		07/28/23		USD	42.00		USD	3,520		(73,480	)
Hess Corp.		88		07/28/23		USD	141.00		USD	1,196		(22,220	)
Newmont Corp.		570		07/28/23		USD	43.00		USD	2,432		(75,525	)
Nutrien Ltd.		363		07/28/23		USD	63.00		USD	2,144		(20,873	)
Shell PLC, ADR		1,092		07/28/23		USD	63.00		USD	6,593		(51,870	)
Teck Resources Ltd., Class B		534		07/28/23		USD	46.00		USD	2,248		(29,637	)
Vale SA, ADR		1,000		07/28/23		USD	15.00		USD	1,342		(12,000	)
Vale SA, ADR		570		07/28/23		USD	14.50		USD	765		(10,545	)
Alcoa Corp.		191		08/04/23		USD	36.00		USD	648		(21,774	)
ArcelorMittal SA, Registered Shares		263		08/04/23		USD	29.00		USD	719		(10,520	)
Barrick Gold Corp.		438		08/04/23		USD	17.00		USD	742		(24,528	)
CF Industries Holdings, Inc.		463		08/04/23		USD	75.00		USD	3,214		(56,717	)
ConocoPhillips		133		08/04/23		USD	104.00		USD	1,378		(46,218	)
Deere & Co.		115		08/04/23		USD	410.00		USD	4,660		(106,950	)
Exxon Mobil Corp.		257		08/04/23		USD	109.00		USD	2,756		(61,680	)
Nutrien Ltd.		902		08/04/23		USD	61.00		USD	5,326		(153,340	)
Schlumberger NV		242		08/04/23		USD	50.00		USD	1,189		(41,140	)
Shell PLC, ADR		936		08/04/23		USD	61.00		USD	5,652		(131,040	)
Vale SA, ADR		1,715		08/04/23		USD	14.50		USD	2,302		(41,160	)
Albemarle Corp.		108		08/11/23		USD	220.00		USD	2,409		(153,360	)
AGCO Corp.		176		08/18/23		USD	135.00		USD	2,313		(79,200	)
BHP Group Ltd., ADR		956		08/18/23		USD	62.50		USD	5,704		(109,940	)
Bunge Ltd.		333		08/18/23		USD	100.00		USD	3,142		(57,442	)
Canadian Natural Resources Ltd.		324		08/18/23		CAD	76.00		CAD	2,413		(54,907	)
Cenovus Energy, Inc.		1,464		08/18/23		CAD	23.00		CAD	3,294		(108,301	)
Darling Ingredients, Inc.		199		08/18/23		USD	64.75		USD	1,269		(62,289	)
Deere & Co.		57		08/18/23		USD	420.00		USD	2,310		(56,430	)
Deere & Co.		58		08/18/23		USD	410.00		USD	2,350		(83,230	)
Exxon Mobil Corp.		393		08/18/23		USD	110.00		USD	4,215		(95,499	)
FMC Corp.		305		08/18/23		USD	112.00		USD	3,182		(19,789	)
Franco-Nevada Corp.		148		08/18/23		USD	152.00		USD	2,110		(24,608	)
Schlumberger NV		339		08/18/23		USD	50.00		USD	1,665		(71,359	)
Sociedad Quimica y Minera de Chile SA, ADR		295		08/18/23		USD	76.00		USD	2,142		(48,450	)
Stelco Holdings, Inc.		780		08/18/23		CAD	50.00		CAD	3,371		(26,201	)
Teck Resources Ltd., Class B		343		08/18/23		USD	45.00		USD	1,444		(44,076	)
Vale SA, ADR		1,715		08/18/23		USD	15.20		USD	2,302		(22,919	)
Packaging Corp. of America		58		09/15/23		USD	140.00		USD	767		(14,065	)
Stelco Holdings, Inc.		415		09/15/23		CAD	46.00		CAD	1,794		(55,761	)
Teck Resources Ltd., Class B		589		09/15/23		USD	46.00		USD	2,480		(89,822	)
											$	(4,534,593	)

OTC Options Written

Description	Counterparty	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call
BP PLC	Morgan Stanley & Co. International PLC		1,842,400		07/11/23		GBP	4.97		GBP	8,446	$	(1,942	)
Smurfit Kappa Group PLC	UBS AG		34,000		07/11/23		EUR	35.84		EUR	1,040		(91	)
TotalEnergies SE	Morgan Stanley & Co. International PLC		149,200		07/11/23		EUR	57.90		EUR	7,849		(588	)
TotalEnergies SE	UBS AG		54,800		07/11/23		EUR	58.79		EUR	2,883		(123	)
Glencore PLC	Barclays Bank PLC		1,657,735		07/12/23		GBP	4.50		GBP	7,401		(128,277	)

S C H E D U L E    O F   I N V E S T M E N T S 95

Schedule of Investments  (unaudited)  (continued) June 30, 2023      BlackRock Resources & Commodities Strategy Trust (BCX)

OTC Options Written (continued)

Description	Counterparty	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call (continued)
Kerry Group PLC, Class A	Morgan Stanley & Co. International PLC		36,800		07/13/23		EUR	94.06		EUR	3,292	$	(3,232	)
TotalEnergies SE	Barclays Bank PLC		105,000		07/13/23		EUR	54.14		EUR	5,524		(24,432	)
AGCO Corp.	JPMorgan Chase Bank N.A.		16,000		07/25/23		USD	123.49		USD	2,103		(165,867	)
BP PLC	Barclays Bank PLC		971,000		08/02/23		GBP	5.02		GBP	4,452		(19,953	)
Eni SpA	Goldman Sachs International		332,900		08/03/23		EUR	12.92		EUR	4,392		(172,665	)
UPM-Kymmene OYJ	Morgan Stanley & Co. International PLC		37,300		08/03/23		EUR	27.66		EUR	1,019		(28,190	)
Smurfit Kappa Group PLC	Morgan Stanley & Co. International PLC		33,500		08/10/23		EUR	33.95		EUR	1,025		(4,383	)
Eni SpA	JPMorgan Chase Bank N.A.		55,800		08/14/23		EUR	13.07		EUR	736		(27,367	)
Anglo American PLC	Morgan Stanley & Co. International PLC		29,400		08/16/23		GBP	24.45		GBP	659		(23,760	)
Glencore PLC	Bank of America N.A.		1,640,000		08/16/23		GBP	4.60		GBP	7,322		(246,333	)
UPM-Kymmene OYJ	Bank of America N.A.		82,300		08/16/23		EUR	28.19		EUR	2,247		(59,583	)
BHP Group Ltd., ADR	Morgan Stanley & Co. International PLC		75,500		09/01/23		USD	63.44		USD	4,505		(54,785	)
												$	(961,571	)

Balances Reported in the Statements of Assets and Liabilities for Options Written

Description	Swap Premiums Paid		Swap Premiums Received		Unrealized Appreciation		Unrealized Depreciation			Value
Options Written	$	N/A	$	N/A	$	3,105,586	$	(955,181	)	$	(5,496,164	)

Derivative Financial Instruments Categorized by Risk Exposure

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

	Commodity Contracts		Credit Contracts		Equity Contracts		Foreign Currency Exchange Contracts		Interest Rate Contracts		Other Contracts		Total
Liabilities — Derivative Financial Instruments
Options written
Options written at value	$	—	$	—	$	5,496,164	$	—	$	—	$	—	$	5,496,164

For the period ended June 30, 2023, the effect of derivative financial instruments in the Statements of Operations was as follows:

	Commodity Contracts		Credit Contracts		Equity Contracts			Foreign Currency Exchange Contracts		Interest Rate Contracts		Other Contracts		Total
Net Realized Gain (Loss) from:
Options purchased(a)	$	—	$	—	$	(1,777,915	)	$	—	$	—	$	—	$	(1,777,915	)
Options written		—		—		20,987,215			—		—		—		20,987,215
	$	—	$	—	$	19,209,300		$	—	$	—	$	—	$	19,209,300
Net Change in Unrealized Appreciation (Depreciation) on:
Options written	$	—	$	—	$	(1,324,185	)	$	—	$	—	$	—	$	(1,324,185	)

^(a)  Options purchased are included in net realized gain (loss) from investments — unaffiliated.

Average Quarterly Balances of Outstanding Derivative Financial Instruments

Options:
Average value of option contracts purchased	$	—	(a)
Average value of option contracts written	$	6,183,235

^(a)  Derivative not held at any quarter-end. The risk exposure table serves as an indicator of activity during the period.

For more information about the Trust’s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.

96 2 0 2 3   B L A C K R O C K  S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Schedule of Investments  (unaudited)  (continued) June 30, 2023      BlackRock Resources & Commodities Strategy Trust (BCX)

Derivative Financial Instruments — Offsetting as of Period End

The Trust’s derivative assets and liabilities (by type) were as follows:

	Assets		Liabilities
Derivative Financial Instruments
Options	$	—	$	5,496,164
Total derivative assets and liabilities in the Statements of Assets and Liabilities		—		5,496,164
Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”)		—		(4,534,593	)
Total derivative assets and liabilities subject to an MNA	$	—	$	961,571

The following table presents the Trust’s derivative liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral pledged by the Trust:

Counterparty		Derivative Liabilities Subject to an MNA by Counterparty		Derivatives Available for Offset		Non-Cash Collateral Pledged	(a)		Cash Collateral Pledged		Net Amount of Derivative Liabilities	(b)
Bank of America N.A.	$	305,916	$	—	$	—		$	—	$	305,916
Barclays Bank PLC		172,662		—		(172,662	)		—		—
Goldman Sachs International		172,665		—		(172,665	)		—		—
JPMorgan Chase Bank N.A.		193,234		—		(193,234	)		—		—
Morgan Stanley & Co. International PLC		116,880		—		(86,800	)		—		30,080
UBS AG		214		—		—			—		214
	$	961,571	$	—	$	(625,361	)	$	—	$	336,210

^(a)  Excess of collateral received/pledged, if any, from the individual counterparty is not shown for financial reporting purposes.

^(b)  Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.

Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of financial instruments. For a description of the input levels and information about the Trust’s policy regarding valuation of financial instruments, refer to the Notes to Financial Statements.

The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust’s financial instruments into major categories is disclosed in the Schedule of Investments above.

	Level 1		Level 2		Level 3		Total
Assets
Investments
Long-Term Investments
Common Stocks
Chemicals	$	90,304,521	$	—	$	—	$	90,304,521
Containers & Packaging		4,134,097		6,080,572		—		10,214,669
Energy Equipment & Services		10,869,225		—		—		10,869,225
Food Products		44,963,252		9,718,826		7,662,007		62,344,085
Machinery		47,615,221		—		—		47,615,221
Metals & Mining		234,550,870		72,758,717		21		307,309,608
Oil, Gas & Consumable Fuels		230,508,732		110,595,439		606		341,104,777
Paper & Forest Products		—		9,818,596		—		9,818,596
Short-Term Securities
Money Market Funds		35,301,139		—		—		35,301,139
	$	698,247,057	$	208,972,150	$	7,662,634		914,881,841
Investments Valued at NAV(a)								7,296,133
							$	922,177,974

S C H E D U L E    O F   I N V E S T M E N T S 97

Schedule of Investments  (unaudited)  (continued) June 30, 2023      BlackRock Resources & Commodities Strategy Trust (BCX)

Fair Value Hierarchy as of Period End (continued)

	Level 1		Level 2		Level 3		Total
Derivative Financial Instruments(b)
Liabilities
Equity Contracts	$	(4,010,054)	$	(1,486,110)	$	—	$	(5,496,164)

^(a) Certain investments of the Trust were fair valued using NAV as a practical expedient as no quoted market value is available and therefore have been excluded from the fair value hierarchy.

^(b)  Derivative financial instruments are options written. Options written are shown at value.

		Value	Valuation Approach	Unobservable Inputs(a)	Range of Unobservable Inputs Utilized	(a)	Weighted Average of Unobservable Inputs Based on Fair Value
Assets
Common Stocks	$	7,662,007	Market	EBITDA Multiple	10.75x		—

^(a)  A significant change in unobservable input would have resulted in a correlated (inverse) significant change to value.

See notes to financial statements.

98 2 0 2 3   B L A C K R O C K  S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Consolidated Schedule of Investments  (unaudited) June 30, 2023      BlackRock Science and Technology Term Trust (BSTZ) (Percentages shown are based on Net Assets)

Security	Shares		Value
Common Stocks
Automobiles — 3.0%
Tesla, Inc.(a)(b)		187,958	$	49,201,766
Broadline Retail — 2.4%
Coupang, Inc.(b)		615,525		10,710,135
MercadoLibre, Inc.(b)		17,814		21,102,464
Prosus NV		120,538		8,827,494
				40,640,093
Communications Equipment — 0.8%
Accton Technology Corp.		1,169,000		13,149,146
Consumer Finance — 0.7%
Kaspi.KZ JSC, GDR, Registered Shares(c)		150,312		11,990,607
Diversified Consumer Services — 0.2%
Think & Learn Private Ltd., (Acquired 09/30/20, Cost: $7,113,729)(d)(e)		4,651		3,401,837
Electrical Equipment — 0.5%
Array Technologies, Inc.(b)		351,496		7,943,810
Electronic Equipment, Instruments & Components — 7.1%
Delta Electronics, Inc.		1,394,000		15,448,763
Ibiden Co. Ltd.		193,900		11,032,411
Jabil, Inc.		304,355		32,849,035
Lotes Co. Ltd.		247,000		6,839,447
Samsung SDI Co. Ltd.		44,074		22,505,700
Unimicron Technology Corp.		2,063,000		11,731,586
Yageo Corp.		690,000		10,931,266
Zhejiang Supcon Technology Co. Ltd., Class A		641,074		5,554,962
				116,893,170
Entertainment — 3.5%
CTS Eventim AG & Co. KGaA		139,432		8,818,535
Nexon Co. Ltd.		391,900		7,515,335
Roku, Inc.(b)		92,872		5,940,093
Spotify Technology SA(b)		85,051		13,654,938
Take-Two Interactive Software, Inc.(b)		148,131		21,798,958
				57,727,859
Financial Services — 3.2%
Adyen NV(b)(f)		12,935		22,399,125
GMO Payment Gateway, Inc.		180,200		14,134,799
Shift4 Payments, Inc., Class A(b)(g)		146,133		9,923,892
Wise PLC, Class A(b)		825,079		6,896,488
				53,354,304
Health Care Technology — 0.3%
M3, Inc.		260,200		5,673,558
Hotels, Restaurants & Leisure(b) — 1.2%
Expedia Group, Inc.		51,482		5,631,616
Trip.com Group Ltd., ADR(h)		425,602		14,896,070
				20,527,686
Household Durables — 0.5%
Nikon Corp.		653,300		8,481,717
Interactive Media & Services — 0.6%
Pinterest, Inc., Class A(b)		352,060		9,625,320
IT Services — 5.1%
Automattic, Inc., Series E, (Acquired 02/03/21, Cost: $34,000,000)(d)(e)		400,000		19,668,000
CNEX Labs, Inc., (Acquired 12/14/21, Cost: $5,699,998)(d)(e)		1,161,804		3,287,905

Security	Shares		Value
IT Services (continued)
Klarna Holdings AB, (Acquired 08/07/19, Cost: $23,354,997)(d)(e)		86,839	$	19,109,032
MongoDB, Inc.(b)(h)		67,482		27,734,427
TRAX Ltd., Series D, (Acquired 09/12/19, Cost: $10,999,987)(d)(e)		293,333		8,635,724
TRAX Ltd., Series E, (Acquired 02/18/21, Cost: $9,999,998)(d)(e)		191,806		5,646,769
				84,081,857
Machinery — 0.4%
Shenzhen Inovance Technology Co. Ltd., Class A		723,000		6,403,338
Media — 1.6%
Informa PLC		2,885,996		26,646,882
Professional Services — 1.8%
Legalzoom.com, Inc.(b)		784,927		9,481,918
Wolters Kluwer NV		164,401		20,874,567
				30,356,485
Semiconductors & Semiconductor Equipment — 25.7%
Alchip Technologies Ltd.		175,000		10,136,733
Alphawave IP Group PLC(b)		4,942,789		9,001,704
Amkor Technology, Inc.		232,073		6,904,172
ASM International NV		78,086		33,155,641
ASPEED Technology, Inc.		131,000		12,065,722
Axcelis Technologies, Inc.(b)		69,303		12,705,319
BE Semiconductor Industries NV		209,531		22,724,506
Credo Technology Group Holding Ltd.(b)		1,784,875		30,949,732
eMemory Technology, Inc.		100,000		7,157,457
First Solar, Inc.(b)		46,293		8,799,836
Lasertec Corp.		117,200		17,710,855
Lattice Semiconductor Corp.(b)		408,294		39,224,805
Marvell Technology, Inc.(h)		371,856		22,229,552
Monolithic Power Systems, Inc.(h)		62,212		33,608,789
NVIDIA Corp.(a)		163,249		69,057,592
Rambus, Inc.(b)		306,150		19,645,645
Silergy Corp.		553,000		6,888,826
SK Hynix, Inc.		190,602		16,747,127
SOITEC(b)		152,404		25,782,997
Wolfspeed, Inc.(b)(h)		360,998		20,067,879
				424,564,889
Software — 13.9%
Altium Ltd.		762,952		18,893,698
Appier Group, Inc.(b)		510,800		6,266,516
Databricks, Inc., (Acquired 07/24/20, Cost: $5,501,686)(d)(e)		343,659		19,090,257
DataRobot, Inc., (Acquired 03/01/21, Cost: $1,384,813)(d)(e)		92,093		493,619
Freee KK(b)		469,300		10,693,625
Glodon Co. Ltd., Class A		1,215,236		5,439,334
Kinaxis, Inc.(b)		79,191		11,315,989
Manhattan Associates, Inc.(b)		30,524		6,101,137
Palo Alto Networks, Inc.(b)		107,009		27,341,870
Rapid7, Inc.(b)		176,285		7,982,185
Samsara, Inc., Class A(b)		193,735		5,368,397
SiteMinder Ltd.(b)		3,570,959		6,960,321
Snorkel AI, Inc., (Acquired 10/13/20, Cost: $2,017,593)(d)(e)		500,250		5,537,768
Snyk Ltd., (Acquired 11/02/ 20, Cost: $9,287,400)(d)(e)		1,267,643		14,565,218
Synopsys, Inc.(b)(h)		120,923		52,651,083

C O N S O L I D A T E D   S C H E D U L E   O F   I N V E S T M E N T S 99

Consolidated Schedule of Investments  (unaudited)  (continued) June 30, 2023      BlackRock Science and Technology Term Trust (BSTZ) (Percentages shown are based on Net Assets)

Security	Shares		Value
Software (continued)
Unity Software, Inc.(b)		314,022	$	13,634,835
Xero Ltd.(b)		210,116		16,834,479
				229,170,331
Specialty Retail — 0.5%
Farfetch Ltd., Class A(b)		1,310,577		7,915,885
Technology Hardware, Storage & Peripherals — 2.1%
Pure Storage, Inc., Class A(b)		737,933		27,170,693
Wiwynn Corp.		161,000		7,358,093
				34,528,786
Total Common Stocks — 75.1%     (Cost: $904,437,318)			1,242,279,326
Preferred Securities
Preferred Stocks — 27.0%(d)(e)
Communications Equipment — 1.0%
Astranis Space Technologies Corp., Series C, (Acquired 03/19/21, Cost: $17,000,010)		775,515		16,999,289
Consumer Staples Distribution & Retail — 2.5%
GrubMarket, Inc., Series D, (Acquired 07/23/20, Cost: $8,000,001)		1,762,969		41,905,773
Diversified Consumer Services — 1.5%
FlixMobility GmbH, Series F, (Acquired 07/26/19, Cost: $16,947,253)		850		21,798,406
Think & Learn Private Ltd., Series F, (Acquired 09/30/20, Cost: $14,251,080)		4,920		3,598,589
				25,396,995
Entertainment — 0.4%
ResearchGate GmbH, Series D, (Acquired 09/24/20, Cost: $6,999,988)		424,688		6,247,161
IT Services — 6.5%
ByteDance Ltd., Series E-1, (Acquired 11/11/20, Cost: $33,777,337)		308,260		54,193,360
Deep Instinct Ltd., Series D-2, (Acquired 03/19/21, Cost: $12,000,008)		1,974,374		14,412,930
Farmer’s Business Network, Inc., Series F, (Acquired 07/31/20, Cost: $11,961,002)		361,834		15,602,282
Trumid Holdings LLC(i)
Class J-A, (Acquired 07/24/20, Cost: $9,999,857)		20,154		11,153,627
Class J-B, (Acquired 07/24/20, Cost: $5,999,914)		20,154		11,153,627
				106,515,826
Professional Services — 0.8%
Rapyd Financial Network Ltd., Series E, (Acquired 03/31/21, Cost: $13,999,978)		190,705		13,391,305
Semiconductors & Semiconductor Equipment — 3.8%
Mythic AI, Inc., Series C, (Acquired 01/26/21, Cost: $7,000,000)		1,018,908		10
PsiQuantum Corp.
Series C, (Acquired 09/09/19, Cost: $9,101,310)		1,962,335		42,680,786
Series D, (Acquired 05/21/21, Cost: $19,999,969)		762,595		20,155,386
				62,836,182
Software — 10.5%
Databricks, Inc.
Series F, (Acquired 10/22/19, Cost: $13,200,019)		922,038		51,219,211
Series G, (Acquired 02/01/21, Cost: $18,500,004)		312,909		17,382,095

Security	Shares		Value
Software (continued)
DataRobot, Inc., Series F, (Acquired 10/27/20, Cost: $11,499,999)		875,059	$	5,696,634
SambaNova Systems, Inc.
Series C, (Acquired 02/20/20, Cost: $33,904,161)		636,800		52,949,920
Series D, (Acquired 04/09/21, Cost: $6,999,979)		73,670		6,125,660
Snorkel AI, Inc., Series B, (Acquired 10/13/20, Cost: $999,996)		247,943		2,744,729
Snyk Ltd., (Acquired 11/02/20, Cost: $13,212,590)		2,663,936		30,608,625
Unqork, Inc.
Series B, (Acquired 09/19/19, Cost: $6,801,016)		597,680		4,267,435
Series C, (Acquired 09/18/20, Cost: $7,994,787)		292,000		2,575,440
				173,569,749
				446,862,280
Total Preferred Securities — 27.0% (Cost: $300,150,258)				446,862,280
Warrants
IT Services — 0.0%
TRAX Ltd., (Acquired 09/12/19, Cost: $0), (Issued 09/23/19, Exercisable 07/12/23, 1 Share for 1 Warrant, Expires 09/15/23, Strike Price USD 46.88)(b)(d)(e)		46,928		—
Total Warrants — 0.0% (Cost: $ — )				—
Total Long-Term Investments — 102.1% (Cost: $1,204,587,576)				1,689,141,606
Short-Term Securities
Money Market Funds — 0.3%
BlackRock Liquidity Funds, T-Fund, Institutional Class, 4.98%(j)(k)		3,399,844		3,399,844
SL Liquidity Series, LLC, Money Market Series, 5.28%(j)(k)(l)		2,600,319		2,600,319
Total Short-Term Securities — 0.3% (Cost: $6,000,142)				6,000,163
Total Investments Before Options Written — 102.4% (Cost: $1,210,587,718)				1,695,141,769
Options Written — (1.9)%
(Premiums Received: $(16,740,064))				(32,484,997	)
Total Investments, Net of Options Written — 100.5% (Cost: $1,193,847,654)				1,662,656,772
Liabilities in Excess of Other Assets — (0.5)%				(8,951,978	)
Net Assets — 100.0%			$	1,653,704,794

^(a)  All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives.

^(b)  Non-income producing security.

^(c)  This security may be resold to qualified foreign investors and foreign institutional buyers under Regulation S of the Securities Act of 1933.

^(d)  Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy.

^(e)  Restricted security as to resale, excluding 144A securities. The Trust held restricted securities with a current value of $546,298,409, representing 33.0% of its net assets as of period end, and an original cost of $409,510,459.

^(f)  Security exempt from registration pursuant to Rule 144A under the Securities Act of 1933, as amended. These securities may be resold in transactions exempt from registration to qualified institutional investors.

^(g)  All or a portion of this security is on loan.

100 2 0 2 3   B L A C K R O C K  S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Consolidated Schedule of Investments  (unaudited)  (continued) June 30, 2023               BlackRock Science and Technology Term Trust (BSTZ)

^(h)  All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.

⁽ⁱ⁾ All or a portion of the security is held by a wholly-owned subsidiary. See Note 1 of the Notes to Consolidated Financial Statements for details on the wholly-owned subsidiary.

^(j)  Affiliate of the Trust.

^(k)  Annualized 7-day yield as of period end.

^(l) All or a portion of this security was purchased with the cash collateral from loaned securities.

For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

Affiliates

Investments in issuers considered to be affiliate(s) of the Trust during the six months ended June 30, 2023 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

Affiliated Issuer	Value at 12/31/22		Purchases at Cost			Proceeds from Sales			Net Realized Gain (Loss)		Change in Unrealized Appreciation (Depreciation)		Value at 06/30/23		Shares Held at 06/30/23		Income			Capital Gain Distributions from Underlying Funds
BlackRock Liquidity Funds, T-Fund, Institutional Class	$	20,683,361	$	—		$	(17,283,517	)(a)	$	—	$	—	$	3,399,844		3,399,844	$	221,875		$	—
SL Liquidity Series, LLC, Money Market Series		—		2,592,612	(a)		—			7,686		21		2,600,319		2,600,319		32,129	(b)		—
									$	7,686	$	21	$	6,000,163			$	254,004		$	—

^(a)  Represents net amount purchased (sold).

^(b)  All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities.

Derivative Financial Instruments Outstanding as of Period End

Exchange-Traded Options Written

Description	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call
Coupang, Inc.		645		07/07/23		USD	17.00		USD	1,122	$	(36,120	)
Expedia Group, Inc.		53		07/07/23		USD	120.00		USD	580		(345	)
Marvell Technology, Inc.		400		07/07/23		USD	62.75		USD	2,391		(6,645	)
MongoDB, Inc.		42		07/07/23		USD	420.00		USD	1,726		(19,215	)
NVIDIA Corp.		120		07/07/23		USD	380.00		USD	5,076		(523,200	)
Palo Alto Networks, Inc.		164		07/07/23		USD	240.00		USD	4,190		(259,940	)
Spotify Technology SA		128		07/07/23		USD	150.00		USD	2,055		(139,520	)
Tesla, Inc.		162		07/07/23		USD	220.00		USD	4,241		(680,400	)
Coupang, Inc.		900		07/14/23		USD	17.50		USD	1,566		(39,600	)
Expedia Group, Inc.		53		07/14/23		USD	120.00		USD	580		(1,087	)
Farfetch Ltd., Class A		1,534		07/14/23		USD	5.50		USD	927		(95,875	)
Marvell Technology, Inc.		479		07/14/23		USD	61.00		USD	2,863		(52,211	)
MercadoLibre, Inc.		43		07/14/23		USD	1,290.00		USD	5,094		(35,475	)
NVIDIA Corp.		246		07/14/23		USD	400.00		USD	10,406		(664,200	)
Palo Alto Networks, Inc.		203		07/14/23		USD	220.00		USD	5,187		(730,800	)
Pinterest, Inc., Class A		244		07/14/23		USD	25.00		USD	667		(59,902	)
Roku, Inc.		185		07/14/23		USD	80.00		USD	1,183		(1,665	)
Spotify Technology SA		109		07/14/23		USD	157.50		USD	1,750		(59,405	)
Take-Two Interactive Software, Inc.		196		07/14/23		USD	136.00		USD	2,884		(227,360	)
Tesla, Inc.		215		07/14/23		USD	235.00		USD	5,628		(632,637	)
Unity Software, Inc.		325		07/14/23		USD	40.00		USD	1,411		(134,062	)
Amkor Technology, Inc.		400		07/21/23		USD	28.00		USD	1,190		(88,000	)
Amkor Technology, Inc.		125		07/21/23		USD	31.00		USD	372		(7,500	)
Array Technologies, Inc.		859		07/21/23		USD	25.00		USD	1,941		(27,918	)
Axcelis Technologies, Inc.		91		07/21/23		USD	150.00		USD	1,668		(317,135	)
Axcelis Technologies, Inc.		100		07/21/23		USD	175.00		USD	1,833		(120,000	)
Coupang, Inc.		950		07/21/23		USD	17.50		USD	1,653		(52,725	)
Credo Technology Group Holding Ltd.		1,015		07/21/23		USD	8.36		USD	1,760		(914,048	)
Credo Technology Group Holding Ltd.		505		07/21/23		USD	9.73		USD	876		(385,804	)

C O N S O L I D A T E D   S C H E D U L E   O F   I N V E S T M E N T S 101

Consolidated Schedule of Investments  (unaudited)  (continued) June 30, 2023      BlackRock Science and Technology Term Trust (BSTZ)

Exchange-Traded Options Written (continued)

Description	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call (continued)
Credo Technology Group Holding Ltd.		1,322		07/21/23		USD	20.00		USD	2,292	$	(19,830	)
Farfetch Ltd., Class A		2,180		07/21/23		USD	6.00		USD	1,317		(82,840	)
Jabil, Inc.		446		07/21/23		USD	95.00		USD	4,814		(593,180	)
Kinaxis, Inc.		165		07/21/23		CAD	190.00		CAD	3,123		(52,935	)
Lattice Semiconductor Corp.		217		07/21/23		USD	90.00		USD	2,085		(163,835	)
Legalzoom.com, Inc.		600		07/21/23		USD	12.50		USD	725		(22,500	)
MongoDB, Inc.		57		07/21/23		USD	280.00		USD	2,343		(753,825	)
Monolithic Power Systems, Inc.		125		07/21/23		USD	431.00		USD	6,753		(1,387,034	)
NVIDIA Corp.		122		07/21/23		USD	390.00		USD	5,161		(464,515	)
Pinterest, Inc., Class A		274		07/21/23		USD	26.00		USD	749		(46,580	)
Pure Storage, Inc., Class A		1,779		07/21/23		USD	24.44		USD	6,550		(2,216,027	)
Rambus, Inc.		784		07/21/23		USD	50.75		USD	5,031		(1,069,356	)
Rapid7, Inc.		360		07/21/23		USD	55.00		USD	1,630		(19,800	)
Roku, Inc.		185		07/21/23		USD	80.00		USD	1,183		(4,070	)
Shift4 Payments, Inc., Class A		131		07/21/23		USD	75.00		USD	890		(9,825	)
Synopsys, Inc.		321		07/21/23		USD	410.00		USD	13,977		(905,220	)
Take-Two Interactive Software, Inc.		197		07/21/23		USD	145.00		USD	2,899		(87,173	)
Tesla, Inc.		179		07/21/23		USD	195.00		USD	4,686		(1,213,620	)
Trip.com Group Ltd., ADR		1,300		07/21/23		USD	37.00		USD	4,550		(52,000	)
Unity Software, Inc.		304		07/21/23		USD	35.00		USD	1,320		(263,720	)
Wolfspeed, Inc.		817		07/21/23		USD	50.00		USD	4,542		(526,965	)
Lattice Semiconductor Corp.		509		07/27/23		USD	91.00		USD	4,890		(384,862	)
Expedia Group, Inc.		112		07/28/23		USD	110.00		USD	1,225		(40,600	)
Farfetch Ltd., Class A		1,528		07/28/23		USD	6.50		USD	923		(38,964	)
First Solar, Inc.		97		07/28/23		USD	205.00		USD	1,844		(46,075	)
Marvell Technology, Inc.		180		07/28/23		USD	66.00		USD	1,076		(11,700	)
MercadoLibre, Inc.		30		07/28/23		USD	1,290.00		USD	3,554		(54,750	)
MongoDB, Inc.		70		07/28/23		USD	380.00		USD	2,877		(281,050	)
NVIDIA Corp.		207		07/28/23		USD	425.00		USD	8,757		(366,907	)
Palo Alto Networks, Inc.		61		07/28/23		USD	255.00		USD	1,559		(51,240	)
Pinterest, Inc., Class A		480		07/28/23		USD	25.00		USD	1,312		(130,560	)
Shift4 Payments, Inc., Class A		306		07/28/23		USD	73.00		USD	2,078		(47,733	)
Spotify Technology SA		103		07/28/23		USD	167.50		USD	1,654		(63,345	)
Take-Two Interactive Software, Inc.		199		07/28/23		USD	143.00		USD	2,928		(125,867	)
Tesla, Inc.		122		07/28/23		USD	280.00		USD	3,194		(126,270	)
Tesla, Inc.		103		07/28/23		USD	295.00		USD	2,696		(70,040	)
Unity Software, Inc.		404		07/28/23		USD	45.00		USD	1,754		(92,516	)
Coupang, Inc.		630		08/04/23		USD	17.50		USD	1,096		(50,715	)
Marvell Technology, Inc.		428		08/04/23		USD	61.00		USD	2,559		(100,580	)
NVIDIA Corp.		121		08/04/23		USD	455.00		USD	5,119		(116,765	)
Pinterest, Inc., Class A		275		08/04/23		USD	28.00		USD	752		(38,775	)
Tesla, Inc.		165		08/04/23		USD	290.00		USD	4,319		(146,850	)
First Solar, Inc.		134		08/11/23		USD	200.00		USD	2,547		(106,865	)
MercadoLibre, Inc.		16		08/11/23		USD	1,290.00		USD	1,895		(62,960	)
Unity Software, Inc.		223		08/11/23		USD	45.00		USD	968		(84,740	)
Array Technologies, Inc.		577		08/18/23		USD	25.00		USD	1,304		(70,683	)
Credo Technology Group Holding Ltd.		1,520		08/18/23		USD	10.00		USD	2,636		(1,147,600	)
Credo Technology Group Holding Ltd.		2,813		08/18/23		USD	20.00		USD	4,878		(126,585	)
Jabil, Inc.		771		08/18/23		USD	100.00		USD	8,321		(693,900	)
Kinaxis, Inc.		151		08/18/23		CAD	190.00		CAD	2,858		(102,015	)
Lattice Semiconductor Corp.		452		08/18/23		USD	95.00		USD	4,342		(334,480	)
Legalzoom.com, Inc.		870		08/18/23		USD	12.50		USD	1,051		(73,950	)
Manhattan Associates, Inc.		122		08/18/23		USD	195.00		USD	2,439		(164,090	)
MongoDB, Inc.		100		08/18/23		USD	390.00		USD	4,110		(405,500	)
Monolithic Power Systems, Inc.		126		08/18/23		USD	530.00		USD	6,807		(536,130	)
Pinterest, Inc., Class A		274		08/18/23		USD	26.00		USD	749		(73,021	)
Pure Storage, Inc., Class A		1,190		08/18/23		USD	37.00		USD	4,382		(199,325	)
Rambus, Inc.		440		08/18/23		USD	70.00		USD	2,823		(99,000	)
Rapid7, Inc.		360		08/18/23		USD	50.00		USD	1,630		(129,600	)
Samsara, Inc., Class A		387		08/18/23		USD	30.00		USD	1,072		(50,310	)
Shift4 Payments, Inc., Class A		306		08/18/23		USD	68.50		USD	2,078		(129,197	)
Trip.com Group Ltd., ADR		458		08/18/23		USD	39.00		USD	1,603		(24,045	)

102 2 0 2 3   B L A C K R O C K  S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Consolidated Schedule of Investments  (unaudited) (continued) June 30, 2023      BlackRock Science and Technology Term Trust (BSTZ)

Exchange-Traded Options Written (continued)

Description	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call (continued)
Wolfspeed, Inc.		589		08/18/23		USD	60.00		USD	3,274	$	(223,820	)
Pinterest, Inc., Class A		220		09/15/23		USD	29.00		USD	601		(34,980	)
Samsara, Inc., Class A		387		09/15/23		USD	30.00		USD	1,072		(87,075	)
											$	(23,613,679	)

OTC Options Written

Description	Counterparty	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call
Adyen NV	Goldman Sachs International		5,600		07/11/23		EUR	1,489.94		EUR	8,887	$	(624,711	)
Delta Electronics, Inc.	BNP Paribas SA		479,000		07/11/23		TWD	309.73		TWD	165,329		(536,514	)
GMO Payment Gateway, Inc.	UBS AG		25,600		07/11/23		JPY	11,720.91		JPY	289,752		(12,048	)
Lattice Semiconductor Corp.	Citibank N.A.		46,200		07/11/23		USD	85.77		USD	4,438		(490,013	)
Prosus NV	Goldman Sachs International		17,000		07/11/23		EUR	72.62		EUR	1,141		(1,925	)
ASM International NV	Goldman Sachs International		33,000		07/12/23		EUR	356.48		EUR	12,841		(1,196,303	)
Glodon Co. Ltd., Class A	Morgan Stanley & Co. International PLC		350,000		07/12/23		CNY	39.93		CNY	11,389		(619	)
Informa PLC	Goldman Sachs International		336,300		07/12/23		GBP	7.34		GBP	2,445		(29,154	)
Lotes Co. Ltd.	UBS AG		40,000		07/12/23		TWD	934.28		TWD	34,496		(5,692	)
Shenzhen Inovance Technology Co. Ltd., Class A	Morgan Stanley & Co. International PLC		452,000		07/12/23		CNY	62.03		CNY	29,102		(159,900	)
SiteMinder Ltd.	UBS AG		35,000		07/12/23		AUD	3.34		AUD	102		(225	)
Wise PLC, Class A	JPMorgan Chase Bank N.A.		135,000		07/12/23		GBP	6.26		GBP	889		(85,334	)
Alphawave IP Group PLC	Morgan Stanley & Co. International PLC		100,000		07/13/23		GBP	1.28		GBP	143		(21,445	)
Ibiden Co. Ltd.	Citibank N.A.		23,500		07/13/23		JPY	8,413.65		JPY	192,935		(18,988	)
Ibiden Co. Ltd.	UBS AG		52,800		07/13/23		JPY	7,799.04		JPY	433,489		(153,402	)
Nikon Corp.	UBS AG		230,800		07/13/23		JPY	1,602.07		JPY	432,373		(420,446	)
Unimicron Technology Corp.	Goldman Sachs International		674,000		07/13/23		TWD	187.53		TWD	119,371		(22,781	)
Wiwynn Corp.	Goldman Sachs International		8,000		07/13/23		TWD	1,234.90		TWD	11,387		(48,983	)
Wolters Kluwer NV	Goldman Sachs International		65,700		07/13/23		EUR	112.99		EUR	7,645		(282,393	)
BE Semiconductor Industries NV	Morgan Stanley & Co. International PLC		44,400		07/18/23		EUR	97.93		EUR	4,413		(172,056	)
Lotes Co. Ltd.	Citibank N.A.		47,000		07/18/23		TWD	988.98		TWD	40,532		(3,477	)
Wise PLC, Class A	Morgan Stanley & Co. International PLC		51,000		07/18/23		GBP	6.33		GBP	336		(33,744	)
Xero Ltd.	Goldman Sachs International		41,150		07/18/23		AUD	107.07		AUD	4,949		(337,181	)
Altium Ltd.	UBS AG		70,000		07/19/23		AUD	38.48		AUD	2,602		(15,072	)
Altium Ltd.	UBS AG		43,900		07/19/23		AUD	40.34		AUD	1,632		(1,875	)
SK Hynix, Inc.	Morgan Stanley & Co. International PLC		43,400		07/19/23		KRW	106,605.00		KRW	5,024,613		(308,139	)
SOITEC	Morgan Stanley & Co. International PLC		7,200		07/19/23		EUR	131.26		EUR	1,116		(190,319	)
SOITEC	Morgan Stanley & Co. International PLC		6,600		07/19/23		EUR	144.13		EUR	1,023		(88,666	)
Wiwynn Corp.	Morgan Stanley & Co. International PLC		70,000		07/19/23		TWD	1,175.93		TWD	99,637		(559,313	)
Altium Ltd.	UBS AG		63,000		07/25/23		AUD	39.63		AUD	2,342		(8,617	)
CTS Eventim AG & Co. KGaA	Goldman Sachs International		13,700		07/25/23		EUR	72.20		EUR	794		(14	)
Freee KK	BNP Paribas SA		94,600		07/25/23		JPY	3,729.71		JPY	311,040		(31,527	)
GMO Payment Gateway, Inc.	BNP Paribas SA		25,000		07/25/23		JPY	11,462.45		JPY	282,961		(43,092	)
Informa PLC	Goldman Sachs International		377,800		07/25/23		GBP	7.22		GBP	2,747		(89,700	)
Lasertec Corp.	BNP Paribas SA		89,700		07/25/23		JPY	23,385.53		JPY	1,955,940		(199,215	)
Alphawave IP Group PLC	Goldman Sachs International		200,000		07/26/23		GBP	1.26		GBP	287		(52,738	)
BE Semiconductor Industries NV	Goldman Sachs International		21,000		07/26/23		EUR	109.12		EUR	2,087		(12,811	)
CTS Eventim AG & Co. KGaA	Barclays Bank PLC		10,000		07/26/23		EUR	72.98		EUR	580		(7	)
Kaspi.KZ JSC, GDR, Registered Shares	Morgan Stanley & Co. International PLC		30,000		07/26/23		USD	83.53		USD	2,393		(38,892	)
M3, Inc.	UBS AG		104,000		07/26/23		JPY	3,281.90		JPY	327,215		(30,645	)
SiteMinder Ltd.	Citibank N.A.		24,500		07/26/23		AUD	3.22		AUD	72		(967	)
SOITEC	Morgan Stanley & Co. International PLC		12,200		07/26/23		EUR	140.88		EUR	1,891		(211,168	)
Wise PLC, Class A	Goldman Sachs International		47,200		07/26/23		GBP	6.29		GBP	311		(36,441	)
Zhejiang Supcon Technology Co. Ltd., Class A	Morgan Stanley & Co. International PLC		256,343		07/26/23		CNY	71.33		CNY	16,148		(10,372	)
Amkor Technology, Inc.	Citibank N.A.		40,300		07/31/23		USD	27.56		USD	1,199		(109,814	)
Axcelis Technologies, Inc.	Citibank N.A.		8,600		07/31/23		USD	191.10		USD	1,577		(45,903	)
Legalzoom.com, Inc.	Citibank N.A.		80,000		07/31/23		USD	12.98		USD	966		(27,043	)
Synopsys, Inc.	Citibank N.A.		16,200		07/31/23		USD	467.88		USD	7,054		(63,423	)
Alphawave IP Group PLC	Morgan Stanley & Co. International PLC		100,000		08/01/23		GBP	1.35		GBP	143		(19,460	)

C O N S O L I D A T E D   S C H E D U L E    O F   I N V E S T M E N T S 103

Consolidated Schedule of Investments  (unaudited) (continued) June 30, 2023      BlackRock Science and Technology Term Trust (BSTZ)

OTC Options Written (continued)

Description	Counterparty	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call (continued)
Altium Ltd.	UBS AG		54,000		08/01/23		AUD	39.19		AUD	2,007	$	(14,393	)
CTS Eventim AG & Co. KGaA	UBS AG		17,100		08/01/23		EUR	62.84		EUR	991		(10,728	)
Delta Electronics, Inc.	Citibank N.A.		80,000		08/01/23		TWD	349.86		TWD	27,612		(20,802	)
Freee KK	Bank of America N.A.		93,100		08/01/23		JPY	3,648.39		JPY	306,108		(52,181	)
Informa PLC	Morgan Stanley & Co. International PLC		377,800		08/01/23		GBP	7.22		GBP	2,747		(104,103	)
Kaspi.KZ JSC, GDR, Registered Shares	Morgan Stanley & Co. International PLC		30,000		08/01/23		USD	84.33		USD	2,393		(40,435	)
SOITEC	Morgan Stanley & Co. International PLC		15,000		08/01/23		EUR	160.16		EUR	2,326		(56,281	)
SOITEC	Morgan Stanley & Co. International PLC		9,600		08/01/23		EUR	143.71		EUR	1,488		(147,706	)
Yageo Corp.	Goldman Sachs International		60,000		08/01/23		TWD	510.24		TWD	29,604		(9,985	)
Accton Technology Corp.	BNP Paribas SA		350,000		08/02/23		TWD	395.90		TWD	122,612		(34,569	)
Alchip Technologies Ltd.	Morgan Stanley & Co. International PLC		87,000		08/02/23		TWD	1,936.00		TWD	156,950		(205,118	)
Appier Group, Inc.	Societe Generale		204,300		08/02/23		JPY	1,921.70		JPY	361,655		(85,213	)
ASPEED Technology, Inc.	Morgan Stanley & Co. International PLC		43,000		08/02/23		TWD	2,874.41		TWD	123,348		(228,597	)
eMemory Technology, Inc.	Morgan Stanley & Co. International PLC		39,000		08/02/23		TWD	2,461.00		TWD	86,937		(47,927	)
Nexon Co. Ltd.	Societe Generale		160,000		08/02/23		JPY	3,046.83		JPY	442,736		(11,956	)
SiteMinder Ltd.	Citibank N.A.		37,300		08/02/23		AUD	3.33		AUD	109		(1,352	)
SK Hynix, Inc.	Morgan Stanley & Co. International PLC		10,600		08/02/23		KRW	124,740.00		KRW	1,227,210		(10,703	)
Wise PLC, Class A	Goldman Sachs International		84,400		08/02/23		GBP	6.82		GBP	555		(39,696	)
Altium Ltd.	Citibank N.A.		37,100		08/08/23		AUD	36.92		AUD	1,379		(35,451	)
Alphawave IP Group PLC	Morgan Stanley & Co. International PLC		150,000		08/10/23		GBP	1.50		GBP	215		(17,435	)
BE Semiconductor Industries NV	Morgan Stanley & Co. International PLC		39,400		08/10/23		EUR	110.42		EUR	3,916		(54,300	)
CTS Eventim AG & Co. KGaA	Morgan Stanley & Co. International PLC		17,000		08/10/23		EUR	59.82		EUR	985		(28,454	)
GMO Payment Gateway, Inc.	Societe Generale		22,200		08/10/23		JPY	12,629.90		JPY	251,269		(11,264	)
SOITEC	Goldman Sachs International		10,300		08/10/23		EUR	157.04		EUR	1,597		(72,066	)
Wise PLC, Class A	Goldman Sachs International		95,000		08/10/23		GBP	6.39		GBP	625		(72,895	)
Samsung SDI Co. Ltd.	BNP Paribas SA		18,600		08/14/23		KRW	700,667.27		KRW	12,514,775		(189,004	)
Prosus NV	JPMorgan Chase Bank N.A.		31,300		08/15/23		EUR	66.12		EUR	2,101		(127,598	)
Xero Ltd.	UBS AG		42,800		08/15/23		AUD	116.91		AUD	5,148		(193,722	)
Altium Ltd.	Goldman Sachs International		37,100		08/16/23		AUD	38.27		AUD	1,379		(24,144	)
Informa PLC	Bank of America N.A.		69,600		08/16/23		GBP	7.29		GBP	506		(19,242	)
Yageo Corp.	Morgan Stanley & Co. International PLC		212,000		08/16/23		TWD	512.12		TWD	104,602		(51,431	)
												$	(8,871,318	)

Balances Reported in the Consolidated Statements of Assets and Liabilities for Options Written

Description	Swap Premiums Paid		Swap Premiums Received		Unrealized Appreciation		Unrealized Depreciation			Value
Options Written	$	N/A	$	N/A	$	2,852,790	$	(18,597,723	)	$	(32,484,997	)

Derivative Financial Instruments Categorized by Risk Exposure

As of period end, the fair values of derivative financial instruments located in the Consolidated Statements of Assets and Liabilities were as follows:

	Commodity Contracts		Credit Contracts		Equity Contracts		Foreign Currency Exchange Contracts		Interest Rate Contracts		Other Contracts		Total
Liabilities — Derivative Financial Instruments
Options written
Options written at value	$	—	$	—	$	32,484,997	$	—	$	—	$	—	$	32,484,997

104 2 0 2 3   B L A C K R O C K  S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Consolidated Schedule of Investments  (unaudited) (continued) June 30, 2023      BlackRock Science and Technology Term Trust (BSTZ)

For the period ended June 30, 2023, the effect of derivative financial instruments in the Consolidated Statements of Operations was as follows:

	Commodity Contracts		Credit Contracts		Equity Contracts			Foreign Currency Exchange Contracts		Interest Rate Contracts		Other Contracts		Total
Net Realized Gain (Loss) from:
Options purchased(a)	$	—	$	—	$	(4,070,240	)	$	—	$	—	$	—	$	(4,070,240	)
Options written		—		—		(10,876,120	)		—		—		—		(10,876,120	)
	$	—	$	—	$	(14,946,360	)	$	—	$	—	$	—	$	(14,946,360	)
Net Change in Unrealized Appreciation (Depreciation) on:
Options written	$	—	$	—	$	(25,448,128	)	$	—	$	—	$	—	$	(25,448,128	)

^(a)  Options purchased are included in net realized gain (loss) from investments — unaffiliated.

Average Quarterly Balances of Outstanding Derivative Financial Instruments

Options:
Average value of option contracts purchased	$	—	(a)
Average value of option contracts written	$	27,055,570

^(a)  Derivative not held at any quarter-end. The risk exposure table serves as an indicator of activity during the period.

For more information about the Trust’s investment risks regarding derivative financial instruments, refer to the Notes to Consolidated Financial Statements.

Derivative Financial Instruments — Offsetting as of Period End

The Trust’s derivative assets and liabilities (by type) were as follows:

	Assets		Liabilities
Derivative Financial Instruments
Options	$	—	$	32,484,997
Total derivative assets and liabilities in the Consolidated Statements of Assets and Liabilities		—		32,484,997
Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”)		—		(23,613,679	)
Total derivative assets and liabilities subject to an MNA	$	—	$	8,871,318

The following table presents the Trust’s derivative liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral pledged by the Trust:

Counterparty		Derivative Liabilities Subject to an MNA by Counterparty		Derivatives Available for Offset		Non-Cash Collateral Pledged			Cash Collateral Pledged			Net Amount of Derivative Liabilities	(a)
Bank of America N.A	$	71,423	$	—	$	—		$	—		$	71,423
Barclays Bank PLC		7		—		—			—			7
BNP Paribas SA		1,033,921		—		(582,507	)		(440,000	)		11,414
Citibank N.A.		817,233		—		—			(540,000	)		277,233
Goldman Sachs International		2,953,921		—		(2,490,385	)		—			463,536
JPMorgan Chase Bank N.A.		212,932		—		(122,510	)		—			90,422
Morgan Stanley & Co. International PLC		2,806,583		—		(1,979,318	)		—			827,265
Societe Generale		108,433		—		(106,709	)		—			1,724
UBS AG		866,865		—		(616,842	)		—			250,023
	$	8,871,318	$	—	$	(5,898,271	)	$	(980,000	)	$	1,993,047

^(a)  Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Consolidated Statements of Assets and Liabilities.

C O N S O L I D A T E D   S C H E D U L E    O F   I N V E S T M E N T S 105

Consolidated Schedule of Investments  (unaudited) (continued) June 30, 2023      BlackRock Science and Technology Term Trust (BSTZ)

Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of financial instruments. For a description of the input levels and information about the Trust’s policy regarding valuation of financial instruments, refer to the Notes to Consolidated Financial Statements.

The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust’s financial instruments into major categories is disclosed in the Consolidated Schedule of Investments above.

	Level 1			Level 2			Level 3		Total
Assets
Investments
Long-Term Investments
Common Stocks
Automobiles	$	49,201,766		$	—		$	—	$	49,201,766
Broadline Retail		31,812,599			8,827,494			—		40,640,093
Communications Equipment		—			13,149,146			—		13,149,146
Consumer Finance		—			11,990,607			—		11,990,607
Diversified Consumer Services		—			—			3,401,837		3,401,837
Electrical Equipment		7,943,810			—			—		7,943,810
Electronic Equipment, Instruments & Components		32,849,035			84,044,135			—		116,893,170
Entertainment		41,393,989			16,333,870			—		57,727,859
Financial Services		9,923,892			43,430,412			—		53,354,304
Health Care Technology		—			5,673,558			—		5,673,558
Hotels, Restaurants & Leisure		20,527,686			—			—		20,527,686
Household Durables		—			8,481,717			—		8,481,717
Interactive Media & Services		9,625,320			—			—		9,625,320
IT Services		27,734,427			—			56,347,430		84,081,857
Machinery		—			6,403,338			—		6,403,338
Media		—			26,646,882			—		26,646,882
Professional Services		9,481,918			20,874,567			—		30,356,485
Semiconductors & Semiconductor Equipment		272,195,025			152,369,864			—		424,564,889
Software		124,395,496			65,087,973			39,686,862		229,170,331
Specialty Retail		7,915,885			—			—		7,915,885
Technology Hardware, Storage & Peripherals		27,170,693			7,358,093			—		34,528,786
Preferred Securities
Preferred Stocks		—			—			446,862,280		446,862,280
Warrants		—			—			—		—
Short-Term Securities
Money Market Funds		3,399,844			—			—		3,399,844
	$	675,571,385		$	470,671,656		$	546,298,409		1,692,541,450
Investments Valued at NAV(a)										2,600,319
									$	1,695,141,769
Derivative Financial Instruments(b)
Liabilities
Equity Contracts	$	(17,072,973	)	$	(15,412,024	)	$	—	$	(32,484,997	)

^(a)  Certain investments of the Trust were fair valued using NAV as a practical expedient as no quoted market value is available and therefore have been excluded from the fair value hierarchy.

^(b)  Derivative financial instruments are options written. Options written are shown at value.

A reconciliation of Level 3 financial instruments is presented when the Trust had a significant amount of Level 3 investments and derivative financial instruments at the beginning and/or end of the period in relation to net assets. The following table is a reconciliation of Level 3 investments for which significant unobservable inputs were used in determining fair value:

	Common Stocks		Preferred Stocks		Warrants			Total
Assets
Opening balance, as of December 31, 2022	$	94,490,236	$	413,908,201	$	44,581		$	508,443,018
Transfers into Level 3		—		—		—			—
Transfers out of Level 3		—		—		—			—
Accrued discounts/premiums		—		—		—			—
Net realized gain (loss)		—		—		—			—
Net change in unrealized appreciation (depreciation)(a)(b)		4,945,893		32,954,079		(44,581	)		37,855,391

106 2 0 2 3   B L A C K R O C K  S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Consolidated Schedule of Investments  (unaudited) (continued) June 30, 2023      BlackRock Science and Technology Term Trust (BSTZ)

	Common Stocks		Preferred Stocks		Warrants			Total
Purchases	$	—	$	—	$	—		$	—
Sales		—		—		—			—
Closing balance, as of June 30, 2023	$	99,436,129	$	446,862,280	$	—	(c)	$	546,298,409
Net change in unrealized appreciation (depreciation) on investments still held at June 30, 2023(b)	$	4,945,893	$	32,954,079	$	(44,581	)	$	37,855,391

^(a)  Included in the related net change in unrealized appreciation (depreciation) in the Consolidated Statements of Operations.

^(b)  Any difference between net change in unrealized appreciation (depreciation) and net change in unrealized appreciation (depreciation) on investments still held at June 30, 2023 is generally due to investments no longer held or categorized as Level 3 at period end.

^(c)  Rounds to less than $1.

The following table summarizes the valuation approaches used and unobservable inputs utilized by the BlackRock Valuation Committee (the “Valuation Committee”) to determine the value of certain of the Trust’s Level 3 financial instruments as of period end.

	Value		Valuation Approach		Unobservable Inputs		Range of    Unobservable    Inputs    Utilized(a)		Weighted Average of Unobservable Inputs Based on Fair Value
Assets
Common Stocks	$	99,436,129		Market		Revenue Multiple		1.80x ‑ 28.00x		13.48x
						Volatility		60% - 70%		61%
						Time to Exit		1.0 - 3.0 years		1.3 years
Preferred Stocks		446,862,280		Market		Revenue Multiple		1.80x - 29.00x		16.30x
						Time to Exit		3.0 ‑ 4.0 years		3.9 years
						Volatility		40% - 70%		52%
						Market Adjustment Multiple		1.10x-1.10x		1.10x
						Gross Profit Multiple		6.75x		—
	$	546,298,409

^(a)  A significant change in unobservable input would have resulted in a correlated (inverse) significant change to value.

See notes to financial statements.

C O N S O L I D A T E D   S C H E D U L E    O F   I N V E S T M E N T S 107

Consolidated Schedule of Investments  (unaudited) June 30, 2023      BlackRock Science and Technology Trust (BST) (Percentages shown are based on Net Assets)

Security	Shares		Value
Common Stocks
Automobiles — 2.5%
Tesla, Inc.(a)(b)		109,155	$	28,573,504
Broadline Retail(a)(b) — 3.5%
Alibaba Group Holding Ltd., ADR(c)		61,846		5,154,864
Amazon.com, Inc.		167,904		21,887,965
MercadoLibre, Inc.		11,296		13,381,242
				40,424,071
Capital Markets — 0.7%
S&P Global, Inc.(a)		21,150		8,478,824
Communications Equipment(a) — 0.9%
Arista Networks, Inc.(b)		32,419		5,253,823
Motorola Solutions, Inc.		18,742		5,496,654
				10,750,477
Diversified Consumer Services(d)(e) — 1.1%
Grammarly, Inc., (Acquired 11/17/21, Cost: $18,749,975)	715,323		12,260,636
Think & Learn Private Ltd., (Acquired 09/30/20, Cost: $1,524,948)		997		729,227
				12,989,863
Electrical Equipment — 0.6%
NEXTracker, Inc., Class A(a)(b)		169,000		6,727,890
Electronic Equipment, Instruments & Components — 1.8%
Flex Ltd.(a)(b)		331,320		9,157,685
Keyence Corp.		8,900		4,228,892
Samsung SDI Co. Ltd.		15,649		7,990,917
				21,377,494
Entertainment(a)(b) — 2.3%
Netflix, Inc.		18,894		8,322,618
ROBLOX Corp., Class A		100,227		4,039,148
Spotify Technology SA		49,956		8,020,436
Take-Two Interactive Software, Inc.		41,735		6,141,723
				26,523,925
Financial Services — 6.0%
Adyen NV(b)(f)		6,260		10,840,241
GMO Payment Gateway, Inc.		83,100		6,518,323
Mastercard, Inc., Class A(a)(g)		69,644		27,390,985
Visa, Inc., Class A(a)		84,576		20,085,109
Wise PLC, Class A(b)		524,987		4,388,146
				69,222,804
Ground Transportation — 0.8%
Uber Technologies, Inc.(a)(b)		223,554		9,650,826
Health Care Technology — 0.4%
M3, Inc.		216,700		4,725,058
Hotels, Restaurants & Leisure — 0.5%
Trip.com Group Ltd.(b)		183,250		6,397,146
Interactive Media & Services — 4.3%
Alphabet, Inc., Class A(a)(b)		165,033		19,754,450
Meta Platforms, Inc., Class A(a)(b)		76,259		21,884,808
Patreon, Inc., (Acquired 08/19/21, Cost: $3,352,226)(d)(e)		59,524		1,552,981
Tencent Holdings Ltd.		159,400		6,758,747
				49,950,986

Security	Shares		Value
IT Services — 4.1%
Automattic, Inc., Series E, (Acquired 02/03/21, Cost: $7,999,945)(d)(e)		94,117	$	4,627,733
Klarna Holdings AB, (Acquired 08/07/19, Cost: $7,971,978)(d)(e)		26,430		5,815,955
MongoDB, Inc.(a)(b)		34,887		14,338,208
Shopify, Inc., Class A(a)(b)		95,452		6,166,199
Snowflake, Inc., Class A(a)(b)		19,997		3,519,072
Teya Services Ltd., Series C, (Acquired 12/17/21, Cost: $24,999,987)(d)(e)		12,871		8,536,948
TRAX Ltd., Series D, (Acquired 09/12/19, Cost: $4,000,012)(d)(e)		106,667		3,140,277
TRAX Ltd., Series E, (Acquired 02/18/21, Cost: $1,999,989)(d)(e)		38,361		1,129,348
				47,273,740
Professional Services — 1.0%
Ant Group Co., Ltd., Series C, (Acquired 05/18/18, Cost: $6,492,862)(d)(e)		1,703,548		5,604,673
RELX PLC		190,385		6,351,373
				11,956,046
Semiconductors & Semiconductor Equipment — 22.4%
Advanced Micro Devices, Inc.(a)(b)		157,505		17,941,395
ASM International NV		30,899		13,119,843
ASML Holding NV		43,842		31,799,863
Broadcom, Inc.(a)		30,124		26,130,461
Credo Technology Group Holding Ltd.(a)(b)		575,627		9,981,372
First Solar, Inc.(a)(b)		25,696		4,884,553
Lam Research Corp.(a)		18,864		12,126,911
Marvell Technology, Inc.(a)		168,624		10,080,343
Micron Technology, Inc.(a)		120,238		7,588,220
Monolithic Power Systems, Inc.(a)		23,218		12,543,060
NVIDIA Corp.(a)(g)		163,532		69,177,307
Renesas Electronics Corp.(b)		286,700		5,410,690
SOITEC(b)		67,686		11,450,802
STMicroelectronics NV		159,584		7,958,994
Taiwan Semiconductor Manufacturing Co. Ltd., ADR(a) .		80,676		8,141,822
Wolfspeed, Inc.(a)(b)(c)		208,765		11,605,246
				259,940,882
Software — 21.2%
Adobe, Inc.(a)(b)		12,508		6,116,287
ANSYS, Inc.(a)(b)		33,940		11,209,364
Autodesk, Inc.(a)(b)		24,894		5,093,561
Cadence Design Systems, Inc.(a)(b)		117,682		27,598,783
Constellation Software, Inc.		3,923		8,128,095
Crowdstrike Holdings, Inc., Class A(a)(b)		33,034		4,851,704
Dassault Systemes SE		154,850		6,861,551
Databricks, Inc., (Acquired 07/24/20, Cost: $960,476)(d)(e)		59,997		3,332,833
DataRobot, Inc., (Acquired 03/01/21, Cost: $583,275)(d)(e)		38,789		207,909
Intuit, Inc.(a)		26,351		12,073,765
Microsoft Corp.(a)		295,517		100,635,359
Oracle Corp.(a)		162,983		19,409,645
Salesforce, Inc.(a)(b)		55,935		11,816,828
ServiceNow, Inc.(a)(b)		15,190		8,536,324
SiteMinder Ltd.(b)		1,082,492		2,109,935
Snorkel AI, Inc., (Acquired 06/30/21, Cost: $997,636)(d)(e)		66,422		735,292
Snyk Ltd., (Acquired 09/02/21, Cost: $5,192,307)(d)(e)		361,972		4,159,058

108 2 0 2 3   B L A C K R O C K  S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Consolidated Schedule of Investments  (unaudited) (continued) June 30, 2023 BlackRock Science and Technology Trust (BST) (Percentages shown are based on Net Assets)

Security	Shares		Value
Software (continued)
Unity Software, Inc.(a)(b)		150,439	$	6,532,061
Xero Ltd.(b)		80,662		6,462,634
				245,870,988
Specialty Retail — 0.0%
AceVector Limited, Series I, (Acquired 08/31/18, Cost: $1,998,435)(d)(e)		168,640		130,124
Technology Hardware, Storage & Peripherals —8.7%
Apple, Inc.(a)		497,410		96,482,618
Samsung Electronics Co. Ltd.		82,578		4,547,011
				101,029,629
Total Common Stocks — 82.8%     (Cost: $518,661,506)			961,994,277
	Par (000)
Convertible Notes
Financial Services — 0.0%
Wyre, Inc., (Acquired: 12/14/21, Cost: $8,000,000), 0.00%(d)(e)	$	80		1
Total Convertible Notes — 0.0%     (Cost: $8,000,000) 1
	Shares
Preferred Securities
Preferred Stocks — 18.4%(d)(e)
Chemicals — 0.7%
Solugen, Inc., Series C, (Acquired 09/02/21, Cost: $9,999,977)		269,284		8,048,899
Consumer Staples Distribution & Retail — 1.5%
Grubmarket, Inc., Series E, (Acquired 10/18/21, Cost: $6,999,994)		709,724		16,870,140
Diversified Consumer Services — 1.0%
FlixMobility GmbH, Series F, (Acquired 07/26/19, Cost: $5,482,937)		275		7,052,425
Grammarly, Inc., Series 3, (Acquired 11/17/21, Cost: $6,249,992)		238,441		4,086,879
Think & Learn Private Ltd., Series F, (Acquired 09/30/20, Cost: $3,052,975)		1,054		770,917
				11,910,221
Diversified Telecommunication Services — 0.4%
Discord, Inc., Series I, (Acquired 09/13/21, Cost: $7,000,088)		12,713		4,774,276
Financial Services — 0.5% Trumid Holdings LLC, Class L, (Acquired 09/15/21, Cost: $9,999,695)(h)		11,420		6,320,056
Interactive Media & Services — 0.3%
Patreon, Inc., Series D, (Acquired 07/14/21, Cost: $6,666,632)		119,047		3,105,936

Security	Shares		Value
IT Services — 5.7%
ByteDance Ltd., Series E-1, (Acquired 11/11/20, Cost: $9,650,746)		88,075	$	15,483,943
Deep Instinct Ltd., Series D-2, (Acquired 03/19/21, Cost: $2,999,391)		493,493		3,602,499
Farmer’s Business Network, Inc.
Series F, (Acquired 07/31/20, Cost: $2,999,886)		90,750		3,913,140
Series G, (Acquired 09/15/21, Cost: $6,999,963)		112,616		4,856,002
MNTN Digital, Inc., Series D, (Acquired 11/05/21, Cost: $24,999,980)		1,088,598		14,315,063
Trumid Holdings LLC(h)
Class J-A, (Acquired 07/24/20, Cost: $2,499,716)		5,038		2,788,130
Class J-B, (Acquired 07/24/20, Cost: $1,499,830)		5,038		2,788,130
Voltron Data, Inc.
Seed Shares, (Acquired 07/14/21, Cost: $5,000,000)		9,090,909		9,272,727
Series A, (Acquired 01/18/22, Cost: $10,000,000)		6,201,935		8,682,709
				65,702,343
Semiconductors & Semiconductor Equipment — 2.7%
PsiQuantum Corp.
Series C, (Acquired 09/09/19, Cost: $3,200,234)		690,003		15,007,565
Series D, (Acquired 05/21/21, Cost: $5,000,025)		190,650		5,038,880
Rivos, Inc., Series A, (Acquired 12/03/21, Cost: $12,003,705)		4,500,000		11,115,000
				31,161,445
Software — 5.6%
Bolt Financial, Inc., Series E, (Acquired 01/18/22, Cost: $29,999,955)		598,682		14,679,683
Databricks, Inc.
Series F, (Acquired 10/22/19, Cost: $3,999,999)		279,405		15,520,948
Series G, (Acquired 02/01/21, Cost: $4,500,001)		76,113		4,228,077
DataRobot, Inc., Series F, (Acquired 10/27/20, Cost: $2,999,996)		228,276		1,486,077
Prosimo, Inc., Series B, (Acquired 11/04/21, Cost: $4,999,998)		2,515,811		4,025,297
SambaNova Systems, Inc., Series C, (Acquired 02/20/20, Cost: $9,972,125)		187,300		15,573,995
Snorkel AI, Inc., Series C, (Acquired 06/30/21, Cost: $4,999,985)		332,896		3,685,159
Snyk Ltd., Series F, (Acquired 09/02/21, Cost: $4,807,688)		337,018		3,872,337
Unqork, Inc.
Series B, (Acquired 09/19/19, Cost: $3,198,417)		281,080		2,006,911
Series C, (Acquired 09/18/20, Cost: $1,303,260)		47,600		419,832
				65,498,316
				213,391,632
Total Preferred Securities — 18.4%     (Cost: $213,087,190)			213,391,632

C O N S O L I D A T E D   S C H E D U L E   O F   I N V E S T M E N T S 109

Consolidated Schedule of Investments  (unaudited) (continued) June 30, 2023      BlackRock Science and Technology Trust (BST) (Percentages shown are based on Net Assets)

Security	Shares		Value
Warrants
IT Services — 0.0%
TRAX Ltd., (Acquired 09/12/19, Cost: $0), (Issued 09/23/19, Exercisable 07/12/23, 1 Share for 1 Warrant, Expires 09/15/23, Strike Price USD 46.88)(b)(d)(e)		17,065	$	—
Total Warrants — 0.0%     (Cost: $—)			—
Total Long-Term Investments — 101.2%     (Cost: $739,748,696)			1,175,385,910
Short-Term Securities
Money Market Funds — 0.3%
BlackRock Liquidity Funds, T-Fund, Institutional Class, 4.98%(i)(j)		359,934		359,934
SL Liquidity Series, LLC, Money Market Series, 5.28%(i)(j)(k)		2,573,433		2,573,433
Total Short-Term Securities — 0.3%     (Cost: $2,933,194)			2,933,367
Total Investments Before Options Written — 101.5%     (Cost: $742,681,890)			1,178,319,277
Options Written — (1.6)%     (Premiums Received: $(12,549,700))			(19,101,911)
Total Investments, Net of Options Written — 99.9%     (Cost: $730,132,190)			1,159,217,366
Other Assets Less Liabilities — 0.1%			1,703,406
Net Assets — 100.0%			$ 1,160,920,772

^(a)  All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.

^(b)  Non-income producing security.

^(c)  All or a portion of this security is on loan.

^(d)  Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy.

^(e) Restricted security as to resale, excluding 144A securities. The Trust held restricted securities with a current value of $265,354,627, representing 22.9% of its net assets as of period end, and an original cost of $307,911,241.

^(f)  Security exempt from registration pursuant to Rule 144A under the Securities Act of 1933, as amended. These securities may be resold in transactions exempt from registration to qualified institutional investors.

^(g)  All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives.

^(h)  All or a portion of the security is held by a wholly-owned subsidiary. See Note 1 of the Notes to Consolidated Financial Statements for details on the wholly-owned subsidiary.

⁽ⁱ⁾ Affiliate of the Trust.

^(j) Annualized 7-day yield as of period end.

^(k)  All or a portion of this security was purchased with the cash collateral from loaned securities.

For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

Affiliates

Investments in issuers considered to be affiliate(s) of the Trust during the six months ended June 30, 2023 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

Affiliated Issuer	Value at 12/31/22		Purchases at Cost			Proceeds from Sales			Net Realized Gain (Loss)		Change in Unrealized Appreciation (Depreciation)		Value at 06/30/23		Shares Held at 06/30/23		Income			Capital Gain Distributions from Underlying Funds
BlackRock Liquidity Funds, T-Fund, Institutional Class	$	5,779,501	$	—		$	(5,419,567	)(a)	$	—	$	—	$	359,934		359,934	$	161,024		$	—
SL Liquidity Series, LLC, Money Market Series		825,025		1,747,720	(a)		—			595		93		2,573,433		2,573,433		8,501	(b)		—
									$	595	$	93	$	2,933,367			$	169,525		$	—

^(a)  Represents net amount purchased (sold).

^(b)  All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities.

Derivative Financial Instruments Outstanding as of Period End

Exchange-Traded Options Written

Description	Number of Contracts		Expiration Date		Exercise Price		Notional Amount (000)		Value
Call
Adobe, Inc.		28		07/07/23		USD        440.00		USD        1,369	$	(138,670	)

110 2 0 2 3   B L A C K R O C K  S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Consolidated Schedule of Investments  (unaudited) (continued) June 30, 2023      BlackRock Science and Technology Trust (BST)

Exchange-Traded Options Written (continued)

Description	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call (continued)
Alibaba Group Holding Ltd., ADR		184		07/07/23		USD	85.00		USD	1,534	$	(16,376	)
Alphabet, Inc., Class A		176		07/07/23		USD	124.34		USD	2,107		(2,810	)
Amazon.com, Inc.		48		07/07/23		USD	123.00		USD	626		(35,760	)
Apple, Inc.		359		07/07/23		USD	185.00		USD	6,964		(329,382	)
Intuit, Inc.		59		07/07/23		USD	440.00		USD	2,703		(112,100	)
Marvell Technology, Inc.		160		07/07/23		USD	62.75		USD	956		(2,658	)
Microsoft Corp.		273		07/07/23		USD	340.00		USD	9,297		(94,868	)
MongoDB, Inc.		34		07/07/23		USD	420.00		USD	1,397		(15,555	)
NVIDIA Corp.		211		07/07/23		USD	380.00		USD	8,926		(919,960	)
S&P Global, Inc.		46		07/07/23		USD	380.00		USD	1,844		(99,130	)
Salesforce, Inc.		128		07/07/23		USD	215.00		USD	2,704		(12,160	)
Shopify, Inc., Class A		218		07/07/23		USD	67.00		USD	1,408		(10,464	)
Spotify Technology SA		105		07/07/23		USD	150.00		USD	1,686		(114,450	)
Tesla, Inc.		110		07/07/23		USD	220.00		USD	2,879		(462,000	)
Advanced Micro Devices, Inc.		51		07/14/23		USD	120.00		USD	581		(6,911	)
Alphabet, Inc., Class A		115		07/14/23		USD	125.00		USD	1,377		(5,520	)
Amazon.com, Inc.		56		07/14/23		USD	129.00		USD	730		(19,180	)
Apple, Inc.		376		07/14/23		USD	185.00		USD	7,293		(355,320	)
Arista Networks, Inc.		54		07/14/23		USD	170.00		USD	875		(6,210	)
Crowdstrike Holdings, Inc., Class A		72		07/14/23		USD	162.50		USD	1,057		(2,556	)
Lam Research Corp.		39		07/14/23		USD	620.00		USD	2,507		(116,317	)
Marvell Technology, Inc.		218		07/14/23		USD	61.00		USD	1,303		(23,762	)
Mastercard, Inc., Class A		137		07/14/23		USD	385.00		USD	5,388		(136,315	)
MercadoLibre, Inc.		31		07/14/23		USD	1,290.00		USD	3,672		(25,575	)
Meta Platforms, Inc., Class A		28		07/14/23		USD	285.00		USD	804		(20,860	)
Micron Technology, Inc.		12		07/14/23		USD	72.00		USD	76		(84	)
Micron Technology, Inc.		142		07/14/23		USD	68.00		USD	896		(3,550	)
Microsoft Corp.		199		07/14/23		USD	330.00		USD	6,777		(237,805	)
Netflix, Inc.		32		07/14/23		USD	420.00		USD	1,410		(77,920	)
NVIDIA Corp.		200		07/14/23		USD	400.00		USD	8,460		(540,000	)
Oracle Corp.		171		07/14/23		USD	110.00		USD	2,036		(157,747	)
ROBLOX Corp., Class A		227		07/14/23		USD	43.00		USD	915		(13,393	)
ServiceNow, Inc.		32		07/14/23		USD	545.00		USD	1,798		(72,320	)
Snowflake, Inc., Class A		24		07/14/23		USD	200.00		USD	422		(2,052	)
Spotify Technology SA		51		07/14/23		USD	157.50		USD	819		(27,795	)
Take-Two Interactive Software, Inc.		76		07/14/23		USD	136.00		USD	1,118		(88,160	)
Tesla, Inc.		141		07/14/23		USD	235.00		USD	3,691		(414,892	)
Uber Technologies, Inc.		501		07/14/23		USD	41.00		USD	2,163		(124,749	)
Unity Software, Inc.		187		07/14/23		USD	40.00		USD	812		(77,138	)
Visa, Inc., Class A		34		07/14/23		USD	230.00		USD	807		(28,390	)
Cadence Design Systems, Inc.		300		07/17/23		USD	211.00		USD	7,036		(728,624	)
Advanced Micro Devices, Inc.		223		07/21/23		USD	113.00		USD	2,540		(108,155	)
Alphabet, Inc., Class A		222		07/21/23		USD	125.00		USD	2,657		(19,980	)
Amazon.com, Inc.		106		07/21/23		USD	120.00		USD	1,382		(116,865	)
Amazon.com, Inc.		149		07/21/23		USD	130.00		USD	1,942		(53,268	)
ANSYS, Inc.		85		07/21/23		USD	320.00		USD	2,807		(114,750	)
Credo Technology Group Holding Ltd.		417		07/21/23		USD	8.36		USD	723		(375,525	)
Credo Technology Group Holding Ltd.		667		07/21/23		USD	20.00		USD	1,157		(10,005	)
Crowdstrike Holdings, Inc., Class A		76		07/21/23		USD	160.00		USD	1,116		(8,246	)
Flex Ltd.		800		07/21/23		USD	24.00		USD	2,211		(292,000	)
Lam Research Corp.		45		07/21/23		USD	615.00		USD	2,893		(165,262	)
Mastercard, Inc., Class A		185		07/21/23		USD	385.00		USD	7,276		(210,900	)
Micron Technology, Inc.		266		07/21/23		USD	72.50		USD	1,679		(3,059	)
Microsoft Corp.		86		07/21/23		USD	330.00		USD	2,929		(122,980	)
Microsoft Corp.		185		07/21/23		USD	340.00		USD	6,300		(132,275	)
MongoDB, Inc.		28		07/21/23		USD	280.00		USD	1,151		(370,300	)
Monolithic Power Systems, Inc.		37		07/21/23		USD	431.00		USD	1,999		(410,562	)
Motorola Solutions, Inc.		45		07/21/23		USD	300.00		USD	1,320		(7,313	)
Motorola Solutions, Inc.		44		07/21/23		USD	290.00		USD	1,290		(28,820	)
Netflix, Inc.		25		07/21/23		USD	360.00		USD	1,101		(207,750	)
NEXTracker, Inc., Class A		378		07/21/23		USD	45.00		USD	1,505		(11,340	)
NVIDIA Corp.		127		07/21/23		USD	390.00		USD	5,372		(483,552	)

C O N S O L I D A T E D    S C H E D U L E    O F   I N V E S T M E N T S 111

Consolidated Schedule of Investments  (unaudited) (continued) June 30, 2023      BlackRock Science and Technology Trust (BST)

Exchange-Traded Options Written (continued)

Description	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call (continued)
Oracle Corp.		197		07/21/23		USD	105.00		USD	2,346	$	(280,232	)
Salesforce, Inc.		47		07/21/23		USD	210.00		USD	993		(26,673	)
ServiceNow, Inc.		18		07/21/23		USD	570.00		USD	1,012		(20,430	)
Taiwan Semiconductor Manufacturing Co. Ltd., ADR		280		07/21/23		USD	105.00		USD	2,826		(45,500	)
Take-Two Interactive Software, Inc.		93		07/21/23		USD	145.00		USD	1,369		(41,153	)
Tesla, Inc.		125		07/21/23		USD	195.00		USD	3,272		(847,500	)
Uber Technologies, Inc.		516		07/21/23		USD	40.00		USD	2,228		(183,180	)
Unity Software, Inc.		116		07/21/23		USD	35.00		USD	504		(100,630	)
Visa, Inc., Class A		20		07/21/23		USD	230.00		USD	475		(17,950	)
Wolfspeed, Inc.		533		07/21/23		USD	50.00		USD	2,963		(343,785	)
Advanced Micro Devices, Inc.		210		07/28/23		USD	127.00		USD	2,392		(30,240	)
Alibaba Group Holding Ltd., ADR		118		07/28/23		USD	92.00		USD	984		(12,685	)
Alphabet, Inc., Class A		97		07/28/23		USD	126.00		USD	1,161		(17,751	)
Amazon.com, Inc.		48		07/28/23		USD	137.00		USD	626		(14,136	)
Apple, Inc.		357		07/28/23		USD	185.00		USD	6,925		(382,882	)
Arista Networks, Inc.		95		07/28/23		USD	165.00		USD	1,540		(42,275	)
Autodesk, Inc.		114		07/28/23		USD	220.00		USD	2,333		(15,390	)
Broadcom, Inc.		135		07/28/23		USD	890.00		USD	11,710		(226,800	)
First Solar, Inc.		81		07/28/23		USD	205.00		USD	1,540		(38,475	)
Marvell Technology, Inc.		130		07/28/23		USD	66.00		USD	777		(8,450	)
MercadoLibre, Inc.		17		07/28/23		USD	1,290.00		USD	2,014		(31,025	)
Meta Platforms, Inc., Class A		216		07/28/23		USD	280.00		USD	6,199		(398,520	)
Microsoft Corp.		120		07/28/23		USD	345.00		USD	4,086		(99,600	)
MongoDB, Inc.		30		07/28/23		USD	380.00		USD	1,233		(120,450	)
Netflix, Inc.		29		07/28/23		USD	465.00		USD	1,277		(38,933	)
NVIDIA Corp.		180		07/28/23		USD	425.00		USD	7,614		(319,050	)
Oracle Corp.		205		07/28/23		USD	127.00		USD	2,441		(10,763	)
ROBLOX Corp., Class A		236		07/28/23		USD	43.00		USD	951		(28,674	)
S&P Global, Inc.		49		07/28/23		USD	400.00		USD	1,964		(40,915	)
Shopify, Inc., Class A		219		07/28/23		USD	68.00		USD	1,415		(56,831	)
Spotify Technology SA		68		07/28/23		USD	167.50		USD	1,092		(41,820	)
Take-Two Interactive Software, Inc.		18		07/28/23		USD	143.00		USD	265		(11,385	)
Tesla, Inc.		68		07/28/23		USD	280.00		USD	1,780		(70,380	)
Tesla, Inc.		46		07/28/23		USD	295.00		USD	1,204		(31,280	)
Unity Software, Inc.		200		07/28/23		USD	45.00		USD	868		(45,800	)
Visa, Inc., Class A		114		07/28/23		USD	235.00		USD	2,707		(79,515	)
Adobe, Inc.		28		08/04/23		USD	500.00		USD	1,369		(35,280	)
Advanced Micro Devices, Inc.		224		08/04/23		USD	115.00		USD	2,552		(141,680	)
Alphabet, Inc., Class A		58		08/04/23		USD	121.00		USD	694		(23,490	)
Amazon.com, Inc.		291		08/04/23		USD	137.00		USD	3,793		(98,212	)
Apple, Inc.		280		08/04/23		USD	190.00		USD	5,431		(230,300	)
Intuit, Inc.		59		08/04/23		USD	470.00		USD	2,703		(60,770	)
Marvell Technology, Inc.		250		08/04/23		USD	61.00		USD	1,495		(58,750	)
Microsoft Corp.		173		08/04/23		USD	340.00		USD	5,891		(211,060	)
NVIDIA Corp.		181		08/04/23		USD	455.00		USD	7,657		(174,665	)
Salesforce, Inc.		76		08/04/23		USD	220.00		USD	1,606		(25,270	)
ServiceNow, Inc.		18		08/04/23		USD	570.00		USD	1,012		(39,510	)
Snowflake, Inc., Class A		38		08/04/23		USD	190.00		USD	669		(21,660	)
Tesla, Inc.		117		08/04/23		USD	290.00		USD	3,063		(104,130	)
Visa, Inc., Class A		226		08/04/23		USD	240.00		USD	5,367		(106,220	)
First Solar, Inc.		60		08/11/23		USD	200.00		USD	1,141		(47,850	)
MercadoLibre, Inc.		14		08/11/23		USD	1,290.00		USD	1,658		(55,090	)
Snowflake, Inc., Class A		27		08/11/23		USD	200.00		USD	475		(11,340	)
Unity Software, Inc.		173		08/11/23		USD	45.00		USD	751		(65,740	)
Alphabet, Inc., Class A		78		08/18/23		USD	130.00		USD	934		(13,026	)
Amazon.com, Inc.		57		08/18/23		USD	125.00		USD	743		(56,573	)
ANSYS, Inc.		69		08/18/23		USD	341.00		USD	2,279		(63,587	)
Apple, Inc.		377		08/18/23		USD	190.00		USD	7,313		(328,932	)
Cadence Design Systems, Inc.		229		08/18/23		USD	240.00		USD	5,371		(170,605	)
Credo Technology Group Holding Ltd.		420		08/18/23		USD	10.00		USD	728		(317,100	)
Credo Technology Group Holding Ltd.		1,086		08/18/23		USD	20.00		USD	1,883		(48,870	)
Flex Ltd.		710		08/18/23		USD	26.55		USD	1,962		(116,999	)

112 2 0 2 3   B L A C K R O C K  S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Consolidated Schedule of Investments  (unaudited) (continued) June 30, 2023      BlackRock Science and Technology Trust (BST)

Exchange-Traded Options Written (continued)

Description	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call (continued)
Meta Platforms, Inc., Class A		99		08/18/23		USD	300.00		USD	2,841	$	(121,522	)
MongoDB, Inc.		66		08/18/23		USD	390.00		USD	2,713		(267,630	)
Monolithic Power Systems, Inc.		68		08/18/23		USD	530.00		USD	3,674		(289,340	)
NEXTracker, Inc., Class A		600		08/18/23		USD	45.00		USD	2,389		(88,500	)
Taiwan Semiconductor Manufacturing Co. Ltd., ADR		83		08/18/23		USD	110.00		USD	838		(11,952	)
Wolfspeed, Inc.		361		08/18/23		USD	60.00		USD	2,007		(137,180	)
											$	(16,596,286	)

OTC Options Written

Description	Counterparty	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call
Adyen NV	Goldman Sachs International		3,000		07/11/23		EUR	1,489.94		EUR	4,761	$	(334,667	)
GMO Payment Gateway, Inc.	UBS AG		17,400		07/11/23		JPY	11,720.91		JPY	196,941		(8,189	)
Renesas Electronics Corp.	Citibank N.A.		67,300		07/12/23		JPY	2,192.87		JPY	183,270		(244,332	)
SiteMinder Ltd.	UBS AG		15,000		07/12/23		AUD	3.34		AUD	44		(97	)
Wise PLC, Class A	JPMorgan Chase Bank N.A.		97,700		07/12/23		GBP	6.26		GBP	643		(61,757	)
Keyence Corp.	UBS AG		4,000		07/13/23		JPY	69,721.80		JPY	274,251		(21,601	)
ASM International NV	Morgan Stanley & Co. International PLC		15,100		07/18/23		EUR	415.64		EUR	5,876		(40,305	)
Dassault Systemes SE	Morgan Stanley & Co. International PLC		70,800		07/18/23		EUR	42.75		EUR	2,875		(9,126	)
Renesas Electronics Corp.	Goldman Sachs International		67,300		07/18/23		JPY	2,256.97		JPY	183,270		(219,312	)
STMicroelectronics NV	Morgan Stanley & Co. International PLC		43,800		07/18/23		EUR	41.38		EUR	2,002		(209,416	)
STMicroelectronics NV	Morgan Stanley & Co. International PLC		30,200		07/18/23		EUR	42.64		EUR	1,380		(107,585	)
Wise PLC, Class A	Morgan Stanley & Co. International PLC		41,500		07/18/23		GBP	6.32		GBP	273		(27,458	)
Xero Ltd.	Goldman Sachs International		18,150		07/18/23		AUD	107.07		AUD	2,183		(148,720	)
Samsung Electronics Co. Ltd.	Morgan Stanley & Co. International PLC		38,000		07/19/23		KRW	69,488.00		KRW	2,757,055		(91,297	)
GMO Payment Gateway, Inc.	BNP Paribas SA		600		07/25/23		JPY	11,462.45		JPY	6,791		(1,034	)
M3, Inc.	UBS AG		99,800		07/26/23		JPY	3,281.90		JPY	314,000		(29,407	)
RELX PLC	Morgan Stanley & Co. International PLC		85,600		07/26/23		GBP	26.04		GBP	2,249		(70,801	)
SiteMinder Ltd.	Citibank N.A.		11,000		07/26/23		AUD	3.22		AUD	32		(434	)
SOITEC	Morgan Stanley & Co. International PLC		5,800		07/26/23		EUR	140.88		EUR	899		(100,391	)
Wise PLC, Class A	Goldman Sachs International		27,700		07/26/23		GBP	6.28		GBP	182		(21,386	)
ASML Holding NV	Goldman Sachs International		20,100		08/01/23		EUR	701.02		EUR	13,361		(213,844	)
SOITEC	Morgan Stanley & Co. International PLC		13,000		08/01/23		EUR	160.16		EUR	2,015		(48,777	)
SOITEC	Morgan Stanley & Co. International PLC		5,800		08/01/23		EUR	143.71		EUR	899		(89,239	)
Trip.com Group Ltd.	BNP Paribas SA		88,300		08/01/23		HKD	317.70		HKD	24,154		(15,841	)
SiteMinder Ltd.	Citibank N.A.		16,400		08/02/23		AUD	3.33		AUD	48		(594	)
Wise PLC, Class A	Goldman Sachs International		61,100		08/02/23		GBP	6.82		GBP	402		(28,737	)
GMO Payment Gateway, Inc.	Societe Generale		19,400		08/10/23		JPY	12,629.90		JPY	219,578		(9,844	)
SOITEC	Goldman Sachs International		5,800		08/10/23		EUR	157.04		EUR	899		(40,581	)
Wise PLC, Class A	Goldman Sachs International		70,000		08/10/23		GBP	6.39		GBP	461		(53,712	)
Samsung SDI Co. Ltd.	BNP Paribas SA		7,700		08/14/23		KRW	700,667.26		KRW	5,180,848		(78,243	)
Tencent Holdings Ltd.	Citibank N.A.		77,800		08/15/23		HKD	344.60		HKD	25,849		(96,973	)
Xero Ltd.	UBS AG		18,100		08/15/23		AUD	116.91		AUD	2,177		(81,925	)
												$	(2,505,625	)

Balances Reported in the Consolidated Statements of Assets and Liabilities for Options Written

Description	Swap Premiums Paid		Swap Premiums Received		Unrealized Appreciation		Unrealized Depreciation		Value
Options Written		$       N/A		$       N/A		$   2,663,738		$ (9,215,949)		$ (19,101,911	)

C O N S O L I D A T E D   S C H E D U L E   O F   I N V E S T M E N T S 113

Consolidated Schedule of Investments  (unaudited) (continued) June 30, 2023 BlackRock Science and Technology Trust (BST)

Derivative Financial Instruments Categorized by Risk Exposure

As of period end, the fair values of derivative financial instruments located in the Consolidated Statements of Assets and Liabilities were as follows:

	Commodity Contracts		Credit Contracts		Equity Contracts		Foreign Currency Exchange Contracts		Interest Rate Contracts		Other Contracts		Total
Liabilities — Derivative Financial Instruments
Options written
Options written at value	$	—	$	—	$	19,101,911	$	—	$	—	$	—	$	19,101,911

For the period ended June 30, 2023, the effect of derivative financial instruments in the Consolidated Statements of Operations was as follows:

	Commodity Contracts		Credit Contracts		Equity Contracts			Foreign Currency Exchange Contracts		Interest Rate Contracts		Other Contracts		Total
Net Realized Gain (Loss) from:
Options purchased(a)	$	—	$	—	$	(2,858,012	)	$	—	$	—	$	—	$	(2,858,012	)
Options written		—		—		(27,510,651	)		—		—		—		(27,510,651	)
	$	—	$	—	$	(30,368,663	)	$	—	$	—	$	—	$	(30,368,663	)
Net Change in Unrealized Appreciation (Depreciation) on:
Options written	$	—	$	—	$	(13,957,447	)	$	—	$	—	$	—	$	(13,957,447	)

^(a)  Options purchased are included in net realized gain (loss) from investments — unaffiliated.

Average Quarterly Balances of Outstanding Derivative Financial Instruments

Options:
Average value of option contracts purchased	$	—	(a)
Average value of option contracts written	$	18,056,104

^(a)  Derivative not held at any quarter-end. The risk exposure table serves as an indicator of activity during the period.

For more information about the Trust’s investment risks regarding derivative financial instruments, refer to the Notes to Consolidated Financial Statements.

Derivative Financial Instruments — Offsetting as of Period End

The Trust’s derivative assets and liabilities (by type) were as follows:

	Assets		Liabilities
Derivative Financial Instruments
Options	$	—	$	19,101,911
Total derivative assets and liabilities in the Consolidated Statements of Assets and Liabilities		—		19,101,911
Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”)		—		(16,596,286	)
Total derivative assets and liabilities subject to an MNA	$	—	$	2,505,625

114 2 0 2 3   B L A C K R O C K  S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Consolidated Schedule of Investments  (unaudited) (continued) June 30, 2023      BlackRock Science and Technology Trust (BST)

The following table presents the Trust’s derivative liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral pledged by the Trust:

Counterparty		Derivative Liabilities Subject to an MNA by Counterparty		Derivatives Available for Offset		Non-Cash Collateral Pledged		Cash Collateral Pledged	(a)		Net Amount of Derivative Liabilities	(b)
BNP Paribas SA	$	95,118	$	—	$	—	$	—		$	95,118
Citibank N.A.		342,333		—		—		(330,000	)		12,333
Goldman Sachs International		1,060,959		—		—		—			1,060,959
JPMorgan Chase Bank N.A.		61,757		—		—		(61,757	)		—
Morgan Stanley & Co. International PLC		794,395		—		—		—			794,395
Societe Generale		9,844		—		—		—			9,844
UBS AG		141,219		—		—		—			141,219
	$	2,505,625	$	—	$	—	$	(391,757	)	$	2,113,868

^(a)  Excess of collateral received/pledged, if any, from the individual counterparty is not shown for financial reporting purposes.

^(b)  Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Consolidated Statements of Assets and Liabilities.

Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of financial instruments. For a description of the input levels and information about the Trust’s policy regarding valuation of financial instruments, refer to the Notes to Consolidated Financial Statements.

The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust’s financial instruments into major categories is disclosed in the Consolidated Schedule of Investments above.

	Level 1		Level 2		Level 3		Total
Assets
Investments
Long-Term Investments
Common Stocks
Automobiles	$	28,573,504	$	—	$	—	$	28,573,504
Broadline Retail		40,424,071		—		—		40,424,071
Capital Markets		8,478,824		—		—		8,478,824
Communications Equipment		10,750,477		—		—		10,750,477
Diversified Consumer Services		—		—		12,989,863		12,989,863
Electrical Equipment		6,727,890		—		—		6,727,890
Electronic Equipment, Instruments & Components		9,157,685		12,219,809		—		21,377,494
Entertainment		26,523,925		—		—		26,523,925
Financial Services		47,476,094		21,746,710		—		69,222,804
Ground Transportation		9,650,826		—		—		9,650,826
Health Care Technology		—		4,725,058		—		4,725,058
Hotels, Restaurants & Leisure		—		6,397,146		—		6,397,146
Interactive Media & Services		41,639,258		6,758,747		1,552,981		49,950,986
IT Services		24,023,479		—		23,250,261		47,273,740
Professional Services		—		6,351,373		5,604,673		11,956,046
Semiconductors & Semiconductor Equipment		190,200,690		69,740,192		—		259,940,882
Software		222,001,776		15,434,120		8,435,092		245,870,988
Specialty Retail		—		—		130,124		130,124
Technology Hardware, Storage & Peripherals		96,482,618		4,547,011		—		101,029,629
Convertible Notes		—		—		1		1
Preferred Securities
Preferred Stocks		—		—		213,391,632		213,391,632
Warrants		—		—		—		—
Short-Term Securities
Money Market Funds		359,934		—		—		359,934
	$	762,471,051	$	147,920,166	$	265,354,627		1,175,745,844
Investments Valued at NAV(a)								2,573,433
							$	1,178,319,277

C O N S O L I D A T E D   S C H E D U L E   O F   I N V E S T M E N T S 115

Consolidated Schedule of Investments  (unaudited)  (continued) June 30, 2023      BlackRock Science and Technology Trust (BST)

Fair Value Hierarchy as of Period End (continued)

	Level 1			Level 2			Level 3		Total
Derivative Financial Instruments(b)
Liabilities
Equity Contracts	$	(14,895,521	)	$	(4,206,390	)	$	—	$	(19,101,911	)

^(a)  Certain investments of the Trust were fair valued using NAV as a practical expedient as no quoted market value is available and therefore have been excluded from the fair value hierarchy.

^(b)  Derivative financial instruments are options written. Options written are shown at value.

A reconciliation of Level 3 financial instruments is presented when the Trust had a significant amount of Level 3 investments and derivative financial instruments at the beginning and/or end of the period in relation to net assets. The following table is a reconciliation of Level 3 investments for which significant unobservable inputs were used in determining fair value:

	Common Stocks			Convertible Notes			Preferred Stocks		Warrants			Total
Assets
Opening balance, as of December 31, 2022	$	60,069,300		$	1,920,000		$	195,967,596	$	16,212		$	257,973,108
Transfers into Level 3		—			—			—		—			—
Transfers out of Level 3		—			—			—		—			—
Other(a)		(7,504,341	)		—			7,504,341		—			—
Accrued discounts/premiums		—			—			—		—			—
Net realized gain (loss)		—			—			—		—			—
Net change in unrealized appreciation (depreciation)(b)(c)		(601,965	)		(1,919,999	)		9,919,695		(16,212	)		7,381,519
Purchases		—			—			—		—			—
Sales		—			—			—		—			—
Closing balance, as of June 30, 2023	$	51,962,994		$	1		$	213,391,632	$	—	(d)	$	265,354,627
Net change in unrealized appreciation (depreciation) on investments still held at June 30, 2023	$	(601,965	)	$	(1,919,999	)	$	9,919,695	$	(16,212	)	$	7,381,519

^(a)  Certain Level 3 investments were re-classified between Common Stocks and Preferred Stocks.

^(b)  Included in the related net change in unrealized appreciation (depreciation) in the Consolidated Statements of Operations.

^(c)  Any difference between net change in unrealized appreciation (depreciation) and net change in unrealized appreciation (depreciation) on investments still held at June 30, 2023 is generally due to investments no longer held or categorized as Level 3 at period end.

^(d)  Rounds to less than $1.

The following table summarizes the valuation approaches used and unobservable inputs utilized by the BlackRock Valuation Committee (the “Valuation Committee”) to determine the value of certain of the Trust’s Level 3 financial instruments as of period end. The table does not include Level 3 financial instruments with values based upon unadjusted third-party pricing information in the amount of $1. A significant change in third party information could result in a significantly lower or higher value of such Level 3 financial instruments.

		Value	Valuation Approach	Unobservable Inputs	Range of Unobservable Inputs Utilized	(a)	Weighted Average of Unobservable Inputs Based on Fair Value
Assets
Common Stocks	$	51,962,994	Market	Revenue Multiple	1.80x - 28.00x		10.99x
				Volatility	70%		—
				Time to Exit	3.0 years		—
				Gross Profit Multiple	18.00x		—
			Income	Discount	11%		—
Preferred Stocks		213,391,632	Market	Revenue Multiple	1.80x ‑ 29.00x		15.21x
				Volatility	50% - 75%		65%
				Time to Exit	3.0 ‑ 5.0 years		4.1 years
				Market Adjustment Multiple	1.10x - 1.10x		1.10x
				Gross Profit Multiple	6.75x		—
	$	265,354,626

^(a)  A significant change in unobservable input would have resulted in a correlated (inverse) significant change to value.

See notes to financial statements.

116 2 0 2 3   B L A C K R O C K  S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Schedule of Investments  (unaudited) June 30, 2023
     BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI) (Percentages shown are based on Net Assets)

Security	Shares		Value
Common Stocks
Building Products — 5.6%
Johnson Controls International PLC(a)		167,509	$	11,414,063
Kingspan Group PLC		99,765		6,640,739
Trane Technologies PLC(a)		56,900		10,882,694
				28,937,496
Chemicals — 4.1%
Air Liquide SA		45,218		8,109,175
LG Chem Ltd.		9,200		4,683,368
Linde PLC		21,328		8,134,281
				20,926,824
Commercial Services & Supplies(a) — 5.2%
Republic Services, Inc.		69,750		10,683,607
Waste Management, Inc.		94,200		16,336,164
				27,019,771
Construction & Engineering — 5.2%
Quanta Services, Inc.(a)		48,460		9,519,967
Vinci SA		148,150		17,214,351
				26,734,318
Electric Utilities — 30.5%
American Electric Power Co., Inc.(a)		155,650		13,105,730
Duke Energy Corp.(a)		118,418		10,626,831
EDP - Energias de Portugal SA		1,804,300		8,818,815
Enel SpA		3,587,775		24,190,298
Exelon Corp.(a)		312,408		12,727,502
FirstEnergy Corp.(a)		87,550		3,403,944
Iberdrola SA		893,763		11,671,476
Neoenergia SA		902,200		4,000,189
NextEra Energy, Inc.(a)(b)		552,380		40,986,596
Orsted A/S(c)		74,600		7,072,250
PG&E Corp.(a)(d)		655,400		11,325,312
SSE PLC		167,800		3,934,923
Xcel Energy, Inc.(a)		87,390		5,433,036
				157,296,902
Electrical Equipment — 5.6%
Eaton Corp. PLC(a)		27,240		5,477,964
Prysmian SpA		135,350		5,660,838
Schneider Electric SE		29,782		5,410,693
Sunrun, Inc.(d)(e)		132,650		2,369,129
Vestas Wind Systems A/S(d)		379,121		10,079,814
				28,998,438
Electronic Equipment, Instruments & Components — 1.6%
Rogers Corp.(d)		21,600		3,497,688
Samsung SDI Co. Ltd.		9,150		4,672,305
				8,169,993
Ground Transportation — 1.0%
Union Pacific Corp.(a)		25,800		5,279,196
Independent Power and Renewable Electricity Producers — 8.7%
AES Corp.(a)		229,590		4,759,402
China Longyuan Power Group Corp. Ltd., Class H		3,620,000		3,739,005
EDP Renovaveis SA		503,430		10,060,290
Orron Energy AB(d)		2,103,600		2,215,723
RWE AG		489,545		21,332,554
Sunnova Energy International, Inc.(d)(e)		140,150		2,566,147
				44,673,121
Machinery — 5.4%
Atlas Copco AB, B Shares		1,064,300		13,270,199

Security	Shares		Value
Machinery (continued)
Ingersoll Rand, Inc.(a)		144,050	$	9,415,108
Spirax-Sarco Engineering PLC		37,650		4,962,423
				27,647,730
Multi-Utilities — 10.0%
CMS Energy Corp.(a)		130,410		7,661,588
Dominion Energy, Inc.(a)		176,898		9,161,547
National Grid PLC		564,774		7,487,977
Public Service Enterprise Group, Inc.(a)		200,142		12,530,891
Sempra Energy(a)(b)		100,350		14,609,956
				51,451,959
Oil, Gas & Consumable Fuels — 10.1%
Cheniere Energy, Inc.(a)		90,400		13,773,344
Enterprise Products Partners LP(a)		198,313		5,225,547
Kinder Morgan, Inc.(a)		615,200		10,593,744
TC Energy Corp.		159,550		6,448,241
Williams Cos., Inc.(a)(b)		481,655		15,716,403
				51,757,279
Semiconductors & Semiconductor Equipment — 5.5%
Analog Devices, Inc.(a)		28,224		5,498,317
ASML Holding NV		7,050		5,113,568
Canadian Solar, Inc.(a)(d)(e)		82,140		3,177,997
First Solar, Inc.(a)(d)		19,584		3,722,723
Infineon Technologies AG		132,850		5,471,059
STMicroelectronics NV		109,950		5,483,578
				28,467,242
Total Long-Term Investments — 98.5% (Cost: $356,356,062)				507,360,269
Short-Term Securities
Money Market Funds — 2.9%
BlackRock Liquidity Funds, T-Fund, Institutional Class, 4.98%(f)(g)		12,129,346		12,129,346
SL Liquidity Series, LLC, Money Market Series, 5.28%(f)(g)(h)		2,504,624		2,504,624
Total Short-Term Securities — 2.9% (Cost: $14,633,993)				14,633,970
Total Investments Before Options Written — 101.4% (Cost: $370,990,055)				521,994,239
Options Written — (0.9)% (Premiums Received: $(4,020,391))				(4,647,061	)
Total Investments, Net of Options Written — 100.5% (Cost: $366,969,664)				517,347,178
Liabilities in Excess of Other Assets — (0.5)%				(2,349,892	)
Net Assets — 100.0%			$	514,997,286

^(a)  All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.

^(b)  All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives.

^(c)  Security exempt from registration pursuant to Rule 144A under the Securities Act of 1933, as amended. These securities may be resold in transactions exempt from registration to qualified institutional investors.

^(d)  Non-income producing security.

^(e)  All or a portion of this security is on loan.

^(f)  Affiliate of the Trust.

^(g)  Annualized 7-day yield as of period end.

^(h)  All or a portion of this security was purchased with the cash collateral from loaned securities.

S C H E D U L E   O F   I N V E S T M E N T S 117

Schedule of Investments  (unaudited) (continued) June 30, 2023      BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI)

For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

Affiliates

Investments in issuers considered to be affiliate(s) of the Trust during the six months ended June 30, 2023 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

Affiliated Issuer	Value at 12/31/22		Purchases at Cost			Proceeds from Sales		Net Realized Gain (Loss)		Change in Unrealized Appreciation (Depreciation)			Value at 06/30/23		Shares Held at 06/30/23		Income			Capital Gain Distributions from Underlying Funds
BlackRock Liquidity Funds, T-Fund, Institutional Class	$	11,042,199	$	1,087,147	(a)	$	—	$	—	$	—		$	12,129,346		12,129,346	$	304,175		$	—
SL Liquidity Series, LLC, Money Market Series		225,179		2,278,780	(a)		—		810		(145	)		2,504,624		2,504,624		6,757	(b)		—
								$	810	$	(145	)	$	14,633,970			$	310,932		$	—

^(a)  Represents net amount purchased (sold).

^(b)  All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities.

Derivative Financial Instruments Outstanding as of Period End

Exchange-Traded Options Written

Description	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call
Analog Devices, Inc.		24		07/07/23		USD	185.00		USD	468	$	(24,481	)
Enterprise Products Partners LP		216		07/07/23		USD	26.00		USD	569		(8,748	)
PG&E Corp.		271		07/07/23		USD	17.50		USD	468		(2,439	)
Waste Management, Inc.		175		07/07/23		USD	160.00		USD	3,035		(238,000	)
Analog Devices, Inc.		23		07/14/23		USD	180.00		USD	448		(35,305	)
Cheniere Energy, Inc.		97		07/14/23		USD	150.00		USD	1,478		(38,800	)
Enterprise Products Partners LP		369		07/14/23		USD	26.52		USD	972		(5,028	)
Kinder Morgan, Inc.		768		07/14/23		USD	17.50		USD	1,322		(5,376	)
PG&E Corp.		272		07/14/23		USD	17.50		USD	470		(5,576	)
Williams Cos., Inc.		493		07/14/23		USD	31.00		USD	1,609		(83,810	)
AES Corp.		570		07/21/23		USD	21.26		USD	1,182		(15,677	)
American Electric Power Co., Inc.		509		07/21/23		USD	90.50		USD	4,286		(4,984	)
Cheniere Energy, Inc.		144		07/21/23		USD	150.00		USD	2,194		(69,840	)
CMS Energy Corp.		456		07/21/23		USD	61.56		USD	2,679		(7,019	)
Dominion Energy, Inc.		310		07/21/23		USD	55.00		USD	1,605		(5,425	)
Duke Energy Corp.		205		07/21/23		USD	100.00		USD	1,840		(1,025	)
Duke Energy Corp.		219		07/21/23		USD	92.50		USD	1,965		(9,307	)
Eaton Corp. PLC		46		07/21/23		USD	170.00		USD	925		(145,360	)
Enterprise Products Partners LP		89		07/21/23		USD	26.00		USD	235		(4,717	)
Enterprise Products Partners LP		198		07/21/23		USD	26.33		USD	522		(6,202	)
Exelon Corp.		390		07/21/23		USD	44.00		USD	1,589		(3,900	)
Exelon Corp.		457		07/21/23		USD	42.00		USD	1,862		(10,282	)
FirstEnergy Corp.		150		07/21/23		USD	40.00		USD	583		(3,000	)
FirstEnergy Corp.		156		07/21/23		USD	39.00		USD	607		(9,360	)
Ingersoll Rand, Inc.		192		07/21/23		USD	58.80		USD	1,255		(129,492	)
Johnson Controls International PLC		100		07/21/23		USD	65.00		USD	681		(35,500	)
Kinder Morgan, Inc.		1,055		07/21/23		USD	17.00		USD	1,817		(45,365	)
Linde PLC		39		07/21/23		USD	375.00		USD	1,486		(38,025	)
NextEra Energy, Inc.		1,298		07/21/23		USD	77.50		USD	9,631		(38,940	)
PG&E Corp.		272		07/21/23		USD	17.00		USD	470		(14,008	)
Public Service Enterprise Group, Inc.		207		07/21/23		USD	64.85		USD	1,296		(6,394	)
Quanta Services, Inc.		84		07/21/23		USD	180.00		USD	1,650		(146,580	)
Sempra Energy		351		07/21/23		USD	150.00		USD	5,110		(16,672	)
TC Energy Corp.		279		07/21/23		CAD	56.00		CAD	1,494		(1,895	)
Trane Technologies PLC		139		07/21/23		USD	175.00		USD	2,659		(236,300	)
Waste Management, Inc.		170		07/21/23		USD	170.00		USD	2,948		(79,050	)

118 2 0 2 3   B L A C K R O C K  S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Schedule of Investments  (unaudited) (continued) June 30, 2023      BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI)

Exchange-Traded Options Written (continued)

Description	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call (continued)
Analog Devices, Inc.		51		07/28/23		USD	195.00		USD	994	$	(26,775	)
Cheniere Energy, Inc.		75		07/28/23		USD	155.00		USD	1,143		(20,625	)
First Solar, Inc.		32		07/28/23		USD	205.00		USD	608		(15,200	)
Johnson Controls International PLC		357		07/28/23		USD	65.05		USD	2,433		(136,578	)
PG&E Corp.		1,478		07/28/23		USD	17.50		USD	2,554		(54,686	)
Williams Cos., Inc.		478		07/28/23		USD	31.40		USD	1,560		(73,528	)
Canadian Solar, Inc.		143		08/04/23		USD	40.00		USD	553		(21,092	)
Union Pacific Corp.		89		08/04/23		USD	205.00		USD	1,821		(49,395	)
Williams Cos., Inc.		670		08/04/23		USD	31.40		USD	2,186		(113,361	)
Public Service Enterprise Group, Inc.		218		08/10/23		USD	61.75		USD	1,365		(46,344	)
First Solar, Inc.		36		08/11/23		USD	200.00		USD	684		(28,710	)
AES Corp.		330		08/18/23		USD	21.00		USD	684		(23,100	)
American Electric Power Co., Inc.		66		08/18/23		USD	85.00		USD	556		(12,870	)
Canadian Solar, Inc.		144		08/18/23		USD	41.00		USD	557		(25,200	)
Dominion Energy, Inc.		309		08/18/23		USD	54.01		USD	1,600		(27,253	)
Eaton Corp. PLC		50		08/18/23		USD	189.50		USD	1,006		(70,680	)
Exelon Corp.		340		08/18/23		USD	40.46		USD	1,385		(38,796	)
Ingersoll Rand, Inc.		310		08/18/23		USD	64.00		USD	2,026		(80,266	)
Johnson Controls International PLC		129		08/18/23		USD	63.75		USD	879		(34,929	)
Kinder Morgan, Inc.		339		08/18/23		USD	17.00		USD	584		(17,458	)
Linde PLC		35		08/18/23		USD	378.00		USD	1,334		(46,761	)
Public Service Enterprise Group, Inc.		275		08/18/23		USD	62.63		USD	1,722		(48,304	)
Quanta Services, Inc.		85		08/18/23		USD	190.00		USD	1,670		(99,875	)
Republic Services, Inc.		122		08/18/23		USD	150.00		USD	1,869		(70,760	)
Republic Services, Inc.		122		08/18/23		USD	146.50		USD	1,869		(103,804	)
TC Energy Corp.		279		08/18/23		CAD	56.00		CAD	1,494		(9,688	)
Trane Technologies PLC		60		08/18/23		USD	186.00		USD	1,148		(60,248	)
Xcel Energy, Inc.		153		08/18/23		USD	66.00		USD	951		(6,952	)
											$	(2,895,120	)

OTC Options Written

Description	Counterparty	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call
Neoenergia SA	JPMorgan Chase Bank N.A.		157,900		07/06/23		BRL	16.27		BRL	3,352	$	(154,185	)
NextEra Energy, Inc.	JPMorgan Chase Bank N.A.		62,900		07/06/23		USD	78.35		USD	4,667		(543	)
Atlas Copco AB, B Shares	Goldman Sachs International		282,000		07/11/23		SEK	139.18		SEK	37,922		(36,917	)
EDP Renovaveis SA	Morgan Stanley & Co. International PLC		29,600		07/11/23		EUR	21.20		EUR	542		—
Enel SpA	Goldman Sachs International		668,700		07/11/23		EUR	6.26		EUR	4,132		(19,220	)
Infineon Technologies AG	Barclays Bank PLC		19,200		07/11/23		EUR	36.13		EUR	725		(39,636	)
Orron Energy AB	UBS AG		264,000		07/11/23		SEK	10.69		SEK	2,999		(20,863	)
Orsted A/S	Goldman Sachs International		6,900		07/11/23		DKK	677.46		DKK	4,463		(1,585	)
Schneider Electric SE	UBS AG		4,600		07/11/23		EUR	164.71		EUR	766		(17,167	)
Vestas Wind Systems A/S	UBS AG		51,000		07/11/23		DKK	222.55		DKK	9,252		(24	)
Neoenergia SA	Citibank N.A.		157,900		07/12/23		BRL	16.64		BRL	3,352		(143,206	)
Prysmian SpA	Goldman Sachs International		22,800		07/12/23		EUR	35.96		EUR	874		(61,131	)
Air Liquide SA	Goldman Sachs International		15,200		07/13/23		EUR	159.49		EUR	2,498		(86,845	)
EDP Renovaveis SA	UBS AG		63,200		07/13/23		EUR	19.00		EUR	1,157		(4,765	)
Enel SpA	Morgan Stanley & Co. International PLC		570,700		07/13/23		EUR	5.98		EUR	3,526		(134,046	)
Iberdrola SA	Goldman Sachs International		107,700		07/13/23		EUR	11.52		EUR	1,289		(22,481	)
Infineon Technologies AG	Barclays Bank PLC		6,200		07/13/23		EUR	36.76		EUR	234		(9,918	)
National Grid PLC	Morgan Stanley & Co. International PLC		129,400		07/13/23		GBP	10.61		GBP	1,351		(4,675	)
RWE AG	Morgan Stanley & Co. International PLC		133,700		07/13/23		EUR	39.89		EUR	5,339		(73,110	)
Xcel Energy, Inc.	Citibank N.A.		15,200		07/17/23		USD	68.89		USD	945		(31	)
STMicroelectronics NV	Morgan Stanley & Co. International PLC		43,300		07/18/23		EUR	42.64		EUR	1,979		(154,253	)
EDP - Energias de Portugal SA	UBS AG		183,500		07/25/23		EUR	4.71		EUR	822		(3,392	)
ASML Holding NV	Goldman Sachs International		2,400		08/01/23		EUR	701.02		EUR	1,595		(25,534	)
EDP Renovaveis SA	Goldman Sachs International		83,400		08/02/23		EUR	19.81		EUR	1,527		(5,655	)
Infineon Technologies AG	Citibank N.A.		21,100		08/02/23		EUR	40.03		EUR	796		(11,956	)
Vestas Wind Systems A/S	UBS AG		81,700		08/02/23		DKK	210.13		DKK	14,822		(21,436	)

S C H E D U L E    O F   I N V E S T M E N T S 119

Schedule of Investments  (unaudited) (continued) June 30, 2023      BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI)

 OTC Options Written  (continued)

Description	Counterparty	Number of Contracts		Expiration Date		Exercise Price			Notional Amount (000)			Value
Call (continued)
China Longyuan Power Group Corp. Ltd., Class H	Morgan Stanley & Co. International PLC		670,000		08/03/23		HKD	8.23		HKD	5,423	$	(31,172	)
EDP - Energias de Portugal SA	Goldman Sachs International		243,700		08/03/23		EUR	4.51		EUR	1,092		(23,654	)
Kingspan Group PLC	Goldman Sachs International		20,600		08/03/23		EUR	60.64		EUR	1,257		(41,315	)
EDP - Energias de Portugal SA	Morgan Stanley & Co. International PLC		204,300		08/10/23		EUR	4.79		EUR	915		(4,494	)
Iberdrola SA	Goldman Sachs International		205,000		08/10/23		EUR	12.18		EUR	2,453		(19,390	)
Orron Energy AB	UBS AG		472,000		08/10/23		SEK	12.81		SEK	5,362		(18,191	)
Schneider Electric SE	UBS AG		5,900		08/10/23		EUR	167.52		EUR	982		(31,029	)
Atlas Copco AB, B Shares	UBS AG		90,600		08/11/23		SEK	140.80		SEK	12,184		(31,990	)
LG Chem Ltd.	BNP Paribas SA		3,300		08/14/23		KRW	727,560.39		KRW	2,213,525		(29,178	)
Samsung SDI Co. Ltd.	BNP Paribas SA		3,300		08/14/23		KRW	700,667.27		KRW	2,220,363		(33,533	)
Orsted A/S	Barclays Bank PLC		19,200		08/15/23		DKK	643.32		DKK	12,420		(77,353	)
RWE AG	UBS AG		37,700		08/15/23		EUR	40.74		EUR	1,506		(31,725	)
Spirax-Sarco Engineering PLC	Morgan Stanley & Co. International PLC		13,200		08/15/23		GBP	103.66		GBP	1,370		(64,743	)
China Longyuan Power Group Corp. Ltd., Class H	Societe Generale		597,000		08/16/23		HKD	8.80		HKD	4,832		(18,332	)
Kingspan Group PLC	UBS AG		14,400		08/16/23		EUR	58.07		EUR	878		(63,249	)
Prysmian SpA	Goldman Sachs International		24,500		08/16/23		EUR	37.25		EUR	939		(52,299	)
Vinci SA	Goldman Sachs International		51,800		08/16/23		EUR	107.49		EUR	5,516		(127,720	)
												$	(1,751,941	)

Balances Reported in the Statements of Assets and Liabilities for Options Written

Description	Swap Premiums Paid		Swap Premiums Received		Unrealized Appreciation		Unrealized Depreciation			Value
Options Written	$	N/A	$	N/A	$	1,321,604	$	(1,948,274	)	$	(4,647,061	)

Derivative Financial Instruments Categorized by Risk Exposure

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

	Commodity Contracts		Credit Contracts		Equity Contracts		Foreign Currency Exchange Contracts		Interest Rate Contracts		Other Contracts		Total
Liabilities — Derivative Financial Instruments
Options written
Options written at value	$	—	$	—	$	4,647,061	$	—	$	—	$	—	$	4,647,061

For the period ended June 30, 2023, the effect of derivative financial instruments in the Statements of Operations was as follows:

	Commodity Contracts		Credit Contracts		Equity Contracts			Foreign Currency Exchange Contracts		Interest Rate Contracts		Other Contracts		Total
Net Realized Gain (Loss) from:
Options purchased(a)	$	—	$	—	$	(2,511,082	)	$	—	$	—	$	—	$	(2,511,082	)
Options written		—		—		7,355,793			—		—		—		7,355,793
	$	—	$	—	$	4,844,711		$	—	$	—	$	—	$	4,844,711
Net Change in Unrealized Appreciation (Depreciation) on:
Options written	$	—	$	—	$	(2,148,041	)	$	—	$	—	$	—	$	(2,148,041	)

^(a)  Options purchased are included in net realized gain (loss) from investments — unaffiliated.

120 2 0 2 3   B L A C K R O C K  S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Schedule of Investments  (unaudited) (continued) June 30, 2023      BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI)

Average Quarterly Balances of Outstanding Derivative Financial Instruments

Options:
Average value of option contracts purchased	$	—	(a)
Average value of option contracts written	$	4,767,092

^(a)  Derivative not held at any quarter-end. The risk exposure table serves as an indicator of activity during the period.

For more information about the Trust’s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.

Derivative Financial Instruments — Offsetting as of Period End

The Trust’s derivative assets and liabilities (by type) were as follows:

	Assets		Liabilities
Derivative Financial Instruments
Options	$	—	$	4,647,061
Total derivative assets and liabilities in the Statements of Assets and Liabilities		—		4,647,061
Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”)		—		(2,895,120	)
Total derivative assets and liabilities subject to an MNA	$	—	$	1,751,941

The following table presents the Trust’s derivative liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral pledged by the Trust:

Counterparty		Derivative Liabilities Subject to an MNA by Counterparty		Derivatives Available for Offset		Non-Cash Collateral Pledged	(a)		Cash Collateral Pledged		Net Amount of Derivative Liabilities	(b)
Barclays Bank PLC	$	126,907	$	—	$	—		$	—	$	126,907
BNP Paribas SA		62,711		—		—			—		62,711
Citibank N.A.		155,193		—		—			—		155,193
Goldman Sachs International		523,746		—		(523,746	)		—		—
JPMorgan Chase Bank N.A.		—		—		—			—		—
JPMorgan Chase Bank N.A.		154,728		—		—			—		154,728
Morgan Stanley & Co. International PLC		466,493		—		(466,493	)		—		—
Societe Generale		18,332		—		—			—		18,332
UBS AG		243,831		—		(101,605	)		—		142,226
	$	1,751,941	$	—	$	(1,091,844	)	$	—	$	660,097

^(a) Excess of collateral received/pledged, if any, from the individual counterparty is not shown for financial reporting purposes.

^(b)  Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.

Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of financial instruments. For a description of the input levels and information about the Trust’s policy regarding valuation of financial instruments, refer to the Notes to Financial Statements.

The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust’s financial instruments into major categories is disclosed in the Schedule of Investments above.

	Level 1		Level 2		Level 3		Total
Assets
Investments
Long-Term Investments
Common Stocks
Building Products	$	22,296,757	$	6,640,739	$	—	$	28,937,496
Chemicals		—		20,926,824		—		20,926,824
Commercial Services & Supplies		27,019,771		—		—		27,019,771
Construction & Engineering		9,519,967		17,214,351		—		26,734,318
Electric Utilities		101,609,140		55,687,762		—		157,296,902
Electrical Equipment		7,847,093		21,151,345		—		28,998,438
Electronic Equipment, Instruments & Components		3,497,688		4,672,305		—		8,169,993

S C H E D U L E    O F   I N V E S T M E N T S 121

Schedule of Investments  (unaudited) (continued) June 30, 2023      BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI)

Fair Value Hierarchy as of Period End (continued)

	Level 1			Level 2			Level 3		Total
Common Stocks (continued)
Ground Transportation	$	5,279,196		$	—		$	—	$	5,279,196
Independent Power and Renewable Electricity Producers		7,325,549			37,347,572			—		44,673,121
Machinery		9,415,108			18,232,622			—		27,647,730
Multi-Utilities		43,963,982			7,487,977			—		51,451,959
Oil, Gas & Consumable Fuels		51,757,279			—			—		51,757,279
Semiconductors & Semiconductor Equipment		12,399,037			16,068,205			—		28,467,242
Short-Term Securities
Money Market Funds		12,129,346			—			—		12,129,346
	$	314,059,913		$	205,429,702		$	—		519,489,615
Investments Valued at NAV(a)										2,504,624
									$	521,994,239
Derivative Financial Instruments(b)
Liabilities
Equity Contracts	$	(1,832,520	)	$	(2,814,541	)	$	—	$	(4,647,061	)

^(a)  Certain investments of the Trust were fair valued using NAV as a practical expedient as no quoted market value is available and therefore have been excluded from the fair value hierarchy.

^(b)  Derivative financial instruments are options written. Options written are shown at value.

See notes to financial statements.

122 2 0 2 3   B L A C K R O C K  S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Statements of Assets and Liabilities  (unaudited)

June 30, 2023

	BGR			CII		BDJ(a)		BOE
ASSETS
Investments, at value — unaffiliated(b)(c)	$	376,970,659		$	851,951,940	$	1,621,096,079	$	720,323,581
Investments, at value — affiliated(d)		5,580,127			13,210,741		54,579,536		7,220,667
Cash		—			78,854		618,995		—
Foreign currency, at value(e)		72,920			—		350		24
Receivables:
Investments sold		—			—		2,007,008		18,593,884
Options written		351,823			292,952		468,222		267,733
Securities lending income — affiliated		—			185		176		—
Dividends — unaffiliated		1,003,830			598,232		1,841,336		3,087,670
Dividends — affiliated		26,148			52,053		234,948		30,931
Deferred offering costs		—			—		183,545		—
Total assets		384,005,507			866,184,957		1,681,030,195		749,524,490
LIABILITIES
Bank overdraft		—			—		—		121,987
Collateral on securities loaned		—			36		—		—
Options written, at value(f)		2,556,321			17,316,604		24,895,659		7,357,120
Payables:
Investments purchased		—			—		4,943,264		18,180,386
Accounting services fees		7,138			6,688		13,969		8,304
Capital shares redeemed		—			—		—		244,425
Custodian fees		7,693			5,415		28,105		22,097
Income dividend distributions		104,091			239,245		360,396		134,236
Investment advisory fees		611,666			1,173,263		2,152,635		985,770
Offering costs		—			—		40,169		—
Trustees’ and Officer’s fees		388,227			222,722		906,967		619,214
Options written		183,102			399,610		660,151		422,366
Other accrued expenses		35,165			54,902		88,843		37,299
Professional fees		42,005			71,543		113,986		92,030
Transfer agent fees		27,601			33,841		71,515		37,694
Total liabilities		3,963,009			19,523,869		34,275,659		28,262,928
Commitments and contingent liabilities
NET ASSETS	$	380,042,498		$	846,661,088	$	1,646,754,536	$	721,261,562
NET ASSETS CONSIST OF
Paid-in capital(g)(h)(i)	$	522,651,015		$	561,558,505	$	1,313,614,608	$	691,062,562
Accumulated earnings (loss)		(142,608,517	)		285,102,583		333,139,928		30,199,000
NET ASSETS	$	380,042,498		$	846,661,088	$	1,646,754,536	$	721,261,562
Net asset value(g)(h)(i)	$	13.66		$	19.18	$	8.83	$	11.59
(a) Consolidated Statement of Assets and Liabilities.
(b) Investments, at cost — unaffiliated	$	265,831,324		$	560,929,271	$	1,384,197,244	$	639,242,116
(c)  Securities loaned, at value	$	—		$	35	$	—	$	—
(d) Investments, at cost — affiliated	$	5,580,127		$	13,210,741	$	54,579,536	$	7,220,667
(e) Foreign currency, at cost	$	72,915		$	—	$	500	$	29
(f)  Premiums received	$	2,918,083		$	12,842,348	$	19,373,563	$	6,795,289
(g) Shares outstanding		27,827,910			44,132,101		186,494,195		62,231,328
(h) Shares authorized		Unlimited			200 million		Unlimited		Unlimited
(i)  Par value	$	0.001		$	0.10	$	0.001	$	0.001

See notes to financial statements.

F I N A N C I A L   S T A T E M E N T S 123

Statements of Assets and Liabilities (unaudited) (continued)

June 30, 2023

	BGY		BMEZ			BME			BIGZ
ASSETS
Investments, at value — unaffiliated(a)(b)	$	624,617,914	$	2,015,497,800		$	575,660,264		$	2,142,798,067
Investments, at value — affiliated(c)		8,600,233		120,586,546			28,054,199			43,581,539
Cash		—		—			—			44,727
Cash pledged as collateral for OTC derivatives		404,000		36,000			—			—
Foreign currency, at value(d)		2,773		1,095			606			327
Receivables:
Investments sold		5,329,011		16,433,865			3,211,272	(e)		33,407
Options written		105,310		282,459			81,434			44,947
Securities lending income — affiliated		—		73,468			4,588			5,848
Dividends — unaffiliated		2,856,514		843,067			587,611			242,179
Dividends — affiliated		51,397		238,313			106,171			26,238
Unrealized appreciation on forward foreign currency exchange contracts		—		963,121			—			—
Deferred offering costs		—		—			76,536			—
Total assets		641,967,152		2,154,955,734			607,782,681			2,186,777,279
LIABILITIES
Bank overdraft		—		—			96,188			—
Collateral on securities loaned		—		38,936,758			2,539,395			20,797,076
Options written, at value(f)		5,767,908		19,267,653			6,153,073			15,626,686
Payables:
Investments purchased		1,548,838		28,135,758			357,904			11,568,041
Accounting services fees		6,688		92,858			3,461			96,429
Capital shares redeemed		228,679		1,211,990			—			—
Custodian fees		20,777		102,646			8,741			31,865
Deferred foreign capital gain tax		4,332		—			—			—
Income dividend distributions		160,242		2,405,897			170,169			2,278,542
Investment advisory fees		1,056,434		4,284,886			984,655			4,273,155
Trustees’ and Officer’s fees		515,415		166,734			24,402			136,660
Options written		59,643		220,943			86,620			—
Other accrued expenses		40,989		99,694			36,730			330,876
Professional fees		75,066		137,702			44,816			205,938
Proxy fees		—		336,238			—			1,925,064
Transfer agent fees		34,904		62,220			27,281			98,028
Unrealized depreciation on forward foreign currency exchange contracts		—		886,235			—			—
Total liabilities		9,519,915		96,348,212			10,533,435			57,368,360
Commitments and contingent liabilities
NET ASSETS	$	632,447,237	$	2,058,607,522		$	597,249,246		$	2,129,408,919
NET ASSETS CONSIST OF
Paid-in capital(g)(h)(i)	$	569,568,227	$	2,152,208,233		$	427,832,253		$	4,230,518,571
Accumulated earnings (loss)		62,879,010		(93,600,711	)		169,416,993			(2,101,109,652	)
NET ASSETS	$	632,447,237	$	2,058,607,522		$	597,249,246		$	2,129,408,919
Net asset value(g)(h)(i)	$	6.24	$	19.06		$	42.83		$	9.38
(a) Investments, at cost — unaffiliated	$	537,755,495	$	1,933,514,723		$	389,745,046		$	2,409,342,917
(b) Securities loaned, at value	$	—	$	38,179,428		$	2,525,185		$	20,635,627
(c)  Investments, at cost — affiliated	$	8,600,233	$	120,199,643		$	28,054,559		$	43,582,102
(d) Foreign currency, at cost	$	2,787	$	1,090		$	610		$	324
(e) $866,058 is expected to be collected after 01/05/24.
(f)  Premiums received	$	6,096,040	$	17,074,460		$	4,910,324		$	10,673,712
(g) Shares outstanding		101,375,400		108,030,011			13,943,973			226,909,123
(h) Shares authorized		Unlimited		Unlimited			Unlimited			Unlimited
(i)  Par value	$	0.001	$	0.001		$	0.001		$	0.001

See notes to financial statements.

124 2 0 2 3   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Statements of Assets and Liabilities  (unaudited) (continued)

June 30, 2023

	BCX			BSTZ(a)		BST(a)		BUI
ASSETS
Investments, at value — unaffiliated(b)(c)	$	879,580,702		$	1,689,141,606	$	1,175,385,910	$	507,360,269
Investments, at value — affiliated(d)		42,597,272			6,000,163		2,933,367		14,633,970
Cash		64,297			125		28,769		—
Cash pledged as collateral for OTC derivatives		—			980,000		400,000		—
Foreign currency, at value(e)		50,418			1,671		2,124		—
Receivables:
Investments sold		6,387,022			3,326,093		5,319,863		—
Options written		446,216			65,354		110,273		—
Securities lending income — affiliated		1,925			1,625		1,196		770
Capital shares sold		—			—		1,536,058		—
Dividends — unaffiliated		2,132,508			1,201,580		127,268		1,107,904
Dividends — affiliated		165,945			19,542		4,193		54,044
Deferred offering costs		—			—		195,238		101,917
Total assets		931,426,305			1,700,737,759		1,186,044,259		523,258,874
LIABILITIES
Bank overdraft		—			—		—		9,339
Collateral on securities loaned		7,295,540			2,592,613		2,572,576		2,503,830
Options written, at value(f)		5,496,164			32,484,997		19,101,911		4,647,061
Payables:
Investments purchased		4,845,418			3,400,010		1,141,084		—
Accounting services fees		9,552			79,162		7,914		7,914
Capital shares redeemed		553,530			738,534		—		—
Custodian fees		12,875			66,845		23,777		15,167
Deferred capital gain tax		—			1,703,021		—		—
Income dividend distributions		160,684			1,957,192		—		32,429
Investment advisory fees		1,518,608			3,315,023		1,842,774		851,316
Offering costs		—			—		125,910		—
Trustees’ and Officer’s fees		240,376			163,207		859		292
Options written		207,254			—		21,411		—
Other accrued expenses		146,928			172,984		124,428		131,606
Professional fees		95,792			293,780		99,913		36,646
Transfer agent fees		50,870			65,597		60,930		25,988
Total liabilities		20,633,591			47,032,965		25,123,487		8,261,588
Commitments and contingent liabilities
NET ASSETS	$	910,792,714		$	1,653,704,794	$	1,160,920,772	$	514,997,286
NET ASSETS CONSIST OF
Paid-in capital(g)(h)(i)	$	1,060,084,926		$	1,352,097,543	$	822,271,047	$	386,968,032
Accumulated earnings (loss)		(149,292,212	)		301,607,251		338,649,725		128,029,254
NET ASSETS	$	910,792,714		$	1,653,704,794	$	1,160,920,772	$	514,997,286
Net asset value(g)(h)(i)	$	10.61		$	21.50	$	34.14	$	22.96
(a) Consolidated Statement of Assets and Liabilities.
(b) Investments, at cost — unaffiliated	$	763,798,215		$	1,204,587,576	$	739,748,696	$	356,356,062
(c)  Securities loaned, at value	$	7,265,282		$	2,587,371	$	2,534,680	$	2,513,264
(d) Investments, at cost — affiliated	$	42,597,889		$	6,000,142	$	2,933,194	$	14,633,993
(e) Foreign currency, at cost	$	50,418		$	1,667	$	2,228	$	—
(f)  Premiums received	$	7,646,569		$	16,740,064	$	12,549,700	$	4,020,391
(g) Shares outstanding		85,858,746			76,915,834		34,003,298		22,426,304
(h) Shares authorized		Unlimited			Unlimited		Unlimited		Unlimited
(i)  Par value	$	0.001		$	0.001	$	0.001	$	0.001

See notes to financial statements.

F I N A N C I A L   S T A T E M E N T S 125

Statements of Operations (unaudited)

Six Months Ended June 30, 2023

	BGR			CII			BDJ(a)			BOE
INVESTMENT INCOME
Dividends — unaffiliated	$	7,972,248		$	5,135,481		$	22,276,272		$	13,025,511
Dividends — affiliated		154,603			275,672			1,609,010			227,151
Securities lending income — affiliated — net		—			5,638			669			2,629
Foreign taxes withheld		(395,535	)		(206,030	)		(497,815	)		(949,374	)
Total investment income		7,731,316			5,210,761			23,388,136			12,305,917
EXPENSES
Investment advisory		2,304,590			3,418,010			6,477,962			3,542,495
Transfer agent		34,200			42,608			83,465			47,944
Professional		31,628			31,677			29,502			40,806
Trustees and Officer		29,138			28,754			95,554			44,111
Accounting services		21,838			25,107			47,405			30,046
Custodian		21,563			15,390			64,292			54,123
Registration		4,918			7,479			31,274			10,818
Printing and postage		4,170			1,091			1,425			4,509
Miscellaneous		22,015			25,904			76,315			51,835
Total expenses		2,474,060			3,596,020			6,907,194			3,826,687
Less:
Fees waived and/or reimbursed by the Manager		(424,975	)		(4,353	)		(25,644	)		(623,534	)
Total expenses after fees waived and/or reimbursed		2,049,085			3,591,667			6,881,550			3,203,153
Net investment income		5,682,231			1,619,094			16,506,586			9,102,764
REALIZED AND UNREALIZED GAIN (LOSS)
Net realized gain (loss) from:
Investments — unaffiliated		7,344,860			15,670,075			49,788,460			2,532,070
Investments — affiliated		—			(514	)		(232	)		1,183
Foreign currency transactions		6,581			—			35,951			53,088
Options written		10,781,255			(9,665,066	)		4,987,132			6,365,169
		18,132,696			6,004,495			54,811,311			8,951,510
Net change in unrealized appreciation (depreciation) on:
Investments — unaffiliated		(26,803,427	)		100,591,585			21,435,577			47,384,704
Foreign currency translations		1,904			—			(144	)		11,837
Options written		(2,063,487	)		(9,874,294	)		(13,463,460	)		(3,947,548	)
		(28,865,010	)		90,717,291			7,971,973			43,448,993
Net realized and unrealized gain (loss)		(10,732,314	)		96,721,786			62,783,284			52,400,503
NET INCREASE (DECREASE) IN NET ASSETS RESULTING FROM OPERATIONS	$	(5,050,083	)	$	98,340,880		$	79,289,870		$	61,503,267

^(a)  Consolidated Statement of Operations.

See notes to financial statements.

126 2 0 2 3   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Statements of Operations (unaudited) (continued)

Six Months Ended June 30, 2023

	BGY			BMEZ			BME			BIGZ
INVESTMENT INCOME
Dividends — unaffiliated	$	11,803,041		$	3,210,565		$	3,695,294		$	2,497,916
Dividends — affiliated		242,490			1,083,366			571,208			254,336
Securities lending income — affiliated — net		—			354,806			20,778			38,615
Foreign taxes withheld		(1,241,131	)		(189,015	)		(29,580	)		(103,356	)
Total investment income		10,804,400			4,459,722			4,257,700			2,687,511
EXPENSES
Investment advisory		3,121,413			12,726,811			2,919,113			12,893,415
Custodian		66,370			60,528			23,591			35,088
Professional		51,724			54,936			46,893			98,309
Transfer agent		44,594			72,990			36,917			107,482
Trustees and Officer		33,414			59,527			17,026			57,562
Accounting services		25,107			106,747			15,173			106,033
Registration		17,616			19,347			3,384			41,576
Printing and postage		4,865			847			3,922			2,685
Proxy		—			339,023			—			1,955,280
Miscellaneous		51,022			97,108			26,932			378,963
Total expenses		3,416,125			13,537,864			3,092,951			15,676,393
Less:
Fees waived and/or reimbursed by the Manager		(3,762	)		(17,262	)		(8,990	)		(4,023	)
Total expenses after fees waived and/or reimbursed		3,412,363			13,520,602			3,083,961			15,672,370
Net investment income (loss)		7,392,037			(9,060,880	)		1,173,739			(12,984,859	)
REALIZED AND UNREALIZED GAIN (LOSS)
Net realized gain (loss) from:
Investments — unaffiliated		16,415,062	(a)		(14,994,932	)		7,647,313			(211,505,456	)
Investments — affiliated		—			3,681			1,229			(4,346	)
Forward foreign currency exchange contracts		—			1,506,894			—			—
Foreign currency transactions		164,635			(202,000	)		(6,236	)		9,819
Options written		10,247,181			10,910,202			4,698,971			1,213,830
		26,826,878			(2,776,155	)		12,341,277			(210,286,153	)
Net change in unrealized appreciation (depreciation) on:
Investments — unaffiliated		33,878,445	(b)		143,002,051			1,215,104			452,889,940
Investments — affiliated		—			536,386			(625	)		(563	)
Forward foreign currency exchange contracts		—			(4,887,669	)		—			—
Foreign currency translations		12,090			13,134			2,680			(5,297	)
Options written		(978,314	)		(4,568,856	)		(3,421,738	)		(10,524,710	)
		32,912,221			134,095,046			(2,204,579	)		442,359,370
Net realized and unrealized gain		59,739,099			131,318,891			10,136,698			232,073,217
NET INCREASE IN NET ASSETS RESULTING FROM OPERATIONS	$	67,131,136		$	122,258,011		$	11,310,437		$	219,088,358
(a) Net of foreign capital gain tax and capital gain tax refund, if applicable of	$	1,918		$	—		$	—		$	—
(b) Net of reduction in deferred foreign capital gain tax of	$	68,395		$	—		$	—		$	—

See notes to financial statements.

F I N A N C I A L   S T A T E M E N T S 127

Statements of Operations (unaudited) (continued)

Six Months Ended June 30, 2023

	BCX			BSTZ(a)			BST(a)			BUI
INVESTMENT INCOME
Dividends — unaffiliated	$	18,971,153		$	3,483,653		$	2,140,945		$	7,956,228
Dividends — affiliated		704,650			221,875			161,025			304,176
Securities lending income — affiliated — net		11,156			32,129			8,500			6,756
Foreign taxes withheld		(995,151	)		(421,174	)		(83,205	)		(461,073	)
Total investment income		18,691,808			3,316,483			2,227,265			7,806,087
EXPENSES
Investment advisory		4,743,463			9,800,290			5,248,932			2,521,855
Transfer agent		61,953			77,261			74,167			35,458
Custodian		48,312			83,091			61,475			35,322
Trustees and Officer		36,937			47,124			26,834			13,724
Professional		35,056			53,931			54,755			35,807
Accounting services		29,275			85,490			24,305			24,305
Registration		14,921			14,111			5,815			9,524
Printing and postage		4,319			4,023			4,121			4,018
Miscellaneous		55,896			380,892			255,990			47,530
Total expenses		5,030,132			10,546,213			5,756,394			2,727,543
Less:
Fees waived and/or reimbursed by the Manager		(10,865	)		(3,534	)		(2,612	)		(4,778	)
Total expenses after fees waived and/or reimbursed		5,019,267			10,542,679			5,753,782			2,722,765
Net investment income (loss)		13,672,541			(7,226,196	)		(3,526,517	)		5,083,322
REALIZED AND UNREALIZED GAIN (LOSS)
Net realized gain (loss) from:
Investments — unaffiliated		4,692,520			(33,134,872	)		7,717,881			8,009,466
Investments — affiliated		2,968			7,686			595			810
Foreign currency transactions		(9,193	)		(260,677	)		(45,216	)		40,314
Options written		20,987,215			(10,876,120	)		(27,510,651	)		7,355,793
Payment by affiliate		—			127,092			—			—
		25,673,510			(44,136,891	)		(19,837,391	)		15,406,383
Net change in unrealized appreciation (depreciation) on:
Investments — unaffiliated		(67,428,508	)		305,904,026	(b)		255,357,301	(b)		11,000,594
Investments — affiliated		(617	)		21			93			(145	)
Foreign currency translations		10,699			6,820			(240	)		22,696
Options written		(1,324,185	)		(25,448,128	)		(13,957,447	)		(2,148,041	)
		(68,742,611	)		280,462,739			241,399,707			8,875,104
Net realized and unrealized gain (loss)		(43,069,101	)		236,325,848			221,562,316			24,281,487
NET INCREASE (DECREASE) IN NET ASSETS RESULTING FROM OPERATIONS	$	(29,396,560	)	$	229,099,652		$	218,035,799		$	29,364,809
(a) Consolidated Statement of Operations.
(b) Net of reduction in deferred capital gain tax of	$	—		$	1,756,279		$	113,475		$	—

See notes to financial statements.

128 2 0 2 3   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Statements of Changes in Net Assets

	BGR								CII
	Six Months Ended     06/30/23     (unaudited)				Year Ended 12/31/22				Six Months Ended 06/30/23 (unaudited)				Year Ended 12/31/22
INCREASE (DECREASE) IN NET ASSETS
OPERATIONS
Net investment income		$	5,682,231			$	12,071,039			$	1,619,094			$	2,696,846
Net realized gain			18,132,696				34,809,940				6,004,495				100,213,617
Net change in unrealized appreciation (depreciation)			(28,865,010	)			66,906,553				90,717,291				(211,028,139	)
Net increase (decrease) in net assets resulting from operations			(5,050,083	)			113,787,532				98,340,880				(108,117,676	)
DISTRIBUTIONS TO SHAREHOLDERS(a)
From net investment income			(10,606,571	)(b)			(11,890,970	)			(26,346,864	)			(92,693,757	)
Return of capital			—				(4,610,793	)			—				—
Decrease in net assets resulting from distributions to shareholders			(10,606,571	)			(16,501,763	)			(26,346,864	)			(92,693,757	)
CAPITAL SHARE TRANSACTIONS
Redemption of shares resulting from share repurchase program (including transaction costs)			(2,793,432	)			(12,296,655	)			—				—
NET ASSETS
Total increase (decrease) in net assets			(18,450,086	)			84,989,114				71,994,016				(200,811,433	)
Beginning of period			398,492,584				313,503,470				774,667,072				975,478,505
End of period		$	380,042,498			$	398,492,584			$	846,661,088			$	774,667,072

^(a)  Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

^(b)  A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year-end.

See notes to financial statements.

F I N A N C I A L   S T A T E M E N T S 129

Statements of Changes in Net Assets (continued)

	BDJ(a)						BOE
		Six Months Ended						Six Months Ended
	06/30/23			Year Ended			06/30/23			Year Ended
		(unaudited)			12/31/22			(unaudited	)		12/31/22
INCREASE (DECREASE) IN NET ASSETS
OPERATIONS
Net investment income	$	16,506,586		$	30,038,016		$	9,102,764		$	12,760,469
Net realized gain		54,811,311			147,475,079			8,951,510			15,653,551
Net change in unrealized appreciation (depreciation)		7,971,973			(250,207,024	)		43,448,993			(137,096,032	)
Net increase (decrease) in net assets resulting from operations		79,289,870			(72,693,929	)		61,503,267			(108,682,012	)
DISTRIBUTIONS TO SHAREHOLDERS(b)
From net investment income and net realized gain		(62,879,687	)		(204,152,869	)		(23,663,713	)(c)		(38,142,002	)
Return of capital		—			—			—			(9,962,064	)
Decrease in net assets resulting from distributions to shareholders		(62,879,687	)		(204,152,869	)		(23,663,713	)		(48,104,066	)
CAPITAL SHARE TRANSACTIONS
Reinvestment of distributions		702,786			3,650,249			—			—
Redemption of shares resulting from share repurchase program (including transaction costs)		—			—			(5,041,877	)		(12,470,648	)
Net increase (decrease) in net assets derived from capital share transactions		702,786			3,650,249			(5,041,877	)		(12,470,648	)
NET ASSETS
Total increase (decrease) in net assets		17,112,969			(273,196,549	)		32,797,677			(169,256,726	)
Beginning of period		1,629,641,567			1,902,838,116			688,463,885			857,720,611
End of period	$	1,646,754,536		$	1,629,641,567		$	721,261,562		$	688,463,885

^(a)  Consolidated Statement of Changes in Net Assets.

^(b) Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

^(c) A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year-end.

See notes to financial statements.

130 2 0 2 3   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Statements of Changes in Net Assets (continued)

		BGY								BMEZ
	Six Months Ended								Six Months Ended
			06/30/23			Year Ended			06/30/23			Year Ended
			(unaudited)			12/31/22			(unaudited)			12/31/22
INCREASE (DECREASE) IN NET ASSETS
OPERATIONS
Net investment income			$	7,392,037		$	10,518,833		$	(9,060,880	)	$	(20,420,947	)
Net realized gain				26,826,878			14,980,788			(2,776,155	)		(26,244,107	)
Net change in unrealized appreciation (depreciation)				32,912,221			(92,154,694	)		134,095,046			(636,053,199	)
Net increase in net assets resulting from operations				67,131,136			(66,655,073	)		122,258,011			(682,718,253	)
DISTRIBUTIONS TO SHAREHOLDERS(a)
From net investment income and net realized gain				(20,711,473	)(b)		(20,170,266	)		(94,535,074	)(b)		(183,050,144	)
Return of capital				—			(21,930,456	)		—			(11,869,565	)
Decrease in net assets resulting from distributions to shareholders				(20,711,473	)		(42,100,722	)		(94,535,074	)		(194,919,709	)
CAPITAL SHARE TRANSACTIONS
Redemption of shares resulting from share repurchase program (including transaction costs)				(7,443,801	)		(7,282,700	)		(25,534,135	)		(47,829,587	)
NET ASSETS
Total increase in net assets				38,975,862			(116,038,495	)		2,188,802			(925,467,549	)
Beginning of period				593,471,375			709,509,870			2,056,418,720			2,981,886,269
End of period			$	632,447,237		$	593,471,375		$	2,058,607,522		$	2,056,418,720

^(a) Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

^(b) A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year-end.

See notes to financial statements.

F I N A N C I A L   S T A T E M E N T S 131

Statements of Changes in Net Assets (continued)

		BME						BIGZ
	Six Months Ended						Six Months Ended
		06/30/23			Year Ended			06/30/23			Year Ended
		(unaudited)			12/31/22			(unaudited)			12/31/22
INCREASE (DECREASE) IN NET ASSETS
OPERATIONS
Net investment income	$	1,173,739		$	1,539,556		$	(12,984,859	)	$	(31,271,483	)
Net realized gain		12,341,277			13,676,395			(210,286,153	)		(1,316,372,963	)
Net change in unrealized appreciation (depreciation)		(2,204,579	)		(41,687,030	)		442,359,370			(308,670,678	)
Net increase in net assets resulting from operations		11,310,437			(26,471,079	)		219,088,358			(1,656,315,124	)
DISTRIBUTIONS TO SHAREHOLDERS(a)
From net investment income and net realized gain		(17,790,290	)(b)		(32,998,527	)		(95,613,895	)(b)		—
Return of capital		—			(1,403,564	)		—			(233,929,900	)
Decrease in net assets resulting from distributions to shareholders		(17,790,290	)		(34,402,091	)		(95,613,895	)		(233,929,900	)
CAPITAL SHARE TRANSACTIONS
Net proceeds from the issuance of shares		3,020,683			33,618,939			—			—
Reinvestment of distributions		511,503			1,676,333			—			—
Redemption of shares resulting from share repurchase program (including transaction costs)		—			—			(20,553,458	)		(64,919,571	)
Net increase in net assets derived from capital share transactions		3,532,186			35,295,272			(20,553,458	)		(64,919,571	)
NET ASSETS
Total increase in net assets		(2,947,667	)		(25,577,898	)		102,921,005			(1,955,164,595	)
Beginning of period		600,196,913			625,774,811			2,026,487,914			3,981,652,509
End of period	$	597,249,246		$	600,196,913		$	2,129,408,919		$	2,026,487,914

^(a)  Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

^(b)  A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year-end.

See notes to financial statements.

132 2 0 2 3   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Statements of Changes in Net Assets (continued)

		BCX						BSTZ(a)
	Six Months Ended						Six Months Ended
		06/30/23			Year Ended			06/30/23			Year Ended
		(unaudited)			12/31/22			(unaudited)			12/31/22
INCREASE (DECREASE) IN NET ASSETS
OPERATIONS
Net investment income	$	13,672,541		$	26,122,375		$	(7,226,196	)	$	(23,377,483	)
Net realized gain		25,673,510			164,961,884			(44,136,891	)		116,813,048
Net change in unrealized appreciation (depreciation)		(68,742,611	)		(53,573,504	)		280,462,739			(1,429,494,278	)
Net increase in net assets resulting from operations		(29,396,560	)		137,510,755			229,099,652			(1,336,058,713	)
DISTRIBUTIONS TO SHAREHOLDERS(b)
From net investment income and net realized gain		(26,971,653	)(c)		(26,024,883	)		(79,787,564	)(c)		(70,402,537	)
Return of capital		—			(22,531,891	)		—			(110,549,120	)
Decrease in net assets resulting from distributions to shareholders		(26,971,653	)		(48,556,774	)		(79,787,564	)		(180,951,657	)
CAPITAL SHARE TRANSACTIONS
Redemption of shares resulting from share repurchase program (including transaction costs)		(16,020,113	)		(7,554,830	)		(20,264,931	)		(7,293,625	)
NET ASSETS
Total increase in net assets		(72,388,326	)		81,399,151			129,047,157			(1,524,303,995	)
Beginning of period		983,181,040			901,781,889			1,524,657,637			3,048,961,632
End of period	$	910,792,714		$	983,181,040		$	1,653,704,794		$	1,524,657,637

^(a)  Consolidated Statement of Changes in Net Assets.

^(b)  Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

^(c)  A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year-end.

See notes to financial statements.

F I N A N C I A L   S T A T E M E N T S 133

Statements of Changes in Net Assets (continued)

		BST(a)						BUI
		Six Months Ended						Six Months Ended
		06/30/23			Year Ended			06/30/23			Year Ended
		(unaudited)			12/31/22			(unaudited	)		12/31/22
INCREASE (DECREASE) IN NET ASSETS
OPERATIONS
Net investment income	$	(3,526,517	)	$	(9,272,089	)	$	5,083,322		$	7,295,744
Net realized gain		(19,837,391	)		51,379,805			15,406,383			7,425,254
Net change in unrealized appreciation (depreciation)		241,399,707			(696,878,029	)		8,875,104			(59,248,817	)
Net increase in net assets resulting from operations		218,035,799			(654,770,313	)		29,364,809			(44,527,819	)
DISTRIBUTIONS TO SHAREHOLDERS(b)
From net investment income and net realized gain		(50,340,460	)(c)		(69,684,200	)		(16,221,897	)		(18,983,124	)
Return of capital		—			(27,306,002	)		—			(13,135,583	)
Decrease in net assets resulting from distributions to shareholders		(50,340,460	)		(96,990,202	)		(16,221,897	)		(32,118,707	)
CAPITAL SHARE TRANSACTIONS
Net proceeds from the issuance of shares		28,980,927			28,525,537			2,884,055			14,467,890
Reinvestment of distributions		3,541,305			2,771,741			577,353			766,909
Net increase in net assets derived from capital share transactions		32,522,232			31,297,278			3,461,408			15,234,799
NET ASSETS
Total increase in net assets		200,217,571			(720,463,237	)		16,604,320			(61,411,727	)
Beginning of period		960,703,201			1,681,166,438			498,392,966			559,804,693
End of period	$	1,160,920,772		$	960,703,201		$	514,997,286		$	498,392,966

^(a)  Consolidated Statement of Changes in Net Assets.

^(b)  Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

^(c)  A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year-end.

See notes to financial statements.

134 2 0 2 3   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Statements of Cash Flows (unaudited)

Six Months Ended June 30, 2023

	BGR				CII				BDJ				BOE
CASH PROVIDED BY (USED FOR) OPERATING ACTIVITIES
Net increase (decrease) in net assets resulting from operations		$	(5,050,083	)		$	98,340,880			$	79,289,870			$	61,503,267
Adjustments to reconcile net increase (decrease) in net assets resulting from operations to net cash provided by operating activities:
Proceeds from sales of long-term investments			74,992,878				157,003,741				401,294,041				197,423,412
Purchases of long-term investments			(77,631,130	)			(122,543,650	)			(381,054,163	)			(186,972,173	)
Net proceeds from sales (purchases) of short-term securities			2,115,348				1,449,901				21,462,669				(575,732	)
Premiums paid on closing options written			(6,030,822	)			(62,027,870	)			(78,834,704	)			(22,823,200	)
Premiums received from options written			14,660,411				52,247,149				82,073,435				28,471,419
Net realized gain on investments and options written			(18,125,343	)			(5,992,588	)			(54,732,505	)			(8,874,938	)
Net unrealized (appreciation) depreciation on investments, options written and foreign currency translations			28,866,914				(90,717,291	)			(7,972,117	)			(43,437,156	)
(Increase) Decrease in Assets
Receivables
Dividends — affiliated			(2,297	)			34,480				87,806				(4,232	)
Dividends — unaffiliated			(283,214	)			(41,410	)			528,495				(1,406,646	)
Securities lending income — affiliated			—				(185	)			(176	)			—
Deferred offering costs			—				—				(183,545	)			—
Increase (Decrease) in Liabilities
Collateral on securities loaned			—				36				—				—
Payables
Accounting services fees			(7,548	)			(8,970	)			(16,709	)			(10,705	)
Custodian fees			(8,348	)			(2,539	)			(24,582	)			(19,012	)
Investment advisory fees			283,901				594,719				1,018,430				497,661
Trustees’ and Officer’s fees			(18,548	)			(5,713	)			(4,000	)			(27,612	)
Other accrued expenses			6,685				3,563				48,121				8,492
Professional fees			(28,787	)			(30,870	)			(58,601	)			(39,471	)
Transfer agent fees			5,085				6,652				11,090				6,459
Other liabilities			—				—				(666,808	)			—
Net cash provided by operating activities			13,745,102				28,310,035				62,266,047				23,719,833
CASH PROVIDED BY (USED FOR) FINANCING ACTIVITIES
Cash dividends paid to shareholders			(10,594,053	)			(28,206,943	)			(61,816,505	)			(23,665,342	)
Payments for offering costs			—				—				40,169				—
Net payments on redemption of capital shares including change in redemptions payable			(3,053,269	)			—				—				(5,129,851	)
Increase (decrease) in bank overdraft			(83,281	)			(24,238	)			—				121,987
Net cash used for financing activities			(13,730,603	)			(28,231,181	)			(61,776,336	)			(28,673,206	)
CASH IMPACT FROM FOREIGN EXCHANGE FLUCTUATIONS
Cash impact from foreign exchange fluctuations			(4	)			—				(19	)			(155	)
CASH AND FOREIGN CURRENCY
Net increase (decrease) in restricted and unrestricted cash and foreign currency			14,495				78,854				489,692				(4,953,528	)
Restricted and unrestricted cash and foreign currency at beginning of period			58,425				—				129,653				4,953,552
Restricted and unrestricted cash and foreign currency at end of period		$	72,920			$	78,854			$	619,345			$	24
NON-CASH FINANCING ACTIVITIES
Reinvestment of distributions		$	—			$	—			$	702,786			$	—
RECONCILIATION OF RESTRICTED AND UNRESTRICTED CASH AND FOREIGN CURRENCY AT THE END OF PERIOD TO THE STATEMENTS OF ASSETS AND LIABILITIES
Cash		$	—			$	78,854			$	618,995			$	—
Foreign currency at value			72,920				—				350				24
		$	72,920			$	78,854			$	619,345			$	24

See notes to financial statements.

F I N A N C I A L   S T A T E M E N T S 135

Statements of Cash Flows (unaudited) (continued)

Six Months Ended June 30, 2023

	BGY				BMEZ				BME				BIGZ
CASH PROVIDED BY (USED FOR) OPERATING ACTIVITIES
Net increase in net assets resulting from operations		$	67,131,136			$	122,258,011			$	11,310,437			$	219,088,358
Adjustments to reconcile net increase in net assets resulting from operations to net cash provided by operating activities:
Proceeds from sales of long-term investments			180,371,258				592,584,440				127,546,373				499,748,974
Purchases of long-term investments			(172,426,499	)			(493,425,801	)			(115,885,086	)			(369,813,331	)
Net purchases of short-term securities			(2,977,912	)			(20,398,213	)			(4,182,299	)			(22,623,220	)
Premiums paid on closing options written			(12,561,917	)			(59,616,696	)			(18,700,573	)			(37,128,294	)
Premiums received from options written			23,076,227				66,945,476				21,840,501				37,092,362
Net realized (gain) loss on investments and options written			(26,653,193	)			8,655,540				(12,344,703	)			210,296,050
Net unrealized (appreciation) depreciation on investments, options written and foreign currency translations			(32,831,736	)			(134,081,912	)			2,207,259				(442,364,666	)
(Increase) Decrease in Assets
Receivables
Dividends — affiliated			(35,525	)			(65,158	)			(34,120	)			(8,677	)
Dividends — unaffiliated			(1,569,133	)			(47,744	)			(63,321	)			(34,182	)
Securities lending income — affiliated			—				(31,642	)			(132	)			1,740
Deferred offering costs			—				—				1,638				—
Increase (Decrease) in Liabilities
Collateral on securities loaned			—				37,106,764				1,863,500				20,612,476
Payables
Accounting services fees			(8,970	)			17,720				(5,553	)			16,829
Custodian fees			(22,144	)			(15,700	)			(8,000	)			3,753
Deferred foreign capital gain tax			(68,395	)			—				—				—
Investment advisory fees			548,025				2,073,943				473,307				2,064,720
Trustees’ and Officer’s fees			(32,695	)			24,093				1,065				24,642
Other accrued expenses			12,124				240,621				(1,809	)			1,921,240
Professional fees			(29,020	)			(29,171	)			(30,859	)			740
Transfer agent fees			7,062				9,695				5,062				19,240
Net cash provided by operating activities			21,928,693				122,204,266				13,992,687				118,918,754
CASH PROVIDED BY (USED FOR) FINANCING ACTIVITIES
Cash dividends paid to shareholders			(20,713,879	)			(94,666,536	)			(17,108,618	)			(95,733,591	)
Payments for offering costs			—				—				(497	)			—
Net payments on redemption of capital shares including change in redemptions payable			(7,215,122	)			(27,441,442	)			—				(23,140,455	)
Increase (decrease) in bank overdraft			—				(95,313	)			93,268				—
Proceeds from issuance of capital shares			—				—				3,020,683				—
Net cash used for financing activities			(27,929,001	)			(122,203,291	)			(13,995,164	)			(118,874,046	)
CASH IMPACT FROM FOREIGN EXCHANGE FLUCTUATIONS
Cash impact from foreign exchange fluctuations			(1,815	)			5				(35	)			11
CASH AND FOREIGN CURRENCY
Net increase (decrease) in restricted and unrestricted cash and foreign currency			(6,002,123	)			980				(2,512	)			44,719
Restricted and unrestricted cash and foreign currency at beginning of period			6,408,896				36,115				3,118				335
Restricted and unrestricted cash and foreign currency at end of period		$	406,773			$	37,095			$	606			$	45,054
NON-CASH FINANCING ACTIVITIES
Reinvestment of distributions		$	—			$	—			$	511,503			$	—
RECONCILIATION OF RESTRICTED AND UNRESTRICTED CASH AND FOREIGN CURRENCY AT THE END OF PERIOD TO THE STATEMENTS OF ASSETS AND LIABILITIES
Cash		$	—			$	—			$	—			$	44,727
Cash pledged
Collateral — OTC derivatives			404,000				36,000				—				—
Foreign currency at value			2,773				1,095				606				327
		$	406,773			$	37,095			$	606			$	45,054

See notes to financial statements.

136 2 0 2 3   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Statements of Cash Flows (unaudited) (continued)

Six Months Ended June 30, 2023

	BCX				BSTZ				BST				BUI
CASH PROVIDED BY (USED FOR) OPERATING ACTIVITIES
Net increase (decrease) in net assets resulting from operations		$	(29,396,560	)		$	229,099,652			$	218,035,799			$	29,364,809
Adjustments to reconcile net increase (decrease) in net assets resulting from operations to net cash provided by operating activities:
Proceeds from sales of long-term investments			179,903,562				440,553,865				209,447,723				75,952,652
Purchases of long-term investments			(152,715,617	)			(345,391,538	)			(168,497,320	)			(74,411,625	)
Net proceeds from sales (purchases) of short-term securities			(23,190,818	)			14,690,905				3,671,847				(3,365,927	)
Premiums paid on closing options written			(17,477,287	)			(80,333,905	)			(79,489,390	)			(9,371,170	)
Premiums received from options written			35,798,683				67,882,732				52,814,221				16,154,646
Net realized (gain) loss on investments and options written			(25,670,034	)			44,519,071				19,927,729				(15,366,023	)
Net unrealized (appreciation) depreciation on investments, options written and foreign currency translations			68,742,611				(278,699,571	)			(240,917,450	)			(8,852,408	)
(Increase) Decrease in Assets
Receivables
Dividends — affiliated			(88,201	)			38,971				29,669				(15,289	)
Dividends — unaffiliated			(530,534	)			(955,652	)			246,448				(101,325	)
Securities lending income — affiliated			(1,925	)			(1,625	)			78				1,362
Other assets			—				680,607				—				—
Deferred offering costs			—				—				10,137				1,420
Increase (Decrease) in Liabilities
Collateral on securities loaned			7,295,540				2,592,613				1,747,720				2,278,779
Payables
Accounting services fees			(10,133	)			11,456				(8,419	)			(8,419	)
Custodian fees			(13,437	)			4,341				(13,674	)			(11,020	)
Deferred capital gain tax			—				(1,756,279	)			(113,475	)			—
Investment advisory fees			680,923				1,632,936				996,843				423,106
Trustees’ and Officer’s fees			(12,643	)			17,658				(2,127	)			(154	)
Other accrued expenses			27,589				(10,367	)			(26,025	)			21,117
Professional fees			(37,412	)			(81,577	)			(75,284	)			(26,352	)
Transfer agent fees			8,505				10,925				13,802				4,523
Net cash provided by operating activities			43,312,812				94,505,218				17,798,852				12,672,702
CASH PROVIDED BY (USED FOR) FINANCING ACTIVITIES
Cash dividends paid to shareholders			(26,978,948	)			(80,155,346	)			(47,374,981	)			(15,762,439	)
Payments for offering costs			—				—				(4,000	)			—
Net payments on redemption of capital shares including change in redemptions payable			(16,170,958	)			(21,466,837	)			—				—
Increase (decrease) in bank overdraft			(117,583	)			—				(88,084	)			9,339
Proceeds from issuance of capital shares			—				—				27,444,869				2,884,055
Net cash used for financing activities			(43,267,489	)			(101,622,183	)			(20,022,196	)			(12,869,045	)
CASH IMPACT FROM FOREIGN EXCHANGE FLUCTUATIONS
Cash impact from foreign exchange fluctuations			(11	)			(68	)			(941	)			—
CASH AND FOREIGN CURRENCY
Net increase (decrease) in restricted and unrestricted cash and foreign currency			45,312				(7,117,033	)			(2,224,285	)			(196,343	)
Restricted and unrestricted cash and foreign currency at beginning of period			69,403				8,098,829				2,655,178				196,343
Restricted and unrestricted cash and foreign currency at end of period		$	114,715			$	981,796			$	430,893			$	—
NON-CASH FINANCING ACTIVITIES
Reinvestment of distributions		$	—			$	—			$	3,541,305			$	577,353
RECONCILIATION OF RESTRICTED AND UNRESTRICTED CASH AND FOREIGN CURRENCY AT THE END OF PERIOD TO THE STATEMENTS OF ASSETS AND LIABILITIES
Cash		$	64,297			$	125			$	28,769			$	—
Cash pledged
Collateral — OTC derivatives			—				980,000				400,000				—
Foreign currency at value			50,418				1,671				2,124				—
		$	114,715			$	981,796			$	430,893			$	—

See notes to financial statements.

F I N A N C I A L   S T A T E M E N T S 137

Financial Highlights

(For a share outstanding throughout each period)

								BGR
	Six Months Ended 06/30/23 (unaudited)				Year Ended 12/31/22			Year Ended 12/31/21			Year Ended 12/31/20			Year Ended 12/31/19			Year Ended 12/31/18
Net asset value, beginning of period		$	14.21		$	10.77		$	8.17		$	12.57		$	11.98		$	15.79
Net investment income(a)			0.20			0.42			0.28			0.32			0.34			0.28
Net realized and unrealized gain (loss)			(0.37	)		3.60			2.77			(4.06	)		1.18			(3.16	)
Net increase (decrease) from investment operations			(0.17	)		4.02			3.05			(3.74	)		1.52			(2.88	)
Distributions(b)
From net investment income			(0.38	)(c)		(0.42	)		(0.28	)		(0.32	)		(0.34	)		(0.27	)
Return of capital			—			(0.16	)		(0.17	)		(0.34	)		(0.59	)		(0.66	)
Total distributions			(0.38	)		(0.58	)		(0.45	)		(0.66	)		(0.93	)		(0.93	)
Net asset value, end of period		$	13.66		$	14.21		$	10.77		$	8.17		$	12.57		$	11.98
Market price, end of period		$	12.04		$	12.53		$	9.48		$	7.10		$	11.88		$	10.45
Total Return(d)
Based on net asset value			(0.87	)%(e)		38.51	%		38.36	%(f)		(29.03	)%		13.74	%		(18.84	)%
Based on market price			(0.92	)%(e)		38.76	%		40.14	%		(34.74	)%		23.23	%		(21.16	)%
Ratios to Average Net Assets(g)
Total expenses			1.29	%(h)		1.26	%		1.33	%		1.37	%		1.35	%		1.29	%
Total expenses after fees waived and/or reimbursed			1.07	%(h)		1.04	%		1.11	%		1.15	%		1.16	%		1.14	%
Net investment income			2.96	%(h)		3.21	%		2.88	%		3.77	%		2.67	%		1.87	%
Supplemental Data
Net assets, end of period (000)		$	380,042		$	398,493		$	313,503		$	237,868		$	374,896		$	357,391
Portfolio turnover rate			20	%		76	%		61	%		62	%		24	%		32	%

^(a)  Based on average shares outstanding.

^(b)  Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

^(c)  A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year-end.

^(d)  Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices.

^(e)  Not annualized.

^(f)  Includes payment from an affiliate, which had no impact on the Trust’s total return.

^(g)  Excludes fees and expenses incurred indirectly as a result of investments in underlying funds.

^(h) Annualized.

See notes to financial statements.

138 2 0 2 3   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Financial Highlights (continued)

(For a share outstanding throughout each period)

	CII
	Six Months Ended 06/30/23 (unaudited)				Year Ended 12/31/22				Year Ended 12/31/21				Year Ended 12/31/20				Year Ended 12/31/19				Year Ended 12/31/18
Net asset value, beginning of period		$	17.55			$	22.10			$	19.12			$	17.96			$	15.28			$	17.19
Net investment income(a)			0.04				0.06				0.04				0.13				0.18				0.17
Net realized and unrealized gain (loss)			2.19				(2.51	)			4.04				2.08				3.50				(1.09	)
Net increase (decrease) from investment operations			2.23				(2.45	)			4.08				2.21				3.68				(0.92	)
Distributions(b)
From net investment income			(0.60	)			(0.04	)			(0.04	)			(0.13	)			(0.19	)			(0.17	)(c)
From net realized gain			—				(2.06	)			(1.06	)			(0.92	)			(0.44	)			(0.28	)(c)
Return of capital			—				—				—				—				(0.37	)			(0.54	)
Total distributions			(0.60	)			(2.10	)			(1.10	)			(1.05	)			(1.00	)			(0.99	)
Net asset value, end of period		$	19.18			$	17.55			$	22.10			$	19.12			$	17.96			$	15.28
Market price, end of period		$	18.51			$	17.12			$	22.12			$	17.40			$	17.25			$	14.08
Total Return(d)
Based on net asset value			12.93	%(e)			(10.95	)%			21.97	%			13.94	%			25.08	%			(5.44	)%
Based on market price			11.73	%(e)			(13.21	)%			34.15	%			7.97	%			30.38	%			(8.56	)%
Ratios to Average Net Assets(f)
Total expenses			0.89	%(g)			0.89	%			0.90	%			0.91	%			0.91	%			0.90	%
Total expenses after fees waived and/or reimbursed			0.89	%(g)			0.89	%			0.90	%			0.91	%			0.91	%			0.90	%
Net investment income			0.40	%(g)			0.31	%			0.21	%			0.78	%			1.08	%			1.00	%
Supplemental Data
Net assets, end of period (000)		$	846,661			$	774,667			$	975,479			$	843,673			$	792,638			$	674,077
Portfolio turnover rate			15	%			32	%			27	%			46	%			32	%			27	%

^(a)  Based on average shares outstanding.

^(b)  Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

^(c) Amount previously presented incorrectly as solely distributions from net investment income has been revised to reflect the proper classification of distributions between net realized gain and net investment income.

^(d)  Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices.

^(e) Not annualized.

^(f)  Excludes fees and expenses incurred indirectly as a result of investments in underlying funds.

^(g)  Annualized.

See notes to financial statements.

F I N A N C I A L   H I G H L I G H T S 139

Financial Highlights (continued)

(For a share outstanding throughout each period)

	BDJ
		Six Months Ended 06/30/23 (unaudited)(a)					Year Ended 12/31/22	(a)		Year Ended 12/31/21			Year Ended 12/31/20			Year Ended 12/31/19			Year Ended 12/31/18
Net asset value, beginning of period			$	8.74		$	10.23		$	9.35		$	10.03		$	8.74		$	9.96
Net investment income(b)				0.09			0.16			0.15			0.18			0.18			0.18	(c)
Net realized and unrealized gain (loss)				0.34			(0.56	)		1.60			(0.26	)		1.86			(0.84	)
Net increase (decrease) from investment operations				0.43			(0.40	)		1.75			(0.08	)		2.04			(0.66	)
Distributions(d)
From net investment income				(0.34	)		(0.04	)		(0.28	)		(0.15	)		(0.08	)		(0.18	)(e)
From net realized gain				—			(1.05	)		(0.59	)		(0.45	)		(0.67	)		(0.38	)(e)
Total distributions				(0.34	)		(1.09	)		(0.87	)		(0.60	)		(0.75	)		(0.56	)
Net asset value, end of period			$	8.83		$	8.74		$	10.23		$	9.35		$	10.03		$	8.74
Market price, end of period			$	8.34		$	9.01		$	10.08		$	8.47		$	9.92		$	7.77
Total Return(f)
Based on net asset value				5.07	%(g)		(3.71	)%(h)		19.33	%		0.77	%		24.52	%		(6.59	)%
Based on market price				(3.73	)%(g)		0.74	%		29.80	%		(7.70	)%		38.53	%		(10.39	)%
Ratios to Average Net Assets(i)
Total expenses				0.85	%(j)		0.84	%		0.85	%		0.86	%		0.87	%		0.85	%
Total expenses after fees waived and/or reimbursed				0.85	%(j)		0.84	%		0.85	%		0.86	%		0.87	%		0.85	%
Net investment income				2.04	%(j)		1.69	%		1.44	%		2.15	%		1.99	%		1.85	%(c)
Supplemental Data
Net assets, end of period (000)			$	1,646,755		$	1,629,642		$	1,902,838		$	1,739,122		$	1,881,675		$	1,638,237
Portfolio turnover rate				24	%		81	%		40	%		48	%		40	%		34	%

^(a)  Consolidated Financial Highlights.

^(b)  Based on average shares outstanding.

^(c)  Net investment income per share and the ratio of net investment income to average net assets includes $0.01 per share and 0.14%, respectively, resulting from a special dividend.

^(d)  Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

^(e)  Amount previously presented incorrectly as solely distributions from net investment income has been revised to reflect the proper classification of distributions between net realized gain and net investment income.

^(f)  Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices.

^(g) Not annualized.

^(h) Includes payment from an affiliate, which had no impact on the Trust’s total return.

⁽ⁱ⁾ Excludes fees and expenses incurred indirectly as a result of investments in underlying funds.

^(j)  Annualized.

See notes to financial statements.

140 2 0 2 3   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Financial Highlights (continued)

(For a share outstanding throughout each period)

	BOE
	Six Months Ended 06/30/23 (unaudited)				Year Ended 12/31/22			Year Ended 12/31/21			Year Ended 12/31/20			Year Ended 12/31/19			Year Ended 12/31/18
Net asset value, beginning of period		$	10.97		$	13.40		$	12.28		$	12.32		$	11.07		$	13.22
Net investment income(a)			0.15			0.20			0.19			0.26			0.30			0.31
Net realized and unrealized gain (loss)			0.85			(1.87	)		1.69			0.46			1.71			(1.61	)
Net increase (decrease) from investment operations			1.00			(1.67	)		1.88			0.72			2.01			(1.30	)
Distributions(b)
From net investment income			(0.38	)(c)		(0.19	)		(0.19	)		(0.26	)		(0.31	)		(0.31	)(d)
From net realized gain			—			(0.41	)		(0.57	)		—			—			(0.52	)(d)
Return of capital			—			(0.16	)		—			(0.50	)		(0.45	)		(0.02	)
Total distributions			(0.38	)		(0.76	)		(0.76	)		(0.76	)		(0.76	)		(0.85	)
Net asset value, end of period		$	11.59		$	10.97		$	13.40		$	12.28		$	12.32		$	11.07
Market price, end of period		$	10.07		$	9.56		$	12.18		$	10.91		$	10.99		$	9.37
Total Return(e)
Based on net asset value			9.67	%(f)		(11.87	)%		16.21	%		7.65	%		19.54	%		(9.63	)%
Based on market price			9.34	%(f)		(15.51	)%		18.89	%		7.22	%		25.98	%		(19.16	)%
Ratios to Average Net Assets(g)
Total expenses			1.08	%(h)		1.06	%		1.07	%		1.09	%		1.12	%		1.08	%
Total expenses after fees waived and/or reimbursed			0.91	%(h)		0.89	%		0.90	%		0.92	%		0.94	%		0.94	%
Total expenses after fees waived and/or reimbursed and excluding professional fees for foreign withholding taxes			0.90	%(h)		0.88	%		0.90	%		0.92	%		0.94	%		0.94	%
Net investment income			2.57	%(h)		1.72	%		1.46	%		2.33	%		2.62	%		2.52	%
Supplemental Data
Net assets, end of period (000)		$	721,262		$	688,464		$	857,721		$	786,230		$	807,712		$	754,602
Portfolio turnover rate			28	%		44	%		65	%		61	%		26	%		28	%

^(a)  Based on average shares outstanding.

^(b)  Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

^(c) A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year-end.

^(d) Amount previously presented incorrectly as solely distributions from net investment income has been revised to reflect the proper classification of distributions between net realized gain and net investment income.

^(e) Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices.

^(f) Not annualized.

^(g)  Excludes fees and expenses incurred indirectly as a result of investments in underlying funds.

^(h)  Annualized.

See notes to financial statements.

F I N A N C I A L   H I G H L I G H T S 141

Financial Highlights (continued)

(For a share outstanding throughout each period)

	BGY
	Six Months Ended 06/30/23 (unaudited)				Year Ended 12/31/22			Year Ended 12/31/21			Year Ended 12/31/20			Year Ended 12/31/19			Year Ended 12/31/18
Net asset value, beginning of period		$	5.78		$	6.81		$	6.49		$	6.47		$	5.79		$	7.06
Net investment income(a)			0.07			0.10			0.09			0.12			0.16			0.17	(b)
Net realized and unrealized gain (loss)			0.59			(0.72	)		0.64			0.31			0.93			(1.00	)
Net increase (decrease) from investment operations			0.66			(0.62	)		0.73			0.43			1.09			(0.83	)
Distributions(c)
From net investment income			(0.20	)(d)		(0.10	)		(0.14	)		(0.13	)		(0.16	)		(0.16	)(e)
From net realized gain			—			(0.10	)		(0.15	)		—			(0.19	)		(0.28	)(e)
Return of capital			—			(0.21	)		(0.12	)		(0.28	)		(0.06	)		—
Total distributions			(0.20	)		(0.41	)		(0.41	)		(0.41	)		(0.41	)		(0.44	)
Net asset value, end of period		$	6.24		$	5.78		$	6.81		$	6.49		$	6.47		$	5.79
Market price, end of period		$	5.44		$	5.02		$	6.28		$	5.87		$	5.89		$	4.98
Total Return(f)
Based on net asset value			12.03	%(g)		(8.33	)%		11.92	%		8.18	%		20.20	%		(11.48	)%
Based on market price			12.45	%(g)		(13.67	)%		14.11	%		7.49	%		27.22	%		(17.55	)%
Ratios to Average Net Assets(h)
Total expenses			1.09	%(i)		1.08	%		1.09	%		1.10	%		1.13	%		1.09	%
Total expenses after fees waived and/or reimbursed			1.09	%(i)		1.03	%		0.99	%		1.00	%		1.03	%		0.99	%
Total expenses after fees waived and/or reimbursed and excluding professional fees for foreign withholding taxes			1.09	%(i)		1.02	%		0.99	%		1.00	%		1.03	%		0.99	%
Net investment income			2.37	%(i)		1.71	%		1.34	%		1.99	%		2.57	%		2.59	%(b)
Supplemental Data
Net assets, end of period (000)		$	632,447		$	593,471		$	709,510		$	676,949		$	683,247		$	623,234
Portfolio turnover rate			26	%		41	%		71	%		60	%		28	%		60	%

^(a)  Based on average shares outstanding.

^(b)  Net investment income per share and the ratio of net investment income to average net assets includes $0.10 per share and 29%, respectively, resulting from a non-recurring dividend.

^(c)  Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

^(d)  A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year-end.

^(e)  Amount previously presented incorrectly as solely distributions from net investment income has been revised to reflect the proper classification of distributions between net realized gain and net investment income.

^(f)  Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices.

^(g) Not annualized.

^(h) Excludes fees and expenses incurred indirectly as a result of investments in underlying funds.

⁽ⁱ⁾  Annualized.

See notes to financial statements.

142 2 0 2 3   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Financial Highlights (continued)

(For a share outstanding throughout each period)

	BMEZ
		Six Months Ended 06/30/23 (unaudited)					Year Ended 12/31/22			Year Ended 12/31/21			Period from 01/30/20 to 12/31/20	(a)
Net asset value, beginning of period			$	18.76		$	26.47		$	30.73		$	20.00
Net investment loss(b)				(0.08	)		(0.18	)		(0.32	)		(0.22	)
Net realized and unrealized gain (loss)				1.25			(5.79	)		(2.23	)		11.85
Net increase (decrease) from investment operations				1.17			(5.97	)		(2.55	)		11.63
Distributions(c)
From net investment income				(0.87	)(d)		—			—			—
From net realized gain				—			(1.63	)		(1.71	)		(0.90	)
Return of capital				—			(0.11	)		—			—
Total distributions				(0.87	)		(1.74	)		(1.71	)		(0.90	)
Net asset value, end of period			$	19.06		$	18.76		$	26.47		$	30.73
Market price, end of period			$	16.42		$	15.43		$	25.36		$	28.65
Total Return(e)
Based on net asset value				7.11	%(f)		(21.66	)%		(8.31	)%		59.62	%(f)(g)
Based on market price				12.18	%(f)		(32.75	)%		(5.76	)%		48.82	%(f)
Ratios to Average Net Assets(h)
Total expenses				1.32	%(i)(j)		1.32	%		1.30	%		1.29	%(j)
Total expenses after fees waived and/or reimbursed				1.32	%(i)(j)		1.32	%		1.30	%		1.28	%(j)
Net investment loss				(0.89	)%(j)		(0.91	)%		(1.10	)%		(1.00	)%(j)
Supplemental Data
Net assets, end of period (000)			$	2,058,608		$	2,056,419		$	2,981,886		$	3,462,638
Portfolio turnover rate				26	%		63	%		44	%		43	%

^(a) Commencement of operations.

^(b)  Based on average shares outstanding.

^(c)  Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

^(d)  A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year-end.

^(e)  Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices.

^(f) Not annualized.

^(g)  Includes payment from an affiliate, which had no impact on the Trust’s total return.

^(h)  Excludes fees and expenses incurred indirectly as a result of investments in underlying funds.

⁽ⁱ⁾  Includes non-recurring expenses of proxy costs. Without these costs, total expenses, total expenses after fees waived and/or reimbursed would have been 1.30% and 1.30%, respectively.

^(j)  Annualized.

See notes to financial statements.

F I N A N C I A L   H I G H L I G H T S 143

Financial Highlights (continued)

(For a share outstanding throughout each period)

	BME
	Six Months Ended 06/30/23 (unaudited)				Year Ended 12/31/22			Year Ended 12/31/21			Year Ended 12/31/20			Year Ended 12/31/19			Year Ended 12/31/18
Net asset value, beginning of period		$	43.30		$	47.96		$	45.66		$	41.19		$	35.87		$	35.69
Net investment income(a)			0.08			0.11			—			0.01			0.06			0.07
Net realized and unrealized gain (loss)			0.73			(2.21	)		4.74			6.86			7.66			2.51
Net increase (decrease) from investment operations			0.81			(2.10	)		4.74			6.87			7.72			2.58
Distributions(b)
From net investment income			(1.28	)(c)		(0.12	)		(0.00	)(d)		(0.05	)		(0.12	)		(0.07	)(e)
From net realized gain			—			(2.34	)		(2.44	)		(2.35	)		(2.28	)		(2.33	)(e)
Return of capital			—			(0.10	)		—			—			—			—
Total distributions			(1.28	)		(2.56	)		(2.44	)		(2.40	)		(2.40	)		(2.40	)
Net asset value, end of period		$	42.83		$	43.30		$	47.96		$	45.66		$	41.19		$	35.87
Market price, end of period		$	40.64		$	43.58		$	48.50		$	47.59		$	42.50		$	36.45
Total Return(f)
Based on net asset value			2.00	%(g)		(4.19	)%		10.66	%(h)		17.50	%		22.26	%		7.26	%
Based on market price			(3.83	)%(g)		(4.64	)%		7.37	%		18.69	%		24.15	%		6.57	%
Ratios to Average Net Assets(i)
Total expenses			1.06	%(j)		1.08	%		1.08	%		1.10	%		1.09	%		1.11	%
Total expenses after fees waived and/or reimbursed			1.06	%(j)		1.07	%		1.08	%		1.10	%		1.09	%		1.11	%
Net investment income			0.40	%(j)		0.27	%		0.01	%		0.01	%		0.16	%		0.19	%
Supplemental Data
Net assets, end of period (000)		$	597,249		$	600,197		$	625,775		$	545,936		$	446,773		$	352,675
Portfolio turnover rate			20	%		41	%		49	%		28	%		47	%		37	%

^(a)  Based on average shares outstanding.

^(b)  Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

^(c)  A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year-end.

^(d) Amount is greater than $(0.005) per share.

^(e) Amount previously presented incorrectly as solely distributions from net investment income has been revised to reflect the proper classification of distributions between net realized gain and net investment income.

^(f) Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices.

^(g) Not annualized.

^(h) Includes payment from an affiliate, which had no impact on the Trust’s total return.

⁽ⁱ⁾ Excludes fees and expenses incurred indirectly as a result of investments in underlying funds.

^(j)  Annualized.

See notes to financial statements.

144 2 0 2 3   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Financial Highlights (continued)

(For a share outstanding throughout each period)

	BIGZ
		Six Months Ended 06/30/23 (unaudited)					Year Ended 12/31/22			Period from 03/29/21 to 12/31/21	(a)
Net asset value, beginning of period			$	8.82		$	16.72		$	20.00
Net investment loss(b)				(0.06	)		(0.13	)		(0.15	)
Net realized and unrealized gain (loss)				1.04			(6.78	)		(2.43	)
Net increase (decrease) from investment operations				0.98			(6.91	)		(2.58	)
Distributions(c)
From net investment income				(0.42	)(d)		—			—
Return of capital				—			(0.99	)		(0.70	)
Total distributions				(0.42	)		(0.99	)		(0.70	)
Net asset value, end of period			$	9.38		$	8.82		$	16.72
Market price, end of period			$	7.85		$	6.81		$	14.54
Total Return(e)
Based on net asset value				12.30	%(f)		(41.14	)%(g)		(13.03	)%(f)
Based on market price				21.72	%(f)		(47.74	)%		(24.37	)%(f)
Ratios to Average Net Assets(h)
Total expenses				1.42	%(i)(j)(k)		1.36	%		1.29	%(j)
Total expenses after fees waived and/or reimbursed				1.42	%(i)(j)(k)		1.36	%		1.28	%(j)
Net investment loss				(1.26	)%(j)		(1.22	)%		(1.02	)%(j)
Supplemental Data
Net assets, end of period (000)			$	2,129,409		$	2,026,488		$	3,981,653
Portfolio turnover rate				18	%		41	%		55	%

^(a) Commencement of operations.

^(b)  Based on average shares outstanding.

^(c)  Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

^(d)  A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year-end.

^(e)  Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices.

^(f) Not annualized.

^(g) Includes payment from an affiliate, which had no impact on the Trust’s total return.

^(h) Excludes fees and expenses incurred indirectly as a result of investments in underlying funds.

⁽ⁱ⁾  Includes non-recurring expenses of proxy costs. Without these costs, total expenses, total expenses after fees waived and/or reimbursed would have been 1.33% and 1.33%, respectively.

^(j)  Annualized.

^(k)  The Proxy costs was not annualized in the calculation of the expense ratios. If these expense was annualized, the total expenses and total expenses after fees waived and/or reimbursed would have been 1.52% and 1.52% respectively.

See notes to financial statements.

F I N A N C I A L   H I G H L I G H T S 145

Financial Highlights (continued)

(For a share outstanding throughout each period)

	BCX
	Six Months Ended 06/30/23 (unaudited)				Year Ended 12/31/22			Year Ended 12/31/21			Year Ended 12/31/20			Year Ended 12/31/19			Year Ended 12/31/18
Net asset value, beginning of period		$	11.23		$	10.21		$	8.45		$	9.04		$	8.44		$	10.64
Net investment income(a)			0.16			0.30			0.29			0.20			0.23			0.22
Net realized and unrealized gain (loss)			(0.47	)		1.27			1.95			(0.26	)		0.99			(1.80	)
Net increase (decrease) from investment operations			(0.31	)		1.57			2.24			(0.06	)		1.22			(1.58	)
Distributions(b)
From net investment income			(0.31	)(c)		(0.29	)		(0.38	)		(0.23	)		(0.23	)		(0.19	)
Return of capital			—			(0.26	)		(0.10	)		(0.30	)		(0.39	)		(0.43	)
Total distributions			(0.31	)		(0.55	)		(0.48	)		(0.53	)		(0.62	)		(0.62	)
Net asset value, end of period		$	10.61		$	11.23		$	10.21		$	8.45		$	9.04		$	8.44
Market price, end of period		$	9.07		$	9.97		$	9.35		$	7.41		$	8.07		$	7.06
Total Return(d)
Based on net asset value			(2.42	)%(e)		16.31	%		27.20	%		1.56	%		15.88	%		(14.90	)%
Based on market price			(6.04	)%(e)		12.76	%		32.83	%		(0.23	)%		23.67	%		(22.47	)%
Ratios to Average Net Assets(f)
Total expenses			1.06	%(g)		1.05	%		1.07	%		1.09	%		1.11	%		1.08	%
Total expenses after fees waived and/or reimbursed			1.06	%(g)		1.05	%		1.07	%		1.09	%		1.11	%		1.08	%
Total expenses after fees waived and/or reimbursed and excluding professional fees for foreign withholding taxes			1.06	%(g)		1.05	%		1.07	%		1.09	%		1.11	%		1.08	%
Net investment income			2.88	%(g)		2.73	%		3.05	%		2.62	%		2.56	%		2.17	%
Supplemental Data
Net assets, end of period (000)		$	910,793		$	983,181		$	901,782		$	746,615		$	822,754		$	798,282
Portfolio turnover rate			17	%		92	%		66	%		78	%		69	%		66	%

^(a)  Based on average shares outstanding.

^(b)  Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

^(c)  A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year-end.

^(d)  Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices.

^(e)  Not annualized.

^(f)  Excludes fees and expenses incurred indirectly as a result of investments in underlying funds.

^(g)  Annualized.

See notes to financial statements.

146 2 0 2 3   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Financial Highlights (continued)

(For a share outstanding throughout each period)

	BSTZ
			Six Months Ended 06/30/23 (unaudited)	(a)		Year Ended 12/31/22	(a)		Year Ended 12/31/21	(a)		Year Ended 12/31/20	(a)		Period from 06/27/19 to 12/31/19	(b)
Net asset value, beginning of period		$	19.53		$	38.82		$	38.72		$	20.95		$	20.00
Net investment loss(c)			(0.09	)		(0.30	)		(0.51	)		(0.30	)		(0.05	)
Net realized and unrealized gain (loss)			3.09			(16.69	)		3.69			19.32			1.50
Net increase (decrease) from investment operations			3.00			(16.99	)		3.18			19.02			1.45
Distributions(d)
From net investment income			(1.03	)(e)		—			—			—			—
From net realized gain			—			(0.89	)		(3.08	)		(1.10	)		—
Return of capital			—			(1.41	)		—			(0.15	)		(0.50	)
Total distributions			(1.03	)		(2.30	)		(3.08	)		(1.25	)		(0.50	)
Net asset value, end of period		$	21.50		$	19.53		$	38.82		$	38.72		$	20.95
Market price, end of period		$	18.11		$	15.64		$	38.94		$	36.38		$	20.50
Total Return(f)
Based on net asset value			16.60	%(g)(h)		(43.98	)%		8.41	%		94.60	%(g)		7.40	%(h)
Based on market price			22.64	%(h)		(55.27	)%		15.75	%		86.85	%		5.10	%(h)
Ratios to Average Net Assets(i)
Total expenses			1.35	%(j)		1.33	%		1.31	%		1.33	%		1.32	%(j)
Total expenses after fees waived and/or reimbursed			1.34	%(j)		1.33	%		1.31	%		1.33	%		1.30	%(j)
Net investment loss			(0.92	)%(j)		(1.16	)%		(1.25	)%		(1.16	)%		(0.48	)%(j)
Supplemental Data
Net assets, end of period (000)		$	1,653,705		$	1,524,658		$	3,048,962		$	3,023,744		$	1,635,966
Portfolio turnover rate			21	%		47	%		18	%		45	%		16	%

^(a)  Consolidated Financial Highlights.

^(b)  Commencement of operations.

^(c)  Based on average shares outstanding.

^(d)  Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

^(e)  A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year-end.

^(f)  Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices.

^(g)  Includes payment from an affiliate, which had no impact on the Trust’s total return.

^(h)  Not annualized.

⁽ⁱ⁾  Excludes fees and expenses incurred indirectly as a result of investments in underlying funds.

^(j)  Annualized.

See notes to financial statements.

F I N A N C I A L   H I G H L I G H T S 147

Financial Highlights (continued)

(For a share outstanding throughout each period)

		BST
	Six Months Ended 06/30/23 (unaudited)(a)				Year Ended 12/31/22(a)					Year Ended 12/31/21	(a)		Year Ended 12/31/20	(a)	Year Ended 12/31/19				Year Ended 12/31/18
Net asset value, beginning of period		$	29.11			$	52.40		$	51.94		$	32.45			$	26.21			$	27.73
Net investment loss(b)			(0.11	)			(0.29	)		(0.43	)		(0.28	)			(0.17	)			(0.13	)
Net realized and unrealized gain (loss)			6.64				(20.00	)		5.84			21.82				9.92				0.37
Net increase (decrease) from investment operations			6.53				(20.29	)		5.41			21.54				9.75				0.24
Distributions(c)
From net investment income			(1.50	)(d)			—			—			—				—				—	(e)
From net realized gain			—				(2.16	)		(4.27	)		(2.05	)			(3.51	)			(1.76	)(e)
Return of capital			—				(0.84	)		—			—				—				—
Total distributions			(1.50	)			(3.00	)		(4.27	)		(2.05	)			(3.51	)			(1.76	)
Dilutive effect of rights offer (Note 10)			—				—			(0.68	)		—				—				—
Net asset value, end of period		$	34.14			$	29.11		$	52.40		$	51.94			$	32.45			$	26.21
Market price, end of period		$	34.44			$	28.37		$	49.97		$	53.30			$	33.27			$	27.48
Total Return(f)
Based on net asset value			22.90	%(g)			(39.56	)%(h)		9.44	%		68.76	%(i)			37.82	%			0.24	%
Based on market price			27.21	%(g)			(38.23	)%		1.70	%		68.92	%			34.77	%			9.18	%
Ratios to Average Net Assets(j)
Total expenses			1.10	%(k)			1.11	%		1.05	%		1.09	%			1.08	%			1.09	%
Total expenses after fees waived and/or reimbursed			1.10	%(k)			1.11	%		1.00	%		0.99	%			0.92	%			0.89	%
Total expenses after fees waived and/or reimbursed and excluding dividend expense			1.10	%(k)			1.10	%		1.00	%		0.99	%			0.92	%			0.89	%
Net investment loss			(0.67	)%(k)			(0.77	)%		(0.78	)%		(0.73	)%			(0.52	)%			(0.43	)%
Supplemental Data
Net assets, end of period (000)		$	1,160,921			$	960,703		$	1,681,166		$	1,297,344			$	742,672			$	587,908
Portfolio turnover rate			16	%			38	%		31	%		20	%			32	%			53	%

^(a) Consolidated Financial Highlights.

^(b) Based on average shares outstanding.

^(c) Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

^(d)  A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year-end.

^(e)  Amount previously presented incorrectly as solely distributions from net investment income has been revised to reflect the proper classification of distributions between net realized gain and net investment income.

^(f)  Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices.

^(g)  Not annualized.

^(h) Includes payment from an affiliate, which had no impact on the Trust’s total return.

⁽ⁱ⁾ For financial reporting purposes, the market value of a certain investment was adjusted as of the report date. Accordingly, the net asset value (NAV) per share and total return performance based on NAV presented herein are different than the information previously published as of December 31, 2020.

^(j) Excludes fees and expenses incurred indirectly as a result of investments in underlying funds.

^(k)  Annualized.

See notes to financial statements.

148 2 0 2 3   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Financial Highlights (continued)

(For a share outstanding throughout each period)

	BUI
		Six Months Ended 06/30/23 (unaudited)				Year Ended 12/31/22				Year Ended 12/31/21				Year Ended 12/31/20				Year Ended 12/31/19				Year Ended 12/31/18
Net asset value, beginning of period			$	22.37			$	25.86			$	23.80			$	22.02			$	18.77			$	21.12
Net investment income(a)				0.23				0.33				0.24				0.33				0.37				0.49
Net realized and unrealized gain (loss)				1.09				(2.37	)			3.27				2.90				4.33				(1.39	)
Net increase (decrease) from investment operations				1.32				(2.04	)			3.51				3.23				4.70				(0.90	)
Distributions(b)
From net investment income				(0.73	)			(0.30	)			(0.24	)			(0.20	)			(0.24	)			(0.63	)(c)
From net realized gain				—				(0.56	)			(0.76	)			(1.08	)			(1.06	)			(0.81	)(c)
Return of capital				—				(0.59	)			(0.45	)			(0.17	)			(0.15	)			(0.01	)
Total distributions				(0.73	)			(1.45	)			(1.45	)			(1.45	)			(1.45	)			(1.45	)
Net asset value, end of period			$	22.96			$	22.37			$	25.86			$	23.80			$	22.02			$	18.77
Market price, end of period			$	22.04			$	20.77			$	26.62			$	25.04			$	22.31			$	19.76
Total Return(d)
Based on net asset value				5.97	%(e)			(7.73	)%			15.13	%			15.87	%			25.63	%			(4.40	)%
Based on market price				9.56	%(e)			(16.78	)%			12.65	%			20.32	%			20.91	%			(1.68	)%
Ratios to Average Net Assets(f)
Total expenses				1.08	%(g)			1.08	%			1.08	%			1.13	%			1.12	%			1.12	%
Total expenses after fees waived and/or reimbursed				1.08	%(g)			1.08	%			1.07	%			1.10	%			1.10	%			1.09	%
Net investment income				2.02	%(g)			1.44	%			0.97	%			1.58	%			1.78	%			2.46	%
Supplemental Data
Net assets, end of period (000)			$	514,997			$	498,393			$	559,805			$	444,526			$	383,337			$	318,933
Portfolio turnover rate				15	%			36	%			20	%			39	%			39	%			28	%

^(a) Based on average shares outstanding.

^(b) Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

^(c)  Amount previously presented incorrectly as solely distributions from net investment income has been revised to reflect the proper classification of distributions between net realized gain and net investment income.

^(d)  Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices.

^(e)  Not annualized.

^(f)  Excludes fees and expenses incurred indirectly as a result of investments in underlying funds.

^(g)  Annualized.

See notes to financial statements.

F I N A N C I A L   H I G H L I G H T S 149

Notes to Financial Statements (unaudited)

1. ORGANIZATION

The following are registered under the Investment Company Act of 1940, as amended (the “1940 Act”), as closed-end management investment companies and are referred to herein collectively as the “Trusts”, or individually as a “Trust”:

Trust Name	Herein Referred To As	Organized	Diversification Classification
BlackRock Energy and Resources Trust	BGR	Delaware	Non-diversified
BlackRock Enhanced Capital and Income Fund, Inc.	CII	Maryland	Diversified
BlackRock Enhanced Equity Dividend Trust	BDJ	Delaware	Diversified
BlackRock Enhanced Global Dividend Trust	BOE	Delaware	Diversified
BlackRock Enhanced International Dividend Trust	BGY	Delaware	Diversified
BlackRock Health Sciences Term Trust	BMEZ	Maryland	Non-diversified
BlackRock Health Sciences Trust	BME	Delaware	Diversified
BlackRock Innovation and Growth Term Trust	BIGZ	Maryland	Non-diversified
BlackRock Resources & Commodities Strategy Trust	BCX	Delaware	Non-diversified
BlackRock Science and Technology Term Trust	BSTZ	Delaware	Non-diversified
BlackRock Science and Technology Trust	BST	Delaware	Diversified
BlackRock Utilities, Infrastructure & Power Opportunities Trust	BUI	Delaware	Diversified

The Boards of Directors and Boards of Trustees of the Trusts are collectively referred to throughout this report as the “Board,” and the trustees thereof are collectively referred to throughout this report as “Trustees”. The Trusts determine and make available for publication the net asset values (“NAVs”) of their Common Shares on a daily basis.

On March 31, 2023, the Board approved a proposal to change the name of BlackRock Innovation and Growth Trust, BlackRock Health Sciences Trust II and BlackRock Science and Technology Trust II , effective as of April 5, 2023, to BlackRock Innovation and Growth Term Trust, BlackRock Health Sciences Term Trust and BlackRock Science and Technology Term Trust, respectively. There were no changes to the Trusts’ investment policies or strategies in conjunction with the name changes.

The Trusts, together with certain other registered investment companies advised by BlackRock Advisors, LLC (the “Manager”) or its affiliates, are included in a complex of funds referred to as the BlackRock Fixed-Income Complex.

Basis of Consolidation: The accompanying consolidated financial statements of BDJ include the accounts of BDJ Subsidiary, LLC (the “BDJ Taxable Subsidiary”), which is a wholly-owned taxable subsidiary of BDJ. The BDJ Taxable Subsidiary enables BDJ to hold certain pass-through investments and satisfy Regulated Investment Company (“RIC”) tax requirements. Income earned and gains realized on the investment held by the BDJ Taxable Subsidiary are taxable to such subsidiary. A tax provision for income, if any, is shown as income tax in the Consolidated Statement of Operations for BDJ. A tax provision for realized and unrealized gains, if any, is included as a reduction of realized and/or unrealized gain (loss) in the Consolidated Statement of Operations for BDJ. Taxes payable or deferred as of June 30, 2023, if any, are disclosed in the Consolidated Statements of Assets and Liabilities. BDJ may invest up to 25% of its total assets in the BDJ Taxable Subsidiary. The net assets of the BDJ Taxable Subsidiary as of period end were $10,037,117, which is 0.6% of BDJ’s consolidated net assets. Intercompany accounts and transactions, if any, have been eliminated. The BDJ Taxable Subsidiary is subject to the same investment policies and restrictions that apply to BDJ.

The accompanying consolidated financial statements of BSTZ include the accounts of BSTZ Subsidiary, LLC (the “BSTZ Taxable Subsidiary”), which is a wholly-owned taxable subsidiary of BSTZ. The BSTZ Taxable Subsidiary enables BSTZ to hold certain pass-through investments and satisfy Regulated Investment Company (“RIC”) tax requirements. Income earned and gains realized on the investment held by the BSTZ Taxable Subsidiary are taxable to such subsidiary. A tax provision for income, if any, is shown as income tax in the Consolidated Statement of Operations for BSTZ. A tax provision for realized and unrealized gains, if any, is included as a reduction of realized and/or unrealized gain (loss) in the Consolidated Statement of Operations for BSTZ. Taxes payable or deferred as of June 30, 2023, if any, are disclosed in the Consolidated Statements of Assets and Liabilities. BSTZ may invest up to 25% of its total assets in the BSTZ Taxable Subsidiary. The net assets of the BSTZ Taxable Subsidiary as of period end were $22,333,200, which is 1.4% of BSTZ’s consolidated net assets. Intercompany accounts and transactions, if any, have been eliminated. The BSTZ Taxable Subsidiary is subject to the same investment policies and restrictions that apply to BSTZ.

The accompanying consolidated financial statements of BST include the accounts of BST Subsidiary, LLC (the “BST Taxable Subsidiary”), which is a wholly-owned taxable subsidiary of BST. The BST Taxable Subsidiary enables BST to hold certain pass-through investments and satisfy Regulated Investment Company (“RIC”) tax requirements. Income earned and gains realized on the investment held by the BST Taxable Subsidiary are taxable to such subsidiary. A tax provision for income, if any, is shown as income tax in the Consolidated Statement of Operations for BST. A tax provision for realized and unrealized gains, if any, is included as a reduction of realized and/or unrealized gain (loss) in the Consolidated Statement of Operations for BST. Taxes payable or deferred as of June 30, 2023, if any, are disclosed in the Consolidated Statements of Assets and Liabilities. BST may invest up to 25% of its total assets in the BST Taxable Subsidiary. The net assets of the BST Taxable Subsidiary as of period end were $11,909,641, which is 1.0% of BST’s consolidated net assets. Intercompany accounts and transactions, if any, have been eliminated. The BST Taxable Subsidiary is subject to the same investment policies and restrictions that apply to BST.

2. SIGNIFICANT ACCOUNTING POLICIES

The financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), which may require management to make estimates and assumptions that affect the reported amounts of assets and liabilities in the financial statements, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of increases and decreases in net assets from operations during the reporting period. Actual results could differ from those estimates. Each Trust is considered an investment company under U.S. GAAP and follows the accounting and reporting guidance applicable to investment companies. Below is a summary of significant accounting policies:

150 2 0 2 3   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Notes to Financial Statements (unaudited) (continued)

Investment Transactions and Income Recognition: For financial reporting purposes, investment transactions are recorded on the dates the transactions are executed. Realized gains and losses on investment transactions are determined using the specific identification method. Dividend income and capital gain distributions, if any, are recorded on the ex-dividend dates. Non-cash dividends, if any, are recorded on the ex-dividend dates at fair value. Dividends from foreign securities where the ex-dividend dates may have passed are subsequently recorded when the Trusts are informed of the ex-dividend dates. Under the applicable foreign tax laws, a withholding tax at various rates may be imposed on capital gains, dividends and interest. Upon notification from issuers, a portion of the dividend income received from a real estate investment trust may be redesignated as a reduction of cost of the related investment and/or realized gain.

Foreign Currency Translation: Each Trust’s books and records are maintained in U.S. dollars. Securities and other assets and liabilities denominated in foreign currencies are translated into U.S. dollars using exchange rates determined as of the close of trading on the New York Stock Exchange (“NYSE”). Purchases and sales of investments are recorded at the rates of exchange prevailing on the respective dates of such transactions. Generally, when the U.S. dollar rises in value against a foreign currency, the investments denominated in that currency will lose value; the opposite effect occurs if the U.S. dollar falls in relative value.

Each Trust does not isolate the effect of fluctuations in foreign exchange rates from the effect of fluctuations in the market prices of investments for financial reporting purposes. Accordingly, the effects of changes in exchange rates on investments are not segregated in the Statements of Operations from the effects of changes in market prices of those investments, but are included as a component of net realized and unrealized gain (loss) from investments. Each Trust reports realized currency gains (losses) on foreign currency related transactions as components of net realized gain (loss) for financial reporting purposes, whereas such components are generally treated as ordinary income for U.S. federal income tax purposes.

Foreign Taxes: The Trusts may be subject to foreign taxes (a portion of which may be reclaimable) on income, stock dividends, capital gains on investments, or certain foreign currency transactions. All foreign taxes are recorded in accordance with the applicable foreign tax regulations and rates that exist in the foreign jurisdictions in which each Trust invests. These foreign taxes, if any, are paid by each Trust and are reflected in its Statements of Operations as follows: foreign taxes withheld at source are presented as a reduction of income, foreign taxes on securities lending income are presented as a reduction of securities lending income, foreign taxes on stock dividends are presented as “Foreign taxes withheld”, and foreign taxes on capital gains from sales of investments and foreign taxes on foreign currency transactions are included in their respective net realized gain (loss) categories. Foreign taxes payable or deferred as of June 30, 2023, if any, are disclosed in the Statements of Assets and Liabilities.

The Trusts file withholding tax reclaims in certain jurisdictions to recover a portion of amounts previously withheld. The Trusts may record a reclaim receivable based on collectability, which includes factors such as the jurisdiction’s applicable laws, payment history and market convention. The Statements of Operations include tax reclaims recorded as well as professional and other fees, if any, associated with recovery of foreign withholding taxes.

Collateralization: If required by an exchange or counterparty agreement, the Trusts may be required to deliver/deposit cash and/or securities to/with an exchange, or broker-dealer or custodian as collateral for certain investments.

Distributions: Distributions paid by the Trusts are recorded on the ex-dividend dates. Subject to the Trusts’ managed distribution plan, the Trusts intend to make monthly cash distributions to shareholders, which may consist of net investment income, and net realized and unrealized gains on investments and/or return of capital.

The character of distributions is determined in accordance with U.S. federal income tax regulations, which may differ from U.S. GAAP. The portion of distributions that exceeds a Trust’s current and accumulated earnings and profits, which are measured on a tax basis, will constitute a non-taxable return of capital.

Deferred Compensation Plan: Under the Deferred Compensation Plan (the “Plan”) approved by each Trust’s Board, the trustees who are not “interested persons” of the Trusts, as defined in the 1940 Act (“Independent Trustees”), may defer a portion of their annual complex-wide compensation. Deferred amounts earn an approximate return as though equivalent dollar amounts had been invested in common shares of certain funds in the BlackRock Fixed-Income Complex selected by the Independent Trustees. This has the same economic effect for the Independent Trustees as if the Independent Trustees had invested the deferred amounts directly in certain funds in the BlackRock Fixed-Income Complex.

The Plan is not funded and obligations thereunder represent general unsecured claims against the general assets of each Trust, as applicable. Deferred compensation liabilities, if any, are included in the Trustees’ and Officer’s fees payable in the Statements of Assets and Liabilities and will remain as a liability of the Trusts until such amounts are distributed in accordance with the Plan. Net appreciation (depreciation) in the value of participants’ deferral accounts is allocated among the participating funds in the BlackRock Fixed-Income Complex and reflected as Trustees and Officer expense on the Statements of Operations. The Trustees and Officer expense may be negative as a result of a decrease in value of the deferred accounts.

Indemnifications: In the normal course of business, a Trust enters into contracts that contain a variety of representations that provide general indemnification. A Trust’s maximum exposure under these arrangements is unknown because it involves future potential claims against a Trust, which cannot be predicted with any certainty.

Other: Expenses directly related to a Trust are charged to that Trust. Other operating expenses shared by several funds, including other funds managed by the Manager, are prorated among those funds on the basis of relative net assets or other appropriate methods.

3. INVESTMENT VALUATION AND FAIR VALUE MEASUREMENTS

Investment Valuation Policies: Each Trust’s investments are valued at fair value (also referred to as “market value” within the financial statements) each day that the Trust is open for business and, for financial reporting purposes, as of the report date. U.S. GAAP defines fair value as the price a fund would receive to sell an asset or pay to transfer a liability in an orderly transaction between market participants at the measurement date. The Board has approved the designation of each Trust’s Manager as the valuation designee for each Trust. Each Trust determines the fair values of its financial instruments using various independent dealers or pricing services under the Manager’s policies.

N O T E S   T O   F I N A N C I A L   S T A T E M E N T S 151

Notes to Financial Statements (unaudited) (continued)

If a security’s market price is not readily available or does not otherwise accurately represent the fair value of the security, the security will be valued in accordance with the Manager’s policies and procedures as reflecting fair value. The Manager has formed a committee (the “Valuation Committee”) to develop pricing policies and procedures and to oversee the pricing function for all financial instruments, with assistance from other BlackRock pricing committees.

Fair Value Inputs and Methodologies: The following methods and inputs are used to establish the fair value of each Trust’s assets and liabilities:

• Equity investments traded on a recognized securities exchange are valued at that day’s official closing price, as applicable, on the exchange where the stock is primarily traded. Equity investments traded on a recognized exchange for which there were no sales on that day may be valued at the last available bid (long positions) or ask (short positions) price.

• Fixed-income investments for which market quotations are readily available are generally valued using the last available bid price or current market quotations provided by independent dealers or third-party pricing services. Pricing services generally value fixed-income securities assuming orderly transactions of an institutional round lot size, but a fund may hold or transact in such securities in smaller, odd lot sizes. Odd lots may trade at lower prices than institutional round lots. The pricing services may use matrix pricing or valuation models that utilize certain inputs and assumptions to derive values, including transaction data (e.g., recent representative bids and offers), market data, credit quality information, perceived market movements, news, and other relevant information. Certain fixed-income securities, including asset-backed and mortgage related securities may be valued based on valuation models that consider the estimated cash flows of each tranche of the entity, establish a benchmark yield and develop an estimated tranche specific spread to the benchmark yield based on the unique attributes of the tranche. The amortized cost method of valuation may be used with respect to debt obligations with sixty days or less remaining to maturity unless the Manager determines such method does not represent fair value.

• Investments in open-end U.S. mutual funds (including money market funds) are valued at that day’s published NAV.

• The Trusts value their investment in SL Liquidity Series, LLC, Money Market Series (the “Money Market Series”) at fair value, which is ordinarily based upon their pro rata ownership in the underlying fund’s net assets.

• Forward foreign currency exchange contracts are valued at the mean between the bid and ask prices and are determined as of the close of trading on the NYSE based on that day’s prevailing forward exchange rate for the underlying currencies.

• Exchange-traded options are valued at the mean between the last bid and ask prices at the close of the options market in which the options trade. An exchange-traded option for which there is no mean price is valued at the last bid (long positions) or ask (short positions) price. If no bid or ask price is available, the prior day’s price will be used, unless it is determined that the prior day’s price no longer reflects the fair value of the option. Over-the-counter (“OTC”) options and options on swaps (“swaptions”) are valued by an independent pricing service using a mathematical model, which incorporates a number of market data factors, such as the trades and prices of the underlying instruments.

Generally, trading in foreign instruments is substantially completed each day at various times prior to the close of trading on the NYSE. Each business day, the Trusts use current market factors supplied by independent pricing services to value certain foreign instruments (“Systematic Fair Value Price”). The Systematic Fair Value Price is designed to value such foreign securities at fair value as of the close of trading on the NYSE, which follows the close of the local markets.

If events (e.g., market volatility, company announcement or a natural disaster) occur that are expected to materially affect the value of such investment, or in the event that application of these methods of valuation results in a price for an investment that is deemed not to be representative of the market value of such investment, or if a price is not available, the investment will be valued by the Valuation Committee in accordance with the Manager’s policies and procedures as reflecting fair value (“Fair Valued Investments”). The fair valuation approaches that may be used by the Valuation Committee include market approach, income approach and cost approach. Valuation techniques such as discounted cash flow, use of market comparables and matrix pricing are types of valuation approaches and are typically used in determining fair value. When determining the price for Fair Valued Investments, the Valuation Committee seeks to determine the price that each Trust might reasonably expect to receive or pay from the current sale or purchase of that asset or liability in an arm’s-length transaction. Fair value determinations shall be based upon all available factors that the Valuation Committee deems relevant and consistent with the principles of fair value measurement.

For investments in equity or debt issued by privately held companies or funds (“Private Company” or collectively, the “Private Companies”) and other Fair Valued Investments, the fair valuation approaches that are used by the Valuation Committee and third-party pricing services utilized by the Valuation Committee include one or a combination of, but not limited to, the following inputs.

	Standard Inputs Generally Considered By The Valuation Committee And Third-Party Pricing Services
Market approach	(i)  recent market transactions, including subsequent rounds of financing, in the underlying investment or comparable issuers; (ii) recapitalizations and other transactions across the capital structure; and (iii)   market multiples of comparable issuers.
Income approach	(i)  future cash flows discounted to present and adjusted as appropriate for liquidity, credit, and/or market risks; (ii) quoted prices for similar investments or assets in active markets; and (iii)   other risk factors, such as interest rates, yield curves, volatilities, prepayment speeds, loss severities, credit risks, recovery rates, liquidation amounts and/or default rates.
Cost approach	(i)  audited or unaudited financial statements, investor communications and financial or operational metrics issued by the Private Company; (ii) changes in the valuation of relevant indices or publicly traded companies comparable to the Private Company; (iii)   relevant news and other public sources; and

152 2 0 2 3   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Notes to Financial Statements (unaudited) (continued)

Standard Inputs Generally Considered By The Valuation Committee And Third-Party Pricing Services

(iv)   known secondary market transactions in the Private Company’s interests and merger or acquisition activity in companies comparable to the Private Company.

Investments in series of preferred stock issued by Private Companies are typically valued utilizing market approach in determining the enterprise value of the company. Such investments often contain rights and preferences that differ from other series of preferred and common stock of the same issuer. Enterprise valuation techniques such as an option pricing model (“OPM”), a probability weighted expected return model (“PWERM”), current value method or a hybrid of those techniques are used as deemed appropriate under the circumstances. The use of these valuation techniques involve a determination of the exit scenarios of the investment in order to appropriately allocate the enterprise value of the company among the various parts of its capital structure.

The Private Companies are not subject to the public company disclosure, timing, and reporting standards applicable to other investments held by a Trust. Typically, the most recently available information by a Private Company is as of a date that is earlier than the date a Trust is calculating its NAV. This factor may result in a difference between the value of the investment and the price a Trust could receive upon the sale of the investment.

Fair Value Hierarchy: Various inputs are used in determining the fair value of financial instruments. These inputs to valuation techniques are categorized into a fair value hierarchy consisting of three broad levels for financial reporting purposes as follows:

• Level 1 – Unadjusted price quotations in active markets/exchanges for identical assets or liabilities that each Trust has the ability to access;

• Level 2 – Other observable inputs (including, but not limited to, quoted prices for similar assets or liabilities in markets that are active, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the assets or liabilities (such as interest rates, yield curves, volatilities, prepayment speeds, loss severities, credit risks and default rates) or other market–corroborated inputs); and

• Level 3 – Unobservable inputs based on the best information available in the circumstances, to the extent observable inputs are not available (including the Valuation Committee’s assumptions used in determining the fair value of financial instruments).

The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). Accordingly, the degree of judgment exercised in determining fair value is greatest for instruments categorized in Level 3. The inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the fair value hierarchy classification is determined based on the lowest level input that is significant to the fair value measurement in its entirety. Investments classified within Level 3 have significant unobservable inputs used by the Valuation Committee in determining the price for Fair Valued Investments. Level 3 investments include equity or debt issued by Private Companies that may not have a secondary market and/or may have a limited number of investors. The categorization of a value determined for financial instruments is based on the pricing transparency of the financial instruments and is not necessarily an indication of the risks associated with investing in those securities.

As of June 30, 2023, certain investments of CII, BMEZ, BME, BIGZ, BCX, BSTZ, BST and BUI were fair valued using NAV as a practical expedient as no quoted market value is available and therefore have been excluded from the fair value hierarchy.

4. SECURITIES AND OTHER INVESTMENTS

Preferred Stocks: Preferred stock has a preference over common stock in liquidation (and generally in receiving dividends as well), but is subordinated to the liabilities of the issuer in all respects. As a general rule, the market value of preferred stock with a fixed dividend rate and no conversion element varies inversely with interest rates and perceived credit risk, while the market price of convertible preferred stock generally also reflects some element of conversion value. Because preferred stock is junior to debt securities and other obligations of the issuer, deterioration in the credit quality of the issuer will cause greater changes in the value of a preferred stock than in a more senior debt security with similar stated yield characteristics. Unlike interest payments on debt securities, preferred stock dividends are payable only if declared by the issuer’s board of directors. Preferred stock also may be subject to optional or mandatory redemption provisions.

Warrants: Warrants entitle a fund to purchase a specified number of shares of common stock and are non-income producing. The purchase price and number of shares are subject to adjustment under certain conditions until the expiration date of the warrants, if any. If the price of the underlying stock does not rise above the strike price before the warrant expires, the warrant generally expires without any value and a fund will lose any amount it paid for the warrant. Thus, investments in warrants may involve more risk than investments in common stock. Warrants may trade in the same markets as their underlying stock; however, the price of the warrant does not necessarily move with the price of the underlying stock.

Commitments: Commitments are agreements to acquire an investment at a future date (subject to conditions) in connection with a potential public or non-public offering. Such agreements may obligate a fund to make future cash payments. As of June 30, 2023, BDJ had outstanding commitments of $6,962,883. These commitments are not included in the net assets of BDJ as of June 30, 2023.

Securities Lending: Certain Trusts may lend their securities to approved borrowers, such as brokers, dealers and other financial institutions. The borrower pledges and maintains with the Trusts collateral consisting of cash, an irrevocable letter of credit issued by a bank, or securities issued or guaranteed by the U.S. Government. The initial collateral received by each Trust is required to have a value of at least 102% of the current value of the loaned securities for securities traded on U.S. exchanges and a value of at least 105% for all other securities. The collateral is maintained thereafter at a value equal to at least 100% of the current market value of the securities on loan. The market value of the loaned securities is determined at the close of each business day of the Trust and any additional required collateral is delivered to the Trust, or excess collateral returned by the Trust, on the next business day. During the term of the loan, the Trusts are entitled to all distributions made on or in respect of the loaned securities, but do not receive interest income on securities received as collateral. Loans of securities are terminable at any time and the borrower, after notice, is required to return borrowed securities within the standard time period for settlement of securities transactions.

N O T E S   T O   F I N A N C I A L   S T A T E M E N T S 153

Notes to Financial Statements (unaudited) (continued)

As of period end, any securities on loan were collateralized by cash and/or U.S. Government obligations. Cash collateral invested by the securities lending agent, BlackRock Investment Management, LLC (“BIM”), if any, is disclosed in the Schedules of Investments. Any non-cash collateral received cannot be sold, re-invested or pledged by the Trust, except in the event of borrower default. The securities on loan, if any, are disclosed in the Trusts’ Schedules of Investments. The market value of any securities on loan and the value of related collateral, if any, are shown separately in the Statements of Assets and Liabilities as a component of investments at value – unaffiliated and collateral on securities loaned, respectively.

Securities lending transactions are entered into by the Trusts under Master Securities Lending Agreements (each, an “MSLA”), which provide the right, in the event of default (including bankruptcy or insolvency), for the non-defaulting party to liquidate the collateral and calculate a net exposure to the defaulting party or request additional collateral. In the event that a borrower defaults, the Trusts, as lender, would offset the market value of the collateral received against the market value of the securities loaned. When the value of the collateral is greater than that of the market value of the securities loaned, the lender is left with a net amount payable to the defaulting party. However, bankruptcy or insolvency laws of a particular jurisdiction may impose restrictions on or prohibitions against such a right of offset in the event of an MSLA counterparty’s bankruptcy or insolvency. Under the MSLA, absent an event of default, the borrower can resell or re-pledge the loaned securities, and the Trusts can reinvest cash collateral received in connection with loaned securities. Upon an event of default, the parties’ obligations to return the securities or collateral to the other party are extinguished, and the parties can resell or re-pledge the loaned securities or the collateral received in connection with the loaned securities in order to satisfy the defaulting party’s net payment obligation for all transactions under the MSLA. The defaulting party remains liable for any deficiency.

As of period end, the following table is a summary of the Trusts’ securities on loan by counterparty which are subject to offset under an MSLA:

Trust Name/Counterparty	Securities Loaned at Value			Cash Collateral Received(a)					Non-Cash Collateral Received, at Fair Value	(a)		Net Amount	(b)
CII
Credit Suisse Securities (USA) LLC		$	35		$	(35	)	$	—		$	—
BMEZ
Barclays Capital, Inc.		$	2,027,287		$	(2,027,287	)	$	—		$	—
BNP Paribas SA			150,130			(150,130	)		—			—
BofA Securities, Inc.			1,678,329			(1,678,329	)		—			—
Citigroup Global Markets, Inc.			3,121,460			(3,121,460	)		—			—
Goldman Sachs & Co. LLC			11,691,085			(11,691,085	)		—			—
Jefferies LLC			2,388,483			(2,388,483	)		—			—
Morgan Stanley			12,652,155			(12,652,155	)		—			—
National Financial Services LLC			963,376			(955,432	)		—			7,944
State Street Bank & Trust Co.			2,966,935			(2,966,935	)		—			—
Toronto-Dominion Bank			158,858			(156,797	)		—			2,061
UBS Securities LLC			381,330			(372,393	)		—			8,937
		$	38,179,428		$	(38,160,486	)	$	—		$	18,942
BME
BofA Securities, Inc.		$	78,090		$	(78,090	)	$	—		$	—
Citigroup Global Markets, Inc.			183,849			(183,713	)		—			136
J.P. Morgan Securities LLC			1,478,022			(1,478,022	)		—			—
Jefferies LLC			593,711			(591,801	)		—			1,910
Morgan Stanley			191,513			(191,243	)		—			270
		$	2,525,185		$	(2,522,869	)	$	—		$	2,316
BIGZ
Barclays Capital, Inc.		$	3,091,878		$	(3,091,878	)	$	—		$	—
J.P. Morgan Securities LLC			2,530,590			(2,530,590	)		—			—
Jefferies LLC			1,680,930			(1,680,930	)		—			—
Morgan Stanley			12,017,819			(12,017,819	)		—			—
National Financial Services LLC			565,182			(565,182	)		—			—
State Street Bank & Trust Co.			749,228			(749,228	)		—			—
		$	20,635,627		$	(20,635,627	)	$	—		$	—
BCX
Citigroup Global Markets, Inc.		$	7,265,282		$	(7,265,282	)	$	—		$	—
BSTZ
Goldman Sachs & Co. LLC		$	1,195,216		$	(1,195,216	)	$	—		$	—
J.P. Morgan Securities LLC			1,392,155			(1,392,155	)		—			—
		$	2,587,371		$	(2,587,371	)	$	—		$	—
BST
Goldman Sachs & Co. LLC		$	2,534,680		$	(2,534,680	)	$	—		$	—
BUI
Goldman Sachs & Co. LLC		$	684,038		$	(684,038	)	$	—		$	—
J.P. Morgan Securities LLC			1,269,032			(1,246,795	)		—			22,237

154 2 0 2 3   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Notes to Financial Statements (unaudited) (continued)

Trust Name/Counterparty	Securities Loaned at Value			Cash Collateral Received(a)					Non-Cash Collateral Received, at Fair Value	(a)		Net Amount	(b)
BUI (continued)
Jefferies LLC		$	236,107		$	(236,107	)	$	—		$	—
Morgan Stanley			324,087			(323,127	)		—			960
		$	2,513,264		$	(2,490,067	)	$	—		$	23,197

^(a) Collateral received, if any, in excess of the market value of securities on loan is not presented in this table. The total cash collateral received by each Trust is disclosed in the Trust’s Statements of Assets and Liabilities.

^(b)  The market value of the loaned securities is determined as of June 30, 2023. Additional collateral is delivered to each Trust on the next business day in accordance with the MSLA. The net amount would be subject to the borrower default indemnity in the event of default by the counterparty.

The risks of securities lending include the risk that the borrower may not provide additional collateral when required or may not return the securities when due. To mitigate these risks, the Trusts benefit from a borrower default indemnity provided by BIM. BIM’s indemnity allows for full replacement of the securities loaned to the extent the collateral received does not cover the value on the securities loaned in the event of borrower default. Each Trust could incur a loss if the value of an investment purchased with cash collateral falls below the market value of loaned securities or if the value of an investment purchased with cash collateral falls below the value of the original cash collateral received. Such losses are borne entirely by the Trusts.

5. DERIVATIVE FINANCIAL INSTRUMENTS

The Trusts engage in various portfolio investment strategies using derivative contracts both to increase the returns of the Trusts and/or to manage their exposure to certain risks such as credit risk, equity risk, interest rate risk, foreign currency exchange rate risk, commodity price risk or other risks (e.g., inflation risk). Derivative financial instruments categorized by risk exposure are included in the Schedules of Investments. These contracts may be transacted on an exchange or OTC.

Forward Foreign Currency Exchange Contracts: Forward foreign currency exchange contracts are entered into to gain or reduce exposure to foreign currencies (foreign currency exchange rate risk).

A forward foreign currency exchange contract is an agreement between two parties to buy and sell a currency at a set exchange rate on a specified date. These contracts help to manage the overall exposure to the currencies in which some of the investments held by the Trusts are denominated and in some cases, may be used to obtain exposure to a particular market. The contracts are traded OTC and not on an organized exchange.

The contract is marked-to-market daily and the change in market value is recorded as unrealized appreciation (depreciation) in the Statements of Assets and Liabilities. When a contract is closed, a realized gain or loss is recorded in the Statements of Operations equal to the difference between the value at the time it was opened and the value at the time it was closed. Non-deliverable forward foreign currency exchange contracts are settled with the counterparty in cash without the delivery of foreign currency. The use of forward foreign currency exchange contracts involves the risk that the value of a forward foreign currency exchange contract changes unfavorably due to movements in the value of the referenced foreign currencies, and such value may exceed the amount(s) reflected in the Statements of Assets and Liabilities. Cash amounts pledged for forward foreign currency exchange contracts are considered restricted and are included in cash pledged as collateral for OTC derivatives in the Statements of Assets and Liabilities. A Trust’s risk of loss from counterparty credit risk on OTC derivatives is generally limited to the aggregate unrealized gain netted against any collateral held by the Trust.

Options: The Trusts may purchase and write call and put options to increase or decrease their exposure to the risks of underlying instruments, including equity risk, interest rate risk and/or commodity price risk and/or, in the case of options written, to generate gains from options premiums.

A call option gives the purchaser (holder) of the option the right (but not the obligation) to buy, and obligates the seller (writer) to sell (when the option is exercised) the underlying instrument at the exercise or strike price at any time or at a specified time during the option period. A put option gives the holder the right to sell and obligates the writer to buy the underlying instrument at the exercise or strike price at any time or at a specified time during the option period.

Premiums paid on options purchased and premiums received on options written, as well as the daily fluctuation in market value, are included in investments at value – unaffiliated and options written at value, respectively, in the Statements of Assets and Liabilities. When an instrument is purchased or sold through the exercise of an option, the premium is offset against the cost or proceeds of the underlying instrument. When an option expires, a realized gain or loss is recorded in the Statements of Operations to the extent of the premiums received or paid. When an option is closed or sold, a gain or loss is recorded in the Statements of Operations to the extent the cost of the closing transaction exceeds the premiums received or paid. When the Trusts write a call option, such option is typically “covered,” meaning that they hold the underlying instrument subject to being called by the option counterparty. When the Trusts write a put option, cash is segregated in an amount sufficient to cover the obligation. These amounts, which are considered restricted, are included in cash pledged as collateral for options written in the Statements of Assets and Liabilities.

In purchasing and writing options, the Trusts bear the risk of an unfavorable change in the value of the underlying instrument or the risk that they may not be able to enter into a closing transaction due to an illiquid market. Exercise of a written option could result in the Trusts purchasing or selling a security when they otherwise would not, or at a price different from the current market value.

Master Netting Arrangements: In order to define its contractual rights and to secure rights that will help it mitigate its counterparty risk, a Trust may enter into an International Swaps and Derivatives Association, Inc. Master Agreement (“ISDA Master Agreement”) or similar agreement with its counterparties. An ISDA Master Agreement is a bilateral agreement between a Trust and a counterparty that governs certain OTC derivatives and typically contains, among other things, collateral posting terms and netting provisions in the event of a default and/or termination event. Under an ISDA Master Agreement, a Trust may, under certain circumstances, offset with the counterparty certain derivative financial instruments’ payables and/or receivables with collateral held and/or posted and create one single net payment. The provisions of the ISDA Master Agreement typically

N O T E S   T O   F I N A N C I A L   S T A T E M E N T S 155

Notes to Financial Statements (unaudited) (continued)

permit a single net payment in the event of default including the bankruptcy or insolvency of the counterparty. However, bankruptcy or insolvency laws of a particular jurisdiction may impose restrictions on or prohibitions against the right of offset in bankruptcy, insolvency or other events.

Collateral Requirements: For derivatives traded under an ISDA Master Agreement, the collateral requirements are typically calculated by netting the mark-to-market amount for each transaction under such agreement and comparing that amount to the value of any collateral currently pledged by the Trusts and the counterparty.

Cash collateral that has been pledged to cover obligations of the Trusts and cash collateral received from the counterparty, if any, is reported separately in the Statements of Assets and Liabilities as cash pledged as collateral and cash received as collateral, respectively. Non-cash collateral pledged by the Trusts, if any, is noted in the Schedules of Investments. Generally, the amount of collateral due from or to a counterparty is subject to a certain minimum transfer amount threshold before a transfer is required, which is determined at the close of business of the Trusts. Any additional required collateral is delivered to/pledged by the Trusts on the next business day. Typically, the counterparty is not permitted to sell, re-pledge or use cash and non-cash collateral it receives. A Trust generally agrees not to use non-cash collateral that it receives but may, absent default or certain other circumstances defined in the underlying ISDA Master Agreement, be permitted to use cash collateral received. In such cases, interest may be paid pursuant to the collateral arrangement with the counterparty. To the extent amounts due to the Trusts from the counterparties are not fully collateralized, each Trust bears the risk of loss from counterparty non-performance. Likewise, to the extent the Trusts have delivered collateral to a counterparty and stand ready to perform under the terms of their agreement with such counterparty, each Trust bears the risk of loss from a counterparty in the amount of the value of the collateral in the event the counterparty fails to return such collateral. Based on the terms of agreements, collateral may not be required for all derivative contracts.

For financial reporting purposes, the Trusts do not offset derivative assets and derivative liabilities that are subject to netting arrangements, if any, in the Statements of Assets and Liabilities.

6. INVESTMENT ADVISORY AGREEMENT AND OTHER TRANSACTIONS WITH AFFILIATES

Investment Advisory: Each Trust entered into an Investment Advisory Agreement with the Manager, the Trusts’ investment adviser and an indirect, wholly-owned subsidiary of BlackRock, Inc. (“BlackRock”), to provide investment advisory and administrative services. The Manager is responsible for the management of each Trust’s portfolio and provides the personnel, facilities, equipment and certain other services necessary to the operations of each Trust.

For such services, each Trust, except BCX, pays the Manager a monthly fee at the following annual rates:

Average weekly value of each Trust’s net assets:

	BGR			BDJ			BOE			BME
Investment advisory fees		1.20	%		0.80	%		1.00	%		1.00	%

Average daily value of each Trust’s net assets, plus the proceeds of any outstanding debt securities or borrowings for leverage:

	CII
Investment advisory fees		0.85	%

Average daily value of each Trust’s net assets:

	BGY			BUI
Investment advisory fees		1.00	%		1.00	%

Average daily value of each Trust’s managed assets:

	BMEZ			BIGZ			BSTZ			BST
Investment advisory fees		1.25	%		1.25	%		1.25	%		1.00	%

For such services, BCX pays the Manager a monthly fee at an annual rate equal to 1.00% of the sum of the average daily value of the net assets of the Trust (excluding the value of the Trust’s interest in the BCX Subsidiary, LLC (the “BCX Taxable Subsidiary”), which is a wholly-owned taxable subsidiary of BCX) and the average daily value of the net assets of its subsidiary, which fee is allocated pro rata between the Trust and the BCX Taxable Subsidiary based on the average daily value of their respective net assets (excluding, in the case of the Trust, the value of the Trust’s interest in the BCX Taxable Subsidiary). The BCX Taxable Subsidiary had no net assets or activity during the period ended June 30, 2023.

For purposes of calculating these fees, “net assets” mean the total assets of BGR, CII, BDJ, BOE, BGY, BME, BCX and BUI minus the sum of its accrued liabilities.

For purposes of calculating these fees, “managed assets” are determined as total assets of BMEZ, BIGZ, BSTZ and BST (including any assets attributable to money borrowed for investment purposes) less the sum of its accrued liabilities (other than money borrowed for investment purposes).

The Manager provides investment management and other services to BDJ Taxable Subsidiary, BSTZ Taxable Subsidiary and BST Taxable Subsidiary. The Manager does not receive separate compensation from the BDJ Taxable Subsidiary, BSTZ Taxable Subsidiary or BST Taxable Subsidiary for providing investment management or administrative services. However, BDJ pays the Manager based on the Trust’s net assets, which includes the assets of the BDJ Taxable Subsidiary, and BSTZ and BST pay the Manager based on the Trust’s managed assets, which include the assets of the BSTZ Taxable Subsidiary and BST Taxable Subsidiary, respectively.

156 2 0 2 3   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Notes to Financial Statements (unaudited) (continued)

With respect to BGR, BOE, BGY, BCX and BUI, the Manager entered into separate sub-advisory agreements with BlackRock International Limited (“BIL”), an affiliate of the Manager. The Manager pays BIL for services it provides for that portion of each Trust for which BIL acts as sub-adviser, a monthly fee that is equal to a percentage of the investment advisory fees paid by each Trust to the Manager.

Distribution Fees: BDJ, BME, BST and BUI have each entered into Distribution Agreements with BlackRock Investments, LLC (“BRIL”), an affiliate of the Manager, to provide for distribution of BDJ’s, BME’s, BST’s and BUI’s common shares on a reasonable best efforts basis through an equity shelf offering (a “Shelf Offering”) (the “Distribution Agreement”). Pursuant to the Distribution Agreement, BRIL will receive commissions with respect to sales of common shares at a commission rate of 1.00% of the gross proceeds of the sale of BDJ’s, BME’s, BST’s and BUI’s common shares and a portion of such commission is re-allowed to broker-dealers engaged by BRIL. The commissions retained by BRIL during the six months ended June 30, 2023 amounted to $0, $6,106, $58,596 and $5,829 for each of BDJ, BME, BST and BUI, respectively.

Expense Limitations, Waivers and Reimbursements: The Manager voluntarily agreed to waive a portion of the investment advisory fees on the following Trusts as a percentage of their average weekly net assets, as follows:

BGR			BOE
	0.220	%		0.175	%

These voluntary waivers may be reduced or discontinued at any time without notice.

For the six months ended June 30, 2023, the investment advisory fees waived, which are included in fees waived and/or reimbursed by the Manager in the Statements of Operations, were as follows:

Trust Name	Fees Waived and/or Reimbursed by the Manager
BGR	$	422,508
BOE		619,937

With respect to each Trust, the Manager contractually agreed to waive its investment advisory fees by the amount of investment advisory fees each Trust pays to the Manager indirectly through its investment in affiliated money market funds (the “affiliated money market fund waiver”) through June 30, 2024. The contractual agreement may be terminated upon 90 days’ notice by a majority of the Independent trustees, or by a vote of a majority of the outstanding voting securities of a Trust. These amounts are included in fees waived and/or reimbursed by the Manager in the Statements of Operations. For the six months ended June 30, 2023, the amounts waived were as follows:

Trust Name	Fees Waived and/or Reimbursed by the Manager
BGR	$	2,467
CII		4,353
BDJ		25,644
BOE		3,597
BGY		3,762
BMEZ		17,262
BME		8,990
BIGZ		4,023
BCX		10,865
BSTZ		3,534
BST		2,612
BUI		4,778

The Manager contractually agreed to waive its investment advisory fee with respect to any portion of each Trust’s assets invested in affiliated equity and fixed-income mutual funds and affiliated exchange-traded funds that have a contractual management fee through June 30, 2024. The agreement can be renewed for annual periods thereafter, and may be terminated on 90 days’ notice, each subject to approval by a majority of the Trusts’ Independent Trustees. For the six months ended June 30, 2023, there were no fees waived by the Manager pursuant to this arrangement.

Securities Lending: The U.S. Securities and Exchange Commission (“SEC”) has issued an exemptive order which permits BIM, an affiliate of the Manager, to serve as securities lending agent for the Trusts, subject to applicable conditions. As securities lending agent, BIM bears all operational costs directly related to securities lending. The Trusts are responsible for expenses in connection with the investment of cash collateral received for securities on loan (the “collateral investment expenses”). The cash collateral is invested in a private investment company, Money Market Series, managed by the Manager or its affiliates. However, BIM has agreed to cap the collateral investment expenses of the Money Market Series to an annual rate of 0.04%. The investment adviser to the Money Market Series will not charge any advisory fees with respect to shares purchased by the Trusts. The Money Market Series may, under certain circumstances, impose a liquidity fee of up to 2% of the value withdrawn or temporarily restrict withdrawals for up to 10 business days during a 90 day period, in the event that the private investment company’s weekly liquid assets fall below certain thresholds. The Money Market Series seeks current income consistent with maintaining liquidity and preserving capital. Although the Money Market Series is not registered under the 1940 Act, its investments may follow the parameters of investments by a money market fund that is subject to Rule 2a-7 under the 1940 Act.

Securities lending income is equal to the total of income earned from the reinvestment of cash collateral, net of fees and other payments to and from borrowers of securities, and less the collateral investment expenses. Each Trust retains a portion of securities lending income and remits a remaining portion to BIM as compensation for its services as securities lending agent.

N O T E S   T O   F I N A N C I A L   S T A T E M E N T S 157

Notes to Financial Statements (unaudited) (continued)

Pursuant to the current securities lending agreement, each of CII, BDJ, BMEZ, BME, BIGZ and BST retains 81% of securities lending income (which excludes collateral investment expenses), and this amount retained can never be less than 70% of the total of securities lending income plus the collateral investment expenses.

In addition, commencing the business day following the date that the aggregate securities lending income earned across the BlackRock Fixed-Income Complex in a calendar year exceeds a specified threshold, each of CII, BDJ, BMEZ, BME, BIGZ and BST, pursuant to the securities lending agreement, will retain for the remainder of that calendar year securities lending income in an amount equal to 81% of securities lending income (which excludes collateral investment expenses), and this amount retained can never be less than 70% of the total of securities lending income plus the collateral investment expenses.

Pursuant to the current securities lending agreement, each of BGR, BOE, BGY, BCX, BSTZ and BUI retains 82% of securities lending income (which excludes collateral investment expenses), and this amount retained can never be less than 70% of the total of securities lending income plus the collateral investment expenses.

In addition, commencing the business day following the date that the aggregate securities lending income earned across the BlackRock Fixed-Income Complex in a calendar year exceeds a specified threshold, each of BGR, BOE, BGY, BCX, BSTZ and BUI, pursuant to the securities lending agreement, will retain for the remainder of that calendar year securities lending income in an amount equal to 85% of securities lending income (which excludes collateral investment expenses), and this amount retained can never be less than 70% of the total of securities lending income plus the collateral investment expenses.

Prior to January 1, 2023, BIM was permitted to lend each Trust’s securities only when the difference between the borrower rebate rate (i.e., a negotiated interest rate payment for cash collateral pledged in connection with a securities lending transaction) and the risk free rate exceeded a certain level (such securities, the “specials only securities”). Effective January 1, 2023, this limitation no longer applies.

The share of securities lending income earned by each Trust is shown as securities lending income — affiliated — net in the Statements of Operations. For the six months ended June 30, 2023, each Trust paid BIM the following amounts for securities lending agent services:

Trust Name	Amounts
CII	$	1,296
BDJ		150
BOE		564
BMEZ		83,136
BME		4,853
BIGZ		8,663
BCX		2,413
BSTZ		6,950
BST		1,921
BUI		1,477

Trustees and Officers: Certain trustees and/or officers of the Trusts are directors and/or officers of BlackRock or its affiliates. The Trusts reimburse the Manager for a portion of the compensation paid to the Trusts’ Chief Compliance Officer, which is included in Trustees and Officer in the Statements of Operations.

Other Transactions: During the period ended June 30, 2023, BSTZ received a reimbursement of $127,092, from an affiliate, which is included in payment by affiliate in the Statements of Operations, related to an operating event.

The Trusts may purchase securities from, or sell securities to, an affiliated fund provided the affiliation is due solely to having a common investment adviser, common officers, or common trustees. For the six months ended June 30, 2023, the purchase and sale transactions and any net realized gains (losses) with affiliated funds in compliance with Rule 17a-7 under the 1940 Act were as follows:

Trust Name	Purchases		Sales		Net Realized Gain (Loss)
BOE	$	—	$	1,624,132	$	(48,460	)

7. PURCHASES AND SALES

For the six months ended June 30, 2023, purchases and sales of investments, excluding short-term securities, were as follows:

Trust Name	Purchases		Sales
BGR	$	76,896,544	$	74,992,878
CII		122,543,650		157,003,741
BDJ		377,562,734		398,711,983
BOE		197,359,484		215,814,242
BGY		161,645,249		185,591,306
BMEZ		518,044,823		608,804,401
BME		115,800,323		128,989,929
BIGZ		364,125,954		495,444,250
BCX		155,777,579		181,213,465
BSTZ		338,276,712		436,935,898
BST		166,223,567		213,702,659
BUI		71,878,479		75,930,588

158 2 0 2 3   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Notes to Financial Statements (unaudited) (continued)

8. INCOME TAX INFORMATION

It is each Trust’s policy to comply with the requirements of the Internal Revenue Code of 1986, as amended, applicable to regulated investment companies, and to distribute substantially all of its taxable income to its shareholders. Therefore, no U.S. federal income tax provision is required.

Each Trust files U.S. federal and various state and local tax returns. No income tax returns are currently under examination. The statute of limitations on each Trust’s U.S. federal tax returns generally remains open for a period of three years after they are filed. The statutes of limitations on each Trust’s state and local tax returns may remain open for an additional year depending upon the jurisdiction.

Management has analyzed tax laws and regulations and their application to the Trusts as of June 30, 2023, inclusive of the open tax return years, and does not believe that there are any uncertain tax positions that require recognition of a tax liability in the Trusts’ financial statements.

As of December 31, 2022, the Trusts had non-expiring capital loss carryforwards available to offset future realized capital gains and qualified late-year losses as follows:

Trust Name		Non-Expiring Capital Loss Carryforwards	(a)		Qualified Late-Year Losses	(b)
BGR	$	(239,868,252	)	$	(7,022	)
BOE		—			(17,281,763	)
BGY		—			(6,172,726	)
BMEZ		(37,330,690	)		—
BME		—			(2,023,853	)
BIGZ		(1,492,285,027	)		(20,092	)
BCX		(258,642,241	)		—
BSTZ		—			(1,665,789	)
BST		—			(33,095	)
BUI		—			(2,097,980	)

^(a) Amounts available to offset future realized capital gains.

^(b) The Trust has elected to defer certain qualified late-year losses and recognize such losses in the next taxable year.

As of June 30, 2023, gross unrealized appreciation and depreciation based on cost of investments (including short positions and derivatives, if any) for U.S. federal income tax purposes were as follows:

Trust Name	Tax Cost		Gross Unrealized Appreciation		Gross Unrealized Depreciation			Net Unrealized Appreciation (Depreciation)
BGR	$	288,857,480	$	118,696,527	$	(24,641,459	)	$	94,055,068
CII		578,234,755		305,426,078		(22,972,408	)		282,453,670
BDJ		1,437,221,041		291,753,826		(58,821,348	)		232,932,478
BOE		652,173,475		115,923,791		(41,114,849	)		74,808,942
BGY		554,367,952		113,963,276		(34,784,949	)		79,178,327
BMEZ		2,068,430,415		374,547,647		(309,010,023	)		65,537,624
BME		418,375,552		201,712,199		(17,616,037	)		184,096,162
BIGZ		2,466,080,087		267,167,074		(551,820,529	)		(284,653,455	)
BCX		818,997,049		182,115,918		(76,784,588	)		105,331,330
BSTZ		1,213,910,854		578,420,293		(112,934,311	)		465,485,982
BST		744,895,015		542,255,221		(115,383,170	)		426,872,051
BUI		369,807,530		160,968,443		(9,408,404	)		151,560,039

9. PRINCIPAL RISKS

In the normal course of business, the Trusts invest in securities or other instruments and may enter into certain transactions, and such activities subject each Trust to various risks, including among others, fluctuations in the market (market risk) or failure of an issuer to meet all of its obligations. The value of securities or other instruments may also be affected by various factors, including, without limitation: (i) the general economy; (ii) the overall market as well as local, regional or global political and/or social instability; (iii) regulation, taxation or international tax treaties between various countries; or (iv) currency, interest rate and price fluctuations. Local, regional or global events such as war, acts of terrorism, the spread of infectious illness or other public health issues, recessions, or other events could have a significant impact on the Trusts and their investments. BDJ’s, BME’s, BST’s and BUI’s prospectuses provide details of the risks to which each Trust is subject.

The Trusts may be exposed to additional risks when reinvesting cash collateral in money market funds that do not seek to maintain a stable NAV per share of $1.00, which may be subject to redemption gates or liquidity fees under certain circumstances.

Each Trust may invest without limitation in illiquid or less liquid investments or investments in which no secondary market is readily available or which are otherwise illiquid, including private placement securities. A Trust may not be able to readily dispose of such investments at prices that approximate those at which a Trust could sell such investments if they were more widely traded and, as a result of such illiquidity, a Trust may have to sell other investments or engage in borrowing transactions if necessary to raise funds to meet its obligations. Limited liquidity can also affect the market price of investments, thereby adversely affecting a Trust’s NAV and ability to make dividend

N O T E S   T O   F I N A N C I A L   S T A T E M E N T S 159

Notes to Financial Statements (unaudited) (continued)

distributions. Privately issued debt securities are often of below investment grade quality, frequently are unrated and present many of the same risks as investing in below investment grade public debt securities.

Infectious Illness Risk: An outbreak of an infectious illness, such as the COVID-19 pandemic, may adversely impact the economies of many nations and the global economy, and may impact individual issuers and capital markets in ways that cannot be foreseen. An infectious illness outbreak may result in, among other things, closed international borders, prolonged quarantines, supply chain disruptions, market volatility or disruptions and other significant economic, social and political impacts.

Valuation Risk: The market values of equities, such as common stocks and preferred securities or equity related investments, such as futures and options, may decline due to general market conditions which are not specifically related to a particular company. They may also decline due to factors which affect a particular industry or industries. A Trust may invest in illiquid investments. An illiquid investment is any investment that a Trust reasonably expects cannot be sold or disposed of in current market conditions in seven calendar days or less without the sale or disposition significantly changing the market value of the investment. A Trust may experience difficulty in selling illiquid investments in a timely manner at the price that it believes the investments are worth. Prices may fluctuate widely over short or extended periods in response to company, market or economic news. Markets also tend to move in cycles, with periods of rising and falling prices. This volatility may cause each Trust’s NAV to experience significant increases or decreases over short periods of time. If there is a general decline in the securities and other markets, the NAV of a Trust may lose value, regardless of the individual results of the securities and other instruments in which a Trust invests.

The price a Trust could receive upon the sale of any particular portfolio investment may differ from a Trust’s valuation of the investment, particularly for securities that trade in thin or volatile markets or that are valued using a fair valuation technique or a price provided by an independent pricing service. Changes to significant unobservable inputs and assumptions (i.e., publicly traded company multiples, growth rate, time to exit) due to the lack of observable inputs may significantly impact the resulting fair value and therefore a Trust’s results of operations. As a result, the price received upon the sale of an investment may be less than the value ascribed by a Trust, and a Trust could realize a greater than expected loss or lesser than expected gain upon the sale of the investment. A Trust’s ability to value its investments may also be impacted by technological issues and/or errors by pricing services or other third-party service providers.

Counterparty Credit Risk: The Trusts may be exposed to counterparty credit risk, or the risk that an entity may fail to or be unable to perform on its commitments related to unsettled or open transactions, including making timely interest and/or principal payments or otherwise honoring its obligations. The Trusts manage counterparty credit risk by entering into transactions only with counterparties that the Manager believes have the financial resources to honor their obligations and by monitoring the financial stability of those counterparties. Financial assets, which potentially expose the Trusts to market, issuer and counterparty credit risks, consist principally of financial instruments and receivables due from counterparties. The extent of the Trusts’ exposure to market, issuer and counterparty credit risks with respect to these financial assets is approximately their value recorded in the Statements of Assets and Liabilities, less any collateral held by the Trusts.

A derivative contract may suffer a mark-to-market loss if the value of the contract decreases due to an unfavorable change in the market rates or values of the underlying instrument. Losses can also occur if the counterparty does not perform under the contract.

For OTC options purchased, each Trust bears the risk of loss in the amount of the premiums paid plus the positive change in market values net of any collateral held by the Trusts should the counterparty fail to perform under the contracts. Options written by the Trusts do not typically give rise to counterparty credit risk, as options written generally obligate the Trusts, and not the counterparty, to perform. The Trusts may be exposed to counterparty credit risk with respect to options written to the extent each Trust deposits collateral with its counterparty to a written option.

With exchange-traded options purchased, there is less counterparty credit risk to the Trusts since the exchange or clearinghouse, as counterparty to such instruments, guarantees against a possible default. The clearinghouse stands between the buyer and the seller of the contract; therefore, credit risk is limited to failure of the clearinghouse. While offset rights may exist under applicable law, a Trust does not have a contractual right of offset against a clearing broker or clearinghouse in the event of a default (including the bankruptcy or insolvency).

Geographic/Asset Class Risk: A diversified portfolio, where this is appropriate and consistent with a fund’s objectives, minimizes the risk that a price change of a particular investment will have a material impact on the NAV of a fund. The investment concentrations within each Trust’s portfolio are disclosed in its Schedule of Investments.

As of period end, the Trusts listed below invested a significant portion of their assets in securities in the following sectors:

Sectors	Trust Name
Energy		BGR, BCX
Financials		BDJ
Health Care		BME, BMEZ
Information Technology		BST, BSTZ
Materials		BCX
Utilities		BUI

Changes in economic conditions affecting such sectors would have a greater impact on the Trusts and could affect the value, income and/or liquidity of positions in such securities.

Certain Trusts invest a significant portion of their assets in securities within a single or limited number of market sectors. When a fund concentrates its investments in this manner, it assumes the risk that economic, regulatory, political and social conditions affecting such sectors may have a significant impact on the Trust and could affect the income from, or the value or liquidity of, the Trust’s portfolio. Investment percentages in specific sectors are presented in the Schedules of Investments.

Certain Trusts invest a substantial amount of their assets in issuers located in a single country or a limited number of countries. When a fund concentrates its investments in this manner, it assumes the risk that economic, regulatory, political and social conditions in those countries may have a significant impact on their investment performance and could affect the income from, or the value or liquidity of, the Trust’s portfolio. Unanticipated or sudden political or social developments may cause uncertainty in the markets and

160 2 0 2 3   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Notes to Financial Statements (unaudited) (continued)

as a result adversely affect the Trust’s investments. Foreign issuers may not be subject to the same uniform accounting, auditing and financial reporting standards and practices as used in the United States. Foreign securities markets may also be more volatile and less liquid than U.S. securities and may be less subject to governmental supervision not typically associated with investing in U.S. securities. Investment percentages in specific countries are presented in the Schedules of Investments.

Certain Trusts invest a significant portion of their assets in securities of issuers located in the United States. A decrease in imports or exports, changes in trade regulations, inflation and/or an economic recession in the United States may have a material adverse effect on the U.S. economy and the securities listed on U.S. exchanges. Proposed and adopted policy and legislative changes in the United States may also have a significant effect on U.S. markets generally, as well as on the value of certain securities. Governmental agencies project that the United States will continue to maintain elevated public debt levels for the foreseeable future which may constrain future economic growth. Circumstances could arise that could prevent the timely payment of interest or principal on U.S. government debt, such as reaching the legislative “debt ceiling.” Such non-payment would result in substantial negative consequences for the U.S. economy and the global financial system. If U.S. relations with certain countries deteriorate, it could adversely affect issuers that rely on the United States for trade. The United States has also experienced increased internal unrest and discord. If these trends were to continue, they may have an adverse impact on the U.S. economy and the issuers in which the Trusts invest.

Certain Trusts invest a significant portion of their assets in securities of issuers located in Europe or with significant exposure to European issuers or countries. The European financial markets have recently experienced volatility and adverse trends due to concerns about economic downturns in, or rising government debt levels of, several European countries as well as acts of war in the region. These events may spread to other countries in Europe and may affect the value and liquidity of certain of the Trusts’ investments.

Responses to the financial problems by European governments, central banks and others, including austerity measures and reforms, may not work, may result in social unrest and may limit future growth and economic recovery or have other unintended consequences. Further defaults or restructurings by governments and others of their debt could have additional adverse effects on economies, financial markets and asset valuations around the world. The United Kingdom has withdrawn from the European Union, and one or more other countries may withdraw from the European Union and/or abandon the Euro, the common currency of the European Union. These events and actions have adversely affected, and may in the future adversely affect, the value and exchange rate of the Euro and may continue to significantly affect the economies of every country in Europe, including countries that do not use the Euro and non-European Union member states. The impact of these actions, especially if they occur in a disorderly fashion, is not clear but could be significant and far reaching. In addition, Russia launched a large-scale invasion of Ukraine on February 24, 2022. The extent and duration of the military action, resulting sanctions and resulting future market disruptions in the region are impossible to predict, but have been, and may continue to be, significant and have a severe adverse effect on the region, including significant negative impacts on the economy and the markets for certain securities and commodities, such as oil and natural gas, as well as other sectors.

10. CAPITAL SHARE TRANSACTIONS

Each Trust is authorized to issue an unlimited number of shares, with the exception of CII, all of which were initially classified as Common Shares. CII is authorized to issue 200 million Common Shares. The par value for each Trust’s Common Shares is $0.001, except for CII, which is $0.10. The Board is authorized, however, to reclassify any unissued Common Shares to Preferred Shares without the approval of Common Shareholders.

BDJ, BME, BST and BUI have each filed a prospectus with the SEC allowing them to issue an additional 40,000,000, 4,000,000, 18,000,000 and 8,000,000 Common Shares, respectively, through an equity Shelf Offering. Under the Shelf Offerings, BDJ, BME, BST and BUI, subject to market conditions, may raise additional equity capital from time to time in varying amounts and utilizing various offering methods at a net price at or above each Trust’s NAV per Common Share (calculated within 48 hours of pricing). As of period end, 40,000,000, 3,332,695, 16,272,467 and 7,700,504 Common Shares, respectively, remain available for issuance under the Shelf Offerings. During the period ended June 30, 2023, BDJ, BME, BST and BUI issued 0, 71,333, 892,174 and 125,560 shares, respectively, under the Trust’s respective current Shelf Offering and the Trust’s prior Shelf Offering. See Additional Information — Shelf Offering Program for additional information.

Initial costs incurred by each of BDJ, BME, BST and BUI in connection with their Shelf Offerings are recorded as “Deferred offering costs” in the Statements of Assets and Liabilities. As shares are sold, a portion of the costs attributable to the shares sold will be charged against paid-in-capital. Any remaining deferred charges at the end of the Shelf Offering period will be charged to expense.

For the periods shown, shares issued and outstanding increased by the following amounts as a result of shares issued through the Shelf Offering:

Trust Name	Six Months Ended 06/30/23	Year Ended 12/31/22
BME	71,333	774,304
BST	892,174	835,359
BUI	125,560	590,894

For the periods shown, shares issued and outstanding increased by the following amounts as a result of dividend reinvestment:

Trust Name	Six Months Ended 06/30/23	Year Ended 12/31/22
BDJ	78,103	412,658
BME	12,112	38,955
BST	111,117	81,277
BUI	25,289	32,898

The Trusts participate in an open market share repurchase program (the “Repurchase Program”). From December 1, 2022 through November 30, 2023, each Trust may repurchase up to 5% of its outstanding common shares under the Repurchase Program, based on common shares outstanding as of the close of business on November 30,

N O T E S   T O   F I N A N C I A L   S T A T E M E N T S 161

Notes to Financial Statements (unaudited) (continued)

2022, subject to certain conditions. The Repurchase Program has an accretive effect as shares are purchased at a discount to the Trust’s NAV. There is no assurance that the Trusts will purchase shares in any particular amounts. For the six months ended June 30, 2023, CII, BDJ, BME, BST and BUI did not repurchase any shares.

The total cost of the shares repurchased is reflected in the Trusts’ Statements of Changes in Net Assets. For the periods shown, shares repurchased and cost, including transaction costs, were as follows:

	BGR
		Shares		Amounts
Six Months Ended June 30, 2023		224,833	$	2,793,432
Year Ended December 31, 2022		1,055,728		12,296,655
		BOE
		Shares		Amounts
Six Months Ended June 30, 2023		508,486	$	5,041,877
Year Ended December 31, 2022		1,285,502		12,470,648
		BGY
		Shares		Amounts
Six Months Ended June 30, 2023		1,370,240	$	7,443,801
Year Ended December 31, 2022		1,492,331		7,282,700
		BMEZ
		Shares		Amounts
Six Months Ended June 30, 2023		1,567,078	$	25,534,135
Year Ended December 31, 2022		3,072,736		47,829,587
		BIGZ
		Shares		Amounts
Six Months Ended June 30, 2023		2,756,968	$	20,553,458
Year Ended December 31, 2022		8,519,618		64,919,571
		BCX
		Shares		Amounts
Six Months Ended June 30, 2023		1,659,738	$	16,020,113
Year Ended December 31, 2022		797,510		7,554,830
		BSTZ
		Shares		Amounts
Six Months Ended June 30, 2023		1,160,914	$	20,264,931
Year Ended December 31, 2022		461,288		7,293,625

For the period ended June 30, 2023, and year ended December 31, 2022, shares issued and outstanding remained constant for CII.

As of June 30, 2023, BlackRock Financial Management, Inc., an affiliate of the Trust, owned 5,000 Shares of BIGZ.

11. SUBSEQUENT EVENTS

Management’s evaluation of the impact of all subsequent events on the Trusts’ financial statements was completed through the date the financial statements were issued and the following items were noted:

The Trusts declared and paid or will pay distributions to Common Shareholders as follows:

Trust Name	Declaration Date		Record Date		Payable/ Paid Date		Dividend Per Common Share
BGR		07/03/23		07/14/23		07/31/23	$	0.065700
		08/01/23		08/15/23		08/31/23		0.065700
CII		07/03/23		07/14/23		07/31/23		0.099500
		08/01/23		08/15/23		08/31/23		0.099500
BDJ		07/03/23		07/14/23		07/31/23		0.056200
		08/01/23		08/15/23		08/31/23		0.056200
BOE		07/03/23		07/14/23		07/31/23		0.063000
		08/01/23		08/15/23		08/31/23		0.063000
BGY		07/03/23		07/14/23		07/31/23		0.033800
		08/01/23		08/15/23		08/31/23		0.033800

162 2 0 2 3   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Notes to Financial Statements (unaudited) (continued)

Trust Name	Declaration Date		Record Date		Payable/ Paid Date		Dividend Per Common Share
BMEZ		07/03/23		07/14/23		07/31/23	$	0.145000
		08/01/23		08/15/23		08/31/23		0.145000
BME		07/03/23		07/14/23		07/31/23		0.213000
		08/01/23		08/15/23		08/31/23		0.213000
BIGZ		07/03/23		07/14/23		07/31/23		0.070000
		08/01/23		08/15/23		08/31/23		0.070000
BCX		07/03/23		07/14/23		07/31/23		0.051800
		08/01/23		08/15/23		08/31/23		0.051800
BSTZ		07/03/23		07/14/23		07/31/23		0.161300
		08/01/23		08/15/23		08/31/23		0.161300
BST		07/03/23		07/14/23		07/31/23		0.250000
		08/01/23		08/15/23		08/31/23		0.250000
BUI		07/03/23		07/14/23		07/31/23		0.121000
		08/01/23		08/15/23		08/31/23		0.121000

N O T E S   T O   F I N A N C I A L   S T A T E M E N T S 163

Disclosure of Investment Advisory Agreements and Sub-Advisory Agreements

The Boards of Directors/Trustees, as applicable (collectively, the “Board,” the members of which are referred to as “Board Members”) of BlackRock Energy and Resources Trust (“BGR”), BlackRock Enhanced Capital and Income Fund, Inc. (“CII”), BlackRock Enhanced Equity Dividend Trust (“BDJ”), BlackRock Enhanced Global Dividend Trust (“BOE”), BlackRock Enhanced International Dividend Trust (“BGY”), BlackRock Health Sciences Trust (“BME”), BlackRock Health Sciences Term Trust (“BMEZ”), BlackRock Innovation and Growth Term Trust (“BIGZ”), BlackRock Resources & Commodities Strategy Trust (“BCX”), BlackRock Science and Technology Trust (“BST”), BlackRock Science and Technology Term Trust (“BSTZ”) and BlackRock Utilities, Infrastructure & Power Opportunities Trust (“BUI”) (collectively, the “Funds” and each, a “Fund”) met on May 4, 2023 (the “May Meeting”) and June 1-2, 2023 (the “June Meeting”) to consider the approval to continue the investment advisory agreements (the “Advisory Agreements”) between each Fund and BlackRock Advisors, LLC (the “Manager”), each Fund’s investment adviser. The Board also considered the approval to continue the sub-advisory agreements (the “Sub-Advisory Agreements”) between the Manager, BlackRock International Limited (the “Sub-Advisor”) and each of BGR, BOE, BGY, BCX and BUI. The Manager and the Sub-Advisor are referred to herein as “BlackRock.” The Advisory Agreements and the Sub-Advisory Agreements are referred to herein as the “Agreements.”

The Approval Process

Consistent with the requirements of the Investment Company Act of 1940 (the “1940 Act”), the Board considers the approval of the continuation of the Agreements for each Fund on an annual basis. The Board members who are not “interested persons” of each Fund, as defined in the 1940 Act, are considered independent Board members (the “Independent Board Members”). The Board’s consideration entailed a year-long deliberative process during which the Board and its committees assessed BlackRock’s various services to each Fund, including through the review of written materials and oral presentations, and the review of additional information provided in response to requests from the Independent Board Members. The Board had four quarterly meetings per year, each of which extended over a two-day period, as well as additional ad hoc meetings and executive sessions throughout the year, as needed. The committees of the Board similarly met throughout the year. The Board also had an additional one-day meeting to consider specific information regarding the renewal of the Agreements. In considering the renewal of the Agreements, the Board assessed, among other things, the nature, extent and quality of the services provided to each Fund by BlackRock, BlackRock’s personnel and affiliates, including (as applicable): investment management services; accounting oversight; administrative and shareholder services; oversight of each Fund’s service providers; risk management and oversight; and legal, regulatory and compliance services. Throughout the year, including during the contract renewal process, the Independent Board Members were advised by independent legal counsel, and met with independent legal counsel in various executive sessions outside of the presence of BlackRock’s management.

During the year, the Board, acting directly and through its committees, considered information that was relevant to its annual consideration of the renewal of the Agreements, including the services and support provided by BlackRock to each Fund and its shareholders. BlackRock also furnished additional information to the Board in response to specific questions from the Board. Among the matters the Board considered were: (a) investment performance for one-year, three-year, five-year, and/or since inception periods, as applicable, against peer funds, relevant benchmarks, and other performance metrics, as applicable, as well as BlackRock senior management’s and portfolio managers’ analyses of the reasons for any outperformance or underperformance relative to its peers, benchmarks, and other performance metrics, as applicable; (b) leverage management, as applicable; (c) fees, including advisory, administration, if applicable, and other amounts paid to BlackRock and its affiliates by each Fund for services; (d) Fund operating expenses and how BlackRock allocates expenses to each Fund; (e) the resources devoted to risk oversight of, and compliance reports relating to, implementation of each Fund’s investment objective, policies and restrictions, and meeting regulatory requirements; (f) BlackRock’s and each Fund’s adherence to applicable compliance policies and procedures; (g) the nature, character and scope of non-investment management services provided by BlackRock and its affiliates and the estimated cost of such services, as available; (h) BlackRock’s and other service providers’ internal controls and risk and compliance oversight mechanisms; (i) BlackRock’s implementation of the proxy voting policies approved by the Board; (j) execution quality of portfolio transactions; (k) BlackRock’s implementation of each Fund’s valuation and liquidity procedures; (l) an analysis of management fees paid to BlackRock for products with similar investment mandates across the open-end fund, closed-end fund, sub-advised mutual fund, collective investment trust and institutional separate account product channels, as applicable, and the similarities and differences between these products and the services provided as compared to each Fund; (m) BlackRock’s compensation methodology for its investment professionals and the incentives and accountability it creates, along with investment professionals’ investments in the fund(s) they manage; (n) periodic updates on BlackRock’s business; and (o) each Fund’s market discount/premium compared to peer funds.

Prior to and in preparation for the May Meeting, the Board received and reviewed materials specifically relating to the renewal of the Agreements. The Independent Board Members are continuously engaged in a process with their independent legal counsel and BlackRock to review the nature and scope of the information provided to the Board to better assist its deliberations. The materials provided in connection with the May Meeting included, among other things: (a) information independently compiled and prepared by Broadridge Financial Solutions, Inc. (“Broadridge”), based on either a Lipper classification or Morningstar category, regarding each Fund’s fees and expenses as compared with a peer group of funds as determined by Broadridge (“Expense Peers”) and the investment performance of each Fund as compared with a peer group of funds (“Performance Peers”); (b) information on the composition of the Expense Peers and Performance Peers and a description of Broadridge’s methodology; (c) information on the estimated profits realized by BlackRock and its affiliates pursuant to the Agreements and a discussion of fall-out benefits to BlackRock and its affiliates; (d) a general analysis provided by BlackRock concerning investment management fees received in connection with other types of investment products, such as institutional accounts, sub-advised mutual funds, closed-end funds, and open-end funds, under similar investment mandates, as applicable; (e) a review of non-management fees; (f) the existence, impact and sharing of potential economies of scale, if any, with each Fund; (g) a summary of aggregate amounts paid by each Fund to BlackRock; and (h) various additional information requested by the Board as appropriate regarding BlackRock’s and each Fund’s operations.

At the May Meeting, the Board reviewed materials relating to its consideration of the Agreements and the Independent Board Members presented BlackRock with questions and requests for additional information. BlackRock responded to these questions and requests with additional written information in advance of the June Meeting.

At the June Meeting, the Board concluded its assessment of, among other things: (a) the nature, extent and quality of the services provided by BlackRock; (b) the investment performance of each Fund as compared to its Performance Peers and to other metrics, as applicable; (c) the advisory fee and the estimated cost of the services and estimated profits realized by BlackRock and its affiliates from their relationship with each Fund; (d) each Fund’s fees and expenses compared to its Expense Peers; (e) the existence and sharing of potential economies of scale; (f) any fall-out benefits to BlackRock and its affiliates as a result of BlackRock’s relationship with each Fund; and (g) other factors deemed relevant by the Board Members.

164 2 0 2 3   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Disclosure of Investment Advisory Agreements and Sub-Advisory Agreements (continued)

The Board also considered other matters it deemed important to the approval process, such as other payments made to BlackRock or its affiliates relating to securities lending and cash management, and BlackRock’s services related to the valuation and pricing of Fund portfolio holdings. The Board noted the willingness of BlackRock’s personnel to engage in open, candid discussions with the Board. The Board Members evaluated the information available to them on a fund-by-fund basis. The following paragraphs provide more information about some of the primary factors that were relevant to the Board’s decision. The Board Members did not identify any particular information, or any single factor as determinative, and each Board Member may have attributed different weights to the various items and factors considered.

A. Nature, Extent and Quality of the Services Provided by BlackRock

The Board, including the Independent Board Members, reviewed the nature, extent and quality of services provided by BlackRock, including the investment advisory services, and the resulting performance of each Fund. Throughout the year, the Board compared Fund performance to the performance of a comparable group of closed-end funds, relevant benchmarks, and performance metrics, as applicable. The Board met with BlackRock’s senior management personnel responsible for investment activities, including the senior investment officers. The Board also reviewed the materials provided by each Fund’s portfolio management team discussing each Fund’s performance, investment strategies and outlook.

The Board considered, among other factors, with respect to BlackRock: the experience of investment personnel generally and each Fund’s portfolio management team; research capabilities; investments by portfolio managers in the funds they manage; portfolio trading capabilities; use of technology; commitment to compliance; credit analysis capabilities; risk analysis and oversight capabilities; and the approach to training and retaining portfolio managers and other research, advisory and management personnel. The Board also considered BlackRock’s overall risk management program, including the continued efforts of BlackRock and its affiliates to address cybersecurity risks and the role of BlackRock’s Risk & Quantitative Analysis Group. The Board engaged in a review of BlackRock’s compensation structure with respect to each Fund’s portfolio management team and BlackRock’s ability to attract and retain high-quality talent and create performance incentives.

In addition to investment advisory services, the Board considered the nature and quality of the administrative and other non-investment advisory services provided to each Fund. BlackRock and its affiliates provide each Fund with certain administrative, shareholder and other services (in addition to any such services provided to each Fund by third parties) and officers and other personnel as are necessary for the operations of each Fund. In particular, BlackRock and its affiliates provide each Fund with administrative services including, among others: (i) responsibility for disclosure documents, registration statements in connection with BDJ’s, BME’s, BST’s and BUI’s equity shelf programs, and periodic shareholder reports; (ii) preparing communications with analysts to support secondary market trading of each Fund; (iii) oversight of daily accounting and pricing; (iv) responsibility for periodic filings with regulators and stock exchanges; (v) overseeing and coordinating the activities of third-party service providers including, among others, each Fund’s custodian, fund accountant, transfer agent, and auditor; (vi) organizing Board meetings and preparing the materials for such Board meetings; (vii) providing legal and compliance support; (viii) furnishing analytical and other support to assist the Board in its consideration of strategic issues such as the merger, consolidation or repurposing of certain closed-end funds; and (ix) performing or managing administrative functions necessary for the operation of each Fund, such as tax reporting, expense management, fulfilling regulatory filing requirements, and shareholder call center and other services. The Board reviewed the structure and duties of BlackRock’s fund administration, shareholder services, and legal and compliance departments and considered BlackRock’s policies and procedures for assuring compliance with applicable laws and regulations. The Board considered the operation of BlackRock’s business continuity plans.

The Board noted that the engagement of the Sub-Advisor with respect to BGR, BOE, BGY, BCX and BUI facilitates the provision of investment advice and trading by investment personnel out of non-U.S. jurisdictions. The Board considered that this arrangement provides additional flexibility to the portfolio management team, which may benefit each Fund and its shareholders.

B. The Investment Performance of each Fund and BlackRock

The Board, including the Independent Board Members, reviewed and considered the performance history of each Fund throughout the year and at the May Meeting. In preparation for the May Meeting, the Board was provided with reports independently prepared by Broadridge, which included an analysis of each Fund’s performance as of December 31, 2022, as compared to its Performance Peers. The performance information is based on net asset value (NAV), and utilizes Lipper data. Lipper’s methodology calculates a fund’s total return assuming distributions are reinvested on the ex-date at a fund’s ex-date NAV. Broadridge ranks funds in quartiles, ranging from first to fourth, where first is the most desirable quartile position and fourth is the least desirable. In connection with its review, the Board received and reviewed information regarding the investment performance of each Fund as compared to its Performance Peers and certain performance metrics (“Performance Metrics”). The Board and its Performance Oversight Committee regularly review and meet with Fund management to discuss the performance of each Fund throughout the year.

In evaluating performance, the Board focused particular attention on funds with less favorable performance records. The Board also noted that while it found the data provided by Broadridge generally useful, it recognized the limitations of such data, including in particular, that notable differences may exist between a fund and its Performance Peers (for example, the investment objectives and strategies). Further, the Board recognized that the performance data reflects a snapshot of a period as of a particular date and that selecting a different performance period could produce significantly different results. The Board also acknowledged that long-term performance could be impacted by even one period of significant outperformance or underperformance, and that a single investment theme could have the ability to disproportionately affect long-term performance.

The Board reviewed and considered BGR’s performance relative to BGR’s Performance Metrics. Based on an overall rating relative to the Performance Metrics, BGR generally performed above expectations. The Board noted that BlackRock believes that the Performance Metrics are an appropriate performance comparison for BGR, and that BlackRock has explained its rationale for this belief to the Board.

The Board reviewed and considered CII’s performance relative to CII’s Performance Metrics. Based on an overall rating relative to the Performance Metrics, CII generally performed above expectations. The Board noted that BlackRock believes that the Performance Metrics are an appropriate performance comparison for CII, and that BlackRock has explained its rationale for this belief to the Board.

The Board reviewed and considered BDJ’s performance relative to BDJ’s Performance Metrics. Based on an overall rating relative to the Performance Metrics, BDJ generally performed above expectations. The Board noted that BlackRock believes that the Performance Metrics are an appropriate performance comparison for BDJ, and that BlackRock has explained its rationale for this belief to the Board.

D I S C L O S U R E   O F   I N V E S T M E N T   A D V I S O R Y   A G R E E M E N T S   A N D   S U B ‑ A D V I S O R Y   A G R E E M E N T S 165

Disclosure of Investment Advisory Agreements and Sub-Advisory Agreements (continued)

The Board reviewed and considered BOE’s performance relative to BOE’s Performance Metrics. Based on an overall rating relative to the Performance Metrics, BOE generally performed in line with expectations. The Board noted that BlackRock believes that the Performance Metrics are an appropriate performance comparison for BOE, and that BlackRock has explained its rationale for this belief to the Board.

The Board reviewed and considered BGY’s performance relative to BGY’s Performance Metrics. Based on an overall rating relative to the Performance Metrics, BGY generally performed above expectations. The Board noted that BlackRock believes that the Performance Metrics are an appropriate performance comparison for BGY, and that BlackRock has explained its rationale for this belief to the Board.

The Board reviewed and considered BME’s performance relative to BME’s Performance Metrics. Based on an overall rating relative to the Performance Metrics, BME generally performed above expectations. The Board noted that BlackRock believes that the Performance Metrics are an appropriate performance comparison for BME, and that BlackRock has explained its rationale for this belief to the Board.

The Board reviewed and considered BMEZ’s performance relative to BMEZ’s Performance Metrics. Based on an overall rating relative to the Performance Metrics, BMEZ generally performed in line with expectations. The Board noted that BlackRock believes that the Performance Metrics are an appropriate performance comparison for BMEZ, and that BlackRock has explained its rationale for this belief to the Board.

The Board reviewed and considered BIGZ’s performance relative to BIGZ’s Performance Metrics. Based on an overall rating relative to the Performance Metrics, BIGZ generally performed below expectations. The Board noted that BlackRock believes that the Performance Metrics are an appropriate performance comparison for BIGZ, and that BlackRock has explained its rationale for this belief to the Board. The Board and BlackRock reviewed BIGZ’s underperformance relative to the Performance Metrics.

The Board reviewed and considered BCX’s performance relative to BCX’s Performance Metrics. Based on an overall rating relative to the Performance Metrics, BCX generally performed above expectations. The Board noted that BlackRock believes that the Performance Metrics are an appropriate performance comparison for BCX, and that BlackRock has explained its rationale for this belief to the Board.

The Board reviewed and considered BST’s performance relative to BST’s Performance Metrics. Based on an overall rating relative to the Performance Metrics, BST generally performed below expectations. The Board noted that BlackRock believes that the Performance Metrics are an appropriate performance comparison for BST, and that BlackRock has explained its rationale for this belief to the Board. The Board and BlackRock reviewed BST’s underperformance relative to the Performance Metrics.

The Board reviewed and considered BSTZ’s performance relative to BSTZ’s Performance Metrics. Based on an overall rating relative to the Performance Metrics, BSTZ generally performed in line with expectations. The Board noted that BlackRock believes that the Performance Metrics are an appropriate performance comparison for BSTZ, and that BlackRock has explained its rationale for this belief to the Board.

The Board reviewed and considered BUI’s performance relative to BUI’s Performance Metrics. Based on an overall rating relative to the Performance metrics, BUI generally performed above expectations. The Board noted that BlackRock believes that the Performance Metrics are an appropriate performance comparison for BUI, and that BlackRock has explained its rationale for this belief to the Board.

C. Consideration of the Advisory/Management Fees and the Estimated Cost of the Services and Estimated Profits Realized by BlackRock and its Affiliates from their Relationship with each Fund

The Board, including the Independent Board Members, reviewed each Fund’s contractual management fee rate compared with those of its Expense Peers. The contractual management fee rate represents a combination of the advisory fee and any administrative fees, before taking into account any reimbursements or fee waivers. The Board also compared each Fund’s total expense ratio, as well as its actual management fee rate as a percentage of managed assets, which is the total assets of each Fund (including any assets attributable to money borrowed for investment purposes) minus the sum of each Fund’s accrued liabilities (other than money borrowed for investment purposes) to those of its Expense Peers. The total expense ratio represents a fund’s total net operating expenses, excluding any investment related expenses. The total expense ratio gives effect to any expense reimbursements or fee waivers, and the actual management fee rate gives effect to any management fee reimbursements or waivers. The Board considered that the fee and expense information in the Broadridge report for each Fund reflected information for a specific period and that historical asset levels and expenses may differ from current levels, particularly in a period of market volatility. The Board considered the services provided and the fees charged by BlackRock and its affiliates to other types of clients with similar investment mandates, as applicable, including institutional accounts and sub-advised mutual funds (including mutual funds sponsored by third parties).

The Board received and reviewed statements relating to BlackRock’s financial condition. The Board reviewed BlackRock’s profitability methodology and was also provided with an estimated profitability analysis that detailed the revenues earned and the expenses incurred by BlackRock for services provided to each Fund. The Board reviewed BlackRock’s estimated profitability with respect to each Fund and other funds the Board currently oversees for the year ended December 31, 2022 compared to available aggregate estimated profitability data provided for the prior two years. The Board reviewed BlackRock’s estimated profitability with respect to certain other U.S. fund complexes managed by the Manager and/or its affiliates. The Board reviewed BlackRock’s assumptions and methodology of allocating expenses in the estimated profitability analysis, noting the inherent limitations in allocating costs among various advisory products. The Board recognized that profitability may be affected by numerous factors including, among other things, fee waivers and expense reimbursements by the Manager, the types of funds managed, precision of expense allocations and business mix. The Board thus recognized that calculating and comparing profitability at the individual fund level is difficult.

The Board noted that, in general, individual fund or product line profitability of other advisors is not publicly available. The Board reviewed BlackRock’s overall operating margin, in general, compared to that of certain other publicly traded asset management firms. The Board considered the differences between BlackRock and these other firms, including the contribution of technology at BlackRock, BlackRock’s expense management, and the relative product mix.

The Board considered whether BlackRock has the financial resources necessary to attract and retain high quality investment management personnel to perform its obligations under the Agreements and to continue to provide the high quality of services that is expected by the Board. The Board further considered factors including but not limited to

166 2 0 2 3   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Disclosure of Investment Advisory Agreements and Sub-Advisory Agreements (continued)

BlackRock’s commitment of time and resources, assumption of risk, and liability profile in servicing each Fund, including in contrast to what is required of BlackRock with respect to other products with similar investment mandates across the open-end fund, closed-end fund, sub-advised mutual fund, collective investment trust, and institutional separate account product channels, as applicable.

The Board noted that BGR’s contractual management fee rate ranked third out of four funds, and that the actual management fee rate and total expense ratio ranked in the second and first quartiles, respectively, relative to the Expense Peers. In addition, the Board noted that BlackRock had agreed to voluntarily waive a portion of the advisory fee payable by BGR. An advisory fee waiver has been in effect since 2015, the amount of which may have varied from time to time. After discussions between the Board, including Independent Board Members, and BlackRock, the Board and BlackRock agreed to a continuation of the current 22 basis points voluntary advisory fee waiver.

The Board noted that CII’s contractual management fee rate ranked in the first quartile, and that the actual management fee rate and total expense ratio each ranked in the first quartile relative to the Expense Peers.

The Board noted that BDJ’s contractual management fee rate ranked in the first quartile, and that the actual management fee rate and total expense ratio each ranked in the first quartile relative to the Expense Peers.

The Board noted that BOE’s contractual management fee rate ranked in the second quartile, and that the actual management fee rate and total expense ratio each ranked in the first quartile relative to the Expense Peers. In addition, the Board noted that BlackRock had agreed to voluntarily waive a portion of the advisory fee payable by BOE. An advisory fee waiver has been in effect since 2015, the amount of which may have varied from time to time. After discussion between the Board, including the Independent Board Members, and BlackRock, the Board and BlackRock agreed to a continuation of the current 17.5 basis points voluntary advisory fee waiver.

The Board noted that BGY’s contractual management fee rate ranked in the second quartile, and that the actual management fee rate and total expense ratio each ranked in the second quartile relative to the Expense Peers.

The Board noted that BME’s contractual management fee rate ranked first out of four funds, and that the actual management fee rate and total expense ratio each ranked in the first quartile relative to the Expense Peers.

The Board noted that BMEZ’s contractual management fee rate ranked third out of four funds, and that the actual management fee rate and total expense ratio ranked in the fourth and second quartiles, respectively, relative to the Expense Peers.

The Board noted that BIGZ’s contractual management fee rate ranked in the fourth quartile, and that the actual management fee rate and total expense ratio ranked in the third and second quartiles, respectively, relative to the Expense Peers.

The Board noted that BCX’s contractual management fee rate ranked in the first quartile, and that the actual management fee rate and total expense ratio ranked in the second and first quartiles, respectively, relative to the Expense Peers.

The Board noted that BST’s contractual management fee rate ranked first out of four funds, and that the actual management fee rate and total expense ratio each ranked in the first quartile relative to the Expense Peers.

The Board noted that BSTZ’s contractual management fee rate ranked third out of four funds, and that the actual management fee rate and total expense ratio ranked in the fourth and second quartiles, respectively, relative to the Expense Peers.

The Board noted that BUI’s contractual management fee rate ranked in the first quartile, and that the actual management fee rate and total expense ratio ranked in the second and first quartiles, respectively, relative to the Expense Peers.

D. Economies of Scale

The Board, including the Independent Board Members, considered the extent to which economies of scale might be realized as the assets of each Fund increase. The Board also considered the extent to which each Fund benefits from such economies of scale in a variety of ways, and whether there should be changes in the advisory fee rate or breakpoint structure in order to enable each Fund to more fully participate in these economies of scale. The Board considered each Fund’s asset levels and whether the current fee was appropriate.

Based on the Board’s review and consideration of the issue, the Board concluded that most closed-end funds do not have fund level breakpoints because closed-end funds generally do not experience substantial growth after the initial public offering. Closed-end funds are typically priced at scale at a fund’s inception. The Board noted that although each of BDJ, BME, BST and BUI may from time-to-time make additional share offerings pursuant to its equity shelf program, the growth of each Fund’s assets will occur primarily through the appreciation of its investment portfolio.

E. Other Factors Deemed Relevant by the Board Members

The Board, including the Independent Board Members, also took into account other ancillary or “fall-out” benefits that BlackRock or its affiliates may derive from BlackRock’s respective relationships with each Fund, both tangible and intangible, such as BlackRock’s ability to leverage its investment professionals who manage other portfolios and its risk management personnel, an increase in BlackRock’s profile in the investment advisory community, and the engagement of BlackRock’s affiliates as service providers to each Fund, including for administrative, securities lending and cash management services. With respect to securities lending, during the year the Board also considered information provided by independent third-party consultants related to the performance of each BlackRock affiliate as securities lending agent. The Board also considered BlackRock’s overall operations and its efforts to expand the scale of, and improve the quality of, its operations. The Board also noted that, subject to applicable law, BlackRock may use and benefit from third-party research obtained by soft dollars generated by certain registered fund transactions to assist in managing all or a number of its other client accounts.

D I S C L O S U R E   O F   I N V E S T M E N T   A D V I S O R Y   A G R E E M E N T S   A N D   S U B ‑ A D V I S O R Y   A G R E E M E N T S 167

Disclosure of Investment Advisory Agreements and Sub-Advisory Agreements (continued)

In connection with its consideration of the Agreements, the Board also received information regarding BlackRock’s brokerage and soft dollar practices. The Board received reports from BlackRock which included information on brokerage commissions and trade execution practices throughout the year.

The Board noted the competitive nature of the closed-end fund marketplace, and that shareholders are able to sell their Fund shares in the secondary market if they believe that each Fund’s fees and expenses are too high or if they are dissatisfied with the performance of each Fund.

The Board also considered the various notable initiatives and projects BlackRock performed in connection with its closed-end fund product line. These initiatives included developing equity shelf programs; efforts to eliminate product overlap with fund mergers; ongoing services to manage leverage that has become increasingly complex; periodic evaluation of share repurchases and other support initiatives for certain BlackRock funds; and continued communication efforts with shareholders, fund analysts and financial advisers. With respect to the latter, the Independent Board Members noted BlackRock’s continued commitment to supporting the secondary market for the common shares of its closed-end funds through a comprehensive secondary market communication program designed to raise investor and analyst awareness and understanding of closed-end funds. BlackRock’s support services included, among other things: sponsoring and participating in conferences; communicating with closed-end fund analysts covering the BlackRock funds throughout the year; providing marketing and product updates for the closed-end funds; and maintaining and enhancing its closed-end fund website.

Conclusion

At the June Meeting, in a continuation of the discussions that occurred during the May Meeting, and as a culmination of the Board’s year-long deliberative process, the Board, including the Independent Board Members, unanimously approved the continuation of the Advisory Agreements between the Manager and each Fund for a one-year term ending June 30, 2024, and the Sub-Advisory Agreements among the Manager, the Sub-Advisor and each of BGR, BOE, BGY, BCX and BUI for a one-year term ending June 30, 2024. Based upon its evaluation of all of the aforementioned factors in their totality, as well as other information, the Board, including the Independent Board Members, was satisfied that the terms of the Agreements were fair and reasonable and in the best interest of each Fund and its shareholders. In arriving at its decision to approve the Agreements, the Board did not identify any single factor or group of factors as all-important or controlling, but considered all factors together, and different Board Members may have attributed different weights to the various factors considered. The Independent Board Members were advised by independent legal counsel throughout the deliberative process.

168 2 0 2 3   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Additional Information

Trust Certification

The Trusts are listed for trading on the NYSE and have filed with the NYSE their annual chief executive officer certification regarding compliance with the NYSE’s listing standards. The Trusts filed with the SEC the certification of its chief executive officer and chief financial officer required by Section 302 of the Sarbanes-Oxley Act.

Environmental, Social and Governance (“ESG”) Integration

Although the Trusts do not seek to implement a specific sustainability objective, strategy or process unless otherwise disclosed, Trust management will consider ESG factors as part of the investment process for the Trusts. Trust management views ESG integration as the practice of incorporating financially material ESG data or information into investment processes with the objective of enhancing risk-adjusted returns. These ESG considerations will vary depending on the Trusts’ particular investment strategies and may include consideration of third-party research as well as consideration of proprietary BlackRock research across the ESG risks and opportunities regarding an issuer. The ESG characteristics utilized in the Trusts’ investment process are anticipated to evolve over time and one or more characteristics may not be relevant with respect to all issuers that are eligible for investment. Certain of these considerations may affect the Trusts’ exposure to certain companies or industries. While Trust management views ESG considerations as having the potential to contribute to the Trusts’ long-term performance, there is no guarantee that such results will be achieved.

Dividend Policy

Each Trust’s policy is to make monthly distributions to shareholders. In order to provide shareholders with a more stable level of dividend distributions, each Trust employs a managed distribution plan (the “Plan”), the goal of which is to provide shareholders with consistent and predictable cash flows by setting distribution rates based on expected long-term returns of each Trust.

The distributions paid by each Trust for any particular month may be more or less than the amount of net investment income earned by each Trust during such month. Furthermore, the final tax characterization of distributions is determined after the year-end of a Trust and is reported in each Trust’s annual report to shareholders. Distributions can be characterized as ordinary income, capital gains and/or return of capital. Each Trust’s taxable net investment income and net realized capital gains (“taxable income”) may not be sufficient to support the level of distributions paid. To the extent that distributions exceed the Trust’s current and accumulated earnings and profits, the excess may be treated as a non-taxable return of capital.

A return of capital is a return of a portion of an investor’s original investment. A return of capital is not expected to be taxable, but it reduces a shareholder’s tax basis in his or her shares, thus reducing any loss or increasing any gain on a subsequent disposition by the shareholder of his or her shares. It is possible that a substantial portion of the distributions paid during a calendar year may ultimately be classified as return of capital for U.S. federal income tax purposes when the final determination of the source and character of the distributions is made.

Such distributions, under certain circumstances, may exceed a Trust’s total return performance. When total distributions exceed total return performance for the period, the difference reduces the Trust’s total assets and net asset value (“NAV”) per share and, therefore, could have the effect of increasing the Trust’s expense ratio and reducing the amount of assets the Trust has available for long term investment.

General Information

The Trusts, other than BDJ, BME, BST and BUI, do not make available copies of their Statements of Additional Information because the Trusts’ shares, other than BDJ, BME, BST and BUI, are not continuously offered, which means that the Statement of Additional Information of each Trust, other than BDJ, BME, BST and BUI, has not been updated after completion of the respective Trust’s offerings and the information contained in each Trust’s Statement of Additional Information may have become outdated.

BDJ’s, BME’s, BST’s and BUI’s Statements of Additional Information include additional information about the Board and are available, without charge upon request by calling (800)882-0052.

The following information is a summary of certain changes since December 31, 2022. This information may not reflect all of the changes that have occurred since you purchased the relevant Trust.

Except if noted otherwise herein, there were no changes to the Trusts’ charters or by-laws that would delay or prevent a change of control of the Trusts that were not approved by the shareholders.

In accordance with Section 23(c) of the Investment Company Act of 1940, each Trust may from time to time purchase shares of its common stock in the open market or in private transactions.

Quarterly performance, semi-annual and annual reports, current net asset value and other information regarding the Trusts may be found on BlackRock’s website, which can be accessed at blackrock.com. Any reference to BlackRock’s website in this report is intended to allow investors public access to information regarding the Trusts and does not, and is not intended to, incorporate BlackRock’s website in this report.

Electronic Delivery

Shareholders can sign up for e-mail notifications of quarterly statements, annual and semi-annual shareholder reports and, for BDJ, BME, BST and BUI only, prospectuses, by enrolling in the electronic delivery program. Electronic copies of shareholder reports and, for BDJ, BME, BST and BUI only, prospectuses, are available on BlackRock’s website.

To enroll in electronic delivery:

A D D I T I O N A L   I N F O R M A T I O N 169

Additional Information (continued)

Shareholders Who Hold Accounts with Investment Advisers, Banks or Brokerages:

Please contact your financial adviser. Please note that not all investment advisers, banks or brokerages may offer this service.

Householding

The Trusts will mail only one copy of shareholder documents, including for BDJ, BME, BST and BUI only, prospectuses, annual and semi-annual reports, Rule 30e-3 notices and proxy statements, to shareholders with multiple accounts at the same address. This practice is commonly called “householding” and is intended to reduce expenses and eliminate duplicate mailings of shareholder documents. Mailings of your shareholder documents may be householded indefinitely unless you instruct us otherwise. If you do not want the mailing of these documents to be combined with those for other members of your household, please call the Trusts at (800) 882-0052.

Availability of Quarterly Schedule of Investments

The Trusts file their complete schedules of portfolio holdings with the SEC for the first and third quarters of each fiscal year as an exhibit to their reports on Form N-PORT. The Trusts’ Forms N-PORT are available on the SEC’s website at sec.gov. Additionally, each Trust makes its portfolio holdings for the first and third quarters of each fiscal year available at blackrock.com/fundreports.

Availability of Proxy Voting Policies, Procedures and Voting Records

A description of the policies and procedures that the Trusts use to determine how to vote proxies relating to portfolio securities and information about how the Trusts voted proxies relating to securities held in the Trusts’ portfolios during the most recent 12-month period ended June 30 is available without charge, upon request (1) by calling (800) 882-0052; (2) on the BlackRock website at blackrock.com; and (3) on the SEC’s website at sec.gov.

Availability of Trust Updates

BlackRock will update performance and certain other data for the Trusts on a monthly basis on its website in the “Closed-end Funds” section of blackrock.com as well as certain other material information as necessary from time to time. Investors and others are advised to check the website for updated performance information and the release of other material information about the Trusts. This reference to BlackRock’s website is intended to allow investors public access to information regarding the Trusts and does not, and is not intended to, incorporate BlackRock’s website in this report.

Shelf Offering Program

From time to time, BDJ, BME, BST and BUI may seek to raise additional equity capital through a Shelf Offering. In a Shelf Offering, BDJ, BME, BST and BUI may, subject to market conditions, raise additional equity capital by issuing new Common Shares from time to time in varying amounts at a net price at or above BDJ’s, BME’s, BST’s and BUI’s NAV per Common Share (calculated within 48 hours of pricing). While any such Shelf Offering may allow BDJ, BME, BST and BUI to pursue additional investment opportunities without the need to sell existing portfolio investments, it could also entail risks – including that the issuance of additional Common Shares may limit the extent to which the Common Shares are able to trade at a premium to NAV in the secondary market.

BDJ, BME, BST and BUI filed final prospectuses with the SEC in connection with its Shelf Offering on June 2, 2023, April 26, 2022, May 10, 2022 and March 10, 2022, respectively. This report and the prospectuses of BDJ, BME, BST and BUI are not offers to sell BDJ, BME, BST and BUI Common Shares or solicitations of an offer to buy BDJ, BME, BST and BUI Common Shares in any jurisdiction where such offers or sales are not permitted. The prospectuses of BDJ, BME, BST and BUI contains important information about BDJ, BME, BST and BUI, including their investment objectives, risks, charges and expenses. Investors are urged to read the prospectuses of BDJ, BME, BST and BUI carefully and in their entirety before investing. Copies of the final prospectuses for BDJ, BME, BST and BUI can be obtained from BlackRock at blackrock.com.

BlackRock Privacy Principles

BlackRock is committed to maintaining the privacy of its current and former fund investors and individual clients (collectively, “Clients”) and to safeguarding their non-public personal information. The following information is provided to help you understand what personal information BlackRock collects, how we protect that information and why in certain cases we share such information with select parties.

If you are located in a jurisdiction where specific laws, rules or regulations require BlackRock to provide you with additional or different privacy-related rights beyond what is set forth below, then BlackRock will comply with those specific laws, rules or regulations.

BlackRock obtains or verifies personal non-public information from and about you from different sources, including the following: (i) information we receive from you or, if applicable, your financial intermediary, on applications, forms or other documents; (ii) information about your transactions with us, our affiliates, or others; (iii) information we receive from a consumer reporting agency; and (iv) from visits to our websites.

BlackRock does not sell or disclose to non-affiliated third parties any non-public personal information about its Clients, except as permitted by law or as is necessary to respond to regulatory requests or to service Client accounts. These non-affiliated third parties are required to protect the confidentiality and security of this information and to use it only for its intended purpose.

We may share information with our affiliates to service your account or to provide you with information about other BlackRock products or services that may be of interest to you. In addition, BlackRock restricts access to non-public personal information about its Clients to those BlackRock employees with a legitimate business need for the information. BlackRock maintains physical, electronic and procedural safeguards that are designed to protect the non-public personal information of its Clients, including procedures relating to the proper storage and disposal of such information.

170 2 0 2 3   B L A C K R O C K  S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Additional Information (continued)

Trust and Service Providers

Investment Adviser

BlackRock Advisors, LLC

Wilmington, DE 19809

Sub-Adviser

BlackRock International Limited^(a)

Edinburgh, EH3 8BL

United Kingdom

Accounting Agent and Custodian

State Street Bank and Trust Company

Boston, MA 02114

Transfer Agent

Computershare Trust Company, N.A.

Canton, MA 02021

^(a) For BGR, BOE, BGY, BCX and BUI.

^(b) For BDJ, BME, BST and BUI.

Distributor

BlackRock Investments, LLC^(b)

New York, NY 10001

Independent Registered Public Accounting Firm

Deloitte & Touche LLP

Boston, MA 02116

Legal Counsel

Willkie Farr & Gallagher LLP

New York, NY 10019

Address of the Trusts

100 Bellevue Parkway

Wilmington, DE 19809

A D D I T I O N A L   I N F O R M A T I O N 171

Glossary of Terms Used in this Report

Currency Abbreviation

AUD	Australian Dollar
BRL	Brazilian Real
CAD	Canadian Dollar
CHF	Swiss Franc
CNY	Chinese Yuan
DKK	Danish Krone
EUR	Euro
GBP	British Pound
HKD	Hong Kong Dollar
JPY	Japanese Yen
KRW	South Korean Won
MXN	Mexican Peso
NOK	Norwegian Krone
SEK	Swedish Krona
SGD	Singapore Dollar
TWD	New Taiwan Dollar
USD	United States Dollar

Portfolio Abbreviation

ADR	American Depositary Receipt
GDR	Global Depositary Receipt
JSC	Joint Stock Company
LP	Limited Partnership
PJSC	Public Joint Stock Company
S&P	Standard & Poor’s
SAB	Special Assessment Bonds

172 2 0 2 3   B L A C K R O C K  S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S

Want to know more?

blackrock.com   |   800-882-0052

This report is intended for current holders. It is not a prospectus. Past performance results shown in this report should not be considered a representation of future performance. Statements and other information herein are as dated and are subject to change.

CEF-BK9-06/23-SAR

(b) Not Applicable

Item 2 – Code of Ethics – Not Applicable to this semi-annual report

Item 3 – Audit Committee Financial Expert – Not Applicable to this semi-annual report

Item 4 – Principal Accountant Fees and Services – Not Applicable to this semi-annual report

Item 5 – Audit Committee of Listed Registrants – Not Applicable to this semi-annual report

Item 6 – Investments

(a) The registrant’s Schedule of Investments is included as part of the Report to Stockholders filed under Item 1(a) of this Form.

(b) Not Applicable due to no such divestments during the semi-annual period covered since the previous Form N-CSR filing.

Item 7 – Disclosure of Proxy Voting Policies and Procedures for Closed-End Management Investment Companies – Not Applicable to this semi-annual report

Item 8 – Portfolio Managers of Closed-End Management Investment Companies

(a) Not Applicable to this semi-annual report

(b) As of the date of this filing, Mr. Lee is no longer a Portfolio Manager of the Fund.

Item 9 – Purchases of Equity Securities by Closed-End Management Investment Company and Affiliated Purchasers – Not Applicable due to no such purchases during the period covered by this report.

Item 10 – Submission of Matters to a Vote of Security Holders – There have been no material changes to these procedures.

Item 11 – Controls and Procedures

(a) The registrant’s principal executive and principal financial officers, or persons performing similar functions, have concluded that the registrant’s disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940, as amended (the “1940 Act”)) are effective as of a date within 90 days of the filing of this report based on the evaluation of these controls and procedures required by Rule 30a-3(b) under the 1940 Act and Rule 13a-15(b) under the Securities Exchange Act of 1934, as amended.

(b) There were no changes in the registrant’s internal control over financial reporting (as defined in Rule 30a-3(d) under the 1940 Act) that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, the registrant’s internal control over financial reporting.

Item 12 – Disclosure of Securities Lending Activities for Closed-End Management Investment Companies – Not applicable to this semi-annual report

Item 13 – Exhibits attached hereto

(a)(1) Code of Ethics – Not Applicable to this semi-annual report

(a)(2) Section 302 Certifications are attached

(a)(3) Any written solicitation to purchase securities under Rule 23c-1 – Not Applicable

(a)(4) Change in Registrant’s independent public accountant – Not Applicable

(b) Section 906 Certifications are attached

(c) Notices to the registrant’s common shareholders in accordance with the order under Section 6(c) of the 1940 Act granting an exemption from Section 19(b) of the 1940 Act and Rule 19b-1 under the 1940 Act, dated May 9, 2009¹

¹ The Fund has received exemptive relief from the Securities and Exchange Commission permitting it to make periodic distributions of long-term capital gains with respect to its outstanding common stock as frequently as twelve times each year, and as frequently as distributions are specified by or in accordance with the terms of its outstanding preferred stock. This relief is conditioned, in part, on an undertaking by the Fund to make the disclosures to the holders of the Fund’s common shares, in addition to the information required by Section 19(a) of the 1940 Act and Rule 19a-1 thereunder. The Fund is likewise obligated to file with the SEC the information contained in any such notice to shareholders and, in that regard, has attached hereto copies of each such notice made during the period.

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BlackRock Health Sciences Trust

By:	/s/ John M. Perlowski
	John M. Perlowski
	Chief Executive Officer (principal executive officer) of BlackRock Health Sciences Trust

Date: August 25, 2023

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

By:	/s/ John M. Perlowski
	John M. Perlowski
	Chief Executive Officer (principal executive officer) of
	BlackRock Health Sciences Trust

Date: August 25, 2023

By:	/s/ Trent Walker
	Trent Walker
	Chief Financial Officer (principal financial officer) of
	BlackRock Health Sciences Trust

Date: August 25, 2023